{"PMC2527252": [["SUPPLEMENTARY MATERIALTo view all of the supplemental files associated with this article, visit www.biophysj.org.", [["SUPPLEMENTARY", "DISEASE", 0, 13]]]], "PMC7298466": [["Closing loopsClosing resource loops relates to recycling which integrates material quality conservation and is considered as the lowest priority CE strategy in the (Bocken, et al. 2016) framework.", [["Closing loops", "PROBLEM", 0, 13], ["Closing resource loops", "PROBLEM", 13, 35], ["loops", "ANATOMY_MODIFIER", 8, 13], ["loops", "OBSERVATION", 30, 35]]], ["During the COVID-19 crisis, several initiatives simultaneously closed material loops and tackled shortages at the medical sector's input side.", [["the COVID", "TEST", 7, 16], ["crisis", "PROBLEM", 20, 26], ["loops", "OBSERVATION_MODIFIER", 79, 84]]], ["The recent evidence demonstrates the elasticity of bottom-up initiatives by both private companies (e.g. breweries producing disinfection alcohol for medical applications from residue products) and individual citizens (e.g. maker's movements producing mouth masks from textile leftovers and supplying hospitals and care facilities) to recycle locally available resources and thus reduce import dependency.", [["alcohol", "CHEMICAL", 138, 145], ["alcohol", "CHEMICAL", 138, 145], ["mouth", "ORGANISM_SUBDIVISION", 252, 257], ["medical applications from residue products", "TREATMENT", 150, 192], ["elasticity", "OBSERVATION_MODIFIER", 37, 47], ["bottom", "OBSERVATION_MODIFIER", 51, 57]]], ["Future research could investigate how they can increase the sector's resilience in the long run.Closing loopsOn the output side, waste generation by the medical sector increased 65% at the peak of the COVID-19 crisis (INDAVER 2020).", [["Closing loops", "PROBLEM", 96, 109], ["the COVID", "TEST", 197, 206], ["loops", "ANATOMY_MODIFIER", 104, 109]]], ["Flanders does not allow recycling of hazardous medical waste and sends it towards a \u2018safe sink\u2019 for decontamination or incineration.", [["decontamination", "TREATMENT", 100, 115]]], ["Hence, while CE provides solutions to overcome shortages at the input side of the medical sector, the uptake of CE at the output side is hindered by the generation of hazardous waste.", [["CE", "CHEMICAL", 13, 15], ["CE", "CHEMICAL", 112, 114], ["hazardous waste", "OBSERVATION", 167, 182]]], ["The COVID-19 crisis exacerbates this waste management problem.", [["The COVID", "TEST", 0, 9], ["this waste management", "TREATMENT", 32, 53]]], ["This demonstrates the medical sector's disproportional focus on procurement compared to waste management (GGKP 2020).", [["waste management", "TREATMENT", 88, 104]]], ["Hence, resource scientists should further explore possibilities for medical waste treatment and assess possibilities for critical raw materials recovery or reduced import dependency.Slowing and narrowing loopsSlowing loops refers to the design of long-life goods and product-life extension through re- purpose, refurbishment, and remanufacture.", [["medical waste treatment", "TREATMENT", 68, 91], ["critical raw materials", "TREATMENT", 121, 143], ["reduced import dependency", "PROBLEM", 156, 181], ["Slowing and narrowing loops", "PROBLEM", 182, 209], ["Slowing loops", "PROBLEM", 209, 222], ["long-life goods", "TREATMENT", 247, 262], ["narrowing", "OBSERVATION", 194, 203], ["loops", "ANATOMY_MODIFIER", 204, 209], ["loops", "OBSERVATION", 217, 222]]], ["Narrowing refers to resource efficiency and dematerialization.", [["Narrowing", "PROBLEM", 0, 9], ["dematerialization", "PROBLEM", 44, 61], ["resource efficiency", "OBSERVATION", 20, 39]]], ["While the COVID-19 crisis considerably slowed down economic activities it also accelerated the generation of (hazardous) waste.", [["the COVID", "TEST", 6, 15]]], ["Nevertheless, responses to the COVID- 19 challenges in healthcare demonstrate the potential of narrowing and slowing loops with the aim to prevent or postpone waste generation.", [["the COVID- 19 challenges", "TREATMENT", 27, 51], ["narrowing and slowing loops", "PROBLEM", 95, 122], ["narrowing", "OBSERVATION", 95, 104], ["slowing loops", "OBSERVATION", 109, 122]]], ["A hypothesis is that the slowing metabolism of the wider economy created opportunities to citizens and other stakeholders with certain interests, values and knowledge to engage in circular economy practices like sharing, maintenance, repair, and refurbishment of medical equipment and devices (e.g. 3-D printing of spare ventilator parts by companies and households, making mouth masks or donating babyphones to use for patient surveillance in the ICU).", [["mouth", "ORGANISM_SUBDIVISION", 374, 379], ["patient", "ORGANISM", 420, 427], ["patient", "SPECIES", 420, 427], ["circular economy practices", "TREATMENT", 180, 206], ["repair", "TREATMENT", 234, 240], ["medical equipment", "TREATMENT", 263, 280], ["devices", "TREATMENT", 285, 292], ["spare ventilator parts", "TREATMENT", 315, 337], ["slowing", "OBSERVATION_MODIFIER", 25, 32]]], ["The usefulness of lifetime extension, especially through comprehensive refurbishment, was already acknowledged by the medical sector prior to the COVID-19 crisis.", [["the COVID", "TEST", 142, 151]]], ["However, comprehensive refurbishment implies more manufactured processes and is mainly established in an industrial setting (Nasr, et al. 2018).", [["more manufactured", "OBSERVATION_MODIFIER", 45, 62]]], ["The COVID-19 crisis demonstrates the potential of bottom-up initiatives and decentralized medical equipment and medical devices production tackling urgent shortages.", [["The COVID", "TEST", 0, 9], ["decentralized medical equipment", "TREATMENT", 76, 107], ["medical devices production", "TREATMENT", 112, 138]]], ["In this context, decentralized production slows loops and increases the healthcare sector's resilience to supply shocks.", [["decentralized production slows loops", "PROBLEM", 17, 53], ["decentralized", "OBSERVATION_MODIFIER", 17, 30], ["production", "OBSERVATION", 31, 41], ["slows loops", "OBSERVATION", 42, 53], ["increases", "OBSERVATION_MODIFIER", 58, 67]]], ["Additionally, it partially disconnects medical activity from global value chains which have proven to be unreliable in times of crisis (e.g. export bans on critical equipment).", [["global value chains", "PROBLEM", 61, 80], ["crisis", "PROBLEM", 128, 134]]], ["A second option to slow material loops would be to introduce Extended Producer Responsibility (ERP) for non-hazardous medical waste from medical equipment and shift part of the waste treatment responsibility to the producers of the medical equipment (GGKP 2020).", [["A second option", "TREATMENT", 0, 15], ["slow material loops", "PROBLEM", 19, 38], ["non-hazardous medical waste", "TREATMENT", 104, 131], ["medical equipment", "TREATMENT", 137, 154], ["the waste treatment", "TREATMENT", 173, 192]]], ["The recycling of (potentially) hazardous material may be technically possible for a number of targeted streams (e.g. mouth masks), but the implementation of this strategy should be preceded by a revision of the collection infrastructure and logistics, backed-up by a risk-cost-benefit investigation.", [["mouth", "ORGANISM_SUBDIVISION", 117, 122], ["hazardous material", "PROBLEM", 31, 49], ["mouth masks", "TREATMENT", 117, 128], ["this strategy", "TREATMENT", 157, 170], ["a revision of the collection infrastructure", "TREATMENT", 193, 236], ["benefit investigation", "TEST", 277, 298], ["revision", "OBSERVATION", 195, 203]]], ["Hence, industrial ecology research could support managerial decisions by providing the environmental impacts of the alternatives and by developing a framework of these environmental impacts measured against risks and costs.Slowing and narrowing loopsMaintenance and repair workers (e.g. cleaning) play a pivotal role in the slowing of resource loops.", [["Slowing and narrowing loops", "PROBLEM", 223, 250], ["repair workers", "TREATMENT", 266, 280], ["narrowing", "OBSERVATION", 235, 244], ["loops", "OBSERVATION_MODIFIER", 245, 250]]], ["Nevertheless, the current body of literature pays little attention to their roles in resource loop management.", [["resource loop management", "TREATMENT", 85, 109]]], ["Many skills have been made redundant in northern economies like Flanders, through the separation of \u2018mind\u2019 tasks (e.g., design or finance) from the so-called \u2018body tasks\u2019 (e.g., cleaning or caretaking).", [["body", "ANATOMY", 159, 163], ["body", "ORGANISM_SUBDIVISION", 159, 163], ["redundant", "OBSERVATION_MODIFIER", 27, 36]]], ["Hence, very few people in the north today know how to \u2018make\u2019, \u2018maintain\u2019 or \u2018repair\u2019 products and equipment and became dependent on a labor pool to perform jobs that require these skills.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["repair\u2019 products", "TREATMENT", 77, 93], ["a labor pool", "PROBLEM", 132, 144]]], ["The maintenance sector tends to be feminized and racialized and the people working in this sector are often paid low salaries and may not be provided proper protection from the virus in the workplace.", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["virus", "OBSERVATION", 177, 182]]], ["This lack of financial security and investment in personal protection equipment (PPE) forces maintenance workers to work and be exposed to the virus, enhancing another pressure on the healthcare and maintenance industry.", [["personal protection equipment", "TREATMENT", 50, 79], ["the virus", "PROBLEM", 139, 148]]], ["Research should not solely focus on circular solutions to address environmental issues; they should be socially inclusive.Sustaining lifeBesides the above-mentioned efforts to sustain the healthcare sector CE should also integrate biodiversity in the value chain.", [["circular solutions", "TREATMENT", 36, 54]]], ["The introduction of sustaining life acknowledges the potential of a CE to decrease the need for medical services and decrease the likelihood of recurrence of a pandemic in future.", [["medical services", "TREATMENT", 96, 112], ["a pandemic", "PROBLEM", 158, 168]]], ["This type of strategy responds to one of the main CE principles: to be restorative and regenerative.", [["restorative", "OBSERVATION", 71, 82], ["regenerative", "OBSERVATION_MODIFIER", 87, 99]]], ["A body of research outside the field of resource management exists upon prevention of communicable diseases (e.g. COVID-19), and chronic diseases (e.g. cancer), for supporting healing processes and coping with psychological impacts.", [["cancer", "ANATOMY", 152, 158], ["communicable diseases", "DISEASE", 86, 107], ["chronic diseases", "DISEASE", 129, 145], ["cancer", "DISEASE", 152, 158], ["cancer", "CANCER", 152, 158], ["resource management", "TREATMENT", 40, 59], ["communicable diseases", "PROBLEM", 86, 107], ["COVID", "TEST", 114, 119], ["chronic diseases (e.g. cancer", "PROBLEM", 129, 158], ["healing processes", "PROBLEM", 176, 193], ["psychological impacts", "PROBLEM", 210, 231], ["chronic", "OBSERVATION_MODIFIER", 129, 136], ["diseases", "OBSERVATION", 137, 145], ["cancer", "OBSERVATION", 152, 158]]], ["More interdisciplinary research will give leverage to this principle of regenerating natural systems.Circular creativity during COVID-19 and beyondThe potential of circular initiatives in the healthcare sector became apparent during the COVID-19 crisis.", [["COVID-19", "DNA", 128, 136], ["COVID", "TEST", 128, 133], ["the COVID", "TEST", 233, 242], ["circular", "OBSERVATION_MODIFIER", 164, 172]]], ["Prior to the COVID-19 crisis, studies on consumption in the circular economy described \u2018ideas\u2019 to foster collaboration between sectors and turning citizens into co-creators.", [["the COVID", "TEST", 9, 18], ["crisis", "PROBLEM", 22, 28], ["studies", "TEST", 30, 37]]], ["There is a risk however, that this shift is again reversed when the lockdown restrictions and the limited availability of PPE come to an end.Circular creativity during COVID-19 and beyondTo further decrease import dependency in the critical medical value chains, more research is needed to examine how companies can enhance their adaptive capacity, so they can meet societal and their company's needs in times of crisis.", [["PPE", "GENE_OR_GENE_PRODUCT", 122, 125], ["PPE", "PROTEIN", 122, 125], ["COVID-19", "DNA", 168, 176], ["the lockdown restrictions", "TREATMENT", 64, 89], ["PPE", "TREATMENT", 122, 125], ["COVID", "TEST", 168, 173], ["crisis", "PROBLEM", 413, 419], ["dependency", "OBSERVATION_MODIFIER", 214, 224]]], ["The current crisis indeed showed those bottom-up initiatives have been tapping into the window of opportunity to experiment, to incubate ideas of circular economy and to challenge the current system which is still locked in linear thinking.", [["The current crisis", "PROBLEM", 0, 18], ["circular economy", "TREATMENT", 146, 162]]], ["However, the long term impacts of COVID-19 on the circular economy could counter the aforementioned observations of initiatives and changes.Circular creativity during COVID-19 and beyondFinally, while this paper describes the potential of CE to increase resilience of the medical sector in times of crises, this paper also stresses the potential of restorative CE aspects.", [["COVID-19", "CHEMICAL", 34, 42], ["CE", "CHEMICAL", 239, 241], ["COVID-19", "CHEMICAL", 34, 42], ["COVID", "TEST", 34, 39], ["COVID", "TEST", 167, 172], ["crises", "PROBLEM", 299, 305], ["restorative CE aspects", "TREATMENT", 349, 371], ["long term", "OBSERVATION_MODIFIER", 13, 22], ["creativity", "OBSERVATION_MODIFIER", 149, 159]]], ["This rationale is in line with notions of circular economy suggesting the need for sustaining life in addition to slowing, narrowing and closing loops.CRediT authorship contribution statement", [["circular economy", "TREATMENT", 42, 58], ["slowing, narrowing and closing loops", "PROBLEM", 114, 150], ["slowing", "OBSERVATION_MODIFIER", 114, 121], ["narrowing", "OBSERVATION", 123, 132], ["closing loops", "OBSERVATION", 137, 150]]]], "PMC7412718": [["Mindfulness is a theoretical instance that finds its implementation in a set of meditation and psycho educational exercises aimed at understanding certain fundamental themes such as stress, attachment and dependence on internal and external content and therefore the importance of subjective observation of thoughts, emotions, and physical sensations (Kabat-Zinn, 2009; Rosa et al., 2019).", [["psycho educational exercises", "TREATMENT", 95, 123]]], ["Moreover, mindfulness interventions proved to be very helpful in reducing the psychopathological symptomatology of chronic conditions (Bonadonna, 2003; Catalano et al., 2017; Poli et al., 2017, 2019; Conversano and Marchi, 2018; Marchini et al., 2018; Conversano, 2019; Di Giuseppe et al., 2019b, 2020b; Martino et al., 2019a,b, 2020b; Merlo, 2019; Conversano et al., 2020a; Lenzo et al., 2020; Poli et al., 2020).IntroductionThe most widespread protocol used both in the clinical and in the normal context is represented by a group-based intervention named Mindfulness-Based Stress Reduction (MBSR).", [["mindfulness interventions", "TREATMENT", 10, 35], ["chronic conditions", "PROBLEM", 115, 133], ["a group-based intervention", "TREATMENT", 525, 551], ["chronic", "OBSERVATION_MODIFIER", 115, 122]]], ["It is a protocol characterized by the teaching of formal and informal meditation practices, yoga exercises and the sharing of group experiences (Kabat-Zinn, 2009).", [["a protocol", "TREATMENT", 6, 16], ["informal meditation practices", "TREATMENT", 61, 90], ["yoga exercises", "TREATMENT", 92, 106]]], ["The aim of MBSR is to improve mindfulness ability in participants, helping them to integrate their mind and body activity in a non-judgmental way.", [["body", "ANATOMY", 108, 112], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["participants", "SPECIES", 53, 65], ["MBSR", "TREATMENT", 11, 15]]], ["Starting from the MBSR program, in the following years, many protocols based on it have been developed for research purposes, integrating various aspects of psychological and behavioral sciences (Shonin et al., 2013).IntroductionA plethora of research show that mindfulness-based interventions (MBIs) determine significant benefits both in clinical and non-clinical samples.", [["many protocols", "TREATMENT", 56, 70], ["mindfulness-based interventions", "TREATMENT", 262, 293]]], ["On the one hand, MBIs would seem to increase awareness levels, strategies to cope with stressful situations and emotion management; on the other hand, they seem to reduce levels of perceived stress, anxiety, and depressive symptoms (Brown and Ryan, 2003; Cahn and Polich, 2006; Chiesa and Serretti, 2011).", [["anxiety", "DISEASE", 199, 206], ["depressive symptoms", "DISEASE", 212, 231], ["emotion management", "TREATMENT", 112, 130], ["perceived stress", "PROBLEM", 181, 197], ["anxiety", "PROBLEM", 199, 206], ["depressive symptoms", "PROBLEM", 212, 231]]], ["Generally, MBIs have shown a significant correlation with positive improvements in the following areas: attention, cognition, behavior and physiological processes which probably influence the functioning of the individual and their quality of life (Veltri et al., 2012; Jha et al., 2019; Marchi et al., 2019; Marazziti et al., 2020).IntroductionTang et al. (2018), in their review, have emphasized how mindfulness acts mainly on three systems, such as attentional control, emotional regulation and self-awareness.", [["attentional control", "TREATMENT", 452, 471]]], ["The authors also highlighted that mindfulness practice can produce changes in both density and volume in gray matter, finding the following areas involved in mindfulness meditation: various prefrontal regions, anterior cingulate cortex, medial prefrontal cortex, striatum, amygdala, insula, posterior cingulate cortex and precuneus.", [["gray matter", "ANATOMY", 105, 116], ["prefrontal regions", "ANATOMY", 190, 208], ["anterior cingulate cortex", "ANATOMY", 210, 235], ["medial prefrontal cortex", "ANATOMY", 237, 261], ["striatum", "ANATOMY", 263, 271], ["amygdala", "ANATOMY", 273, 281], ["insula", "ANATOMY", 283, 289], ["posterior cingulate cortex", "ANATOMY", 291, 317], ["precuneus", "ANATOMY", 322, 331], ["prefrontal regions", "MULTI-TISSUE_STRUCTURE", 190, 208], ["anterior cingulate cortex", "CANCER", 210, 235], ["medial prefrontal cortex", "CANCER", 237, 261], ["striatum", "MULTI-TISSUE_STRUCTURE", 263, 271], ["amygdala", "MULTI-TISSUE_STRUCTURE", 273, 281], ["insula", "MULTI-TISSUE_STRUCTURE", 283, 289], ["posterior cingulate cortex", "CANCER", 291, 317], ["precuneus", "MULTI-TISSUE_STRUCTURE", 322, 331], ["mindfulness practice", "TREATMENT", 34, 54], ["changes in both density and volume in gray matter", "PROBLEM", 67, 116], ["various prefrontal regions, anterior cingulate cortex, medial prefrontal cortex, striatum, amygdala, insula, posterior cingulate cortex and precuneus", "PROBLEM", 182, 331], ["both", "OBSERVATION_MODIFIER", 78, 82], ["density", "OBSERVATION", 83, 90], ["volume", "OBSERVATION_MODIFIER", 95, 101], ["gray matter", "OBSERVATION", 105, 116], ["prefrontal", "ANATOMY_MODIFIER", 190, 200], ["regions", "ANATOMY_MODIFIER", 201, 208], ["anterior", "ANATOMY_MODIFIER", 210, 218], ["cingulate", "ANATOMY_MODIFIER", 219, 228], ["cortex", "ANATOMY_MODIFIER", 229, 235], ["medial", "ANATOMY_MODIFIER", 237, 243], ["prefrontal", "ANATOMY_MODIFIER", 244, 254], ["cortex", "ANATOMY_MODIFIER", 255, 261], ["striatum", "ANATOMY_MODIFIER", 263, 271], ["amygdala", "ANATOMY", 273, 281], ["insula", "ANATOMY_MODIFIER", 283, 289], ["posterior", "ANATOMY_MODIFIER", 291, 300], ["cingulate cortex", "ANATOMY", 301, 317], ["precuneus", "ANATOMY_MODIFIER", 322, 331]]], ["Furthermore, the central effect that mindfulness practice plays on stress axes, together with plastic brain aspects elicited by practice and positive regulation of the immune system activity, may be conceptualized as the outcome of brain modification through mindfulness.", [["brain", "ANATOMY", 102, 107], ["immune system", "ANATOMY", 168, 181], ["brain", "ANATOMY", 232, 237], ["brain", "ORGAN", 102, 107], ["brain", "ORGAN", 232, 237], ["central effect", "OBSERVATION", 17, 31], ["brain", "ANATOMY", 232, 237], ["modification", "OBSERVATION", 238, 250]]], ["Furthermore, a recent review highlights how meditation can elicit a meta-functioning of awareness in those who practice, allowing an increased mind/body regulation system (Giannandrea et al., 2019).IntroductionIn particular, mindfulness training seems to increase three qualities of attention: (1) Attentional stability, meant to focus sustained attention without wandering.", [["body", "ANATOMY", 148, 152], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["an increased mind/body regulation system", "TREATMENT", 130, 170], ["IntroductionIn particular, mindfulness training", "TREATMENT", 198, 245]]], ["It is estimated that the human mind gets distracted for about half of the waking hours; mindfulness, both state and trait, is associated with a reduction in mental digressions, bringing the person back to focus on the present (Killingsworth and Gilbert, 2010; Smallwood and Schooler, 2015); (2) voluntary control of attention or selective attention, the ability to direct attention to a specific topic rather than another in an appropriate and voluntary manner (Wadlinger and Isaacowitz, 2011); (3) efficiency of attention, or an economic use of cognitive resources, involving less expenditure of cognitive activities for an attention performance on a specific task.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["person", "SPECIES", 190, 196], ["human", "SPECIES", 25, 30], ["mindfulness", "PROBLEM", 88, 99], ["a reduction in mental digressions", "PROBLEM", 142, 175], ["cognitive resources", "TREATMENT", 546, 565]]], ["Regarding neural networks (Menon and Uddin, 2010; Menon, 2011; Piccinni et al., 2012), several studies are investigating the effects of mindfulness on the default mode network (DMN), the neural processes underlying spontaneous thoughts and wandering mind.", [["neural networks", "ANATOMY", 10, 25], ["neural", "ANATOMY", 187, 193], ["neural networks", "MULTI-TISSUE_STRUCTURE", 10, 25], ["network", "MULTI-TISSUE_STRUCTURE", 168, 175], ["DMN", "MULTI-TISSUE_STRUCTURE", 177, 180], ["several studies", "TEST", 87, 102], ["spontaneous thoughts", "PROBLEM", 215, 235], ["spontaneous thoughts", "OBSERVATION", 215, 235]]], ["In psychopathology, the DMN is often found to be hyperactivated and hyperconnected (Whitfield-Gabrieli and Ford, 2012).", [["psychopathology", "DISEASE", 3, 18], ["psychopathology", "PROBLEM", 3, 18], ["hyperactivated", "PROBLEM", 49, 63], ["hyperactivated", "OBSERVATION", 49, 63]]], ["Research investigating expert mindfulness meditators engaging in simple breathing practice showed that activity in brain regions associated with the DMN was present during mind wandering, and in salience network (SN) areas during awareness of mind wandering, while regions of the executive network were active during shifting and sustained attention (Hasenkamp et al., 2012; Scheibner et al., 2017; Orr\u00f9 et al., 2020a,b), and the effects were modulated by lifetime meditation experience (Brewer et al., 2011; Hasenkamp and Barsalou, 2012).", [["brain", "ANATOMY", 115, 120], ["brain", "ORGAN", 115, 120], ["DMN", "MULTI-TISSUE_STRUCTURE", 149, 152], ["salience network", "MULTI-TISSUE_STRUCTURE", 195, 211], ["executive network", "MULTI-TISSUE_STRUCTURE", 280, 297], ["simple breathing practice", "TEST", 65, 90], ["activity in brain regions", "PROBLEM", 103, 128], ["active", "OBSERVATION_MODIFIER", 303, 309]]], ["Furthermore, research has shown that mindfulness training can lead to changes in the SN that regulates the switching between DMN and central executive network.", [["executive network", "MULTI-TISSUE_STRUCTURE", 141, 158], ["mindfulness training", "TREATMENT", 37, 57]]], ["Following mindfulness meditation, but not relaxation training, central regions of the SN, the left anterior cingulate cortex (ACC) and insula, showed improved cerebral blood flow (Tang et al., 2015).", [["SN", "ANATOMY", 86, 88], ["left anterior cingulate cortex", "ANATOMY", 94, 124], ["ACC", "ANATOMY", 126, 129], ["insula", "ANATOMY", 135, 141], ["cerebral", "ANATOMY", 159, 167], ["blood", "ANATOMY", 168, 173], ["SN", "MULTI-TISSUE_STRUCTURE", 86, 88], ["anterior cingulate cortex", "CANCER", 99, 124], ["ACC", "CANCER", 126, 129], ["insula", "CANCER", 135, 141], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 159, 173], ["mindfulness meditation", "TREATMENT", 10, 32], ["relaxation training", "TREATMENT", 42, 61], ["improved cerebral blood flow", "PROBLEM", 150, 178], ["central", "ANATOMY_MODIFIER", 63, 70], ["SN", "ANATOMY", 86, 88], ["left", "ANATOMY_MODIFIER", 94, 98], ["anterior", "ANATOMY_MODIFIER", 99, 107], ["cingulate cortex", "ANATOMY", 108, 124], ["insula", "ANATOMY_MODIFIER", 135, 141], ["improved", "OBSERVATION_MODIFIER", 150, 158], ["cerebral blood", "ANATOMY", 159, 173], ["flow", "OBSERVATION_MODIFIER", 174, 178]]], ["Similarly, loving-kindness meditators showed a deactivation of main nodes of the DMN (Brewer et al., 2011) and, after few weeks of compassion training, novice meditators showed significant reductions of mind wandering (Jazaieri et al., 2014).", [["reductions of mind wandering", "DISEASE", 189, 217], ["compassion training", "TREATMENT", 131, 150], ["novice meditators", "TEST", 152, 169], ["significant reductions of mind wandering", "PROBLEM", 177, 217], ["main", "OBSERVATION_MODIFIER", 63, 67], ["nodes", "OBSERVATION", 68, 73], ["significant", "OBSERVATION_MODIFIER", 177, 188], ["reductions", "OBSERVATION_MODIFIER", 189, 199]]], ["Taken together, these results suggest that though the focus of compassion meditation does not involve regulating attentional processes on a specific object, compassion training does have an impact on attentional processes involved in DMN.IntroductionMental training following a mindfulness-based program seems to increase cognitive abilities both as cognitive capacity and as cognitive flexibility.", [["DMN", "SIMPLE_CHEMICAL", 234, 237], ["compassion meditation", "TREATMENT", 63, 84], ["compassion training", "TREATMENT", 157, 176], ["attentional processes", "TREATMENT", 200, 221], ["IntroductionMental training", "TREATMENT", 238, 265]]], ["The first includes working memory and fluid intelligence, the second supports the adaptation of an individual using new answers and strategies.", [["fluid intelligence", "TEST", 38, 56]]], ["Mindfulness training is associated with an increased working memory capacity, cognitive flexibility and benefits on fluid intelligence (Roeser et al., 2013; Ruocco and Direkoglu, 2013; Jha et al., 2019).", [["Mindfulness training", "TREATMENT", 0, 20], ["an increased working memory capacity", "PROBLEM", 40, 76], ["fluid intelligence", "TEST", 116, 134], ["increased", "OBSERVATION_MODIFIER", 43, 52]]], ["It also promotes creative thinking and problem-solving skills (Colzato et al., 2012; Ostafin and Kassman, 2012; Raffone and Srinivasan, 2017).IntroductionMoreover, through mindfulness programs, participants may notice a different emotional regulation and functioning style; studies on the subject shows that mindfulness influences emotions both in terms of psychological reaction to emotion and tone or emotional value (positive or negative emotions).", [["participants", "SPECIES", 194, 206], ["Raffone", "TREATMENT", 112, 119], ["Srinivasan", "TREATMENT", 124, 134], ["a different emotional regulation and functioning style", "PROBLEM", 218, 272], ["psychological reaction", "PROBLEM", 357, 379], ["emotional value", "TEST", 403, 418]]], ["The increase in emotional regulation, or the set of processes and behavioral and cognitive strategies through which individuals influence their own emotional states following a mindfulness treatment, is related to an enhancement cognitive control mechanisms that refer to areas of the cortex prefrontal, such as the dorsolateral prefrontal cortex and prefrontal cortex ventromedial, and the anterior cingulate cortex, which act on the areas of the limbic system, used to process affective stimuli, such as the amygdala and the hippocampus (Chambers et al., 2009; Dell'Osso et al., 2012; H\u00f6lzel et al., 2013).IntroductionFurthermore, researchers found mindfulness training associated with a lower reactivity to stressful situations and negative emotional stimuli as it would increase the individual's ability to judge the situation more objectively and more emotionally of a positive value compared to those of a negative type (Farb et al., 2007; H\u00fclsheger et al., 2013).", [["cortex prefrontal", "ANATOMY", 285, 302], ["dorsolateral prefrontal cortex", "ANATOMY", 316, 346], ["prefrontal cortex ventromedial", "ANATOMY", 351, 381], ["anterior cingulate cortex", "ANATOMY", 391, 416], ["limbic system", "ANATOMY", 448, 461], ["amygdala", "ANATOMY", 510, 518], ["hippocampus", "ANATOMY", 527, 538], ["cortex prefrontal", "MULTI-TISSUE_STRUCTURE", 285, 302], ["dorsolateral prefrontal cortex", "CANCER", 316, 346], ["prefrontal cortex ventromedial", "CANCER", 351, 381], ["anterior cingulate cortex", "CANCER", 391, 416], ["limbic system", "ANATOMICAL_SYSTEM", 448, 461], ["amygdala", "MULTI-TISSUE_STRUCTURE", 510, 518], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 527, 538], ["The increase in emotional regulation", "PROBLEM", 0, 36], ["behavioral and cognitive strategies", "PROBLEM", 66, 101], ["a mindfulness treatment", "TREATMENT", 175, 198], ["an enhancement cognitive control mechanisms", "PROBLEM", 214, 257], ["affective stimuli", "TEST", 479, 496], ["mindfulness training", "TREATMENT", 651, 671], ["a lower reactivity to stressful situations", "PROBLEM", 688, 730], ["a positive value", "PROBLEM", 872, 888], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["cortex", "ANATOMY_MODIFIER", 285, 291], ["prefrontal", "ANATOMY_MODIFIER", 292, 302], ["dorsolateral", "ANATOMY_MODIFIER", 316, 328], ["prefrontal", "ANATOMY_MODIFIER", 329, 339], ["cortex", "ANATOMY_MODIFIER", 340, 346], ["prefrontal", "ANATOMY_MODIFIER", 351, 361], ["cortex", "ANATOMY_MODIFIER", 362, 368], ["ventromedial", "ANATOMY_MODIFIER", 369, 381], ["anterior", "ANATOMY_MODIFIER", 391, 399], ["cingulate", "ANATOMY_MODIFIER", 400, 409], ["cortex", "ANATOMY_MODIFIER", 410, 416], ["limbic system", "ANATOMY", 448, 461], ["amygdala", "ANATOMY", 510, 518], ["hippocampus", "ANATOMY", 527, 538]]], ["Mindfulness exercises are related to a lower activation of the hypothalamic-pituitary-adrenal axis and cortisol secretion, influencing the stress response and its regulation, leading to a greater brain neuroplasticity and slowing the brain aging process (Brewer et al., 2011; H\u00f6lzel et al., 2013; McEwen and Morrison, 2013; Creswell and Lindsay, 2014; Fox et al., 2014; Luders et al., 2015).IntroductionMore recently, some authors observed the importance of the ethical framework around mindfulness experiences.", [["brain", "ANATOMY", 196, 201], ["brain", "ANATOMY", 234, 239], ["cortisol", "CHEMICAL", 103, 111], ["cortisol", "CHEMICAL", 103, 111], ["pituitary", "ORGAN", 76, 85], ["adrenal", "ORGAN", 86, 93], ["cortisol", "GENE_OR_GENE_PRODUCT", 103, 111], ["brain", "ORGAN", 196, 201], ["brain", "ORGAN", 234, 239], ["Mindfulness exercises", "TREATMENT", 0, 21], ["cortisol secretion", "PROBLEM", 103, 121], ["the stress response", "PROBLEM", 135, 154], ["a greater brain neuroplasticity", "PROBLEM", 186, 217], ["slowing the brain aging process", "PROBLEM", 222, 253], ["pituitary", "ANATOMY", 76, 85], ["adrenal axis", "ANATOMY", 86, 98], ["brain", "ANATOMY", 196, 201], ["neuroplasticity", "OBSERVATION", 202, 217], ["brain", "ANATOMY", 234, 239]]], ["In fact, the changes reported by literature in MBI participants involve a meta-awareness and a different perspective of the self, probably influencing the processing of morally-relevant situations and stimuli thus encouraging moral action (Sevinc and Lazar, 2019).", [["MBI participants", "ORGANISM", 47, 63], ["participants", "SPECIES", 51, 63], ["a meta-awareness", "PROBLEM", 72, 88]]], ["However, HCPs often suffer from psychological distress and therefore experience a varied spectrum of symptoms related to this condition.", [["psychological distress", "DISEASE", 32, 54], ["psychological distress", "PROBLEM", 32, 54], ["a varied spectrum of symptoms", "PROBLEM", 80, 109], ["this condition", "PROBLEM", 121, 135]]], ["Specifically, a situation of psychological stress is able to elicit sleep disturbances (Palagini et al., 2016), cognitive problems, post-traumatic stress disorder (Marazziti et al., 2008; Mula et al., 2008) and also a burnout condition (Carmassi et al., 2016, 2017b, 2018; Moss, 2017; Conversano et al., 2020b).IntroductionThree types of meditation are typically included among \u201cmindfulness meditations\u201d in the West, namely focused attention, open monitoring (both attentional practices), and loving-kindness and compassion (both constructive practices) (Salzberg, 2011; Germer and Siegel, 2014).", [["sleep disturbances", "DISEASE", 68, 86], ["cognitive problems", "DISEASE", 112, 130], ["traumatic stress disorder", "DISEASE", 137, 162], ["psychological stress", "PROBLEM", 29, 49], ["sleep disturbances", "PROBLEM", 68, 86], ["cognitive problems", "PROBLEM", 112, 130], ["post-traumatic stress disorder", "PROBLEM", 132, 162], ["meditation", "TREATMENT", 338, 348], ["open monitoring", "TEST", 443, 458]]], ["Focused attention entails bringing your attention back, again and again, to the breath or another focal object; open monitoring (or choiceless awareness) involves noticing what is most salient and alive in your field of awareness, moment-to-moment; loving-kindness meditation entails intentionally cultivating happiness while compassion meditation is about cultivating goodwill in the face of suffering (Germer and Siegel, 2014).", [["another focal object", "PROBLEM", 90, 110], ["open monitoring", "TEST", 112, 127], ["focal", "OBSERVATION_MODIFIER", 98, 103]]], ["While attentional meditation practices (focused attention and open monitoring) require focusing on a focal object or on a component part of the self, like perception, emotion, cognition or intention, loving-kindness, and compassion meditation require the self as the object of practice (Olendzki, 2013; Germer and Siegel, 2014; Dahl et al., 2015).IntroductionIn particular, compassion is defined by Paul Gilbert, and the Buddhist monk Choden, as a sensitivity to suffering in self and others with a commitment to try to alleviate and prevent it (Gilbert, 2018), while self-compassion is defined by Kristin Neff as \u201cbeing open to and moved by one's own suffering, experiencing feelings of caring and kindness toward oneself, taking an understanding, non-judgmental attitude toward one's inadequacies and failures, and recognizing that one's experience is part of the common human experience\u201d (Neff, 2003).", [["human", "ORGANISM", 873, 878], ["human", "SPECIES", 873, 878], ["human", "SPECIES", 873, 878], ["attentional meditation practices", "TREATMENT", 6, 38], ["open monitoring)", "TREATMENT", 62, 78], ["a focal object", "PROBLEM", 99, 113], ["compassion meditation", "TREATMENT", 221, 242]]], ["Recent brain imaging research supports the notion of evaluating compassion as more emotionally engaging than mindfulness.", [["brain", "ANATOMY", 7, 12], ["brain", "ORGAN", 7, 12], ["Recent brain imaging", "TEST", 0, 20], ["brain", "ANATOMY", 7, 12]]], ["Compassion practice was found to activate regions of the positive affect system, such as the medial orbitofrontal cortex, nucleus accumbens and the ventral striatum (Klimecki et al., 2013, 2014; Engen and Singer, 2015).", [["medial orbitofrontal cortex", "ANATOMY", 93, 120], ["nucleus accumbens", "ANATOMY", 122, 139], ["ventral striatum", "ANATOMY", 148, 164], ["orbitofrontal cortex", "MULTI-TISSUE_STRUCTURE", 100, 120], ["nucleus accumbens", "MULTI-TISSUE_STRUCTURE", 122, 139], ["ventral striatum", "MULTI-TISSUE_STRUCTURE", 148, 164], ["the positive affect system", "PROBLEM", 53, 79], ["positive affect", "OBSERVATION", 57, 72], ["medial", "ANATOMY_MODIFIER", 93, 99], ["orbitofrontal cortex", "ANATOMY", 100, 120], ["nucleus", "ANATOMY_MODIFIER", 122, 129], ["accumbens", "ANATOMY_MODIFIER", 130, 139], ["ventral", "ANATOMY_MODIFIER", 148, 155], ["striatum", "ANATOMY", 156, 164]]], ["Specifically, Engen and Singer (2015) compared compassion meditation in response to cognitive reappraisal and showed that, in response to empathic distress, compassion meditation activated brain systems associated to positive emotion, while cognitive reappraisal recruited cognitive control regions and reduced activation of the negative affect system regions.", [["brain", "ANATOMY", 189, 194], ["empathic distress", "DISEASE", 138, 155], ["brain", "ORGAN", 189, 194], ["compassion meditation", "TREATMENT", 47, 68], ["cognitive reappraisal", "TEST", 84, 105], ["empathic distress", "PROBLEM", 138, 155], ["compassion meditation activated brain systems", "PROBLEM", 157, 202], ["positive emotion", "PROBLEM", 217, 233], ["cognitive reappraisal recruited cognitive control regions", "PROBLEM", 241, 298]]], ["Research also pointed out that mindfulness practitioners show reduced activation and structural changes of the amygdala (H\u00f6lzel et al., 2013; Taren et al., 2013, 2015).", [["amygdala", "ANATOMY", 111, 119], ["amygdala", "MULTI-TISSUE_STRUCTURE", 111, 119], ["reduced activation", "PROBLEM", 62, 80], ["reduced", "OBSERVATION_MODIFIER", 62, 69], ["activation", "OBSERVATION", 70, 80], ["amygdala", "ANATOMY", 111, 119]]], ["Overall, these results suggest that beneficial effects of mindfulness and compassion practices may act through different mechanisms: mindfulness reduces negative affect system's activity while compassion increases activity of positive emotion brain systems.IntroductionInterestingly, it has been shown that transcutaneous vagus nerve stimulation is able to modulate DMN in major depressive disorder (Fang et al., 2016) and that increased vagal activity was associated with higher compassion levels (Stellar et al., 2015).", [["brain", "ANATOMY", 243, 248], ["vagus nerve", "ANATOMY", 322, 333], ["depressive disorder", "DISEASE", 379, 398], ["brain", "ORGAN", 243, 248], ["vagus nerve", "MULTI-TISSUE_STRUCTURE", 322, 333], ["DMN", "SIMPLE_CHEMICAL", 366, 369], ["mindfulness and compassion practices", "TREATMENT", 58, 94], ["positive emotion brain systems", "PROBLEM", 226, 256], ["transcutaneous vagus nerve stimulation", "TREATMENT", 307, 345], ["major depressive disorder", "PROBLEM", 373, 398], ["increased vagal activity", "PROBLEM", 428, 452], ["higher compassion levels", "PROBLEM", 473, 497], ["vagus nerve", "ANATOMY", 322, 333], ["increased", "OBSERVATION_MODIFIER", 428, 437], ["vagal activity", "OBSERVATION", 438, 452]]], ["It has been shown that adopting a true compassionate disposition when viewing pictures of people suffering activated the mesolimbic dopamine pathway (ventral tegmental area and the ventral striatum) implicated in reward and bond formation (Kim et al., 2009).", [["ventral tegmental area", "ANATOMY", 150, 172], ["ventral striatum", "ANATOMY", 181, 197], ["dopamine", "CHEMICAL", 132, 140], ["dopamine", "CHEMICAL", 132, 140], ["people", "ORGANISM", 90, 96], ["dopamine", "SIMPLE_CHEMICAL", 132, 140], ["ventral tegmental area", "MULTI-TISSUE_STRUCTURE", 150, 172], ["ventral striatum", "MULTI-TISSUE_STRUCTURE", 181, 197], ["people", "SPECIES", 90, 96], ["the mesolimbic dopamine pathway", "TREATMENT", 117, 148], ["ventral", "ANATOMY_MODIFIER", 150, 157], ["tegmental", "ANATOMY_MODIFIER", 158, 167], ["ventral striatum", "ANATOMY", 181, 197]]], ["More recently, research showed that the septal nuclei, another area that is relevant for reward and prosocial motivation, was the unique region that was typically activated across empathy for pain, anxiety and happiness.", [["septal nuclei", "ANATOMY", 40, 53], ["pain", "DISEASE", 192, 196], ["anxiety", "DISEASE", 198, 205], ["septal nuclei", "TISSUE", 40, 53], ["the septal nuclei", "PROBLEM", 36, 53], ["pain", "PROBLEM", 192, 196], ["anxiety", "PROBLEM", 198, 205], ["happiness", "PROBLEM", 210, 219], ["septal nuclei", "ANATOMY", 40, 53]]], ["Septal activation in course of these empathic experiences was predictive of helping (Morelli et al., 2014).", [["Septal activation", "PROBLEM", 0, 17], ["activation", "OBSERVATION", 7, 17], ["course", "OBSERVATION_MODIFIER", 21, 27]]], ["Remarkably, it was recently shown that optogenetic activation of gut-innervating vagal sensory neurons, namely the dorsolateral parabrachial-nigral projections, mimicked the rewarding effects of right vagus excitation and identifies dorsolateral parabrachial region as the mandatory retransmission region linking the right vagal sensory ganglion to dopamine cells in substantia nigra (Han et al., 2018).IntroductionInterestingly, studies investigating compassion are consistent with those emerging from research on the neurobiology of the parental brain.", [["gut", "ANATOMY", 65, 68], ["vagal sensory neurons", "ANATOMY", 81, 102], ["dorsolateral parabrachial-nigral projections", "ANATOMY", 115, 159], ["right vagus", "ANATOMY", 195, 206], ["dorsolateral parabrachial region", "ANATOMY", 233, 265], ["right vagal sensory ganglion", "ANATOMY", 317, 345], ["dopamine cells", "ANATOMY", 349, 363], ["substantia nigra", "ANATOMY", 367, 383], ["brain", "ANATOMY", 548, 553], ["dopamine", "CHEMICAL", 349, 357], ["dopamine", "CHEMICAL", 349, 357], ["gut", "ORGANISM_SUBDIVISION", 65, 68], ["vagal sensory neurons", "CELL", 81, 102], ["vagus", "ORGAN", 201, 206], ["dorsolateral parabrachial", "MULTI-TISSUE_STRUCTURE", 233, 258], ["ganglion", "TISSUE", 337, 345], ["dopamine cells", "CELL", 349, 363], ["substantia nigra", "ORGANISM", 367, 383], ["brain", "ORGAN", 548, 553], ["innervating vagal sensory neurons", "CELL_TYPE", 69, 102], ["dopamine cells", "CELL_TYPE", 349, 363], ["right vagus excitation", "TREATMENT", 195, 217], ["right", "ANATOMY_MODIFIER", 195, 200], ["vagus excitation", "OBSERVATION", 201, 217], ["dorsolateral", "ANATOMY_MODIFIER", 233, 245], ["parabrachial", "ANATOMY_MODIFIER", 246, 258], ["region", "ANATOMY_MODIFIER", 259, 265], ["right", "ANATOMY_MODIFIER", 317, 322], ["vagal", "ANATOMY_MODIFIER", 323, 328], ["sensory ganglion", "ANATOMY", 329, 345], ["dopamine cells", "OBSERVATION", 349, 363], ["consistent with", "UNCERTAINTY", 467, 482], ["parental", "ANATOMY_MODIFIER", 539, 547], ["brain", "ANATOMY", 548, 553]]], ["It has long been observed in animal models that both the septal nuclei and the mesolimbic dopamine pathway are implicated in motivating proactive offspring nurture (Champagne et al., 2001).", [["septal nuclei", "ANATOMY", 57, 70], ["dopamine", "CHEMICAL", 90, 98], ["dopamine", "CHEMICAL", 90, 98], ["septal nuclei", "MULTI-TISSUE_STRUCTURE", 57, 70], ["dopamine", "SIMPLE_CHEMICAL", 90, 98], ["the mesolimbic dopamine pathway", "TREATMENT", 75, 106], ["septal nuclei", "ANATOMY", 57, 70], ["mesolimbic dopamine", "OBSERVATION", 79, 98]]], ["Specifically, ventral tegmental area dopaminergic neurons projecting to the nucleus accumbens motivate caregiving (Numan and Stolzenberg, 2009).", [["ventral tegmental area dopaminergic neurons", "ANATOMY", 14, 57], ["nucleus accumbens", "ANATOMY", 76, 93], ["ventral tegmental area dopaminergic neurons", "CELL", 14, 57], ["nucleus accumbens", "MULTI-TISSUE_STRUCTURE", 76, 93], ["dopaminergic neurons", "CELL_TYPE", 37, 57], ["ventral tegmental area dopaminergic neurons", "PROBLEM", 14, 57], ["ventral", "ANATOMY_MODIFIER", 14, 21], ["tegmental", "ANATOMY_MODIFIER", 22, 31], ["nucleus accumbens", "ANATOMY", 76, 93]]], ["Recent neuroimaging evidence suggests that this system may support human parental motivation to nurture their toddlers (Mascaro et al., 2013; Rilling, 2013), increasing the probability that this system underpins the motivational quality of compassion (Preston and Hofelich, 2012) and that compassion coopts the systems that evolved for maternal attachment (Preston and de Waal, 2001).IntroductionWhile it is very important that health care professionals (HCPs) continue to work with empathy and compassion, since compassionate motivation may impinge on the same circuits of maternal attachment, there may be a cost to this work that is also closely related to past maternal experience of HCPs.", [["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Recent neuroimaging", "TEST", 0, 19]]], ["The concept of compassion fatigue first emerged with the work of Charles Figley, who defined it as \u201cthe formal caregiver's reduced capacity or interest in being empathic or \u2018bearing the suffering of clients\u2019 and is \u2018the natural consequent behaviors and emotions resulting from knowing about a traumatizing event experienced or suffered by a person\u2019\u201d (Figley, 1995, 2002; Di Giuseppe et al., 2018).", [["compassion fatigue", "DISEASE", 15, 33], ["person", "SPECIES", 341, 347], ["compassion fatigue", "PROBLEM", 15, 33], ["reduced capacity", "PROBLEM", 123, 139]]], ["Compassion fatigue can be defined as secondary traumatic stress resulting from knowing about a traumatizing event experienced by a significant traumatized or suffering person (Figley, 1995, 2002).", [["fatigue", "DISEASE", 11, 18], ["person", "SPECIES", 168, 174], ["Compassion fatigue", "PROBLEM", 0, 18], ["secondary traumatic stress", "PROBLEM", 37, 63], ["a traumatizing event", "PROBLEM", 93, 113], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["traumatized", "OBSERVATION", 143, 154]]], ["Prevalence of compassion fatigue has been reported to range as 7.3 to 40%, while the prevalence of secondary traumatic stress has been reported to range from 0 to 38.5% in intensive care units (Mol et al., 2015).", [["compassion fatigue", "DISEASE", 14, 32], ["traumatic stress", "DISEASE", 109, 125], ["compassion fatigue", "PROBLEM", 14, 32], ["secondary traumatic stress", "PROBLEM", 99, 125], ["traumatic stress", "OBSERVATION", 109, 125]]], ["Compassion fatigue often is assumed to accompany another version of fatigue known as burnout.", [["fatigue", "DISEASE", 11, 18], ["fatigue", "DISEASE", 68, 75], ["burnout", "DISEASE", 85, 92], ["Compassion fatigue", "PROBLEM", 0, 18], ["fatigue", "PROBLEM", 68, 75]]], ["Specifically, hard workloads, lack of recognition for achievements, and social disconnection from the team can result in burnout, suggesting the need to reduce the hours supporting the patient for formal (Amankwaa, 2017; Mattioli et al., 2018; Castellanos et al., 2019; Allday et al., 2020) as well informal (Peetoom et al., 2016; Lethin et al., 2017; Hampton and Newcomb, 2018; Wood et al., 2018) caregivers.", [["burnout", "DISEASE", 121, 128], ["patient", "ORGANISM", 185, 192], ["patient", "SPECIES", 185, 192]]], ["Gustin and Wagner (2013) found that developing a compassionate self and the aptitude to be sensitive, non-judgmental and regardful toward oneself promotes a compassionate approach toward others.", [["Gustin", "CHEMICAL", 0, 6]]], ["Thus, developing self-compassion may be an important hindering factor of compassion fatigue and promotion of compassionate care (Neff, 2009) and mindfulness and self-compassion may be appropriate target variables to alleviate work-related stress and promote compassionate caregiving in HCPs.IntroductionThe aim of the present systematic review was to give an overview on recent literature about mindfulness, compassion and self-compassion characteristics and to investigate the effectiveness of techniques involving MBSR or mindfulness-related interventions and/or compassion- or self-compassion-related programs, to identify the interventions with the best level of evidence available to prevent, or mitigate, HCPs' burnout and to improve their levels of mindfulness and/or compassion- or self-compassion, emotional regulation, quality of life and well-being.Search Strategy ::: MethodsSearches were conducted using PubMed and PsycInfo databases.", [["fatigue", "DISEASE", 84, 91], ["burnout", "DISEASE", 717, 724], ["compassion fatigue", "PROBLEM", 73, 91], ["MBSR or mindfulness", "TREATMENT", 516, 535]]], ["PubMed and PsycInfo databases were searched by three independent reviewers (CC, RC, and AP) using a combination of the keywords \u201cHealth Personnel,\u201d \u201cMindfulness,\u201d \u201cSelf-Compassion,\u201d \u201cMBSR,\u201d using the Boolean operators AND/OR.Study Selection ::: MethodsThe selection of studies is shown in Figure 1, using the PRISMA flow diagram (Liberati et al., 2009; Moher et al., 2009).", [["Methods", "TREATMENT", 245, 252], ["The selection of studies", "TEST", 252, 276], ["the PRISMA flow diagram", "TEST", 305, 328]]], ["We removed duplicates and corrigenda (383) and then selected the articles which presented at least one or both mindfulness and compassion component and a healthcare unit/personnel/professional in title or abstract and removed those considered ineligible.", [["both", "OBSERVATION_MODIFIER", 106, 110], ["mindfulness", "OBSERVATION", 111, 122]]], ["Ninety-four full-text articles were retrieved and read in full by three reviewers (CC, RC, and AP) and divided by type and study design and, finally, we excluded descriptive, single case and post intervention studies and reviews.", [["post intervention studies", "TEST", 191, 216]]], ["Qualitative studies are included.", [["Qualitative studies", "TEST", 0, 19]]], ["Studies that did not report measures of mindfulness and self-compassion were excluded.", [["Studies", "TEST", 0, 7]]], ["A total of 58 studies were included in the review (Table 1).Eligibility Criteria ::: MethodsAll studies included in our review examined the effect of MBSR, MBIs (interventions including predominantly mindfulness elements; Spinelli et al., 2019); and compassion-based interventions (CBIs, interventions including predominantly compassion elements; Kirby, 2017); on mindfulness and self-compassion qualities of HCPs.", [["Methods", "TREATMENT", 85, 92], ["All studies", "TEST", 92, 103], ["MBSR", "PROBLEM", 150, 154], ["MBIs (interventions", "TREATMENT", 156, 175], ["interventions", "TREATMENT", 288, 301]]], ["Interventions using yoga, or other meditative practices, and MBIs that used the key therapeutic approaches, such as body scan meditations or acceptance or non-judgmental strategies, were included.Data Extraction ::: MethodsAt an earlier stage, titles and abstracts were screened for eligibility by one reviewer (CC) to characterize abstracts as highly relevant, potentially relevant, or not relevant.", [["body", "ANATOMY", 116, 120], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["yoga", "TREATMENT", 20, 24], ["body scan meditations", "TEST", 116, 137], ["non-judgmental strategies", "TREATMENT", 155, 180]]], ["Studies that were considered ambiguous, with respect to the inclusion criteria, were discussed, and consensus was reached for all articles included.Data Extraction ::: MethodsThe following data was extracted from each eligible study report by RC and verified by CC, GO, AG, or AP: first author name, title, publication date, aim and design, key sample characteristics (including age, gender, and healthcare profession), type of intervention, comparison, main outcome measures, and results.Quality Assessment ::: MethodsThe appraisal of the methodological quality for this systematic review was based on AMSTAR-2 (A MeaSurement Tool to Assess systematic Reviews-2) (Shea et al., 2017) approach.", [["CC", "CHEMICAL", 262, 264], ["Studies", "TEST", 0, 7], ["Methods", "TREATMENT", 168, 175], ["intervention", "TREATMENT", 428, 440], ["Methods", "TREATMENT", 512, 519], ["AMSTAR", "TEST", 603, 609]]], ["It enables a more detailed assessment of systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both.", [["a more detailed assessment", "TEST", 11, 37], ["systematic reviews", "TEST", 41, 59], ["non-randomized studies", "TEST", 87, 109], ["healthcare interventions", "TREATMENT", 113, 137]]], ["Two independent raters assessed each study (CC and RC), and seven discrepancies were found regarding AMSTAR-2 checklist coding.", [["each study", "TEST", 32, 42], ["AMSTAR", "TEST", 101, 107]]], ["Then, a discussion took place to resolve divergences, consulting a third rater (AP), if necessary, until consensus was reached.Analysis ::: MethodsAfter examination of included articles, meta-analysis was not considered suitable as there were insufficient studies with the required level of homogeneity regarding MBIs, CBIs, outcome measures, and the timing of these measures.", [["MethodsAfter examination", "TEST", 140, 164], ["meta-analysis", "TEST", 187, 200], ["MBIs", "TEST", 313, 317], ["CBIs", "TREATMENT", 319, 323], ["outcome measures", "TREATMENT", 325, 341], ["these measures", "TREATMENT", 361, 375]]], ["Therefore, the findings are summarized using a narrative, but systematic, approach.Qualitative Studies ::: ResultsWith regard to mindfulness interventions, Ripp et al. (2017) highlight its importance in the fight against burnout in graduate medical trainees together with \u201cresilience training, stress and self-care management workshops, communication skills training, narrative medicine, reflection opportunities and peer support grounded in group discussions.\u201dQualitative Studies ::: ResultsHunter et al. (2018) conducted a qualitative study through an interpretative phenomenological analysis of semi-structured interviews.", [["burnout", "DISEASE", 221, 228], ["Qualitative Studies", "TEST", 83, 102], ["mindfulness interventions", "TREATMENT", 129, 154], ["resilience training", "TREATMENT", 273, 292], ["stress and self-care management", "TREATMENT", 294, 325], ["communication skills training", "TREATMENT", 337, 366], ["narrative medicine", "TREATMENT", 368, 386], ["a qualitative study", "TEST", 523, 542]]], ["The measures were operated on midwives after a MBI, either at or outside workplace.", [["a MBI", "TEST", 45, 50]]], ["Nine midwives selected to take part in the study, and the findings were divided in four superordinate themes: being challenged and committing, containing the self, reconnecting and moving forward with confidence.", [["the study", "TEST", 39, 48]]], ["Results showed that, despite an initial and normal skepticism about mindfulness practice, those that committed to the concept of living in the present moment benefitted from an increased self-awareness of self which presumably leads to both an increase of positive workplace relationships and individualized and relation patient care.Qualitative Studies ::: ResultsThe research trio of McPherson et al. (2016) conducted a study to explore the experiences of managing work pressures of staff caring for older adults with dementia through compassion and mindfulness skills.", [["dementia", "DISEASE", 520, 528], ["patient", "ORGANISM", 321, 328], ["patient", "SPECIES", 321, 328], ["a study", "TEST", 420, 427], ["dementia", "PROBLEM", 520, 528], ["increase", "OBSERVATION_MODIFIER", 244, 252]]], ["The interviewer used a constructivist grounded theory approach which is guided by participants themselves, finding two main types of work-related pressure (structural or interpersonal) and two different types of responses (helpful and unhelpful).", [["participants", "SPECIES", 82, 94], ["a constructivist grounded theory approach", "TREATMENT", 21, 62]]], ["The authors also found some barriers to the full experience of the self-compassionate and mindful state, which leads to their suggestion of increasing structured mindfulness interventions in HCPs.Qualitative Studies ::: ResultsPlatt et al. (2015) wrote a qualitative paper about a workshop which was planned for general practitioners, comprehending stress management sessions, art or puppetry and mindfulness sessions.", [["stress management sessions", "TREATMENT", 349, 375], ["mindfulness sessions", "TREATMENT", 397, 417]]], ["This workshop's aim was to help the participants develop a better self-awareness when facing stress situations and identify different ways to manage the stress response.", [["participants", "SPECIES", 36, 48], ["stress situations", "PROBLEM", 93, 110], ["the stress response", "PROBLEM", 149, 168]]], ["The 25 participants were interviewed during the workshop and 2 months after it (by an online survey), for feedback.", [["participants", "ORGANISM", 7, 19], ["participants", "SPECIES", 7, 19]]], ["Results showed that this kind of intervention was well-received, with immediate to medium-term impact on the individual.Qualitative Studies ::: ResultsLyddy et al. (2016) explored how health professionals, which had previously followed a mindfulness-based course, and use and perceive mindfulness practice during their work.", [["intervention", "TREATMENT", 33, 45]]], ["The measurement was carried out through a semi-structured guide with open-ended questions, also including questions about role and recent prototypical job experiences.", [["The measurement", "TEST", 0, 15]]], ["Their results highlight that participants varied in the subsequent adoption of mindfulness exercises, often struggling with the formal meditation practice routine and using the informal practice models taught during the course.", [["participants", "SPECIES", 29, 41], ["mindfulness exercises", "TREATMENT", 79, 100]]], ["The authors suggested that mindfulness training in hospitals should include practice in the actual workplace to increase realism and integration of practice on a daily basis and practice in identifying the value of mindfulness at work through guided experimentations.Qualitative Studies ::: ResultsIn their interesting work, Valley and Stallones (2018) also aimed at confirming the role of mindfulness interventions in the development of self-awareness, using the Health Belief Model (HBM) to help explain and predict the adoption of a variety of preventive and treatment health behaviors.", [["mindfulness training", "TREATMENT", 27, 47], ["mindfulness interventions", "TREATMENT", 390, 415]]], ["In their research of what is needed to improve mindfulness interventions in health care workers, they found that adapting the course timing and materials to meet the HCPs' schedule and a didactic material which explains the evidence of those interventions should be provided to the participant in order to increase the participation and adherence to the courses.Qualitative Studies ::: ResultsLooking at the issue from the opposite point of view, Powell et al. (2018) have raised the question of what makes some health professionals more protected from the risk of burnout than others.", [["burnout", "DISEASE", 565, 572], ["mindfulness interventions", "TREATMENT", 47, 72], ["a didactic material", "TREATMENT", 185, 204], ["those interventions", "TREATMENT", 236, 255]]], ["Although only 32 of those staff members replied to the survey, we can highlight that the findings included meditation, mindfulness, exercise, nature and animals, family and friends as activities indicated by the participants which could lead to some sort of balance during work.Randomized Controlled Trials ::: ResultsShapiro et al. (2005) conducted a RCT on the effectiveness of MBSR training in a population of HCPs, directly involved in clinical work, in particular measuring the stress and distress response and job burnout.", [["burnout", "DISEASE", 520, 527], ["participants", "SPECIES", 212, 224], ["MBSR training", "TREATMENT", 380, 393], ["distress response", "PROBLEM", 494, 511]]], ["For the MBSR participants, lower stress level and higher self-compassion was reported, with a reduction of job burnout.", [["burnout", "DISEASE", 111, 118], ["participants", "SPECIES", 13, 25], ["lower stress level", "PROBLEM", 27, 45]]], ["Unfortunately, these results didn't differ significantly from the control group, contrary to their qualitative data.Randomized Controlled Trials ::: ResultsAmutio et al. (2015) tested both acceptability and effectiveness of an MBSR with a maintenance phase (8 week traditional intervention plus 10 month of maintenance) with the aim to alleviate work-stress related symptoms such as burnout and blood pressure levels.", [["blood", "ANATOMY", 395, 400], ["burnout", "DISEASE", 383, 390], ["blood", "ORGANISM_SUBSTANCE", 395, 400], ["a maintenance phase", "TREATMENT", 237, 256], ["traditional intervention", "TREATMENT", 265, 289], ["stress related symptoms", "PROBLEM", 351, 374], ["burnout and blood pressure levels", "TEST", 383, 416]]], ["Their findings showed decreased burnout (especially emotional exhaustion subscale), blood pressure and heart rate, which were still decreasing after 10 months from the MBSR programme.", [["blood", "ANATOMY", 84, 89], ["heart", "ANATOMY", 103, 108], ["decreased burnout", "DISEASE", 22, 39], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["heart", "ORGAN", 103, 108], ["decreased burnout", "PROBLEM", 22, 39], ["blood pressure", "TEST", 84, 98], ["heart rate", "TEST", 103, 113], ["the MBSR programme", "TREATMENT", 164, 182], ["decreased", "OBSERVATION_MODIFIER", 22, 31], ["burnout", "OBSERVATION", 32, 39], ["heart", "ANATOMY", 103, 108], ["rate", "OBSERVATION_MODIFIER", 109, 113], ["decreasing", "OBSERVATION_MODIFIER", 132, 142]]], ["Similarly, Ireland et al. (2017) tested the effectiveness of a mixed mindfulness intervention in reducing stress and burnout among doctors assigned to an emergency department rotation programme.", [["burnout", "DISEASE", 117, 124], ["a mixed mindfulness intervention", "TREATMENT", 61, 93]]], ["Also, their findings suggested a decreased stress and burnout of the participants, to a greater extend that an assigned extra break hour for 10 weeks.Randomized Controlled Trials ::: ResultsFinally, Valley and Stallones (2017) RCT study examined the impact of mindfulness training on occupational safety of hospital HCPs, through an MBSR intervention, measuring safety outcomes (compliance and participation).", [["participants", "SPECIES", 69, 81], ["a decreased stress", "PROBLEM", 31, 49], ["RCT study", "TEST", 227, 236], ["mindfulness training", "TREATMENT", 260, 280], ["an MBSR intervention", "TREATMENT", 330, 350], ["decreased", "OBSERVATION_MODIFIER", 33, 42]]], ["Their results indicated that mindfulness was able to stably decrease workplace cognitive failures while increasing the following of safety rules, collaboration, and safety compliance behaviors.", [["cognitive failures", "PROBLEM", 79, 97]]], ["The authors highlight the importance of these findings which could impact the degree of occupational injuries.Understanding the Link Between Compassion Fatigue and Compassion Satisfaction, Bereavement Overload, Burnout, and Violence ::: Cross-Sectional Studies ::: ResultsWijdenes et al. (2019) conducted a research with the aim of exploring the prevalence and severity of compassion fatigue risk among nurses and to ascertain the differences in demographic characteristics among the participants correlating with the abovementioned risk.", [["injuries", "DISEASE", 101, 109], ["Fatigue", "DISEASE", 152, 159], ["Burnout", "DISEASE", 211, 218], ["Violence", "DISEASE", 224, 232], ["fatigue", "DISEASE", 384, 391], ["participants", "SPECIES", 484, 496], ["occupational injuries", "PROBLEM", 88, 109], ["Compassion Fatigue", "PROBLEM", 141, 159], ["Bereavement Overload", "PROBLEM", 189, 209], ["compassion fatigue", "PROBLEM", 373, 391], ["occupational injuries", "OBSERVATION", 88, 109]]], ["Their measures included the Professional Quality of Life version 5 (ProQOL-5) (Stamm, 2009) and their findings were that nearly half of the sample was at risk for moderate to high compassion fatigue.", [["fatigue", "DISEASE", 191, 198], ["Life version", "TREATMENT", 52, 64], ["moderate to high compassion fatigue", "PROBLEM", 163, 198]]], ["Moreover, nurses' unit was significantly associated with compassion satisfaction while time and experience in service were not protective factors for compassion fatigue.", [["fatigue", "DISEASE", 161, 168], ["compassion fatigue", "PROBLEM", 150, 168]]], ["Lastly, secondary traumatic stress, burnout and compassion satisfaction were significantly correlated.Understanding the Link Between Compassion Fatigue and Compassion Satisfaction, Bereavement Overload, Burnout, and Violence ::: Cross-Sectional Studies ::: ResultsAl-Majid et al. (2018) assessed the degree of compassion satisfaction and compassion fatigue in both care and charge nurses of care units.", [["burnout", "DISEASE", 36, 43], ["Fatigue", "DISEASE", 144, 151], ["Burnout", "DISEASE", 203, 210], ["Violence", "DISEASE", 216, 224], ["fatigue", "DISEASE", 349, 356], ["secondary traumatic stress", "PROBLEM", 8, 34], ["burnout and compassion satisfaction", "PROBLEM", 36, 71], ["Compassion Fatigue", "PROBLEM", 133, 151], ["Bereavement Overload", "PROBLEM", 181, 201], ["ResultsAl", "TEST", 257, 266], ["compassion satisfaction", "PROBLEM", 310, 333], ["compassion fatigue", "PROBLEM", 338, 356], ["secondary", "OBSERVATION_MODIFIER", 8, 17], ["traumatic", "OBSERVATION_MODIFIER", 18, 27], ["stress", "OBSERVATION", 28, 34]]], ["The measurement was conducted through the ProQOL-5, leading to an average overall result concerning compassion variables with significantly lower compassion satisfaction in less experienced nurses (<10 years of work), while other scales such as secondary traumatic stress showed high levels among charge nurses.Understanding the Link Between Compassion Fatigue and Compassion Satisfaction, Bereavement Overload, Burnout, and Violence ::: Cross-Sectional Studies ::: ResultsLikewise, Roney and Acri (2018) investigated pediatric nurses' levels of compassion satisfaction, compassion fatigue, and job satisfaction while considering any correlations among the constructs, using the ProQOL-5.", [["Fatigue", "DISEASE", 353, 360], ["Burnout", "DISEASE", 412, 419], ["fatigue", "DISEASE", 582, 589], ["The measurement", "TEST", 0, 15], ["secondary traumatic stress", "PROBLEM", 245, 271], ["Compassion Fatigue", "PROBLEM", 342, 360], ["Bereavement Overload", "PROBLEM", 390, 410], ["compassion fatigue", "PROBLEM", 571, 589], ["the ProQOL", "TREATMENT", 675, 685]]], ["Their results found participants with higher than the norm levels of compassion satisfaction and slightly lower than the norm levels of secondary trauma and burnout, highlighting an interesting significant relationship between female gender and the compassion satisfaction subscale.Understanding the Link Between Compassion Fatigue and Compassion Satisfaction, Bereavement Overload, Burnout, and Violence ::: Cross-Sectional Studies ::: ResultsAllie et al. (2018) focused their cross-sectional analytic study on HCPs' bereavement overload, defined as a situation where an individual must deal with loss or death in a continuous and close way with the unfortunate result of an abnormal adjustment process.", [["trauma", "DISEASE", 146, 152], ["burnout", "DISEASE", 157, 164], ["Fatigue", "DISEASE", 324, 331], ["Burnout", "DISEASE", 383, 390], ["Violence", "DISEASE", 396, 404], ["bereavement overload", "DISEASE", 518, 538], ["death", "DISEASE", 606, 611], ["participants", "SPECIES", 20, 32], ["secondary trauma", "PROBLEM", 136, 152], ["burnout", "PROBLEM", 157, 164], ["Compassion Fatigue", "PROBLEM", 313, 331], ["Bereavement Overload", "PROBLEM", 361, 381], ["bereavement overload", "PROBLEM", 518, 538], ["loss or death", "PROBLEM", 598, 611], ["an abnormal adjustment process", "PROBLEM", 673, 703], ["slightly", "OBSERVATION_MODIFIER", 97, 105], ["lower", "OBSERVATION_MODIFIER", 106, 111], ["abnormal", "OBSERVATION_MODIFIER", 676, 684], ["adjustment", "OBSERVATION", 685, 695]]], ["Their study investigated through an interviewer-administered questionnaire various quantitative variable such as bereavement overload, compassion fatigue and coping mechanisms.", [["bereavement overload", "DISEASE", 113, 133], ["fatigue", "DISEASE", 146, 153], ["Their study", "TEST", 0, 11], ["bereavement overload", "PROBLEM", 113, 133], ["compassion fatigue", "PROBLEM", 135, 153], ["coping mechanisms", "PROBLEM", 158, 175]]], ["Findings showed that half of the participants reported a suffering from bereavement overload, of which three quarters reported compassion fatigue (especially doctors and final-year medical students).", [["bereavement overload", "DISEASE", 72, 92], ["fatigue", "DISEASE", 138, 145], ["participants", "ORGANISM", 33, 45], ["participants", "SPECIES", 33, 45], ["bereavement overload", "PROBLEM", 72, 92], ["compassion fatigue", "PROBLEM", 127, 145]]], ["Interestingly, also half of the health providers which didn't show bereavement overload, suffered from compassion fatigue.", [["bereavement overload", "DISEASE", 67, 87], ["fatigue", "DISEASE", 114, 121], ["bereavement overload", "PROBLEM", 67, 87], ["compassion fatigue", "PROBLEM", 103, 121]]], ["The authors have deduced that while compassion fatigue may be an effect of bereavement overload it could lead to dysfunctional coping mechanisms such as emotional detachment.Understanding the Link Between Compassion Fatigue and Compassion Satisfaction, Bereavement Overload, Burnout, and Violence ::: Cross-Sectional Studies ::: ResultsCopeland and Henry (2018) designed a cross-sectional study to survey emergency department staff members with the purpose of examining the relationship between exposure to workplace violence (physical and psychological) and compassion fatigue or satisfaction through the Professional Quality of Life model.", [["fatigue", "DISEASE", 47, 54], ["emotional detachment", "DISEASE", 153, 173], ["Fatigue", "DISEASE", 216, 223], ["Burnout", "DISEASE", 275, 282], ["Violence", "DISEASE", 288, 296], ["workplace violence", "DISEASE", 507, 525], ["fatigue", "DISEASE", 570, 577], ["compassion fatigue", "PROBLEM", 36, 54], ["bereavement overload", "PROBLEM", 75, 95], ["dysfunctional coping mechanisms", "PROBLEM", 113, 144], ["emotional detachment", "PROBLEM", 153, 173], ["Compassion Fatigue", "PROBLEM", 205, 223], ["Bereavement Overload", "PROBLEM", 253, 273], ["compassion fatigue", "PROBLEM", 559, 577], ["detachment", "OBSERVATION", 163, 173]]], ["The findings of this study showed that all three of the ProQOL dimensions were significantly associated with exposure to violence, particularly with patient threats, name calling, sexual innuendo and threats of lawsuit.", [["violence", "DISEASE", 121, 129], ["patient", "ORGANISM", 149, 156], ["patient", "SPECIES", 149, 156], ["this study", "TEST", 16, 26]]], ["Furthermore, as the study described above (Al-Majid et al., 2018), also from their findings the most experienced nurses in the sample reported higher compassion satisfaction, lower burnout and secondary traumatic stress, than those with less experience.Understanding the Link Between Compassion Fatigue and Compassion Satisfaction, Bereavement Overload, Burnout, and Violence ::: Cross-Sectional Studies ::: ResultsMoreover, with the intention of observing the relationship between burnout, self-esteem and compassion, Erkorkmaz et al. (2018) conducted an analytical cross-sectional study on nurses, finding that burnout was affecting both compassion satisfaction and personal accomplishment (subscale of the Maslach Burnout Inventory) (Maslach et al., 1997) negatively.Understanding the Link Between Compassion Fatigue and Compassion Satisfaction, Bereavement Overload, Burnout, and Violence ::: Cross-Sectional Studies ::: ResultsUsing the Self-Compassion Scale (SCS)-Short Form (Raes et al., 2011) and the Barriers to Physician Compassion Questionnaire (Fernando and Consedine, 2014).", [["burnout", "DISEASE", 181, 188], ["Fatigue", "DISEASE", 295, 302], ["Burnout", "DISEASE", 354, 361], ["Violence", "DISEASE", 367, 375], ["burnout", "DISEASE", 482, 489], ["burnout", "DISEASE", 613, 620], ["Fatigue", "DISEASE", 812, 819], ["Burnout", "DISEASE", 871, 878], ["Violence", "DISEASE", 884, 892], ["the study", "TEST", 16, 25], ["lower burnout", "PROBLEM", 175, 188], ["secondary traumatic stress", "PROBLEM", 193, 219], ["Compassion Fatigue", "PROBLEM", 284, 302], ["Bereavement Overload", "PROBLEM", 332, 352], ["Compassion Fatigue", "PROBLEM", 801, 819], ["Bereavement Overload", "PROBLEM", 849, 869], ["secondary", "OBSERVATION_MODIFIER", 193, 202], ["traumatic stress", "OBSERVATION", 203, 219]]], ["Dev et al. (2018) evaluated the associations between burnout and barriers to compassion in a large sample of nurses.", [["burnout", "DISEASE", 53, 60]]], ["Their findings showed the expected association in which higher levels of burnout predicted greater barriers to compassion while higher levels of trait self-compassion were associated with lower burnout and predicted lower barriers to compassion.About Mindfulness and Compassion Fatigue Correlation ::: Cross-Sectional Studies ::: ResultsBrown et al. (2017) explored the association between compassion fatigue and mindfulness in mental health professionals, considered that the purpose of the study was to explore whether there is an inverse relationship between the two variables, measured by the Five Facet Mindfulness Questionnaire (FFMQ) (Baer et al., 2008) and the ProQOL-5.", [["burnout", "DISEASE", 73, 80], ["burnout", "DISEASE", 194, 201], ["Fatigue", "DISEASE", 278, 285], ["compassion fatigue", "DISEASE", 390, 408], ["lower burnout", "PROBLEM", 188, 201], ["compassion fatigue", "PROBLEM", 390, 408], ["the study", "TEST", 488, 497], ["the ProQOL", "TREATMENT", 665, 675]]], ["The results showed a moderate, negative correlation between compassion fatigue and mindfulness.", [["fatigue", "DISEASE", 71, 78], ["compassion fatigue", "PROBLEM", 60, 78], ["mindfulness", "PROBLEM", 83, 94], ["moderate", "OBSERVATION_MODIFIER", 21, 29]]], ["These findings suggest that high levels of compassion fatigue are associated to lower levels of mindfulness, meaning that mindfulness traits may be helpful in ameliorating compassion fatigue.About Mindfulness and Compassion Fatigue Correlation ::: Cross-Sectional Studies ::: ResultsSimilarly, Olson et al. (2014) collected data regarding burnout, emotional intelligence, empathy, mindfulness, self-compassion and resilience, in pediatric medicine residents of an urban children's hospital.", [["fatigue", "DISEASE", 54, 61], ["fatigue", "DISEASE", 183, 190], ["Fatigue", "DISEASE", 224, 231], ["burnout", "DISEASE", 339, 346], ["children", "ORGANISM", 470, 478], ["children", "SPECIES", 470, 478], ["high levels of compassion fatigue", "PROBLEM", 28, 61], ["lower levels of mindfulness", "PROBLEM", 80, 107], ["ameliorating compassion fatigue", "PROBLEM", 159, 190], ["burnout", "PROBLEM", 339, 346], ["high", "OBSERVATION_MODIFIER", 28, 32]]], ["Their measure was carried out also through the FFMQ and the SCS (Neff, 2003) and the results reported a negative association between mindfulness/self-compassion and burnout, with a positive association between the two and resilience factors and less emotional exhaustion.", [["burnout", "DISEASE", 165, 172], ["burnout", "PROBLEM", 165, 172], ["a positive association between the two and resilience factors", "PROBLEM", 179, 240], ["less emotional exhaustion", "PROBLEM", 245, 270]]], ["The authors suggest that both mindfulness and self-compassion may protect professionals' personal health and well-being.About Mindfulness and Compassion Fatigue Correlation ::: Cross-Sectional Studies ::: ResultsGracia-Gracia and Oliv\u00e1n-Bl\u00e1zquez (2017) analyzed the ability of self-compassion and mindfulness associated to burnout in nurses of intensive care units, also investigating the relationship between self-compassion as a positive mental state in association with mindfulness.", [["Fatigue", "DISEASE", 153, 160], ["burnout", "DISEASE", 323, 330], ["ResultsGracia", "TEST", 205, 218], ["Gracia", "TEST", 219, 225], ["Oliv\u00e1n", "TEST", 230, 236], ["a positive mental state", "PROBLEM", 429, 452]]], ["The results of this study showed that compassion variables were predictive for burnout (emotional exhaustion, depersonalization and personal accomplishment), in particular the years of overall professional experience, self-kindness, self-judgement and the humanity-isolation factor of compassion.", [["burnout", "DISEASE", 79, 86], ["depersonalization", "DISEASE", 110, 127], ["this study", "TEST", 15, 25], ["compassion variables", "PROBLEM", 38, 58], ["burnout (emotional exhaustion", "PROBLEM", 79, 108], ["self-kindness", "PROBLEM", 218, 231]]], ["Furthermore, the mindfulness subscale appeared to have an inverse significant correlation with emotional exhaustion.About Mindfulness and Compassion Fatigue Correlation ::: Cross-Sectional Studies ::: ResultsThe research group of Montero-Marin et al. (2016), while confirming the validity of the burnout subtype model, assessed the explicative power of the self-compassion construct as a protective factor.", [["Fatigue", "DISEASE", 149, 156], ["emotional exhaustion", "PROBLEM", 95, 115]]], ["According to a previous described study (Gracia-Gracia and Oliv\u00e1n-Bl\u00e1zquez, 2017), they used the SCS for this purpose.", [["a previous described study", "TEST", 13, 39], ["Gracia", "TEST", 41, 47]]], ["Their findings were that negative self-compassion dimensions might play an important role in the development of the burnout subtypes in Spanish HCPs, suggesting that negative self-compassion dimensions should be considered as vulnerability factors.About Mindfulness and Compassion Fatigue Correlation ::: Cross-Sectional Studies ::: ResultsSilver et al. (2018) conducted a research with the aim of assessing relationships between mindfulness and some professional variables such as burnout, compassion fatigue, work engagement, and empathy on genetic counselors that provide immediate clinical aid to patients.", [["burnout", "DISEASE", 116, 123], ["Fatigue", "DISEASE", 281, 288], ["burnout", "DISEASE", 482, 489], ["fatigue", "DISEASE", 502, 509], ["patients", "ORGANISM", 601, 609], ["patients", "SPECIES", 601, 609], ["self-compassion dimensions", "TREATMENT", 175, 201], ["compassion fatigue", "PROBLEM", 491, 509]]], ["They used the Mindfulness Attention Awareness Scale (MAAS) (Brown and Ryan, 2003) to evaluate mindfulness levels and the ProQOL-5 for burnout and compassion fatigue.", [["burnout", "DISEASE", 134, 141], ["fatigue", "DISEASE", 157, 164], ["mindfulness levels", "TEST", 94, 112], ["the ProQOL", "TREATMENT", 117, 127], ["burnout", "PROBLEM", 134, 141], ["compassion fatigue", "PROBLEM", 146, 164]]], ["Their findings showed that half of the participants reported engaging in activities which are typically associated with mindfulness (such as yoga, meditation, or breathing exercises); furthermore, there was a significant positive correlation between empathy/work engagement and mindfulness and moderate negative associations between mindfulness and burnout/compassion fatigue.", [["burnout", "DISEASE", 349, 356], ["fatigue", "DISEASE", 368, 375], ["participants", "ORGANISM", 39, 51], ["participants", "SPECIES", 39, 51], ["meditation", "TREATMENT", 147, 157], ["breathing exercises", "TREATMENT", 162, 181], ["mindfulness", "TEST", 278, 289], ["burnout/compassion fatigue", "PROBLEM", 349, 375], ["moderate", "OBSERVATION_MODIFIER", 294, 302]]], ["According to some other studies, the authors suggest that mindfulness could affect positively professional satisfaction and quality of patient care.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsBrady et al. (2012) assessed the impact of the MBSR program on managing work stress and improving patient outcomes in 16 hospital staff members consisting of psychiatrists, psychologists, nurses, social workers, mental health technicians, and activity therapists.", [["patient", "ORGANISM", 135, 142], ["patient", "ORGANISM", 383, 390], ["patient", "SPECIES", 135, 142], ["patient", "SPECIES", 383, 390], ["some other studies", "TEST", 13, 31], ["MBSR Intervention", "TREATMENT", 148, 165], ["MBSR", "PROBLEM", 187, 191], ["the MBSR program", "TREATMENT", 328, 344]]], ["The structured 4 week MBSR program was successful in influencing the levels of personal stress, mindfulness, and intrapersonal presence of inpatient psychiatric staff members.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsCohen-Katz et al. (2005) reported results exploring the effects of MBSR on 25 nurses.", [["psychiatric", "DISEASE", 149, 160], ["MBSR Intervention", "TREATMENT", 175, 192], ["MBSR", "PROBLEM", 214, 218]]], ["Treatment group subjects significantly decreased scores on 2 of 3 subscales of the Maslach Burnout Inventory compared to wait-list controls, while within-group comparisons for both groups pre-treatment and post-treatment revealed similar results.", [["significantly decreased scores", "PROBLEM", 25, 55], ["decreased", "OBSERVATION_MODIFIER", 39, 48]]], ["Changes were maintained as long as 3 months post-treatment.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsDuarte and Pinto-Gouveia (2017) evaluated the effects of an MSBR program on 29 oncology nurses, with respect to 19 nurses of a waitlist comparison condition.", [["MBSR Intervention", "TREATMENT", 59, 76], ["MBSR", "PROBLEM", 98, 102], ["an MSBR program", "TREATMENT", 253, 268]]], ["Changes in mindfulness mediated changes in burnout, anxiety and stress, and satisfaction with life; changes in self-compassion mediated the influence of the intervention on burnout, depression, anxiety, stress and satisfaction with life; and psychological inflexibility mediated decreases in burnout, compassion fatigue, depression, and stress.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsLamothe et al. (2018) considered the feasibility and acceptability of an MBSR-based intervention and its impact on psychological variables, assessed pre- and post-intervention, like mindfulness, empathy, identification of one's own emotions and those of others, emotional acceptance and recognition of emotions in others, in two studies: in Study 1, 12 students completed the 8 week MBSR program, while in Study 2, 25 HCPs completed the 8 week MBSR program.", [["burnout", "DISEASE", 43, 50], ["anxiety", "DISEASE", 52, 59], ["burnout", "DISEASE", 173, 180], ["depression", "DISEASE", 182, 192], ["anxiety", "DISEASE", 194, 201], ["burnout", "DISEASE", 292, 299], ["fatigue", "DISEASE", 312, 319], ["depression", "DISEASE", 321, 331], ["Changes in mindfulness mediated changes in burnout", "PROBLEM", 0, 50], ["anxiety", "PROBLEM", 52, 59], ["stress", "PROBLEM", 64, 70], ["the intervention", "TREATMENT", 153, 169], ["burnout", "PROBLEM", 173, 180], ["depression", "PROBLEM", 182, 192], ["anxiety", "PROBLEM", 194, 201], ["stress and satisfaction with life", "PROBLEM", 203, 236], ["psychological inflexibility", "PROBLEM", 242, 269], ["compassion fatigue", "PROBLEM", 301, 319], ["depression", "PROBLEM", 321, 331], ["stress", "PROBLEM", 337, 343], ["MBSR Intervention", "TREATMENT", 344, 361], ["MBSR", "PROBLEM", 383, 387], ["an MBSR", "TEST", 551, 558], ["based intervention", "TREATMENT", 559, 577], ["psychological variables", "TEST", 596, 619], ["decreases", "OBSERVATION_MODIFIER", 279, 288]]], ["Participants who completed the program improved on all measures except the identification of others' emotions and empathy.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsWylde et al. (2017) compared the effects of an 8 week MBSR intervention to a smartphone delivered mindfulness intervention, Headspace, an audio-guided mindfulness meditation program, in a group of 95 novice nurses, at the beginning of their internship and 3 months after entering the program, measuring compassion satisfaction, compassion fatigue, burnout, stress, trauma symptoms, and mindfulness variables.", [["fatigue", "DISEASE", 598, 605], ["burnout", "DISEASE", 607, 614], ["trauma", "DISEASE", 624, 630], ["Participants", "SPECIES", 0, 12], ["all measures", "TREATMENT", 51, 63], ["empathy", "PROBLEM", 114, 121], ["MBSR Intervention", "TREATMENT", 122, 139], ["MBSR", "PROBLEM", 161, 165], ["an 8 week MBSR intervention", "TREATMENT", 303, 330], ["a smartphone delivered mindfulness intervention", "TREATMENT", 334, 381], ["Headspace", "TREATMENT", 383, 392], ["compassion fatigue", "PROBLEM", 587, 605], ["burnout", "PROBLEM", 607, 614], ["stress", "PROBLEM", 616, 622], ["trauma symptoms", "PROBLEM", 624, 639], ["mindfulness variables", "PROBLEM", 645, 666]]], ["The smartphone intervention group also reported more compassion satisfaction and less burnout.", [["burnout", "DISEASE", 86, 93]]], ["For novice nurses, smartphone delivered mindfulness interventions may be more beneficial.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsA controlled mixed methods pilot study (Verweij et al., 2016) investigated the feasibility and effectiveness of MBSR on burnout, empathy, and work-related well-being, assessed before and after the intervention, in 43 general practitioner trainers of two Dutch hospitals.", [["burnout", "DISEASE", 346, 353], ["smartphone delivered mindfulness interventions", "TREATMENT", 19, 65], ["MBSR Intervention", "TREATMENT", 89, 106], ["MBSR", "PROBLEM", 128, 132], ["the intervention", "TREATMENT", 419, 435]]], ["The MBSR group showed a greater reduction in depersonalization than the control group, while mindfulness and dedication increased significantly in the MBSR group than in the control group.", [["depersonalization", "DISEASE", 45, 62], ["The MBSR group", "TEST", 0, 14], ["a greater reduction in depersonalization", "PROBLEM", 22, 62], ["greater", "OBSERVATION_MODIFIER", 24, 31], ["reduction", "OBSERVATION_MODIFIER", 32, 41], ["depersonalization", "OBSERVATION", 45, 62]]], ["There was no significant difference in empathy.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsRaab et al. (2015) carried out a pilot study on the effects of an MBSR educational intervention on 22 female mental health professionals' self-compassion, perceived stress, burnout, and quality of life, assessed pre- and post-intervention.", [["burnout", "DISEASE", 357, 364], ["significant difference in empathy", "PROBLEM", 13, 46], ["MBSR Intervention", "TREATMENT", 47, 64], ["MBSR", "PROBLEM", 86, 90], ["a pilot study", "TEST", 215, 228], ["an MBSR educational intervention", "TREATMENT", 247, 279], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["empathy", "OBSERVATION", 39, 46]]], ["Changes in the SCS total score proved to be significant, while, regarding subscales, changes were significant in self-judgment, common humanity, isolation and overidentification.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsRegarding mindfulness-related interventions, an evaluation of the impact of a group-based training program, known as \u201cOccupational Mindfulness\u201d (OM), on coping strategies and well-being of 34 employees within a disability service was carried out by Brooker et al. (2013).", [["overidentification", "PROBLEM", 159, 177], ["MBSR", "PROBLEM", 233, 237], ["interventions", "TREATMENT", 361, 374], ["an evaluation", "TEST", 376, 389], ["a group-based training program", "TREATMENT", 407, 437]]], ["The program was positively evaluated by participants and found to be associated with significant increases in positive affect and the mindfulness facet of observing.", [["participants", "SPECIES", 40, 52], ["significant increases in positive affect", "PROBLEM", 85, 125], ["significant", "OBSERVATION_MODIFIER", 85, 96], ["increases", "OBSERVATION_MODIFIER", 97, 106], ["positive affect", "OBSERVATION", 110, 125]]], ["Conversely, extrinsic job satisfaction showed a significant reduction from baseline to post-training, while negative affect, perceived stress, anxiety, and negative emotional symptoms showed a significant increase.", [["anxiety", "DISEASE", 143, 150], ["a significant reduction", "PROBLEM", 46, 69], ["perceived stress", "PROBLEM", 125, 141], ["anxiety", "PROBLEM", 143, 150], ["negative emotional symptoms", "PROBLEM", 156, 183], ["a significant increase", "PROBLEM", 191, 213], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["reduction", "OBSERVATION_MODIFIER", 60, 69], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["increase", "OBSERVATION_MODIFIER", 205, 213]]], ["Paradoxical increases of negative emotional symptoms are explained by considering that participants were developing higher levels of awareness of their current circumstances, whether positive or negative, internal or external.", [["increases of negative emotional symptoms", "DISEASE", 12, 52], ["participants", "SPECIES", 87, 99], ["Paradoxical increases of negative emotional symptoms", "PROBLEM", 0, 52], ["increases", "OBSERVATION_MODIFIER", 12, 21]]], ["Mindfulness is not directly related to changing circumstances but about developing awareness to what those circumstances are.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsA pre-post qualitative study investigated the effects of short-dose, 1\u20133 min-guided periods of mindfulness, conducted at the beginning of several staff meetings for 20 health professionals, which comprised social workers, therapists, nurses, doctors, administrative staff and leaders.", [["MBSR", "PROBLEM", 180, 184], ["qualitative study", "TEST", 289, 306]]], ["The mindfulness facilitators were interviewed before the intervention and predicted that their groups would experience numerous intra- and interpersonal benefits.", [["the intervention", "TREATMENT", 53, 69]]], ["After implementation, they showed all of these benefits (Duggan and Julliard, 2018).Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsFarina et al. (2018) induced professional nurse educators to offer a 10\u201312 min mindfulness experiential learning session, during the institute's annual professional development forums, to 545 nurses.", [["MBSR", "PROBLEM", 139, 143]]], ["The difference in the self-reported biofeedback card colors, indicating calm or relaxed states before and after the session, was significant.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsFernando et al. (2017) evaluated whether a brief mindfulness intervention increased compassionate responding to difficult patients and assessed whether the self-compassion trait moderated the impact of this experimental manipulation in a sample of 83 medical students.", [["patients", "ORGANISM", 416, 424], ["patients", "SPECIES", 416, 424], ["MBSR", "PROBLEM", 196, 200], ["a brief mindfulness intervention", "TREATMENT", 335, 367], ["the self-compassion trait", "PROBLEM", 446, 471], ["this experimental manipulation", "TREATMENT", 496, 526], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["significant", "OBSERVATION_MODIFIER", 129, 140]]], ["The intervention elicited mindfulness equivalently at both high and low levels of self-compassion.", [["high", "OBSERVATION_MODIFIER", 59, 63]]], ["Furthermore, mindfulness predicted greater patient \u201cliking\u201d and \u201ccaring,\u201d but only among students lower in self-compassion, while mindfulness predicted greater helping behavior, but primarily among students with higher self-compassion.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsThe Mindful Nursing Pilot Study (Horner et al., 2014) was a quasi-experimental research where 46 nurses belonging to a nursing unit participated in the 10 week mindfulness training program while an additional nursing unit served as the control group.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["MBSR", "PROBLEM", 290, 294], ["the 10 week mindfulness training program", "TREATMENT", 536, 576], ["an additional nursing unit", "TREATMENT", 583, 609]]], ["The group that underwent the intervention showed improvement in levels of mindfulness, burnout, and stress as well as patient satisfaction (though mindfulness and burnout scores did not reach significance) while the control group showed no significant differences.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsKlatt et al. (2017) administered a brief experiential introduction to mindfulness to 286 HCPs, including dieticians, nurses, psychologists, and smoking cessation educators, measuring, during the meetings and at 3 month follow-up, participant's previous awareness and use of Complementary and Alternative Medicine techniques, and consequent probability of deepening the knowledge of these modalities for personal and professional use.", [["burnout", "DISEASE", 87, 94], ["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["participant", "SPECIES", 647, 658], ["the intervention", "TREATMENT", 25, 41], ["burnout", "PROBLEM", 87, 94], ["stress", "PROBLEM", 100, 106], ["burnout scores", "PROBLEM", 163, 177], ["MBSR", "PROBLEM", 319, 323], ["Alternative Medicine techniques", "TREATMENT", 709, 740], ["improvement", "OBSERVATION_MODIFIER", 49, 60], ["no", "UNCERTAINTY", 237, 239], ["significant", "OBSERVATION_MODIFIER", 240, 251]]], ["Immediately after the experiential introduction 94.79% of respondents reported a probability to deepen the knowledge of mindfulness for personal use and 92.58% for professional use, while, at 3 month follow-up, 58% had used mindfulness personally and 28% reported that they had used mindfulness techniques professionally.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsPakenham (2015) investigated the effects of an Acceptance and Commitment Therapy (ACT) training, 12 2 h weekly workshops, on stress, therapist skills and characteristics, and the personal acquisition of ACT strategies in 32 clinical psychology trainees that completed measures of work-related stress, psychological distress, self-compassion, counseling self-efficacy, client-therapist alliance, acceptance and action, mindfulness, thought suppression and values, before and after university-based ACT training.", [["psychological distress", "DISEASE", 775, 797], ["MBSR", "PROBLEM", 376, 380], ["Commitment Therapy (ACT) training", "TREATMENT", 536, 569], ["ACT strategies", "TREATMENT", 677, 691], ["psychological distress", "PROBLEM", 775, 797]]], ["Results showed that clinical psychology trainees reported improvements from before to after training on measures of counseling self-efficacy, client\u2013therapist alliance, self-kindness, acceptance, defusion, mindfulness and values, and a marginally significant improvement on somatic symptoms, despite a trend toward increased work-related stress.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsA pilot study (Pflugeisen et al., 2016), using a single-sample, pre-post study design, evaluated the feasibility of implementing an 8 week video-module based mindfulness pilot program aimed to reduce stress, ameliorate well-being, and develop mindfulness skills in 23 physicians in a community hospital setting.", [["somatic symptoms", "PROBLEM", 274, 290], ["increased work-related stress", "PROBLEM", 315, 344], ["MBSR", "PROBLEM", 400, 404], ["ResultsA pilot study", "TEST", 491, 511], ["pre-post study", "TEST", 562, 576], ["an 8 week video-module based mindfulness pilot program", "TREATMENT", 627, 681], ["stress", "PROBLEM", 698, 704], ["significant", "OBSERVATION_MODIFIER", 247, 258], ["improvement", "OBSERVATION_MODIFIER", 259, 270]]], ["Participants experienced three 90 min in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls.", [["Participants", "SPECIES", 0, 12], ["person", "SPECIES", 41, 47]]], ["Physician stress, well-being (emotional exhaustion, depersonalization of patients, sense of personal accomplishment), and mindfulness skills (observing, describing, acting with awareness, acceptance without judgment) were evaluated.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["Significant reductions in stress, personal accomplishment, and emotional exhaustion and improvements in all mindfulness skills were observed at end-of-program.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsSans\u00f3 et al. (2018), in a pre-post pre-experimental study, evaluated the outcome of a 6 week mindfulness training program on mindful attention, self-compassion, and professionals' quality of life in 36 HCPs of palliative care teams.", [["Significant reductions in stress", "PROBLEM", 0, 32], ["emotional exhaustion", "PROBLEM", 63, 83], ["MBSR", "PROBLEM", 214, 218], ["a pre-post pre-experimental study", "TEST", 336, 369], ["a 6 week mindfulness training program", "TREATMENT", 396, 433], ["reductions", "OBSERVATION_MODIFIER", 12, 22]]], ["After the intervention, there was an improvement of mindfulness, self-compassion, and burnout risk levels lowered, regardless of the profession.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsSteinberg et al. (2016) explored the feasibility of a workplace intervention for improving resilience to stress of 32 of surgical intensive care unit HCPs, randomly assigned to an intervention or control group.", [["burnout", "DISEASE", 86, 93], ["the intervention", "TREATMENT", 6, 22], ["mindfulness", "PROBLEM", 52, 63], ["burnout risk levels", "PROBLEM", 86, 105], ["MBSR", "PROBLEM", 199, 203], ["a workplace intervention", "TREATMENT", 349, 373], ["an intervention", "TREATMENT", 474, 489], ["improvement", "OBSERVATION_MODIFIER", 37, 48]]], ["The intervention consisted of a MBI including meditation, mild yoga movement, and music and was carried out in a group format 1 h a week for 8 weeks.", [["The intervention", "TREATMENT", 0, 16], ["meditation", "TREATMENT", 46, 56], ["mild yoga movement", "PROBLEM", 58, 76], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["yoga movement", "OBSERVATION", 63, 76]]], ["Measures of burnout, compassion satisfaction, compassion fatigue and work engagement were obtained before and after the intervention.", [["burnout", "DISEASE", 12, 19], ["fatigue", "DISEASE", 57, 64], ["compassion fatigue", "PROBLEM", 46, 64], ["work engagement", "TEST", 69, 84], ["the intervention", "TREATMENT", 116, 132]]], ["Work satisfaction improved significantly in the intervention group with no difference in the control group.", [["the intervention group", "TREATMENT", 44, 66]]], ["Participants reported that recognizing their stress response was a main benefit of the intervention.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsThe study conducted by Taylor et al. (2016) examined the feasibility and impact of a 10 day mindfulness meditation intervention on 33 pediatric residents using a free smartphone application, Headspace.", [["Participants", "SPECIES", 0, 12], ["the intervention", "TREATMENT", 83, 99], ["MBSR", "PROBLEM", 155, 159], ["The study", "TEST", 253, 262], ["a 10 day mindfulness meditation intervention", "TREATMENT", 336, 380], ["a free smartphone application", "TREATMENT", 413, 442]]], ["Measures of burnout and mindfulness were administered before and after the intervention.", [["burnout and mindfulness", "TREATMENT", 12, 35], ["the intervention", "TREATMENT", 71, 87], ["burnout", "OBSERVATION", 12, 19]]], ["After the intervention, an increased percentage of residents perceived mindfulness as a useful intervention for patients and there was a significant increase in the number of residents who planned to discuss mindfulness as a therapeutic option for their patients, while there were no changes in burnout scores.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsA field study (Wacker and Dziobek, 2018) evaluated a 3 day employee training in non-violent communication on non-violent communication skills, cognitive and emotional empathy, empathic distress and perceived social stressors at work in 29 HCPs.", [["burnout", "DISEASE", 295, 302], ["cognitive and emotional empathy", "DISEASE", 606, 637], ["empathic distress", "DISEASE", 639, 656], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 254, 262], ["the intervention", "TREATMENT", 6, 22], ["a useful intervention", "TREATMENT", 86, 107], ["changes in burnout scores", "PROBLEM", 284, 309], ["MBSR", "PROBLEM", 365, 369], ["ResultsA field study", "TEST", 456, 476], ["cognitive and emotional empathy", "PROBLEM", 606, 637], ["empathic distress", "PROBLEM", 639, 656], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["percentage", "OBSERVATION_MODIFIER", 37, 47], ["significant", "OBSERVATION_MODIFIER", 137, 148], ["increase", "OBSERVATION_MODIFIER", 149, 157]]], ["Participants filled out questionnaires before and 3 months after training.", [["Participants", "SPECIES", 0, 12]]], ["Results showed that communication skills were fostered in training participants, evidenced by the higher levels of emotion verbalization behavior and the enhanced use of non-violent communication at work.", [["participants", "SPECIES", 67, 79]]], ["Empathic distress decreased, and the elevation of social stressors at work was hindered by enhanced emotion verbalization.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsWahl et al. (2018) aimed to conduct a peer support network pilot project through the inclusion of education/training, peer support and resiliency training and to investigate how interventions impact compassion satisfaction and compassion fatigue of 20 nurses, working in a community hospital, that completed pre-intervention and 6 week post-intervention surveys.", [["fatigue", "DISEASE", 513, 520], ["Empathic distress", "PROBLEM", 0, 17], ["MBSR", "PROBLEM", 177, 181], ["education/training", "TREATMENT", 373, 391], ["peer support", "TREATMENT", 393, 405], ["resiliency training", "TREATMENT", 410, 429], ["decreased", "OBSERVATION_MODIFIER", 18, 27], ["elevation", "OBSERVATION_MODIFIER", 37, 46]]], ["Results revealed statistically significant improvements in compassion satisfaction and non-significant improvements in compassion fatigue.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsOfei-Dodoo et al. (2020) examined a group of 43 HCPs that participated in 8 week workplace, group mindfulness-based yoga intervention.", [["fatigue", "DISEASE", 130, 137], ["compassion satisfaction", "PROBLEM", 59, 82], ["compassion fatigue", "PROBLEM", 119, 137], ["MBSR", "PROBLEM", 193, 197], ["group mindfulness", "TREATMENT", 383, 400], ["based yoga intervention", "TREATMENT", 401, 424], ["statistically", "OBSERVATION_MODIFIER", 17, 30], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["improvements", "OBSERVATION_MODIFIER", 43, 55], ["non-significant", "OBSERVATION_MODIFIER", 87, 102], ["improvements", "OBSERVATION_MODIFIER", 103, 115], ["compassion fatigue", "OBSERVATION", 119, 137]]], ["Participants completed online measures regarding depression, anxiety, stress, resilience, burnout, and compassion at baseline and post-intervention.", [["depression", "DISEASE", 49, 59], ["anxiety", "DISEASE", 61, 68], ["burnout", "DISEASE", 90, 97], ["Participants", "SPECIES", 0, 12], ["depression", "PROBLEM", 49, 59], ["anxiety", "PROBLEM", 61, 68]]], ["After the intervention, HCPs showed significant improvements on personal accomplishment, depression, anxiety, stress, perceived resilience, and compassion.Compassion-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsThirteen nursing professionals underwent a stress reduction program, including mindfulness and loving kindness meditation.", [["depression", "DISEASE", 89, 99], ["anxiety", "DISEASE", 101, 108], ["stress reduction", "DISEASE", 350, 366], ["the intervention", "TREATMENT", 6, 22], ["depression", "PROBLEM", 89, 99], ["anxiety", "PROBLEM", 101, 108], ["stress", "PROBLEM", 110, 116], ["MBSR", "PROBLEM", 209, 213], ["a stress reduction program", "TREATMENT", 348, 374], ["loving kindness meditation", "TREATMENT", 402, 428], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["improvements", "OBSERVATION", 48, 60]]], ["Quality of life assessment revealed significant increase as well as perceived stress, burnout, depression, and trait anxiety, while self-compassion did not show significant differences (Santos et al., 2016).Compassion-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsAn observational, mixed-method pilot evaluation study (Orellana-Rios et al., 2017) enrolled 28 staff members of an interdisciplinary palliative care team and explored the feasibility and effectiveness of a 10 week group program with four aims: development of a mindful presence, cultivation of loving-kindness, Tong-len practice in difficult situations and the integration of these practices into daily work occupations.", [["burnout", "DISEASE", 86, 93], ["depression", "DISEASE", 95, 105], ["trait anxiety", "DISEASE", 111, 124], ["Quality of life assessment", "TEST", 0, 26], ["significant increase", "PROBLEM", 36, 56], ["perceived stress", "PROBLEM", 68, 84], ["burnout", "PROBLEM", 86, 93], ["depression", "PROBLEM", 95, 105], ["trait anxiety", "PROBLEM", 111, 124], ["MBSR", "PROBLEM", 261, 265], ["method pilot evaluation study", "TEST", 383, 412], ["a 10 week group program", "TREATMENT", 563, 586], ["difficult situations", "PROBLEM", 691, 711], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["increase", "OBSERVATION", 48, 56]]], ["The investigated variables were burnout, perceived stress, anxiety, depression, somatization symptoms, emotion regulation, perceived job situation and goal attainment.", [["burnout", "DISEASE", 32, 39], ["anxiety", "DISEASE", 59, 66], ["depression", "DISEASE", 68, 78], ["somatization", "DISEASE", 80, 92], ["burnout", "PROBLEM", 32, 39], ["perceived stress", "PROBLEM", 41, 57], ["anxiety", "PROBLEM", 59, 66], ["depression", "PROBLEM", 68, 78], ["somatization symptoms", "PROBLEM", 80, 101]]], ["Significant ameliorations were found in two of three burnout components (emotional exhaustion and personal accomplishment), anxiety, stress, two emotional regulation competences and joy at work.", [["anxiety", "DISEASE", 124, 131], ["Significant ameliorations", "PROBLEM", 0, 25], ["anxiety", "PROBLEM", 124, 131], ["stress", "PROBLEM", 133, 139]]], ["In addition, 85% of the individual goals were achieved.Compassion-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related, or Compassion-Related Interventions\u2014Pre-post Design Studies ::: ResultsA pilot study (Pfaff et al., 2017), with an embedded experimental mixed-methods design, evaluated the impact of 6 week formalized pilot compassion fatigue resiliency intervention on 32 HCPs participants at a regional cancer center.", [["cancer", "ANATOMY", 424, 430], ["fatigue", "DISEASE", 354, 361], ["cancer", "DISEASE", 424, 430], ["cancer", "CANCER", 424, 430], ["participants", "SPECIES", 397, 409], ["MBSR", "PROBLEM", 109, 113], ["ResultsA pilot study", "TEST", 200, 220], ["pilot compassion fatigue resiliency intervention", "TREATMENT", 337, 385], ["cancer", "OBSERVATION", 424, 430]]], ["The impact of the intervention, in a pre- and post-intervention design, was evaluated on compassion fatigue and satisfaction, burnout, clinical stress and silencing responses.", [["fatigue", "DISEASE", 100, 107], ["burnout", "DISEASE", 126, 133], ["the intervention", "TREATMENT", 14, 30], ["compassion fatigue", "PROBLEM", 89, 107], ["burnout", "PROBLEM", 126, 133], ["clinical stress and silencing responses", "PROBLEM", 135, 174]]], ["Participants showed diminished clinical stress at intervention completion, but no other overall changes.MBSR Intervention ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsEliassen et al. (2016) examined the effect of two different training programs, namely two 8 week interventions of mindfulness training and affect-consciousness training, on mindfulness and on the perception of the ward atmosphere of two groups of HCPs, consisting of 27 and 23 participants, respectively.", [["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 515, 527], ["diminished clinical stress", "PROBLEM", 20, 46], ["other overall changes", "PROBLEM", 82, 103], ["MBSR Intervention", "TREATMENT", 104, 121], ["MBSR", "PROBLEM", 143, 147], ["two different training programs", "TREATMENT", 284, 315], ["mindfulness training", "TREATMENT", 352, 372], ["consciousness training", "TREATMENT", 384, 406], ["diminished", "OBSERVATION_MODIFIER", 20, 30], ["no", "UNCERTAINTY", 79, 81]]], ["Measurements were taken at two baseline time points and four times following the intervention.", [["Measurements", "TEST", 0, 12], ["the intervention", "TREATMENT", 77, 93]]], ["Findings in this study indicate that MBSR staff training may give rise to beneficial changes in measures of Support, Program Clarity and Anger and Aggressive Behavior, as indicated by the Ward Atmosphere Scale (WAS) (R\u00f8ssberg and Friis, 2003) subscales, suggesting that the MBSR intervention may modulate staffs' manner of relating to patients.", [["patients", "ORGANISM", 335, 343], ["patients", "SPECIES", 335, 343], ["this study", "TEST", 12, 22], ["MBSR staff training", "TREATMENT", 37, 56], ["the MBSR intervention", "TREATMENT", 270, 291]]], ["Differences on different subscales on the WAS may indicate that the affect-consciousness intervention is different in its effect as compared to the MBSR.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsResearch by Kemper's research group mainly investigated the impact of brief online mindfulness training on mindfulness and other psychological variables of HCPs.", [["consciousness intervention", "TREATMENT", 75, 101], ["brief online mindfulness training", "TREATMENT", 373, 406], ["different", "OBSERVATION_MODIFIER", 105, 114]]], ["Kemper (2016) analyzed data from 178 HCPs and trainees who completed self-reflection exercises included in online mindfulness training, including three 1 h modules: introduction to mindfulness, mindfulness in daily life and mindful breathing and walking.", [["self-reflection exercises", "TREATMENT", 69, 94], ["online mindfulness training", "TREATMENT", 107, 134]]], ["Outcome data was related to mindfulness, measured with the Cognitive and Affective Mindfulness Scale\u2013Revised (CAMS-R) (Feldman et al., 2006), the MAAS and the FFMQ.", [["Outcome data", "TEST", 0, 12], ["mindfulness", "PROBLEM", 28, 39]]], ["Concluding a brief, online training was associated with small but significant improvements in mindfulness scores, measured by all the three tools.", [["online training", "TREATMENT", 20, 35], ["small but significant improvements in mindfulness scores", "PROBLEM", 56, 112], ["small", "OBSERVATION_MODIFIER", 56, 61], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["improvements", "OBSERVATION", 78, 90]]], ["In addition, there were no changes in improvement by gender, among the different HCPs.", [["no", "UNCERTAINTY", 24, 26], ["changes", "OBSERVATION_MODIFIER", 27, 34]]], ["In a related prospective cohort study, Kemper and Rao (2016) investigated the effects of an online training program related to focused attention meditation, including three 1 h modules (introduction to stress, resilience and the relaxation response, clinical effects of the relaxation response and physiological effects of the relaxation response) on resilience, relaxation, stress, positive and negative affect and flourishing variables, assessed before and after training, of 379 HCPs.", [["an online training program", "TREATMENT", 89, 115], ["focused attention meditation", "TREATMENT", 127, 155], ["the relaxation response", "TREATMENT", 225, 248], ["the relaxation response", "TREATMENT", 270, 293], ["the relaxation response", "TREATMENT", 323, 346]]], ["Even brief, online training was associated with small but significant improvements in relaxation, resilience, stress, positive and negative affect, and flourishing.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsLuthar et al. (2017) reported on the effects of an intervention to foster resilience among women health care providers who are mothers at high risk for stress and burnout.", [["burnout", "DISEASE", 477, 484], ["women", "ORGANISM", 405, 410], ["women", "SPECIES", 405, 410], ["MBSR", "PROBLEM", 219, 223], ["an intervention", "TREATMENT", 362, 377], ["stress and burnout", "PROBLEM", 466, 484], ["small", "OBSERVATION_MODIFIER", 48, 53], ["significant", "OBSERVATION_MODIFIER", 58, 69], ["improvements", "OBSERVATION", 70, 82]]], ["40 mothers were assigned randomly to either 12 weekly 1 h sessions of a structured, relational supportive intervention, the Authentic Connections Groups, including minimizing rumination, \u201cgood enough\u201d mothering and shame (Carmassi et al., 2017a) vs. self-compassion, or to 12 weekly hours to be used as needed.", [["mothers", "ORGANISM", 3, 10], ["relational supportive intervention", "TREATMENT", 84, 118]]], ["Participants were evaluated at baseline, after the intervention, and 3 months follow-up on general symptomatology, depression, self-compassion and burnout plus plasma cortisol.", [["plasma", "ANATOMY", 160, 166], ["depression", "DISEASE", 115, 125], ["burnout", "DISEASE", 147, 154], ["cortisol", "CHEMICAL", 167, 175], ["cortisol", "CHEMICAL", 167, 175], ["plasma", "ORGANISM_SUBSTANCE", 160, 166], ["cortisol", "SIMPLE_CHEMICAL", 167, 175], ["Participants", "SPECIES", 0, 12], ["the intervention", "TREATMENT", 47, 63], ["general symptomatology", "PROBLEM", 91, 113], ["depression", "PROBLEM", 115, 125], ["burnout plus plasma cortisol", "TEST", 147, 175]]], ["After the intervention, results showed higher levels of improvements for mothers in the Authentic Connections Groups than control condition for depression and global symptoms.", [["depression", "DISEASE", 144, 154], ["the intervention", "TREATMENT", 6, 22], ["depression", "PROBLEM", 144, 154], ["global symptoms", "PROBLEM", 159, 174]]], ["By 3 months follow-up, significant changes were found for depression and global symptoms and self-compassion, feeling loved, physical affection received, and parenting stress.", [["depression", "DISEASE", 58, 68], ["significant changes", "PROBLEM", 23, 42], ["depression", "PROBLEM", 58, 68], ["global symptoms", "PROBLEM", 73, 88]]], ["Participants in the Authentic Connections Groups (but not control group) condition also showed significantly diminished cortisol levels at both after the intervention and follow-up.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsO'Mahony et al. (2017) evaluated the preliminary outcomes of a group-based 9-session multimodal mindfulness training pilot designed to improve indicators of burnout and mental health symptomatology in 13 health care providers who interact with children in the context of end-of-life care.", [["cortisol", "CHEMICAL", 120, 128], ["burnout", "DISEASE", 488, 495], ["cortisol", "CHEMICAL", 120, 128], ["cortisol", "SIMPLE_CHEMICAL", 120, 128], ["children", "ORGANISM", 575, 583], ["Participants", "SPECIES", 0, 12], ["children", "SPECIES", 575, 583], ["significantly diminished cortisol levels", "PROBLEM", 95, 135], ["the intervention", "TREATMENT", 150, 166], ["MBSR", "PROBLEM", 236, 240], ["multimodal mindfulness training pilot", "TREATMENT", 416, 453], ["burnout and mental health symptomatology", "PROBLEM", 488, 528], ["end-of-life care", "TREATMENT", 602, 618]]], ["Measures were assessed before the program, at the program midpoint, and at the end of the program and were PTSD symptomatology, experiential avoidance, cognitive fusion, depression and burnout.", [["PTSD symptomatology", "DISEASE", 107, 126], ["cognitive fusion", "DISEASE", 152, 168], ["depression", "DISEASE", 170, 180], ["burnout", "DISEASE", 185, 192], ["PTSD symptomatology", "PROBLEM", 107, 126], ["cognitive fusion", "PROBLEM", 152, 168], ["depression", "PROBLEM", 170, 180], ["burnout", "PROBLEM", 185, 192]]], ["Results revealed significant improvements in depressive and PTSD symptoms among HCPs.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsRiley et al. (2016) carried out two studies to compare the impact of Cognitive Behavioral Stress Management (CBSM) and an 8 week Yoga-Based Stress Management (YBSM) interventions for HCPs.", [["depressive", "DISEASE", 45, 55], ["PTSD", "DISEASE", 60, 64], ["depressive and PTSD symptoms", "PROBLEM", 45, 73], ["MBSR", "PROBLEM", 140, 144], ["two studies", "TEST", 267, 278], ["Cognitive Behavioral Stress Management", "TREATMENT", 304, 342], ["an 8 week Yoga", "TREATMENT", 354, 368], ["Based Stress Management", "TREATMENT", 369, 392], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["improvements", "OBSERVATION_MODIFIER", 29, 41], ["depressive", "OBSERVATION_MODIFIER", 45, 55]]], ["Study 1 evaluated YBSM intervention in 37 mental HCPs and gathered data regarding depression, anxiety, stress, health-related quality of life, coping skills, emotion regulation, mindfulness and self-compassion, pre- and post-intervention.", [["depression", "DISEASE", 82, 92], ["anxiety", "DISEASE", 94, 101], ["Study", "TEST", 0, 5], ["YBSM intervention", "TREATMENT", 18, 35], ["depression", "PROBLEM", 82, 92], ["anxiety", "PROBLEM", 94, 101], ["stress", "PROBLEM", 103, 109]]], ["Study 2 investigated YBSM and CBSM in 40 randomly assigned mental health care providers and collected data regarding depression, anxiety, stress, health-related quality of life, burnout, coping skills, and general health data at four time points.", [["depression", "DISEASE", 117, 127], ["anxiety", "DISEASE", 129, 136], ["burnout", "DISEASE", 178, 185], ["Study", "TEST", 0, 5], ["YBSM", "TEST", 21, 25], ["CBSM", "TEST", 30, 34], ["depression", "PROBLEM", 117, 127], ["anxiety", "PROBLEM", 129, 136]]], ["Results of Study 1 showed statistically significant increases in relaxation, coping confidence, self-kindness, self-compassion, general mental health, general physical health, and mindfulness, while results of Study 2 showed significant improvement in compassion satisfaction, depression, stress, heart rate, alcohol consumption, and burnout.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsSuyi et al. (2017) examined the efficacy of a 6 week mindfulness program in improving mindfulness, compassion and self-compassion, and diminishing perceived stress and burnout, among 37 mental HCPs in Singapore.", [["heart", "ANATOMY", 297, 302], ["depression", "DISEASE", 277, 287], ["alcohol", "CHEMICAL", 309, 316], ["burnout", "DISEASE", 334, 341], ["burnout", "DISEASE", 660, 667], ["alcohol", "CHEMICAL", 309, 316], ["heart", "ORGAN", 297, 302], ["Study", "TEST", 11, 16], ["self-kindness", "PROBLEM", 96, 109], ["Study 2", "TEST", 210, 217], ["compassion satisfaction", "PROBLEM", 252, 275], ["depression", "PROBLEM", 277, 287], ["stress, heart rate", "PROBLEM", 289, 307], ["burnout", "PROBLEM", 334, 341], ["MBSR", "PROBLEM", 397, 401], ["a 6 week mindfulness program", "TREATMENT", 536, 564], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["increases", "OBSERVATION_MODIFIER", 52, 61], ["relaxation", "OBSERVATION_MODIFIER", 65, 75], ["significant", "OBSERVATION_MODIFIER", 225, 236], ["improvement", "OBSERVATION_MODIFIER", 237, 248], ["heart", "ANATOMY", 297, 302]]], ["The program comprised 2 h sessions offered once a week and utilized a range of mindfulness techniques to instruct participants to cultivate compassionate and non-judgemental attitudes toward their inner experiences.", [["participants", "SPECIES", 114, 126], ["a range of mindfulness techniques", "TREATMENT", 68, 101]]], ["Participants showed significant amelioration in four of the five mindfulness domains (observe, describe, non-judge, non-react) and in compassion and self-compassion levels, and a significant decrease in stress, following mindfulness intervention.", [["Participants", "SPECIES", 0, 12], ["significant amelioration", "PROBLEM", 20, 44], ["a significant decrease in stress", "PROBLEM", 177, 209], ["mindfulness intervention", "TREATMENT", 221, 245], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["amelioration", "OBSERVATION", 32, 44], ["significant", "OBSERVATION_MODIFIER", 179, 190], ["decrease", "OBSERVATION_MODIFIER", 191, 199], ["stress", "OBSERVATION", 203, 209]]], ["The improvements in mindfulness and self-compassion levels were maintained at three months follow-up.", [["self-compassion levels", "TEST", 36, 58], ["improvements", "OBSERVATION_MODIFIER", 4, 16]]], ["No significant difference was observed for burnout variables.Mindfulness-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsWen et al. (2017) assessed how the self-guided, smartphone-based mindfulness app, Headspace, affects mindfulness, stress and negative emotions variables in 43 medical residents.", [["burnout variables", "PROBLEM", 43, 60], ["MBSR", "PROBLEM", 116, 120], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["Measures were collected before the intervention, at the midpoint (after 15 days), and at the end of the intervention (after 30 days).", [["the intervention", "TREATMENT", 31, 47], ["the intervention", "TREATMENT", 100, 116]]], ["Results showed that both the mindfulness and positive affect scores showed a significant improvement with increasing use of the app, while the negative affect score did not show significant change.Compassion-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsKemper et al. (2015) assessed the impact of online Mind-Body Skills (MBS) training on clinicians' and trainees' stress, mindfulness, and confidence in providing calm, compassionate care.", [["positive affect scores", "PROBLEM", 45, 67], ["significant change", "PROBLEM", 178, 196], ["MBSR", "PROBLEM", 251, 255], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["improvement", "OBSERVATION_MODIFIER", 89, 100]]], ["MBS training (http://mind-bodyhealth.osu.edu) contained 12 1 h modules of continuing medical education\u2013approved material organized in 4 general topics: focused attention meditation (relaxation response), mindfulness meditation, positive affect meditation (positive or sacred word, gratitude, and loving-kindness/compassion meditation) and guided imagery/hypnosis (autogenic training; guided imagery to prepare for surgery, procedures, or childbirth; and guided imagery for sleep and changing habits).", [["continuing medical education\u2013approved material", "TREATMENT", 74, 120], ["focused attention meditation", "TREATMENT", 152, 180], ["mindfulness meditation", "TREATMENT", 204, 226], ["compassion meditation", "TREATMENT", 312, 333], ["imagery/hypnosis", "TREATMENT", 346, 362], ["autogenic training", "TREATMENT", 364, 382], ["surgery", "TREATMENT", 414, 421], ["procedures", "TREATMENT", 423, 433]]], ["Participants who engaged in MBS significantly improved in measures of stress, mindfulness, and confidence in offering calm, compassionate care.", [["Participants", "SPECIES", 0, 12]]], ["In a related prospective cohort study, Kemper and Khirallah (2015) assessed the effects of MBS training on mindfulness, resilience, and empathy of 513 HCPs.", [["cohort study", "TEST", 25, 37], ["MBS training", "TREATMENT", 91, 103]]], ["Completion of MBS training was related with significant ameliorations in stress, mindfulness, empathy and resilience, suggesting that this training is able to reach diverse HCPs.Compassion-Related Interventions ::: Effectiveness of MBSR, Mindfulness-Related or Compassion-Related Interventions\u2014Cohort Design Studies ::: ResultsScarlet et al. (2017) studied the effects of an 8 week Compassion Cultivation Training (CCT) (Jazaieri et al., 2013) on work-related burnout, interpersonal conflict, mindfulness, self-compassion, fear of compassion and job satisfaction scores of 62 HCPs.", [["burnout", "DISEASE", 460, 467], ["MBS training", "TREATMENT", 14, 26], ["significant ameliorations in stress", "PROBLEM", 44, 79], ["MBSR", "PROBLEM", 232, 236], ["an 8 week Compassion Cultivation Training", "TREATMENT", 372, 413], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["ameliorations", "OBSERVATION", 56, 69]]], ["The questionnaires were administered by email during the first, middle, and last weeks of CCT, as well as 1 month follow-up.", [["CCT", "TEST", 90, 93]]], ["Results showed significant improvements in participants' self-compassion, mindfulness, and interpersonal conflict levels.Qualitative Studies ::: DiscussionIn regard of the qualitative studies, most of them investigated the relationship between mindfulness and compassion dispositions with burnout, stress levels, positive workplace relationships, and individualized patients care (Platt et al., 2015; Lyddy et al., 2016; McPherson et al., 2016; Hunter et al., 2018; Powell et al., 2018).", [["burnout", "DISEASE", 289, 296], ["patients", "ORGANISM", 366, 374], ["participants", "SPECIES", 43, 55], ["patients", "SPECIES", 366, 374], ["interpersonal conflict levels", "TEST", 91, 120], ["the qualitative studies", "TEST", 168, 191], ["burnout, stress levels", "TEST", 289, 311], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["improvements", "OBSERVATION_MODIFIER", 27, 39]]], ["From the examined studies, mindfulness dispositions appeared to be important in the fight against burnout and to manage effectively the stress response (Platt et al., 2015).", [["burnout", "DISEASE", 98, 105], ["the examined studies", "TEST", 5, 25], ["the stress response", "PROBLEM", 132, 151]]], ["As a result, the suggestion that we could gain from this information collection is to effectively increase mindfulness training in healthcare settings and provide professionals with less formal tools to tackle their job.Randomized Controlled Trials ::: DiscussionWith regard to the RCT studies, we highlight that MBSR or mixed mindfulness interventions resulted to be more effective than controls in samples of doctors and HCPs in three of the four examined researches.", [["mindfulness training", "TREATMENT", 107, 127], ["the RCT studies", "TEST", 278, 293], ["mixed mindfulness interventions", "TREATMENT", 321, 352]]], ["In particular, mindfulness interventions were most effective on stress (Amutio et al., 2015; Ireland et al., 2017), job burnout (Amutio et al., 2015; Ireland et al., 2017), and safety compliance at work (Valley and Stallones, 2017).", [["burnout", "DISEASE", 120, 127], ["mindfulness interventions", "TREATMENT", 15, 40]]], ["Amutio et al. (2015) also highlighted the importance of a maintenance programme after the mindfulness intervention.Cross-Sectional Design Studies ::: DiscussionWith reference to the cross-sectional selected studies, we observed various researches linking compassion fatigue/compassion satisfaction (risk and prevalence) with violence exposure, coping mechanisms, burnout and bereavement overload (Brown et al., 2017; Allie et al., 2018; Copeland and Henry, 2018).", [["fatigue", "DISEASE", 266, 273], ["burnout", "DISEASE", 363, 370], ["bereavement overload", "DISEASE", 375, 395], ["a maintenance programme", "TREATMENT", 56, 79], ["the mindfulness intervention", "TREATMENT", 86, 114], ["the cross-sectional selected studies", "TEST", 178, 214], ["burnout and bereavement overload", "PROBLEM", 363, 395]]], ["With respect to this topic, the results obtained are somewhat controversial; on the one hand, we observed a confirmation of a high presence of burnout, compassion fatigue and secondary traumatic stress in the investigated samples.", [["samples", "ANATOMY", 222, 229], ["burnout", "DISEASE", 143, 150], ["fatigue", "DISEASE", 163, 170], ["traumatic stress", "DISEASE", 185, 201], ["a confirmation", "TEST", 106, 120], ["burnout", "PROBLEM", 143, 150], ["compassion fatigue", "PROBLEM", 152, 170], ["secondary traumatic stress in the investigated samples", "PROBLEM", 175, 229], ["burnout", "OBSERVATION", 143, 150], ["secondary", "OBSERVATION_MODIFIER", 175, 184], ["traumatic stress", "OBSERVATION", 185, 201]]], ["On the other hand, many studies have observed internal variations concerning these variables, depending on gender or years of experience at work (Al-Majid et al., 2018; Roney and Acri, 2018; Wijdenes et al., 2019).", [["many studies", "TEST", 19, 31], ["internal variations", "PROBLEM", 46, 65]]], ["Supposing that compassion fatigue is a consequence of burnout, some studies have also pointed out the positive correlation between burnout and compassion barriers or between bereavement overload and emotional detachment (Gracia-Gracia and Oliv\u00e1n-Bl\u00e1zquez, 2017; Dev et al., 2018).", [["compassion fatigue", "DISEASE", 15, 33], ["burnout", "DISEASE", 54, 61], ["burnout", "DISEASE", 131, 138], ["bereavement overload", "DISEASE", 174, 194], ["emotional detachment", "DISEASE", 199, 219], ["compassion fatigue", "PROBLEM", 15, 33], ["burnout", "PROBLEM", 54, 61], ["some studies", "TEST", 63, 75], ["compassion barriers", "TREATMENT", 143, 162], ["bereavement overload", "PROBLEM", 174, 194], ["emotional detachment", "PROBLEM", 199, 219], ["Gracia", "TEST", 221, 227], ["emotional detachment", "OBSERVATION", 199, 219]]], ["These findings should elicit some reflections on the role played by the excessive stress load on the behavior of health personnel, redesigning both the therapeutic and interventional approach to this topic.Cross-Sectional Design Studies ::: DiscussionMoreover, as far as correlation between mindfulness and compassion is concerned, findings show that mindfulness approach may be useful in mitigating the negative aspect of compassion fatigue, which is, in turn, predictive for burnout (Brown et al., 2017).", [["fatigue", "DISEASE", 434, 441], ["burnout", "DISEASE", 477, 484], ["the excessive stress load", "PROBLEM", 68, 93], ["interventional approach", "TREATMENT", 168, 191], ["compassion fatigue", "PROBLEM", 423, 441]]], ["Consequently, both mindfulness and compassion satisfaction represent a protective factor on the HCPs' well-being and quality of patient care.", [["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135]]], ["Finally, these findings should elicit a reflection about the negative impact of self-compassion dimensions, which could be studied as a vulnerability factor.MBSR and Mindfulness-Related Interventions ::: DiscussionRegarding pre-post design research, 7 studies investigated the effects of MBSR intervention on HCPs.", [["a vulnerability factor", "PROBLEM", 134, 156], ["MBSR", "TEST", 157, 161], ["7 studies", "TEST", 250, 259], ["MBSR intervention", "TREATMENT", 288, 305]]], ["MBSR proved to be effective in maintaining (Cohen-Katz et al., 2005) or improving mindfulness levels (Brady et al., 2012; Verweij et al., 2016; Duarte and Pinto-Gouveia, 2017; Lamothe et al., 2018), and an MBSR educational intervention was effective at improving self-compassion levels (Raab et al., 2015).", [["MBSR", "TEST", 0, 4], ["improving mindfulness levels", "PROBLEM", 72, 100], ["an MBSR educational intervention", "TREATMENT", 203, 235]]], ["In novice nurses, a smartphone-delivered audio-guided mindfulness meditation program, Headspace, resulted in more acting with awareness compared to the MBSR group (Wylde et al., 2017).", [["mindfulness meditation program", "TREATMENT", 54, 84], ["Headspace", "TREATMENT", 86, 95]]], ["It may be hypothesized that for novice meditators, that are approaching mindfulness, a progressive approach to meditation may be helpful.", [["a progressive approach to meditation", "TREATMENT", 85, 121]]], ["In a cohort study, MBSR seems to promote beneficial changes in measures of support, program clarity, anger and aggressive behavior suggesting that the MBSR intervention may be helpful at regulating staffs' relational abilities with patients (Eliassen et al., 2016).MBSR and Mindfulness-Related Interventions ::: DiscussionStudies employing intervention protocols that were different from standard MBSR, were carried out with very different mindfulness-related interventions.", [["aggressive behavior", "DISEASE", 111, 130], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["a cohort study", "TEST", 3, 17], ["the MBSR intervention", "TREATMENT", 147, 168], ["MBSR", "TEST", 265, 269], ["intervention protocols", "TREATMENT", 340, 362], ["related interventions", "TREATMENT", 452, 473]]], ["Interventions that were found to be effective at improving mindfulness levels were 1\u20133 min-guided periods of mindfulness (Duggan and Julliard, 2018), 10 min mindfulness induction exercises (Fernando et al., 2017), a 10 day mindfulness meditation intervention using a free smartphone application (Headspace) (Taylor et al., 2016), 6 week mindfulness training (Sans\u00f3 et al., 2018), an 8 week video-module based mindfulness program (Pflugeisen et al., 2016) and an ACT training (Pakenham, 2015), while a 10 week mindfulness training program, the Mindful Nursing Pilot Study, resulted in mindfulness improvements that were not statistically significant (Horner et al., 2014), possibly because of sessions that lasted 30 min, instead of 60 or 90 min.", [["Interventions", "TREATMENT", 0, 13], ["a 10 day mindfulness meditation intervention", "TREATMENT", 214, 258], ["a free smartphone application", "TREATMENT", 265, 294], ["Pilot Study", "TEST", 559, 570], ["mindfulness", "PROBLEM", 584, 595]]], ["OM was found to increase positive affect and the mindfulness facet of observing together with a paradoxical increase of negative emotional symptoms, possibly due to a greater awareness of participants current circumstances (Brooker et al., 2013).", [["increase of negative emotional symptoms", "DISEASE", 108, 147], ["participants", "SPECIES", 188, 200], ["a paradoxical increase of negative emotional symptoms", "PROBLEM", 94, 147], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["positive affect", "OBSERVATION", 25, 40]]], ["An 8 week MBI was found to be effective on work satisfaction but not on compassion satisfaction or compassion fatigue (Steinberg et al., 2016), while a peer support network pilot project resulted in statistically significant improvements in compassion satisfaction and non-significant improvements in compassion fatigue (Wahl et al., 2018).", [["fatigue", "DISEASE", 110, 117], ["fatigue", "DISEASE", 312, 319], ["An 8 week MBI", "TEST", 0, 13], ["compassion fatigue", "PROBLEM", 99, 117], ["compassion fatigue", "PROBLEM", 301, 319], ["significant", "OBSERVATION_MODIFIER", 213, 224], ["improvements", "OBSERVATION_MODIFIER", 225, 237], ["non-significant", "OBSERVATION_MODIFIER", 269, 284], ["improvements", "OBSERVATION_MODIFIER", 285, 297]]], ["An 8 week supervised workplace, group mindfulness-based yoga intervention was able to improve compassion levels (Ofei-Dodoo et al., 2020), while A 3 day employee training in non-violent communication was able to reduce empathic distress (Wacker and Dziobek, 2018) and a brief experiential introduction to mindfulness increased the likeliness to investigate, or to use, mindfulness for personal or for professional use (Klatt et al., 2017).", [["empathic distress", "DISEASE", 219, 236], ["group mindfulness", "TREATMENT", 32, 49], ["based yoga intervention", "TREATMENT", 50, 73], ["empathic distress", "PROBLEM", 219, 236]]], ["Ten to twelve minutes of mindfulness experiential learning session was found to produce a statistically significant difference in the self-reported biofeedback card colors indicating calm or relaxed states before and after the session (Farina et al., 2018).", [["significant", "OBSERVATION_MODIFIER", 104, 115], ["difference", "OBSERVATION", 116, 126]]], ["Analogously, cohort studies showed that mindfulness-related interventions were found to be effective at improving depression, global symptoms, self-compassion, feeling loved, physical affection received, parenting stress, and cortisol levels (Luthar et al., 2017), at reducing depressive and PTSD symptomatology (O'Mahony et al., 2017), at improving compassion satisfaction, depression, stress, heart rate, alcohol consumption and burnout (Riley et al., 2016) and at increasing four of the five mindfulness domains (observe, describe, non-judge, non-react) and compassion and self-compassion levels (Suyi et al., 2017).", [["heart", "ANATOMY", 395, 400], ["depression", "DISEASE", 114, 124], ["cortisol", "CHEMICAL", 226, 234], ["depressive", "DISEASE", 277, 287], ["PTSD symptomatology", "DISEASE", 292, 311], ["depression", "DISEASE", 375, 385], ["alcohol", "CHEMICAL", 407, 414], ["burnout", "DISEASE", 431, 438], ["cortisol", "CHEMICAL", 226, 234], ["alcohol", "CHEMICAL", 407, 414], ["cortisol", "SIMPLE_CHEMICAL", 226, 234], ["heart", "ORGAN", 395, 400], ["alcohol", "SIMPLE_CHEMICAL", 407, 414], ["cohort studies", "TEST", 13, 27], ["interventions", "TREATMENT", 60, 73], ["improving depression", "PROBLEM", 104, 124], ["global symptoms", "PROBLEM", 126, 141], ["parenting stress", "TEST", 204, 220], ["cortisol levels", "TEST", 226, 241], ["reducing depressive and PTSD symptomatology", "PROBLEM", 268, 311], ["depression", "PROBLEM", 375, 385], ["stress, heart rate", "PROBLEM", 387, 405], ["burnout", "PROBLEM", 431, 438], ["heart", "ANATOMY", 395, 400]]], ["Kemper's research group investigated the effects of a brief online mindfulness training that was able to improve mindfulness scores, measured by CAMS-R, MAAS, and FFMQ (Kemper, 2016), and relaxation, resilience, stress, positive and negative affect, and flourishing (Kemper and Rao, 2016), while the smartphone-based mindfulness app, Headspace, was able to increase mindfulness and positive affect scores (Wen et al., 2017).Compassion-Related Interventions ::: DiscussionCompassion-related interventions, that mainly included loving-kindness meditation (Santos et al., 2016; Orellana-Rios et al., 2017) or a formalized pilot compassion fatigue resiliency intervention (Pfaff et al., 2017), were found to be effective at improving quality of life (Santos et al., 2016), burnout components of emotional exhaustion and personal accomplishment (Orellana-Rios et al., 2017) and at reducing clinical stress (Pfaff et al., 2017).", [["fatigue", "DISEASE", 636, 643], ["emotional exhaustion", "DISEASE", 791, 811], ["a brief online mindfulness training", "TREATMENT", 52, 87], ["mindfulness scores", "TEST", 113, 131], ["CAMS", "TEST", 145, 149], ["positive affect scores", "PROBLEM", 382, 404], ["a formalized pilot compassion fatigue resiliency intervention", "TREATMENT", 606, 667], ["emotional exhaustion", "PROBLEM", 791, 811]]], ["No other main significant changes were observed.", [["other main significant changes", "PROBLEM", 3, 33], ["main", "OBSERVATION_MODIFIER", 9, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["changes", "OBSERVATION", 26, 33]]], ["In cohort studies, Kemper's research group found that online MBS training was effective at significantly improving stress, mindfulness, and confidence in providing calm, compassionate care (Kemper et al., 2015) and at providing significant ameliorations in stress, mindfulness, empathy and resilience (Kemper and Khirallah, 2015).", [["cohort studies", "TEST", 3, 17], ["online MBS training", "TREATMENT", 54, 73]]], ["CCT (Jazaieri et al., 2013) was found to significantly enhance participants' self-compassion, mindfulness, and interpersonal conflict scores (Scarlet et al., 2017).MBSR, Mindfulness,- and Compassion-Related Interventions ::: DiscussionTaken together these results suggest that MBSR intervention is able to improve, and maintain, mindfulness levels, self-compassion levels and to improve burnout, depression, anxiety, stress (Lamothe et al., 2016).", [["burnout", "DISEASE", 387, 394], ["depression", "DISEASE", 396, 406], ["anxiety", "DISEASE", 408, 415], ["participants", "SPECIES", 63, 75], ["CCT", "TEST", 0, 3], ["MBSR", "TEST", 164, 168], ["MBSR intervention", "TREATMENT", 277, 294], ["mindfulness levels", "TEST", 329, 347], ["self-compassion levels", "TEST", 349, 371], ["burnout", "PROBLEM", 387, 394], ["depression", "PROBLEM", 396, 406], ["anxiety", "PROBLEM", 408, 415], ["stress", "PROBLEM", 417, 423]]], ["MBSR intervention has been shown to be able to modulate anger and aggressive behavior as well, with a suggestion that a smartphone-delivered audio-guided mindfulness meditation program, Headspace, may be helpful for novice HCPs.MBSR, Mindfulness,- and Compassion-Related Interventions ::: DiscussionThe most frequently employed interventional strategies were mindfulness-related trainings (Fox et al., 2018) that proved to be effective at improving nurses' mental health significantly (Guillaumie et al., 2017), for treating burnout in occupational therapy professionals (Luken and Sammons, 2016) and at reducing stress among HCPs (Burton et al., 2017).", [["aggressive behavior", "DISEASE", 66, 85], ["burnout", "DISEASE", 525, 532], ["MBSR intervention", "TREATMENT", 0, 17], ["mindfulness meditation program", "TREATMENT", 154, 184], ["MBSR", "TEST", 228, 232], ["interventional strategies", "TREATMENT", 328, 353]]], ["Overall, as also outlined by West et al. (2016), mindfulness-related interventions, even of brief duration (Gilmartin et al., 2017), were effective at improving mindfulness levels, self-compassion, depression, global symptoms, feeling loved, physical affection received, parenting stress, cortisol levels, work and compassion satisfaction and at increasing the likeliness to investigate, or to use, mindfulness for personal or for professional use, but not at improving compassion fatigue (Steinberg et al., 2016; Wahl et al., 2018).", [["depression", "DISEASE", 198, 208], ["cortisol", "CHEMICAL", 289, 297], ["fatigue", "DISEASE", 481, 488], ["cortisol", "CHEMICAL", 289, 297], ["self-compassion", "PROBLEM", 181, 196], ["depression", "PROBLEM", 198, 208], ["global symptoms", "PROBLEM", 210, 225], ["cortisol levels", "TEST", 289, 304]]], ["Though the true prevalence of burnout (Rotenstein et al., 2018), compassion fatigue, secondary traumatic stress and vicarious trauma in HCPs (Mol et al., 2015) remains open for discussion, compassionate care is fundamental for better clinical and patient outcomes, but during healthcare provision it can be hampered by several factors.", [["burnout", "DISEASE", 30, 37], ["compassion fatigue", "DISEASE", 65, 83], ["traumatic stress", "DISEASE", 95, 111], ["trauma", "DISEASE", 126, 132], ["patient", "ORGANISM", 247, 254], ["patient", "SPECIES", 247, 254], ["compassion fatigue", "PROBLEM", 65, 83], ["secondary traumatic stress", "PROBLEM", 85, 111], ["vicarious trauma", "PROBLEM", 116, 132], ["traumatic stress", "OBSERVATION", 95, 111]]], ["It has been highlighted that stress and negative affect, on which MBSR is particularly effective (Lamothe et al., 2016), were moderately positively associated with compassion fatigue, and that positive affect also had a moderately positive relationship with compassion satisfaction (Zhang et al., 2018).", [["fatigue", "DISEASE", 175, 182], ["compassion fatigue", "PROBLEM", 164, 182], ["negative affect", "OBSERVATION_MODIFIER", 40, 55]]], ["As for the neurobiological studies (H\u00f6lzel et al., 2013; Taren et al., 2013, 2015; Engen and Singer, 2015), mindfulness seems to be effective at improving negative affect and, possibly, compassion fatigue, while compassion satisfaction may be related to cultivation of positive affect.", [["fatigue", "DISEASE", 197, 204], ["the neurobiological studies", "TEST", 7, 34], ["compassion fatigue", "PROBLEM", 186, 204], ["positive affect", "PROBLEM", 269, 284], ["positive affect", "OBSERVATION", 269, 284]]], ["In this regard, CCT (Jazaieri et al., 2013; Scarlet et al., 2017) and MBIs (Wasson et al., 2020) have been shown to improve participants' self-compassion, mindfulness, and interpersonal conflict scores.MBSR, Mindfulness,- and Compassion-Related Interventions ::: DiscussionRemarkably, Egan et al. (2019) reported that HCPs are aware of the burnout potential and their experiences of the necessity to access help to cope with a demanding environment.", [["burnout", "DISEASE", 340, 347], ["participants", "SPECIES", 124, 136], ["CCT", "TEST", 16, 19], ["MBSR", "TEST", 202, 206]]], ["However, HCPs were not tired of being compassionate (compassion fatigue), but rather, tired of having to overcome the organizational barriers to being compassionate.", [["fatigue", "DISEASE", 64, 71], ["compassion fatigue", "PROBLEM", 53, 71]]], ["Participants did not state that they were tired of caring, but they were tired of not being able to care as they would like to.", [["Participants", "SPECIES", 0, 12]]], ["In this regard, MBSR, mindfulness- and compassion-related interventions may prevent HCPs' burnout and promote their enduring compassion and caring.Limitations and Future ResearchThe search strategy used in this review limited the search with the inclusion criteria of English or Italian language and peer-reviewed articles only.", [["burnout", "DISEASE", 90, 97], ["MBSR", "TEST", 16, 20]]], ["Consequently, though an extensive search was carried out, it is not correct to claim that the review is exhaustive given the papers excluded that were written in other languages or articles published in other formats (e.g., unpublished theses).Limitations and Future ResearchDespite these limitations, this systematic review presents a synthesis of mindfulness and compassion characteristics of the healthcare professionals and of MBSR, MBIs, and CBIs that have been delivered specifically to this professional population.", [["an extensive search", "TEST", 21, 40], ["MBSR", "TEST", 431, 435], ["MBIs", "TEST", 437, 441]]], ["Findings of the review depict the potential of MBSR, MBIs and CBIs as a tool for enhancing professionals' mindfulness, self-compassion and quality of life.", [["MBSR", "TEST", 47, 51], ["MBIs", "TEST", 53, 57]]], ["Considering the differences of methodological approach and intervention protocols of the existing MBSR, MBIs, and CBIs studies, for future research it may be suggested to carry out studies that combine structured mindfulness and compassion cultivation trainings (e.g., mindful self-compassion program; Neff and Germer, 2013) to enhance the effects of interventions, to limit the variability of intervention protocols and to improve data comparability.Data Availability StatementAll datasets generated for this study are included in the article/supplementary material.Author ContributionsCC designed and executed the study, assisted with the data analyses, and wrote the paper.", [["methodological approach", "TREATMENT", 31, 54], ["intervention protocols", "TREATMENT", 59, 81], ["the existing MBSR", "TEST", 85, 102], ["MBIs", "TEST", 104, 108], ["CBIs studies", "TEST", 114, 126], ["compassion cultivation trainings", "TEST", 229, 261], ["interventions", "TREATMENT", 351, 364], ["intervention protocols", "TREATMENT", 394, 416], ["this study", "TEST", 505, 515], ["the study", "TEST", 612, 621], ["the data analyses", "TEST", 637, 654]]], ["RC collaborated with the design and writing of the study.", [["the study", "TEST", 47, 56]]], ["AP collaborated with the design and writing of the study.", [["the study", "TEST", 47, 56]]]], "PMC7228791": [["IntroductionAround the turn of 2019, a novel coronavirus was seen as the focal cause of a cluster of symptoms that began in Wuhan, China and spread rapidly across continents with the World Health Organization (WHO) declaring a Public Health Emergency of International Concern known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or coronavirus disease-19 (COVID-19).", [["coronavirus", "DISEASE", 45, 56], ["acute respiratory syndrome coronavirus", "DISEASE", 292, 330], ["coronavirus disease", "DISEASE", 350, 369], ["coronavirus", "ORGANISM", 45, 56], ["SARS-CoV-2", "ORGANISM", 334, 344], ["severe acute respiratory syndrome coronavirus", "SPECIES", 285, 330], ["SARS-CoV-2", "SPECIES", 334, 344], ["a novel coronavirus", "PROBLEM", 37, 56], ["a cluster of symptoms", "PROBLEM", 88, 109], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 285, 330], ["SARS", "TEST", 334, 338], ["CoV", "TEST", 339, 342], ["coronavirus disease", "PROBLEM", 350, 369], ["COVID", "TEST", 374, 379], ["focal", "OBSERVATION_MODIFIER", 73, 78], ["severe", "OBSERVATION_MODIFIER", 285, 291], ["acute", "OBSERVATION_MODIFIER", 292, 297], ["respiratory syndrome", "OBSERVATION", 298, 318], ["coronavirus disease", "OBSERVATION", 350, 369]]], ["As of April 7, the Centers for Disease Control (CDC) reported over 390,000 cases with over 10,000 deaths within the United States (US), and a cumulative incidence increasing from 8.3 to 418 cases per 100,000 persons [1].", [["deaths", "DISEASE", 98, 104], ["persons", "SPECIES", 208, 215]]], ["Globally, over three million cases have been reported, with close to one million confirmed cases and 50,000 deaths in the US as of April 28, signifying a three-fold increase in cases over weeks [2].", [["deaths", "DISEASE", 108, 114], ["the US", "TEST", 118, 124]]], ["Risk factors include existing co-morbidities while middle and older-aged adults are most affected, with the latter often displaying severe disease and higher mortality rates.", [["adults", "ORGANISM", 73, 79], ["Risk factors", "PROBLEM", 0, 12], ["existing co-morbidities", "PROBLEM", 21, 44], ["severe disease", "PROBLEM", 132, 146], ["higher mortality rates", "PROBLEM", 151, 173], ["co-morbidities", "OBSERVATION", 30, 44], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["disease", "OBSERVATION", 139, 146]]], ["Among its various presentations, neurological sequelae were seen in 36.4%, while 5.7% had acute cerebrovascular accidents (CVA) [3].", [["neurological", "ANATOMY", 33, 45], ["cerebrovascular", "ANATOMY", 96, 111], ["neurological sequelae", "DISEASE", 33, 54], ["acute cerebrovascular accidents", "DISEASE", 90, 121], ["CVA", "DISEASE", 123, 126], ["neurological sequelae", "PROBLEM", 33, 54], ["acute cerebrovascular accidents (CVA)", "PROBLEM", 90, 127], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["cerebrovascular", "ANATOMY", 96, 111], ["accidents", "OBSERVATION", 112, 121]]], ["COVID-19 is known to have thrombotic complications in nearly 31% of critically ill patients [4].", [["thrombotic complications", "DISEASE", 26, 50], ["critically ill", "DISEASE", 68, 82], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["COVID", "TEST", 0, 5], ["thrombotic complications", "PROBLEM", 26, 50], ["thrombotic", "OBSERVATION_MODIFIER", 26, 36], ["complications", "OBSERVATION", 37, 50]]], ["Although a temporal relationship between COVID-19 patients and stroke incidence has not been parsed out, we present a case of a young patient with no risk factors who developed a severe COVID-19 infection and neurological sequelae.", [["neurological", "ANATOMY", 209, 221], ["stroke", "DISEASE", 63, 69], ["COVID", "DISEASE", 186, 191], ["infection", "DISEASE", 195, 204], ["neurological sequelae", "DISEASE", 209, 230], ["patients", "ORGANISM", 50, 58], ["patient", "ORGANISM", 134, 141], ["COVID", "PROTEIN", 41, 46], ["patients", "SPECIES", 50, 58], ["patient", "SPECIES", 134, 141], ["COVID", "TEST", 41, 46], ["stroke incidence", "PROBLEM", 63, 79], ["a severe COVID-19 infection", "PROBLEM", 177, 204], ["neurological sequelae", "PROBLEM", 209, 230], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["infection", "OBSERVATION", 195, 204]]], ["Short and long term outcomes in these patients are unknown [5].", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Short and long term outcomes", "PROBLEM", 0, 28], ["long term", "OBSERVATION_MODIFIER", 10, 19]]], ["We aim to strengthen the existing literature, explore the development of strokes in COVID-19 patients, and discuss strategies to identify patients at a higher risk to optimize resource allocation.Case presentationA previously healthy 31-year-old female presented to the emergency department (ED) with symptoms of fever, congestion, rhinorrhea, cough, myalgias, vomiting, and abdominal cramping evolving over five days.", [["abdominal", "ANATOMY", 375, 384], ["strokes", "DISEASE", 73, 80], ["fever", "DISEASE", 313, 318], ["congestion", "DISEASE", 320, 330], ["rhinorrhea", "DISEASE", 332, 342], ["cough", "DISEASE", 344, 349], ["myalgias", "DISEASE", 351, 359], ["vomiting", "DISEASE", 361, 369], ["abdominal cramping", "DISEASE", 375, 393], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 138, 146], ["female", "ORGANISM", 246, 252], ["abdominal", "ORGANISM_SUBDIVISION", 375, 384], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 138, 146], ["strokes", "PROBLEM", 73, 80], ["resource allocation", "TREATMENT", 176, 195], ["symptoms", "PROBLEM", 301, 309], ["fever", "PROBLEM", 313, 318], ["congestion", "PROBLEM", 320, 330], ["rhinorrhea", "PROBLEM", 332, 342], ["cough", "PROBLEM", 344, 349], ["myalgias", "PROBLEM", 351, 359], ["vomiting", "PROBLEM", 361, 369], ["abdominal cramping", "PROBLEM", 375, 393], ["strokes", "OBSERVATION", 73, 80], ["fever", "OBSERVATION", 313, 318], ["congestion", "OBSERVATION", 320, 330], ["rhinorrhea", "OBSERVATION", 332, 342], ["cough", "OBSERVATION", 344, 349], ["myalgias", "OBSERVATION", 351, 359], ["abdominal", "ANATOMY", 375, 384], ["cramping", "OBSERVATION", 385, 393]]], ["She worked at a factory, but was not exposed to any symptomatic contacts and did not use tobacco products, alcohol, or illicit substances.", [["alcohol", "CHEMICAL", 107, 114], ["alcohol", "CHEMICAL", 107, 114], ["tobacco", "ORGANISM", 89, 96], ["alcohol", "SIMPLE_CHEMICAL", 107, 114], ["tobacco", "SPECIES", 89, 96]]], ["On arrival, her vitals were blood pressure - 97/73 mm Hg, heart rate - 127 beats/minute, respiratory rate - 18 breaths/minute while saturating was at 95% on supplemental oxygen, along with persistent fevers despite acetaminophen administration.", [["blood", "ANATOMY", 28, 33], ["heart", "ANATOMY", 58, 63], ["respiratory", "ANATOMY", 89, 100], ["oxygen", "CHEMICAL", 170, 176], ["fevers", "DISEASE", 200, 206], ["acetaminophen", "CHEMICAL", 215, 228], ["Hg", "CHEMICAL", 54, 56], ["oxygen", "CHEMICAL", 170, 176], ["acetaminophen", "CHEMICAL", 215, 228], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["heart", "ORGAN", 58, 63], ["oxygen", "SIMPLE_CHEMICAL", 170, 176], ["acetaminophen", "SIMPLE_CHEMICAL", 215, 228], ["her vitals", "TEST", 12, 22], ["blood pressure", "TEST", 28, 42], ["Hg", "TEST", 54, 56], ["heart rate", "TEST", 58, 68], ["beats/minute", "TEST", 75, 87], ["respiratory rate", "TEST", 89, 105], ["supplemental oxygen", "TREATMENT", 157, 176], ["persistent fevers", "PROBLEM", 189, 206], ["acetaminophen administration", "TREATMENT", 215, 243], ["persistent", "OBSERVATION_MODIFIER", 189, 199], ["fevers", "OBSERVATION", 200, 206]]], ["On exam, she appeared ill, uncomfortable, and in acute distress.", [["exam", "TEST", 3, 7], ["ill", "PROBLEM", 22, 25], ["uncomfortable", "PROBLEM", 27, 40], ["acute distress", "PROBLEM", 49, 63], ["ill", "OBSERVATION", 22, 25], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["distress", "OBSERVATION", 55, 63]]], ["Initial investigations were remarkable for hypernatremia, acute kidney injury (AKI), and bilateral infiltrates on chest radiograph indicative of pneumonia (Figure 1).", [["kidney", "ANATOMY", 64, 70], ["chest", "ANATOMY", 114, 119], ["hypernatremia", "DISEASE", 43, 56], ["acute kidney injury", "DISEASE", 58, 77], ["AKI", "DISEASE", 79, 82], ["pneumonia", "DISEASE", 145, 154], ["kidney", "ORGAN", 64, 70], ["Initial investigations", "TEST", 0, 22], ["hypernatremia", "PROBLEM", 43, 56], ["acute kidney injury", "PROBLEM", 58, 77], ["AKI", "PROBLEM", 79, 82], ["bilateral infiltrates", "PROBLEM", 89, 110], ["chest radiograph", "TEST", 114, 130], ["pneumonia", "PROBLEM", 145, 154], ["hypernatremia", "OBSERVATION", 43, 56], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["kidney", "ANATOMY", 64, 70], ["injury", "OBSERVATION", 71, 77], ["AKI", "OBSERVATION", 79, 82], ["bilateral", "ANATOMY_MODIFIER", 89, 98], ["infiltrates", "OBSERVATION", 99, 110], ["chest", "ANATOMY", 114, 119], ["indicative of", "UNCERTAINTY", 131, 144], ["pneumonia", "OBSERVATION", 145, 154]]], ["Ceftriaxone and azithromycin were started empirically with intravenous hydration, while nasopharyngeal swab for COVID-19 was obtained.", [["intravenous", "ANATOMY", 59, 70], ["nasopharyngeal swab", "ANATOMY", 88, 107], ["Ceftriaxone", "CHEMICAL", 0, 11], ["azithromycin", "CHEMICAL", 16, 28], ["Ceftriaxone", "CHEMICAL", 0, 11], ["azithromycin", "CHEMICAL", 16, 28], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["azithromycin", "SIMPLE_CHEMICAL", 16, 28], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 70], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 88, 107], ["Ceftriaxone", "TREATMENT", 0, 11], ["azithromycin", "TREATMENT", 16, 28], ["intravenous hydration", "TREATMENT", 59, 80], ["nasopharyngeal swab", "TEST", 88, 107], ["COVID", "TEST", 112, 117]]], ["Her hypoxia and fevers continued to worsen with increasing oxygen requirements, evolving hypotension, and tachypnea, requiring intubation and sedation with transfer to the intensive care unit (ICU).Case presentationA chest computed tomography (CT) was consistent with acute respiratory distress syndrome (ARDS) with partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio dropping as low as 77.5 consistent with severe ARDS (Figure 2).", [["respiratory", "ANATOMY", 274, 285], ["hypoxia", "DISEASE", 4, 11], ["fevers", "DISEASE", 16, 22], ["oxygen", "CHEMICAL", 59, 65], ["hypotension", "DISEASE", 89, 100], ["tachypnea", "DISEASE", 106, 115], ["acute respiratory distress syndrome", "DISEASE", 268, 303], ["ARDS", "DISEASE", 305, 309], ["oxygen", "CHEMICAL", 336, 342], ["oxygen", "CHEMICAL", 371, 377], ["ARDS", "DISEASE", 438, 442], ["oxygen", "CHEMICAL", 59, 65], ["oxygen", "CHEMICAL", 336, 342], ["oxygen", "CHEMICAL", 371, 377], ["FiO2", "CHEMICAL", 379, 383], ["oxygen", "SIMPLE_CHEMICAL", 59, 65], ["oxygen", "SIMPLE_CHEMICAL", 336, 342], ["PaO2", "SIMPLE_CHEMICAL", 344, 348], ["oxygen", "SIMPLE_CHEMICAL", 371, 377], ["FiO2", "SIMPLE_CHEMICAL", 379, 383], ["Her hypoxia", "PROBLEM", 0, 11], ["fevers", "PROBLEM", 16, 22], ["increasing oxygen requirements", "PROBLEM", 48, 78], ["evolving hypotension", "PROBLEM", 80, 100], ["tachypnea", "PROBLEM", 106, 115], ["intubation", "TREATMENT", 127, 137], ["sedation", "TREATMENT", 142, 150], ["Case presentationA chest computed tomography", "TEST", 198, 242], ["CT", "TEST", 244, 246], ["acute respiratory distress syndrome", "PROBLEM", 268, 303], ["ARDS", "PROBLEM", 305, 309], ["partial pressure of oxygen", "TREATMENT", 316, 342], ["PaO2", "TEST", 344, 348], ["inspired oxygen", "TREATMENT", 362, 377], ["FiO2", "TEST", 379, 383], ["ratio", "TEST", 385, 390], ["severe ARDS", "PROBLEM", 431, 442], ["hypoxia", "OBSERVATION", 4, 11], ["fevers", "OBSERVATION", 16, 22], ["increasing", "OBSERVATION_MODIFIER", 48, 58], ["oxygen requirements", "OBSERVATION", 59, 78], ["hypotension", "OBSERVATION", 89, 100], ["tachypnea", "OBSERVATION", 106, 115], ["chest", "ANATOMY", 217, 222], ["consistent with", "UNCERTAINTY", 252, 267], ["acute", "OBSERVATION_MODIFIER", 268, 273], ["respiratory", "OBSERVATION", 274, 285], ["distress syndrome", "OBSERVATION", 286, 303], ["partial", "OBSERVATION_MODIFIER", 316, 323], ["pressure", "OBSERVATION_MODIFIER", 324, 332], ["oxygen", "OBSERVATION_MODIFIER", 336, 342], ["consistent with", "UNCERTAINTY", 415, 430], ["severe", "OBSERVATION_MODIFIER", 431, 437], ["ARDS", "OBSERVATION", 438, 442]]], ["Testing to detect SARS-COV-2 came back positive.", [["Testing", "TEST", 0, 7], ["SARS", "TEST", 18, 22], ["COV", "TEST", 23, 26], ["positive", "PROBLEM", 39, 47]]], ["She was started on a course of hydroxychloroquine and optimized to lung-protective ventilation.", [["lung", "ANATOMY", 67, 71], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 31, 49], ["lung", "ORGAN", 67, 71], ["hydroxychloroquine", "TREATMENT", 31, 49], ["lung-protective ventilation", "TREATMENT", 67, 94], ["lung", "ANATOMY", 67, 71], ["protective ventilation", "OBSERVATION", 72, 94]]], ["Initial COVID-19 labs were indicative of cytokine release syndrome, while a high A-a gradient concerning for a V/Q mismatch was consistent with COVID-19 phenotype L (Table 1).Case presentationShe was placed on a short course of therapeutic anticoagulation.", [["COVID", "DNA", 8, 13], ["cytokine", "PROTEIN", 41, 49], ["Initial COVID", "TEST", 0, 13], ["labs", "TEST", 17, 21], ["cytokine release syndrome", "PROBLEM", 41, 66], ["a high A-a gradient", "PROBLEM", 74, 93], ["a V/Q mismatch", "PROBLEM", 109, 123], ["COVID", "TEST", 144, 149], ["therapeutic anticoagulation", "TREATMENT", 228, 255], ["indicative of", "UNCERTAINTY", 27, 40], ["cytokine release syndrome", "OBSERVATION", 41, 66], ["consistent with", "UNCERTAINTY", 128, 143]]], ["She was proned with intermittent paralytics to improve oxygenation and synchronize her to the ventilator.", [["intermittent paralytics", "TREATMENT", 20, 43], ["the ventilator", "TREATMENT", 90, 104]]], ["On daily awakening trials, she displayed significant features of confusion and encephalopathy.", [["confusion", "DISEASE", 65, 74], ["encephalopathy", "DISEASE", 79, 93], ["daily awakening trials", "TREATMENT", 3, 25], ["confusion", "PROBLEM", 65, 74], ["encephalopathy", "PROBLEM", 79, 93], ["confusion", "OBSERVATION", 65, 74], ["encephalopathy", "OBSERVATION", 79, 93]]], ["During saturation and weaning of her paralytic, new left-hand flaccidity was noted.", [["left-hand", "ANATOMY", 52, 61], ["paralytic", "DISEASE", 37, 46], ["her paralytic", "TREATMENT", 33, 46], ["new left-hand flaccidity", "PROBLEM", 48, 72], ["left", "ANATOMY_MODIFIER", 52, 56], ["hand", "ANATOMY", 57, 61], ["flaccidity", "OBSERVATION", 62, 72]]], ["The finding was subtle, and the National Institutes of Health Stroke Scale (NIHSS) could not be assessed due to her inability to follow commands.", [["Stroke", "DISEASE", 62, 68], ["subtle", "OBSERVATION_MODIFIER", 16, 22]]], ["However, brainstem reflexes were preserved with pupillary and cough reflexes to stimuli, the ability to trigger spontaneous breaths, and response to pain.", [["brainstem", "ANATOMY", 9, 18], ["pain", "DISEASE", 149, 153], ["brainstem reflexes", "TEST", 9, 27], ["pupillary and cough reflexes", "TEST", 48, 76], ["stimuli", "TEST", 80, 87], ["pain", "PROBLEM", 149, 153], ["brainstem reflexes", "ANATOMY", 9, 27]]], ["Delays in obtaining an emergent CT scan of her head ensued due to her positivity for COVID-19 and an equivocal stroke-like presentation.", [["head", "ANATOMY", 47, 51], ["stroke", "DISEASE", 111, 117], ["head", "ORGANISM_SUBDIVISION", 47, 51], ["an emergent CT scan of her head", "TEST", 20, 51], ["her positivity", "TEST", 66, 80], ["COVID", "TEST", 85, 90], ["an equivocal stroke", "PROBLEM", 98, 117], ["head", "ANATOMY", 47, 51], ["equivocal", "OBSERVATION_MODIFIER", 101, 110], ["stroke", "OBSERVATION", 111, 117]]], ["After appropriate precautions were set up, the final read of the CT was unrevealing for an acute or subacute infarct or hemorrhage (Figure 3).", [["infarct", "DISEASE", 109, 116], ["hemorrhage", "DISEASE", 120, 130], ["appropriate precautions", "TREATMENT", 6, 29], ["the CT", "TEST", 61, 67], ["an acute or subacute infarct", "PROBLEM", 88, 116], ["hemorrhage", "PROBLEM", 120, 130], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["subacute", "OBSERVATION_MODIFIER", 100, 108], ["infarct", "OBSERVATION", 109, 116], ["hemorrhage", "OBSERVATION", 120, 130]]], ["At the same time, her last known well could not be gauged due to her level of sedation and fluctuating mentation, precluding reperfusion therapies.", [["sedation", "TREATMENT", 78, 86], ["fluctuating mentation", "PROBLEM", 91, 112], ["reperfusion therapies", "TREATMENT", 125, 146]]], ["Atorvastatin and aspirin were started for secondary prevention, while COVID-19 labs were repeated to trend progression of the disease.", [["Atorvastatin", "CHEMICAL", 0, 12], ["aspirin", "CHEMICAL", 17, 24], ["Atorvastatin", "CHEMICAL", 0, 12], ["aspirin", "CHEMICAL", 17, 24], ["Atorvastatin", "SIMPLE_CHEMICAL", 0, 12], ["aspirin", "SIMPLE_CHEMICAL", 17, 24], ["Atorvastatin", "TREATMENT", 0, 12], ["aspirin", "TREATMENT", 17, 24], ["COVID", "TEST", 70, 75], ["labs", "TEST", 79, 83], ["the disease", "PROBLEM", 122, 133], ["disease", "OBSERVATION", 126, 133]]], ["A repeat CT scan revealed ischemic changes in the region supplied by the right middle cerebral artery (MCA) consistent with a cortical stroke (Figure 4).", [["right middle cerebral artery", "ANATOMY", 73, 101], ["MCA", "ANATOMY", 103, 106], ["cortical", "ANATOMY", 126, 134], ["cortical stroke", "DISEASE", 126, 141], ["middle cerebral artery", "MULTI-TISSUE_STRUCTURE", 79, 101], ["MCA", "MULTI-TISSUE_STRUCTURE", 103, 106], ["A repeat CT scan", "TEST", 0, 16], ["ischemic changes in the region", "PROBLEM", 26, 56], ["a cortical stroke", "PROBLEM", 124, 141], ["ischemic", "OBSERVATION", 26, 34], ["region", "ANATOMY_MODIFIER", 50, 56], ["right middle cerebral artery", "ANATOMY", 73, 101], ["MCA", "ANATOMY", 103, 106], ["consistent with", "UNCERTAINTY", 108, 123], ["cortical", "OBSERVATION_MODIFIER", 126, 134], ["stroke", "OBSERVATION", 135, 141]]], ["Follow up echocardiogram, and hypercoagulable workup was negative as seen in Table 1, including ultrasounds in the upper and lower extremities looking for deep vein thromboses (DVTs) to look for sources of thrombi (Figure 5).", [["upper", "ANATOMY", 115, 120], ["lower extremities", "ANATOMY", 125, 142], ["deep vein", "ANATOMY", 155, 164], ["thrombi", "ANATOMY", 206, 213], ["deep vein thromboses", "DISEASE", 155, 175], ["DVTs", "DISEASE", 177, 181], ["thrombi", "DISEASE", 206, 213], ["upper", "ORGANISM_SUBDIVISION", 115, 120], ["lower extremities", "ORGANISM_SUBDIVISION", 125, 142], ["deep vein", "MULTI-TISSUE_STRUCTURE", 155, 164], ["thrombi", "PATHOLOGICAL_FORMATION", 206, 213], ["Follow up echocardiogram", "TEST", 0, 24], ["hypercoagulable workup", "TEST", 30, 52], ["ultrasounds", "TEST", 96, 107], ["deep vein thromboses", "PROBLEM", 155, 175], ["DVTs", "PROBLEM", 177, 181], ["thrombi", "PROBLEM", 206, 213], ["upper", "ANATOMY_MODIFIER", 115, 120], ["lower extremities", "ANATOMY", 125, 142], ["deep vein", "ANATOMY", 155, 164], ["thromboses", "OBSERVATION", 165, 175], ["thrombi", "OBSERVATION", 206, 213]]], ["After remaining on mechanical ventilation and nasogastric (NG) feeding for a prolonged period, a tracheostomy and percutaneous endoscopic gastrostomy (PEG) tube were performed.Case presentationOver the next few days, improvements in her mentation were noted with opening and tracking with her eyes, and the ability to start following commands.", [["eyes", "ANATOMY", 293, 297], ["NG", "CHEMICAL", 59, 61], ["PEG", "CHEMICAL", 151, 154], ["eyes", "ORGAN", 293, 297], ["mechanical ventilation", "TREATMENT", 19, 41], ["nasogastric (NG) feeding", "TREATMENT", 46, 70], ["a prolonged period", "TREATMENT", 75, 93], ["a tracheostomy", "TREATMENT", 95, 109], ["percutaneous endoscopic gastrostomy (PEG) tube", "TREATMENT", 114, 160], ["mechanical ventilation", "OBSERVATION", 19, 41], ["tracheostomy", "OBSERVATION", 97, 109], ["gastrostomy", "OBSERVATION", 138, 149]]], ["Physical therapy assessments recorded low mobility scores and severe disability while continuing to demonstrate periods of confusion.", [["disability", "DISEASE", 69, 79], ["confusion", "DISEASE", 123, 132], ["Physical therapy assessments", "TEST", 0, 28], ["low mobility scores", "PROBLEM", 38, 57], ["severe disability", "PROBLEM", 62, 79], ["confusion", "PROBLEM", 123, 132]]], ["She was improving globally with the ability to tolerate breathing trials and follow commands.", [["breathing trials", "TREATMENT", 56, 72]]], ["Conferred an overall poor prognosis, she was discharged to a rehabilitation facility.DiscussionThe COVID-19 infection is an ongoing global pandemic with a high morbidity and mortality rate.", [["infection", "DISEASE", 108, 117], ["COVID-19", "ORGANISM", 99, 107], ["COVID-19", "SPECIES", 99, 107], ["The COVID", "TEST", 95, 104], ["infection", "PROBLEM", 108, 117], ["an ongoing global pandemic", "PROBLEM", 121, 147], ["a high morbidity", "PROBLEM", 153, 169], ["mortality rate", "TEST", 174, 188], ["infection", "OBSERVATION", 108, 117]]], ["SARS-CoV-2 has the propensity to infect the central nervous system, with autopsy reports revealing hyperemia and edema in affected patients [3].", [["central nervous system", "ANATOMY", 44, 66], ["edema", "ANATOMY", 113, 118], ["SARS", "DISEASE", 0, 4], ["hyperemia", "DISEASE", 99, 108], ["edema", "DISEASE", 113, 118], ["SARS-CoV-2", "ORGANISM", 0, 10], ["central nervous system", "ANATOMICAL_SYSTEM", 44, 66], ["edema", "PATHOLOGICAL_FORMATION", 113, 118], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 0, 8], ["autopsy", "TEST", 73, 80], ["hyperemia", "PROBLEM", 99, 108], ["edema", "PROBLEM", 113, 118], ["central", "ANATOMY_MODIFIER", 44, 51], ["nervous system", "ANATOMY", 52, 66], ["hyperemia", "OBSERVATION", 99, 108], ["edema", "OBSERVATION", 113, 118]]], ["COVID-19 patients with cerebrovascular diseases were noted to be at a higher risk for critical illness and multiorgan dysfunction based on previous reports from the SARS epidemic [6].", [["cerebrovascular", "ANATOMY", 23, 38], ["multiorgan", "ANATOMY", 107, 117], ["cerebrovascular diseases", "DISEASE", 23, 47], ["multiorgan dysfunction", "DISEASE", 107, 129], ["SARS", "DISEASE", 165, 169], ["patients", "ORGANISM", 9, 17], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 23, 38], ["multiorgan", "ORGAN", 107, 117], ["patients", "SPECIES", 9, 17], ["cerebrovascular diseases", "PROBLEM", 23, 47], ["critical illness", "PROBLEM", 86, 102], ["multiorgan dysfunction", "PROBLEM", 107, 129], ["the SARS epidemic", "PROBLEM", 161, 178], ["cerebrovascular", "ANATOMY", 23, 38], ["diseases", "OBSERVATION", 39, 47], ["multiorgan dysfunction", "OBSERVATION", 107, 129]]], ["Amongst retrospective studies looking at the development of neurologic features during critical COVID-19 illness, 3.4% - 5% were found to have new ischemic strokes, with the youngest patient at 55 years of age [5,7].", [["neurologic", "ANATOMY", 60, 70], ["ischemic strokes", "DISEASE", 147, 163], ["patient", "ORGANISM", 183, 190], ["patient", "SPECIES", 183, 190], ["Amongst retrospective studies", "TEST", 0, 29], ["neurologic features", "PROBLEM", 60, 79], ["critical COVID", "TEST", 87, 101], ["new ischemic strokes", "PROBLEM", 143, 163], ["new", "OBSERVATION_MODIFIER", 143, 146], ["ischemic", "OBSERVATION_MODIFIER", 147, 155], ["strokes", "OBSERVATION", 156, 163]]], ["In our patient with no apparent risk factors for a CVA and a young age, this case demonstrates that patients, regardless of their age, are at risk for severe neurological complications from this disease.", [["neurological", "ANATOMY", 158, 170], ["CVA", "DISEASE", 51, 54], ["patient", "ORGANISM", 7, 14], ["patients", "ORGANISM", 100, 108], ["patient", "SPECIES", 7, 14], ["patients", "SPECIES", 100, 108], ["a CVA", "PROBLEM", 49, 54], ["severe neurological complications", "PROBLEM", 151, 184], ["this disease", "PROBLEM", 190, 202], ["CVA", "OBSERVATION", 51, 54], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["neurological", "OBSERVATION_MODIFIER", 158, 170], ["complications", "OBSERVATION", 171, 184]]], ["COVID-19 is known to induce states of hypercoagulability by deranging pathways of hemostasis seen on thromboelastography (TEG) [8].", [["COVID-19", "CHEMICAL", 0, 8], ["hypercoagulability", "DISEASE", 38, 56], ["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5], ["hypercoagulability", "PROBLEM", 38, 56], ["hemostasis", "PROBLEM", 82, 92], ["thromboelastography", "TEST", 101, 120], ["TEG", "TEST", 122, 125], ["hypercoagulability", "OBSERVATION", 38, 56], ["hemostasis", "OBSERVATION", 82, 92]]], ["The viral load contributes to coagulopathy and endothelial dysfunction, similar to patients that developed strokes associated with SARS [5].DiscussionIn our patient, serial d-dimers rose in the days leading up to the stroke, indicating an acute state of hypercoagulability despite receiving therapeutic anticoagulation.", [["endothelial", "ANATOMY", 47, 58], ["coagulopathy", "DISEASE", 30, 42], ["endothelial dysfunction", "DISEASE", 47, 70], ["strokes", "DISEASE", 107, 114], ["SARS", "DISEASE", 131, 135], ["stroke", "DISEASE", 217, 223], ["hypercoagulability", "DISEASE", 254, 272], ["endothelial", "TISSUE", 47, 58], ["patients", "ORGANISM", 83, 91], ["patient", "ORGANISM", 157, 164], ["patients", "SPECIES", 83, 91], ["patient", "SPECIES", 157, 164], ["The viral load", "PROBLEM", 0, 14], ["coagulopathy", "PROBLEM", 30, 42], ["endothelial dysfunction", "PROBLEM", 47, 70], ["strokes", "PROBLEM", 107, 114], ["SARS", "PROBLEM", 131, 135], ["serial d-dimers", "TEST", 166, 181], ["the stroke", "PROBLEM", 213, 223], ["hypercoagulability", "PROBLEM", 254, 272], ["therapeutic anticoagulation", "TREATMENT", 291, 318], ["viral load", "OBSERVATION", 4, 14], ["coagulopathy", "OBSERVATION", 30, 42], ["endothelial dysfunction", "OBSERVATION", 47, 70], ["strokes", "OBSERVATION", 107, 114], ["stroke", "OBSERVATION", 217, 223], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["hypercoagulability", "OBSERVATION", 254, 272]]], ["She received a short course of therapeutic anticoagulation but was suboptimally given due to the lack of data guiding the use of anticoagulation in severely ill COVID-19 patients.", [["COVID", "DISEASE", 161, 166], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["therapeutic anticoagulation", "TREATMENT", 31, 58], ["anticoagulation", "TREATMENT", 129, 144]]], ["Another explanation could be an exaggerated systemic inflammation or a \"cytokine\" storm, often a marker of severe disease manifested in our patient with increasing pro-thrombotic markers, including IL-6 levels.", [["inflammation", "DISEASE", 53, 65], ["patient", "ORGANISM", 140, 147], ["IL-6", "GENE_OR_GENE_PRODUCT", 198, 202], ["cytokine", "PROTEIN", 72, 80], ["pro-thrombotic markers", "PROTEIN", 164, 186], ["IL", "PROTEIN", 198, 200], ["patient", "SPECIES", 140, 147], ["an exaggerated systemic inflammation", "PROBLEM", 29, 65], ["a \"cytokine\" storm", "PROBLEM", 69, 87], ["severe disease", "PROBLEM", 107, 121], ["increasing pro-thrombotic markers", "PROBLEM", 153, 186], ["IL", "TEST", 198, 200], ["exaggerated", "OBSERVATION_MODIFIER", 32, 43], ["systemic", "OBSERVATION_MODIFIER", 44, 52], ["inflammation", "OBSERVATION", 53, 65], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["disease", "OBSERVATION", 114, 121], ["increasing", "OBSERVATION_MODIFIER", 153, 163], ["pro-thrombotic", "OBSERVATION", 164, 178]]], ["Blood cultures and echocardiography were unremarkable for signs of an infection, while carotid ultrasound with dopplers was negative for low flow states between the carotids.", [["Blood cultures", "ANATOMY", 0, 14], ["carotid", "ANATOMY", 87, 94], ["carotids", "ANATOMY", 165, 173], ["infection", "DISEASE", 70, 79], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["carotid", "MULTI-TISSUE_STRUCTURE", 87, 94], ["carotids", "CANCER", 165, 173], ["Blood cultures", "TEST", 0, 14], ["echocardiography", "TEST", 19, 35], ["an infection", "PROBLEM", 67, 79], ["carotid ultrasound", "TEST", 87, 105], ["dopplers", "TEST", 111, 119], ["low flow states between the carotids", "PROBLEM", 137, 173], ["infection", "OBSERVATION", 70, 79], ["low flow", "OBSERVATION", 137, 145], ["carotids", "ANATOMY", 165, 173]]], ["Studies looking at neurological manifestation in COVID-19 patients, signs were most commonly noted early in the disease course presenting with muscle symptoms and confusion, while d-dimer levels were higher compared to non-severe infections [3].DiscussionIn a pooled analysis of the current literature, CVAs were associated with a significantly increased risk (2.5x) of a severe form of COVID-19 disease.", [["neurological", "ANATOMY", 19, 31], ["muscle", "ANATOMY", 143, 149], ["muscle symptoms", "DISEASE", 143, 158], ["confusion", "DISEASE", 163, 172], ["infections", "DISEASE", 230, 240], ["patients", "ORGANISM", 58, 66], ["muscle", "ORGAN", 143, 149], ["d-dimer", "GENE_OR_GENE_PRODUCT", 180, 187], ["patients", "SPECIES", 58, 66], ["Studies", "TEST", 0, 7], ["signs", "PROBLEM", 68, 73], ["muscle symptoms", "PROBLEM", 143, 158], ["confusion", "PROBLEM", 163, 172], ["d-dimer levels", "TEST", 180, 194], ["non-severe infections", "PROBLEM", 219, 240], ["a pooled analysis", "TEST", 258, 275], ["CVAs", "PROBLEM", 303, 307], ["a significantly increased risk", "PROBLEM", 329, 359], ["COVID-19 disease", "PROBLEM", 387, 403], ["muscle", "ANATOMY", 143, 149], ["significantly", "OBSERVATION_MODIFIER", 331, 344], ["increased", "OBSERVATION_MODIFIER", 345, 354], ["severe", "OBSERVATION_MODIFIER", 372, 378], ["19 disease", "OBSERVATION", 393, 403]]], ["Critical illness-related encephalopathy and cytokines have been implicated as components of severe neurological manifestations seen with COVID-19, another feature noted in our patient before the development of her stroke, signifying a potential pre-cursor symptom [7].", [["neurological", "ANATOMY", 99, 111], ["Critical illness", "DISEASE", 0, 16], ["encephalopathy", "DISEASE", 25, 39], ["stroke", "DISEASE", 214, 220], ["COVID-19", "CHEMICAL", 137, 145], ["patient", "ORGANISM", 176, 183], ["cytokines", "PROTEIN", 44, 53], ["patient", "SPECIES", 176, 183], ["Critical illness", "PROBLEM", 0, 16], ["encephalopathy", "PROBLEM", 25, 39], ["cytokines", "PROBLEM", 44, 53], ["severe neurological manifestations", "PROBLEM", 92, 126], ["COVID", "TEST", 137, 142], ["her stroke", "PROBLEM", 210, 220], ["a potential pre-cursor symptom", "PROBLEM", 233, 263], ["illness", "OBSERVATION", 9, 16], ["encephalopathy", "OBSERVATION", 25, 39], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["neurological", "OBSERVATION", 99, 111], ["stroke", "OBSERVATION", 214, 220]]], ["The American Society of Hematology (ASH) recommends that all COVID-19 patients receive pharmacologic thromboprophylaxis, while seriously ill, high risk, or patients with high d-dimer levels should undergo therapeutic doses due to concerns for microvascular thrombosis, although these recommendations are based on limited data [9].DiscussionAmongst care for patients that developed strokes, only a small range of entities across the world can maintain their full range of acute stroke services, with most having to reorganize with the allocation of resources, including beds towards critically ill COVID-19 patients.", [["microvascular", "ANATOMY", 243, 256], ["microvascular thrombosis", "DISEASE", 243, 267], ["strokes", "DISEASE", 381, 388], ["stroke", "DISEASE", 477, 483], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 156, 164], ["d-dimer", "GENE_OR_GENE_PRODUCT", 175, 182], ["microvascular", "MULTI-TISSUE_STRUCTURE", 243, 256], ["patients", "ORGANISM", 357, 365], ["patients", "ORGANISM", 606, 614], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 156, 164], ["patients", "SPECIES", 357, 365], ["patients", "SPECIES", 606, 614], ["all COVID", "TREATMENT", 57, 66], ["pharmacologic thromboprophylaxis", "TREATMENT", 87, 119], ["high d-dimer levels", "PROBLEM", 170, 189], ["therapeutic doses", "TREATMENT", 205, 222], ["microvascular thrombosis", "PROBLEM", 243, 267], ["strokes", "PROBLEM", 381, 388], ["acute stroke services", "TREATMENT", 471, 492], ["microvascular", "ANATOMY", 243, 256], ["thrombosis", "OBSERVATION", 257, 267], ["strokes", "OBSERVATION", 381, 388], ["small", "OBSERVATION_MODIFIER", 397, 402]]], ["The delivery of crucial therapies such as endovascular services, intravenous thrombolysis, or carotid endarterectomies in acute stroke patients has been compromised, with delays increasing door to needle times [10,11].", [["intravenous", "ANATOMY", 65, 76], ["carotid", "ANATOMY", 94, 101], ["carotid endarterectomies", "DISEASE", 94, 118], ["stroke", "DISEASE", 128, 134], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 76], ["carotid", "MULTI-TISSUE_STRUCTURE", 94, 101], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["crucial therapies", "TREATMENT", 16, 33], ["endovascular services", "TREATMENT", 42, 63], ["intravenous thrombolysis", "TREATMENT", 65, 89], ["carotid endarterectomies", "TREATMENT", 94, 118], ["acute stroke", "PROBLEM", 122, 134], ["carotid", "ANATOMY", 94, 101], ["endarterectomies", "OBSERVATION", 102, 118], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["stroke", "OBSERVATION", 128, 134]]], ["Patients that develop strokes requiring hospitalization during the COVID-19 pandemic are at an increased risk for suboptimal outcomes [12].", [["strokes", "DISEASE", 22, 29], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["strokes", "PROBLEM", 22, 29], ["the COVID", "TREATMENT", 63, 72], ["strokes", "OBSERVATION", 22, 29]]], ["Acute stroke management pathways have been delineated in COVID-19 patients keeping in mind practice patterns, resource allocation, and the presence of a large vessel occlusion (LVO).", [["vessel", "ANATOMY", 159, 165], ["stroke", "DISEASE", 6, 12], ["vessel occlusion", "DISEASE", 159, 175], ["LVO", "DISEASE", 177, 180], ["patients", "ORGANISM", 66, 74], ["vessel", "MULTI-TISSUE_STRUCTURE", 159, 165], ["patients", "SPECIES", 66, 74], ["Acute stroke management pathways", "PROBLEM", 0, 32], ["a large vessel occlusion", "PROBLEM", 151, 175], ["stroke", "OBSERVATION", 6, 12], ["large", "OBSERVATION_MODIFIER", 153, 158], ["vessel", "ANATOMY", 159, 165], ["occlusion", "OBSERVATION", 166, 175]]], ["Patients with non-LVO ischemic strokes are recommended to transfer to an infectious disease ward or a dedicated closely monitoring neurological ward [11].ConclusionsSARS-CoV-2 is known to induce states of hypercoagulability placing critically ill patients at high risk for vascular complications.", [["vascular", "ANATOMY", 273, 281], ["ischemic strokes", "DISEASE", 22, 38], ["hypercoagulability", "DISEASE", 205, 223], ["critically ill", "DISEASE", 232, 246], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 247, 255], ["vascular", "MULTI-TISSUE_STRUCTURE", 273, 281], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 247, 255], ["non-LVO ischemic strokes", "PROBLEM", 14, 38], ["ConclusionsSARS", "TEST", 154, 169], ["hypercoagulability", "PROBLEM", 205, 223], ["vascular complications", "PROBLEM", 273, 295], ["ischemic", "OBSERVATION_MODIFIER", 22, 30], ["strokes", "OBSERVATION", 31, 38], ["hypercoagulability", "OBSERVATION", 205, 223], ["vascular", "ANATOMY", 273, 281], ["complications", "OBSERVATION", 282, 295]]], ["Limited knowledge of the sequelae of this infection and guidelines leaves isolated case reports to guide clinical decision making, especially in patients exhibiting neurological complications.", [["neurological", "ANATOMY", 165, 177], ["infection", "DISEASE", 42, 51], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["this infection", "PROBLEM", 37, 51], ["neurological complications", "PROBLEM", 165, 191], ["infection", "OBSERVATION", 42, 51]]], ["Despite being a disease that is known to traditionally affect the elderly, emerging reports of seemingly low-risk patients developing strokes are being published and thromboprophylaxis must be considered in seriously ill, high risk, or patients with high d-dimer levels.", [["strokes", "DISEASE", 134, 141], ["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 236, 244], ["d-dimer", "GENE_OR_GENE_PRODUCT", 255, 262], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 236, 244], ["a disease", "PROBLEM", 14, 23], ["strokes", "PROBLEM", 134, 141], ["thromboprophylaxis", "TREATMENT", 166, 184], ["high d-dimer levels", "PROBLEM", 250, 269], ["disease", "OBSERVATION", 16, 23], ["strokes", "OBSERVATION", 134, 141]]], ["Encephalopathy is a frequently cited neurological manifestation of COVID-19 disease and can present as a sentinel sign for evolving strokes.", [["neurological", "ANATOMY", 37, 49], ["Encephalopathy", "DISEASE", 0, 14], ["COVID-19 disease", "DISEASE", 67, 83], ["strokes", "DISEASE", 132, 139], ["Encephalopathy", "PROBLEM", 0, 14], ["COVID-19 disease", "PROBLEM", 67, 83], ["evolving strokes", "PROBLEM", 123, 139], ["strokes", "OBSERVATION", 132, 139]]], ["Patients that develop strokes are at risk for suboptimal outcomes due to the diversion of resources to manage COVID-19 patients, while the development of acute stroke management pathways can help address these practice patterns.", [["strokes", "DISEASE", 22, 29], ["COVID", "DISEASE", 110, 115], ["stroke", "DISEASE", 160, 166], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 119, 127], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 119, 127], ["strokes", "PROBLEM", 22, 29], ["the diversion of resources", "TREATMENT", 73, 99], ["COVID", "TEST", 110, 115], ["acute stroke management", "TREATMENT", 154, 177], ["strokes", "OBSERVATION", 22, 29], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["stroke", "OBSERVATION", 160, 166]]], ["Further research is needed to parse out a temporal relationship between COVID-19 patients and the incidence of strokes including long term outcomes.", [["strokes", "DISEASE", 111, 118], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["strokes", "PROBLEM", 111, 118], ["long term outcomes", "PROBLEM", 129, 147], ["strokes", "OBSERVATION", 111, 118], ["long term", "OBSERVATION_MODIFIER", 129, 138]]]], "PMC7120691": [["De benauwde pati\u00ebnt op de afdeling Spoedeisende HulpLet tijdens het afnemen van de anamnese op de lengte van de zinnen die de pati\u00ebnt kan uitspreken.", [["De benauwde pati\u00ebnt op de afdeling Spoedeisende HulpLet tijdens het afnemen van de anamnese op de lengte van de zinnen die de pati\u00ebnt kan uitspreken", "SPECIES", 0, 148]]], ["Hoe korter het antwoord, hoe ernstiger de dyspneu.", [["Hoe korter het antwoord", "SPECIES", 0, 23]]], ["Veel praten kan vooral voor emfyseempati\u00ebnten evenwel een mogelijkheid zijn hun intrinsic PEEP op te hogen.", [["Veel", "TEST", 0, 4], ["een mogelijkheid zijn", "TREATMENT", 54, 75], ["intrinsic PEEP", "TREATMENT", 80, 94]]], ["Hetzelfde effect treedt op bij het tuiten van de lippen bij de uitademing, zodat dan de lippen die ventielfunctie uitoefenen (lip pursing).Anamnese ::: Help, ik stik!", [["lip", "ANATOMY", 126, 129], ["lip", "ORGANISM_SUBDIVISION", 126, 129], ["Hetzelfde effect", "PROBLEM", 0, 16], ["lip", "ANATOMY", 126, 129]]], ["De benauwde pati\u00ebnt op de afdeling Spoedeisende HulpAcute kortademigheid wijst onder andere op longembolie, pneumothorax of hartfalen (myocardischemie) (zie tab.", [["pneumothorax", "DISEASE", 108, 120], ["pneumothorax of hartfalen", "PROBLEM", 108, 133], ["pneumothorax", "OBSERVATION", 108, 120]]], ["Dyspneu die acuut is ontstaan in combinatie met het opgeven van sputum en de aanwezigheid van koorts, is waarschijnlijk het gevolg van een infectie.", [["Dyspneu", "PROBLEM", 0, 7]]], ["Hoesten, langer dan 14 dagen, in combinatie met dyspneu, piepen en een voorgeschiedenis van roken, sterkt het vermoeden van COPD.", [["COPD", "DISEASE", 124, 128]]], ["Bloed ophoesten past bij pneumonie, tbc en longembolie.", [["bij pneumonie", "PROBLEM", 21, 34], ["tbc en longembolie", "PROBLEM", 36, 54], ["bij pneumonie", "OBSERVATION", 21, 34]]], ["Bij het vermoeden van decompensatio cordis als oorzaak van dyspneu is het belangrijk aanvullende anamnesevragen te stellen.", [["Bij het vermoeden van decompensatio cordis", "TREATMENT", 0, 42]]]], "e7ee279f558638ffc4c28786a648bb581b2f0683": [["METHODS COVID-19 is an infectious disease pandemic that is spreading more rapidly than our healthcare resources can handle.", [["an infectious disease pandemic", "PROBLEM", 20, 50], ["infectious", "OBSERVATION", 23, 33]]], ["The ethical issues of the pandemic, therefore, represent an intersection of the ethical problems of a contagious and highly morbid disease with the ethical concepts widely used in directing allocation of scarce resources.", [["the pandemic", "PROBLEM", 22, 34], ["a contagious and highly morbid disease", "PROBLEM", 100, 138], ["pandemic", "OBSERVATION_MODIFIER", 26, 34], ["contagious", "OBSERVATION_MODIFIER", 102, 112], ["highly", "OBSERVATION_MODIFIER", 117, 123], ["morbid", "OBSERVATION", 124, 130]]], ["We, use the HIV/AIDS pandemic (which is a well-studied pandemic for which an ethical consensus gradually formed by the 1990s 6 ) and the ethical reasoning for organ allocation in solid organ transplantation (which is also readily accepted and well considered) as the reference points for our ethical exploration.", [["organ", "ANATOMY", 159, 164], ["organ", "ANATOMY", 185, 190], ["HIV/AIDS pandemic", "DISEASE", 12, 29], ["organ", "ORGAN", 159, 164], ["organ", "ORGAN", 185, 190], ["the HIV/AIDS pandemic", "PROBLEM", 8, 29], ["organ allocation", "TREATMENT", 159, 175], ["solid organ transplantation", "TREATMENT", 179, 206], ["our ethical exploration", "TEST", 288, 311]]], ["For each ethical issue, we summarize the accepted standard in the relevant comparisons using the above model; examine the similarities or differences with the COVID-19 with these points of reference; and present our recommendations for ethical action.Ethical analysisAs communities around the globe combat the COVID-19 pandemic, many challenging ethical, social, and legal questions have arisen.", [["the COVID", "TEST", 155, 164], ["ethical action", "TREATMENT", 236, 250], ["Ethical analysisAs", "TEST", 251, 269], ["globe", "ANATOMY", 293, 298]]], ["What are the professional responsibilities of healthcare workers in treating patients with this virus, given the demonstrated high risk of being infected as they care for them?", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["this virus", "PROBLEM", 91, 101], ["infected", "OBSERVATION", 145, 153]]], ["Do providers have the right to refuse to treat a COVID-19 positive patient, or do they have a professional duty to treat the patient, no matter how high the personal risk?Ethical analysisDuring the HIV/AIDS pandemic, this issue was thoroughly analyzed.", [["HIV/AIDS pandemic", "DISEASE", 198, 215], ["patient", "ORGANISM", 67, 74], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 67, 74], ["patient", "SPECIES", 125, 132], ["a COVID", "TEST", 47, 54], ["AIDS pandemic", "PROBLEM", 202, 215]]], ["10 Is there a reasonable limit to these assumed risks?Ethical analysisThere is some degree of inherent risk when providing care to any patient.", [["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["Ethical analysis", "TEST", 54, 70], ["some", "OBSERVATION_MODIFIER", 79, 83], ["degree", "OBSERVATION_MODIFIER", 84, 90]]], ["There was little ethical support for refusing to treat HIV patients during the pandemic solely based on the diagnosis.", [["HIV", "DISEASE", 55, 58], ["HIV", "ORGANISM", 55, 58], ["patients", "ORGANISM", 59, 67], ["HIV", "SPECIES", 55, 58], ["patients", "SPECIES", 59, 67], ["HIV", "SPECIES", 55, 58], ["HIV patients", "PROBLEM", 55, 67]]], ["By comparison, we do have reliable ways to protect ourselves from contracting this Disclosure Information: Nothing to disclose. disease as we care for COVID-19-positive patients.", [["disease", "DISEASE", 128, 135], ["COVID-19", "GENE_OR_GENE_PRODUCT", 151, 159], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["disease", "PROBLEM", 128, 135], ["COVID", "TEST", 151, 156]]], ["We must keep in mind that certain populations (such as those over 60 years of age), providers with underlying chronic conditions, and pregnant caregivers are more vulnerable to the effects of COVID-19.", [["COVID-19", "CHEMICAL", 192, 200], ["underlying chronic conditions", "PROBLEM", 99, 128], ["COVID", "TEST", 192, 197], ["chronic", "OBSERVATION_MODIFIER", 110, 117]]], ["12 These clinicians represent vulnerable subsets among us who are risking more by caring for patients when they lack appropriate protective gear.Ethical analysisRecommendation: When appropriate protective gear is available, we consider it a professional clinician's ethical duty to provide care for COVID-19 positive patients.", [["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 317, 325], ["COVID", "TEST", 299, 304], ["vulnerable", "OBSERVATION_MODIFIER", 30, 40]]], ["We also recommend that the duty to care for COVID-19 positive patients also applies to trainees.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["COVID", "TEST", 44, 49]]], ["Given the risk of spread without appropriate protective equipment, we recommend that each provider use individual judgment to assess their degree of personal risk when caring for a COVID-19 positive patient.", [["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["appropriate protective equipment", "TREATMENT", 33, 65], ["a COVID", "TEST", 179, 186]]], ["All healthcare workers must be thoroughly trained in universal precautions.Ethical analysis2.", [["Ethical analysis2", "TEST", 75, 92]]], ["How is prioritizing patient confidentiality being challenged by the COVID-19 pandemic?", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27]]], ["How should we report positive cases to the public and to hospital staff members?Ethical analysisA consensus formed during the HIV pandemic that physicians have an ethical duty to maintain patient confidentiality, but that duty may be overridden by the need to protect others at risk by association.", [["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195], ["HIV", "SPECIES", 126, 129]]], ["13 During the HIV/AIDS pandemic, a change in public perception emerged about the importance of reporting as increasingly compelling data became available regarding the benefits of early prevention and treatment.", [["HIV/AIDS pandemic", "DISEASE", 14, 31], ["HIV", "SPECIES", 14, 17], ["HIV", "SPECIES", 14, 17], ["AIDS pandemic", "PROBLEM", 18, 31], ["early prevention", "TREATMENT", 180, 196], ["treatment", "TREATMENT", 201, 210]]], ["As these benefits became more apparent, support for clarifying exceptions to protecting patient confidentiality increased in order to warn third parties with exposure to the disease.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["the disease", "PROBLEM", 170, 181], ["disease", "OBSERVATION", 174, 181]]], ["14 Although physicians have an ethical duty to protect patient confidentiality, this responsibility can be superseded by a duty to protect other members of society known to be at risk.Ethical analysisMaintaining the privacy of COVID-19 positive patients becomes an ethical dilemma when doing so causes harm to other members of society.", [["patient", "ORGANISM", 55, 62], ["patients", "ORGANISM", 245, 253], ["patient", "SPECIES", 55, 62], ["patients", "SPECIES", 245, 253], ["COVID", "TEST", 227, 232], ["an ethical dilemma", "PROBLEM", 262, 280]]], ["The key difference between the current COVID-19 pandemic and the HIV/AIDS pandemic is that no prejudicial stigma is associated with a positive COVID-19 test and, therefore, breaking the seal of confidentiality is not as problematic as it was in the early days of HIV/AIDS.", [["HIV/AIDS", "DISEASE", 65, 73], ["HIV/AIDS", "DISEASE", 263, 271], ["HIV", "ORGANISM", 263, 266], ["HIV", "SPECIES", 65, 68], ["HIV", "SPECIES", 263, 266], ["the current COVID", "TEST", 27, 44], ["pandemic", "PROBLEM", 48, 56], ["the HIV/AIDS pandemic", "PROBLEM", 61, 82], ["prejudicial stigma", "PROBLEM", 94, 112], ["HIV/AIDS", "TREATMENT", 263, 271], ["difference", "OBSERVATION_MODIFIER", 8, 18]]], ["This difference should make decisions to inform the public of COVID-19 positive patients less ethically challenging.Ethical analysisRecommendation: We encourage hospitals to warn its providers of the COVID-19 positive status of patients in order to protect the already challenged staff.", [["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 228, 236], ["COVID", "TEST", 62, 67], ["the COVID", "TEST", 196, 205]]], ["Furthermore, we recommend that COVID-19 positive patients who can disclose their condition to those contacts they may have put at risk should be given the opportunity to inform these contacts.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["Ultimately, given the high morbidity and mortality rates and the degree of contagiousness of COVID-19, confidentiality must be limited by public health interests.", [["the high morbidity", "PROBLEM", 18, 36], ["mortality rates", "TEST", 41, 56], ["COVID", "TEST", 93, 98]]], ["It is also crucial that physicians and hospital systems report positive cases to public agencies so that data can be accurately tabulated and analyzed in order to inform treatment decisions and resource allocation.Which members of the population should be screenedand tested for COVID-19 when available tests are limited?Which members of the population should be screenedScreening and testing represent an ethical dilemma as long as the number of tests is limited and the sensitivity and specificity of the tests are suboptimal.", [["COVID", "TEST", 279, 284], ["tests", "TEST", 303, 308], ["Screening", "TEST", 371, 380], ["testing", "TEST", 385, 392], ["an ethical dilemma", "PROBLEM", 403, 421], ["the sensitivity", "TEST", 468, 483], ["the tests", "TEST", 503, 512]]], ["Ethical discussion about screening for HIV evolved as the screening tests improved and the stigma associated with the disease diminished.", [["HIV", "ORGANISM", 39, 42], ["HIV", "SPECIES", 39, 42], ["screening", "TEST", 25, 34], ["HIV", "PROBLEM", 39, 42], ["the screening tests", "TEST", 54, 73], ["the stigma", "PROBLEM", 87, 97], ["the disease diminished", "PROBLEM", 114, 136], ["disease", "OBSERVATION", 118, 125], ["diminished", "OBSERVATION_MODIFIER", 126, 136]]], ["As HIV became more normalized and early detection offered survival benefits, screening became more prevalent.Which members of the population should be screenedWhile HIV screening practices can be extrapolated to the COVID-19 pandemic to some extent, there are clear differences.", [["HIV", "ORGANISM", 3, 6], ["HIV", "ORGANISM", 165, 168], ["HIV", "SPECIES", 3, 6], ["HIV", "SPECIES", 165, 168], ["HIV", "SPECIES", 3, 6], ["HIV", "SPECIES", 165, 168], ["HIV", "PROBLEM", 3, 6], ["screening", "TEST", 77, 86], ["HIV screening practices", "TEST", 165, 188], ["the COVID", "TEST", 212, 221], ["some extent", "OBSERVATION_MODIFIER", 237, 248], ["clear", "OBSERVATION", 260, 265]]], ["We do not fully understand how COVID-19 spreads, leaving us without a good sense of who will most benefit from screening.", [["screening", "TEST", 111, 120]]], ["Additionally, the number of available tests is still limited.", [["available tests", "TEST", 28, 43]]], ["To obtain more reliable results, we will need to test each person multiple times.Which members of the population should be screenedRecommendation: Patients with symptoms should be tested because early diagnosis and supportive treatment are in their best interest and because most of the spread is thought to result from actively symptomatic patients.", [["Patients", "ORGANISM", 147, 155], ["patients", "ORGANISM", 341, 349], ["person", "SPECIES", 59, 65], ["Patients", "SPECIES", 147, 155], ["patients", "SPECIES", 341, 349], ["symptoms", "PROBLEM", 161, 169], ["supportive treatment", "TREATMENT", 215, 235]]], ["As more tests and tests with better detection rates become available, we also recommend screening asymptomatic healthcare workers in order to avoid inadvertent infection of the already high-risk patients with whom they interact.", [["infection", "DISEASE", 160, 169], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["more tests", "TEST", 3, 13], ["tests", "TEST", 18, 23], ["screening asymptomatic healthcare workers", "TREATMENT", 88, 129], ["inadvertent infection", "PROBLEM", 148, 169], ["infection", "OBSERVATION", 160, 169]]], ["Finally, as tests evolve and become widely available, we recommend universal screening to limit exposure by quarantining potentially infected individuals.How do we allocate scarce resources such as ICU beds, ventilators, and certain medication?Much attention is being given to the allocation of scarce resources during the present pandemic.", [["tests", "TEST", 12, 17], ["universal screening", "TEST", 67, 86], ["infected individuals", "PROBLEM", 133, 153], ["ICU beds", "TREATMENT", 198, 206], ["ventilators", "TREATMENT", 208, 219], ["certain medication", "TREATMENT", 225, 243]]], ["It is helpful to divide decisions about the allocation of scarce resources into 2 distinct categories: allocation of clearly finite resources and allocation of nonfinite resources.How do we allocate scarce resources such as ICU beds, ventilators, and certain medication?Solid organ transplantation offers insight into and guidelines for decisions about the allocation of finite resources.", [["organ", "ANATOMY", 276, 281], ["organ", "ORGAN", 276, 281], ["ICU beds", "TREATMENT", 224, 232], ["ventilators", "TREATMENT", 234, 245], ["certain medication", "TREATMENT", 251, 269], ["Solid organ transplantation", "TREATMENT", 270, 297], ["organ", "ANATOMY", 276, 281], ["transplantation", "OBSERVATION", 282, 297]]], ["16 Utilitarian reasoning focuses allocation decisions on ensuring optimal conditions for maximizing the survival of the organ itself and thereby, the recipient.", [["organ", "ANATOMY", 120, 125], ["organ", "ORGAN", 120, 125]]], ["The social worth and the completeness of the recipient's life do not enter the equation because organs are allocated according to a strict protocol.", [["organs", "ANATOMY", 96, 102], ["organs", "ORGAN", 96, 102], ["a strict protocol", "TREATMENT", 130, 147]]], ["18 Once we commit to transplanting an organ into a patient, we do not then retrieve it when a more \"deserving\" patient presents.", [["organ", "ANATOMY", 38, 43], ["organ", "ORGAN", 38, 43], ["patient", "ORGANISM", 51, 58], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 111, 118]]], ["However, with the allocation of nonfinite scarce resources, a ventilator, for example, may be assigned to, but later removed from, a patient depending on the relative demand at any given time.", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["a ventilator", "TREATMENT", 60, 72]]], ["19 These important distinctions between the allocation of clearly finite resources such as organs and the allocation of nonfinite scarce resources that may be reassigned, present discrete ethical challenges.", [["organs", "ANATOMY", 91, 97], ["organs", "ORGAN", 91, 97]]], ["Several strategies have been suggested as ethical justification for the allocation of nonfinite scarce resources: eg treating all patients equally, giving preference to the worst-off patients, using a first come first served format, maximizing total benefits, or rewarding social usefulness.", [["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 183, 191]]], ["20 During the COVID-19 pandemic, resources of relative scarcity include ICU beds, ventilators, and access to testing.", [["ICU beds", "TREATMENT", 72, 80], ["ventilators", "TREATMENT", 82, 93], ["testing", "TEST", 109, 116]]], ["21 Washington University in St Louis, the University of Pittsburgh, and the State of New York have all developed models for assigning scores to patients, based on age and comorbidities, to direct the allocation of these scarce resources to individual patients.How do we allocate scarce resources such as ICU beds, ventilators, and certain medication?An additional feature of the current pandemic is society's collective support for conserving scarce resources.", [["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 251, 259], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 251, 259], ["ICU beds", "TREATMENT", 304, 312], ["ventilators", "TREATMENT", 314, 325], ["certain medication", "TREATMENT", 331, 349], ["collective support", "TREATMENT", 409, 427], ["conserving scarce resources", "TREATMENT", 432, 459]]], ["For example, for a patient without active cardiac disease, whose hemoglobin is greater than 7g/dL, no blood transfusion is indicated whether we are trying to conserve resources or not.", [["cardiac", "ANATOMY", 42, 49], ["blood", "ANATOMY", 102, 107], ["cardiac disease", "DISEASE", 42, 57], ["patient", "ORGANISM", 19, 26], ["cardiac", "ORGAN", 42, 49], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 65, 75], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["hemoglobin", "PROTEIN", 65, 75], ["patient", "SPECIES", 19, 26], ["active cardiac disease", "PROBLEM", 35, 57], ["whose hemoglobin", "TEST", 59, 75], ["blood transfusion", "TREATMENT", 102, 119], ["without", "UNCERTAINTY", 27, 34], ["active", "OBSERVATION_MODIFIER", 35, 41], ["cardiac", "ANATOMY", 42, 49], ["disease", "OBSERVATION", 50, 57]]], ["Guidelines that recommend not transfusing blood above this threshold are based on well-structured studies and show significant increase in morbidity and mortality when not followed.", [["blood", "ANATOMY", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["transfusing blood", "TREATMENT", 30, 47], ["structured studies", "TEST", 87, 105], ["significant increase in morbidity", "PROBLEM", 115, 148], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["morbidity", "OBSERVATION", 139, 148]]], ["And yet, in our experience, clinicians refer to conservation of resources rather than to beneficence as their reason for current practice.How do we allocate scarce resources such as ICU beds, ventilators, and certain medication?Recommendation: First, we recommend that treatment decisions for COVID-19 and non-COVID-19 patients be evaluated first on medical merit before considering matters of resource allocation.", [["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 319, 327], ["ICU beds", "TREATMENT", 182, 190], ["ventilators", "TREATMENT", 192, 203], ["certain medication", "TREATMENT", 209, 227], ["COVID", "TEST", 293, 298], ["resource allocation", "TREATMENT", 394, 413]]], ["Second, we recommend that the adopted protocol for allocating nonfinite scarce resources should be followed systematically, with full transparency and with creative efforts to mitigate the loss experienced by patients to whom limited resources are not directed.", [["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["the adopted protocol", "TREATMENT", 26, 46], ["creative efforts", "TREATMENT", 156, 172], ["the loss", "PROBLEM", 185, 193]]], ["Third, we recommend that protocols be regularly reviewed in order to accommodate the needed changes in response to our growing knowledge of COVID-19.What ethical concerns are created by relaxing FDArules associated with research and by relaxing criteria for certification into the medical field?What ethical concerns are created by relaxing FDADuring the HIV/AIDS pandemic, government authorities were pressured to grant exceptions to the strict regulations for human-subject research.", [["HIV/AIDS pandemic", "DISEASE", 355, 372], ["COVID-19", "CHEMICAL", 140, 148], ["human", "ORGANISM", 462, 467], ["human", "SPECIES", 462, 467], ["human", "SPECIES", 462, 467], ["COVID", "TEST", 140, 145]]], ["[22] [23] [24] Advocates argued that potential treatment agents should be exempt from the established requirements in order to possibly save more lives.", [["treatment agents", "TREATMENT", 47, 63]]], ["FDA regulations were eventually modified to fast track drugs that showed promise in treating HIV.What ethical concerns are created by relaxing FDAAs the COVID-19 pandemic unfolds, researchers are working fervently to identify potential treatments and vaccines against the disease under relaxed regulations and at times with permission to forego established steps in the process.", [["HIV", "DISEASE", 93, 96], ["HIV", "ORGANISM", 93, 96], ["HIV", "SPECIES", 93, 96], ["HIV", "SPECIES", 93, 96], ["HIV", "PROBLEM", 93, 96], ["potential treatments", "TREATMENT", 226, 246], ["vaccines", "TREATMENT", 251, 259], ["the disease", "PROBLEM", 268, 279]]], ["Similarly, state and local requirements for credentialing healthcare providers have been curtailed to increase the number of providers entering the workforce.", [["credentialing healthcare providers", "TREATMENT", 44, 78]]], ["Not surprisingly, unusual alternate remedies have claimed the lives of patients based on information disseminated through nonscientific sources.What ethical concerns are created by relaxing FDARecommendation: We recommend that no therapy or prevention should be promoted that has not been approved by the FDA.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["therapy", "TREATMENT", 230, 237], ["prevention", "TREATMENT", 241, 251]]], ["Transparency is paramount.What ethical concerns are created by relaxing FDA6.", [["FDA6", "GENE_OR_GENE_PRODUCT", 72, 76], ["FDA6", "PROTEIN", 72, 76]]], ["How should we address end-of-life issues, including do not resuscitate orders and goals of care discussions?What ethical concerns are created by relaxing FDAData from the HIV/AIDS pandemic revealed that only 50% of patients had discussed end-of-life care with their physician.", [["HIV/AIDS", "DISEASE", 171, 179], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223]]], ["25 This observation along with the initially exceedingly high mortality rate during the HIV/AIDS pandemic contributed to what has now become standard practice, namely, addressing goals of care with patients early in their hospitalization and public advocacy for the expectation that everyone, regardless of age or health status, should have written advance directives.", [["AIDS", "DISEASE", 92, 96], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["HIV", "SPECIES", 88, 91], ["This observation", "TEST", 3, 19], ["the HIV/AIDS pandemic", "PROBLEM", 84, 105]]], ["Multiple scientific articles have shown the benefit to our system, as well as to individual patients and families, when goals of care are addressed by the medical team on admission to the ICU and then frequently revisited.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100]]], ["In shared decision making, treatment plans are developed to which patients contribute their subjective values and goals and providers contribute their professional and scientific expertise.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["27 Hence, in shared decision making, only interventions for which the expected outcome aligns with the patient's personal values and preferences are implemented.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["However strongly an outcome may be desired by a patient, if that outcome is extremely unlikely to be achieved, we call that intervention medically nonbeneficial.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["As with observing guidelines of transfusion thresholds established as standards of care, and in order to abide by the ethical obligation of nonmaleficence, medically nonbeneficial treatments should not be offered to patients, whether we are in the midst of a pandemic or not.What ethical concerns are created by relaxing FDAMuch attention has recently been directed to whether we should perform CPR on COVID-19 positive patients.", [["patients", "ORGANISM", 216, 224], ["patients", "ORGANISM", 420, 428], ["patients", "SPECIES", 216, 224], ["patients", "SPECIES", 420, 428], ["transfusion thresholds", "TREATMENT", 32, 54], ["medically nonbeneficial treatments", "TREATMENT", 156, 190], ["CPR", "TEST", 395, 398], ["COVID", "TEST", 402, 407]]], ["Current data suggest that at least 20% of patients intubated secondary to COVID-19 may recover, thereby making CPR a non-uniformly futile act.", [["COVID-19", "CHEMICAL", 74, 82], ["COVID-19", "CHEMICAL", 74, 82], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["COVID", "TEST", 74, 79], ["CPR", "TREATMENT", 111, 114]]], ["29 Recommendation: We recommend a stepwise approach to the question of end-of life issues in COVID-19 patients.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["a stepwise approach", "TREATMENT", 32, 51]]], ["First, in line with standard of care, one must address the likely medical benefit of resuscitation to the patient and offer CPR only if the particular clinical scenario suggests a medically defined benefit.", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["resuscitation", "TREATMENT", 85, 98], ["CPR", "TREATMENT", 124, 127]]], ["Second, providers should be required to perform CPR only if adequate protective equipment is available to them; however, if protective gear is available, then the duty to perform CPR should strictly be dictated by its likely medical benefit.", [["CPR", "TREATMENT", 48, 51], ["CPR", "TREATMENT", 179, 182]]], ["Finally, the question of allocation of resources should be considered separately from the CPR question and should follow the algorithms outlined above for allocation of scarce nonfinite resources in general.", [["the algorithms", "TEST", 121, 135]]], ["When CPR is deemed to be medically nonbeneficial, this decision must be promptly communicated to the patient and the patient's family.", [["patient", "ORGANISM", 101, 108], ["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 101, 108], ["patient", "SPECIES", 117, 124], ["CPR", "TREATMENT", 5, 8]]], ["Palliative measures should be offered without delay.DISCUSSIONThe COVID-19 pandemic is swiftly reshaping our medical and societal priorities.", [["Palliative measures", "TREATMENT", 0, 19]]], ["Some ethical obligations stand unchanged.", [["ethical", "OBSERVATION_MODIFIER", 5, 12], ["obligations", "OBSERVATION", 13, 24], ["unchanged", "OBSERVATION_MODIFIER", 31, 40]]], ["Our commitment to transparency, to advocacy, and to honoring human life remains deeply rooted.", [["human", "ORGANISM", 61, 66], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66]]], ["We must be vigilant in our ongoing reconsideration of prioritizing the one or the many, individual patient autonomy or public health.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106]]], ["As our social distancing eventually diminishes, our ability to honor individual patient preferences should inversely expand.", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87]]], ["Frequent reassessment of our methods of triage is therefore a must, and newly learned lessons from our caregivers on the front lines should be incorporated into our evolving methodology.DISCUSSIONThe US has long embraced an ethos of individual liberty epitomized by New Hampshire's state motto \"Live free or die.\"", [["front lines", "ANATOMY", 121, 132], ["front lines", "CELL", 121, 132], ["the front lines", "TREATMENT", 117, 132]]], ["But as our society has changed suddenly from the most extreme version of patient-directed medicine to a society that assigns over-riding priority to the health of the community, the truth about our public health is more complex than we had previously been willing to admit.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80]]], ["Exponential population growth coupled with social interdependence and unlimited movements, along with our significantly increased longevity and access to lifeprolonging technologies, have fundamentally redefined the limits of any one person's claims on our society's means.", [["person", "SPECIES", 234, 240], ["Exponential population growth", "PROBLEM", 0, 29], ["our significantly increased longevity", "PROBLEM", 102, 139]]], ["As providers, any intervention that we perform on a patient affects not just that patient but every other potential patient as well.", [["patient", "ORGANISM", 52, 59], ["patient", "ORGANISM", 82, 89], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 52, 59], ["patient", "SPECIES", 82, 89], ["patient", "SPECIES", 116, 123], ["any intervention", "TREATMENT", 14, 30]]], ["It is no longer \"Live free or die\"; rather, it is \"Live free with consequences to the lives of others.\"", [["no longer", "UNCERTAINTY", 6, 15]]], ["As the pandemic rages and we struggle to keep up, perhaps we may find some instruction on how to care for our shared wealth of individual and societal health.CONCLUSIONSThe COVID-19 pandemic is filled with uncertainty and uncharted territory.", [["CONCLUSIONSThe COVID", "TEST", 158, 178], ["pandemic", "PROBLEM", 182, 190], ["uncharted", "OBSERVATION_MODIFIER", 222, 231], ["territory", "OBSERVATION_MODIFIER", 232, 241]]], ["Despite being in the early stages of the medical, societal, and legal challenges of this crisis, lessons from both the HIV/AIDS pandemic and the models for allocation of scarce resources practiced most widely in organ transplantation may inform our ethical approach to the most pressing challenges of our time.", [["organ", "ANATOMY", 212, 217], ["HIV/AIDS pandemic", "DISEASE", 119, 136], ["organ", "ORGAN", 212, 217], ["HIV", "SPECIES", 119, 122], ["this crisis", "PROBLEM", 84, 95], ["scarce resources", "TREATMENT", 170, 186], ["organ transplantation", "TREATMENT", 212, 233]]], ["The obligations of transparency, advocacy, and response to change define our stepwise recommendations.", [["transparency", "OBSERVATION_MODIFIER", 19, 31]]]], "fbd2594e34b34a2d8ada78a7644ebe8b9ee39921": [["To this end, all three associations recommend physical distancing by limiting face-to-face consultations to urgent situations, routine patient contact via telemedicine and phone visits, and use of local laboratories and pharmacies to reduce clinic and hospital visits and patient travel.", [["patient", "ORGANISM", 135, 142], ["patient", "ORGANISM", 272, 279], ["patient", "SPECIES", 135, 142], ["patient", "SPECIES", 272, 279]]], ["AASLD guidance is most stringent by discouraging clinic entry of anyone with fever or other COVID-19 symptoms and SARS-CoV-2 testing of these patients.", [["fever", "DISEASE", 77, 82], ["SARS", "DISEASE", 114, 118], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["fever", "PROBLEM", 77, 82], ["other COVID-19 symptoms", "PROBLEM", 86, 109], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122]]], ["All recommend COVID-19 testing of liver transplant donors and recipients and patients with encephalopathy or acute decompensation.", [["liver transplant", "ANATOMY", 34, 50], ["encephalopathy", "DISEASE", 91, 105], ["acute decompensation", "DISEASE", 109, 129], ["liver", "ORGAN", 34, 39], ["donors", "ORGANISM", 51, 57], ["recipients", "ORGANISM", 62, 72], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 14, 19], ["liver transplant donors", "TREATMENT", 34, 57], ["recipients", "TREATMENT", 62, 72], ["encephalopathy", "PROBLEM", 91, 105], ["acute decompensation", "PROBLEM", 109, 129], ["liver", "ANATOMY", 34, 39], ["transplant", "OBSERVATION", 40, 50], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["decompensation", "OBSERVATION", 115, 129]]], ["Recent data showed that many SARS-CoV-2-infected patients are asymptomatic, yet capable of transmitting the disease.", [["SARS-CoV-2-infected", "DISEASE", 29, 48], ["SARS-CoV-2", "ORGANISM", 29, 39], ["patients", "ORGANISM", 49, 57], ["CoV-", "SPECIES", 34, 38], ["patients", "SPECIES", 49, 57], ["SARS-CoV", "SPECIES", 29, 37], ["Recent data", "TEST", 0, 11], ["many SARS", "PROBLEM", 24, 33], ["CoV", "TEST", 34, 37], ["asymptomatic", "PROBLEM", 62, 74], ["the disease", "PROBLEM", 104, 115], ["disease", "OBSERVATION", 108, 115]]], ["7 Ideally, all patients with a history of close contact with cases of possible or confirmed COVID-19 or from high-prevalence regions should be tested.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["COVID", "TEST", 92, 97], ["high-prevalence regions", "PROBLEM", 109, 132]]], ["APASL recommends SARS-CoV-2 testing based on clinical and epidemiological factors.", [["SARS", "TEST", 17, 21], ["CoV-2 testing", "TEST", 22, 35]]], ["EASL recommends following an institution's practice.", [["an institution's practice", "TREATMENT", 26, 51]]], ["AASLD and APASL describe the personal protective equipment (PPE) requirements for endoscopy and other procedures.", [["endoscopy", "TEST", 82, 91], ["other procedures", "TREATMENT", 96, 112]]], ["Like SARS-CoV-2 testing, the limiting factor is the availability of PPE.", [["PPE", "GENE_OR_GENE_PRODUCT", 68, 71], ["CoV-2 testing", "TEST", 10, 23], ["PPE", "PROBLEM", 68, 71]]], ["Without adequate supply, many elective procedures will need to be canceled.", [["many elective procedures", "TREATMENT", 25, 49]]]], "963869beb920b86eefb2de2c6ea224da847855c6": [["IntroductionWhile the ideal vaccine would elicit the exact immune response that occurs during natural infection with highly pathogenic influenza virus, expression of influenza virus proteins from live replicating vectors can safely induce a strong humoral and cellular immune response comparable to natural infection (Souza et al. 2005) .", [["cellular", "ANATOMY", 260, 268], ["infection", "DISEASE", 102, 111], ["influenza virus", "DISEASE", 135, 150], ["infection", "DISEASE", 307, 316], ["influenza virus", "ORGANISM", 135, 150], ["influenza virus", "ORGANISM", 166, 181], ["cellular", "CELL", 260, 268], ["influenza virus proteins", "PROTEIN", 166, 190], ["influenza virus", "SPECIES", 135, 150], ["influenza virus", "SPECIES", 166, 181], ["influenza virus", "SPECIES", 166, 181], ["the ideal vaccine", "TREATMENT", 18, 35], ["natural infection", "PROBLEM", 94, 111], ["highly pathogenic influenza virus", "PROBLEM", 117, 150], ["influenza virus proteins", "PROBLEM", 166, 190], ["live replicating vectors", "TREATMENT", 196, 220], ["a strong humoral and cellular immune response", "PROBLEM", 239, 284], ["natural infection", "PROBLEM", 299, 316], ["influenza virus", "OBSERVATION", 135, 150], ["cellular immune response", "OBSERVATION", 260, 284]]], ["Recombinant vectors have been developed because it is considered to be too dangerous to vaccinate people with even vastly attenuated forms of dangerous viruses such as highly pathogenic influenza virus or Ebola virus.", [["influenza virus", "DISEASE", 186, 201], ["Ebola virus", "DISEASE", 205, 216], ["people", "ORGANISM", 98, 104], ["highly pathogenic influenza virus", "ORGANISM", 168, 201], ["Ebola virus", "ORGANISM", 205, 216], ["people", "SPECIES", 98, 104], ["pathogenic influenza virus", "SPECIES", 175, 201], ["Ebola virus", "SPECIES", 205, 216], ["Ebola virus", "SPECIES", 205, 216], ["Recombinant vectors", "TREATMENT", 0, 19], ["dangerous viruses", "PROBLEM", 142, 159], ["highly pathogenic influenza virus", "PROBLEM", 168, 201], ["Ebola virus", "PROBLEM", 205, 216], ["dangerous viruses", "OBSERVATION", 142, 159], ["Ebola virus", "OBSERVATION", 205, 216]]], ["Vaccination with recombinant vectors offers several advantages over vaccination with inactivated influenza viruses.", [["influenza viruses", "DISEASE", 97, 114], ["influenza viruses", "ORGANISM", 97, 114], ["Vaccination", "TREATMENT", 0, 11], ["recombinant vectors", "TREATMENT", 17, 36], ["several advantages over vaccination", "TREATMENT", 44, 79], ["inactivated influenza viruses", "PROBLEM", 85, 114]]], ["Inactivated vaccines induce short-lived antibody-mediated immunity, while recombinant vectors elicit a longer-lasting immune response that stimulates both memory B and T cells.", [["memory B", "ANATOMY", 155, 163], ["T cells", "ANATOMY", 168, 175], ["memory B", "CELL", 155, 163], ["T cells", "CELL", 168, 175], ["memory B and T cells", "CELL_TYPE", 155, 175], ["Inactivated vaccines", "TREATMENT", 0, 20]]], ["Also, the manufacture of the recombinant vaccines entails substantially less risk than growing large quantities of influenza viruses expressing the highly pathogenic hemagglutinin (HA) and neuraminidase (NA) proteins required for inactivation, since the recombinant vectors cannot cause influenza.", [["influenza viruses", "DISEASE", 115, 132], ["influenza", "DISEASE", 287, 296], ["influenza viruses", "ORGANISM", 115, 132], ["hemagglutinin (HA)", "GENE_OR_GENE_PRODUCT", 166, 184], ["neuraminidase (NA) proteins", "GENE_OR_GENE_PRODUCT", 189, 216], ["highly pathogenic hemagglutinin (HA) and neuraminidase (NA) proteins", "PROTEIN", 148, 216], ["the recombinant vaccines", "TREATMENT", 25, 49], ["influenza viruses", "PROBLEM", 115, 132], ["the highly pathogenic hemagglutinin (HA)", "PROBLEM", 144, 184], ["neuraminidase (NA) proteins", "TREATMENT", 189, 216], ["inactivation", "PROBLEM", 230, 242], ["the recombinant vectors", "TREATMENT", 250, 273], ["influenza", "PROBLEM", 287, 296], ["large", "OBSERVATION_MODIFIER", 95, 100], ["quantities", "OBSERVATION_MODIFIER", 101, 111], ["influenza viruses", "OBSERVATION", 115, 132]]], ["Many different viruses and bacteria are currently being tested for their ability to function as a good recombinant vector.Qualities of Ideal VectorsGood vectors should be easy to manipulate genetically, allowing the insertion of large foreign genes or epitopes.", [["epitopes", "PROTEIN", 252, 260], ["Many different viruses", "PROBLEM", 0, 22], ["bacteria", "PROBLEM", 27, 35], ["Ideal Vectors", "TREATMENT", 135, 148], ["the insertion of large foreign genes", "TREATMENT", 212, 248], ["epitopes", "PROBLEM", 252, 260], ["different", "OBSERVATION_MODIFIER", 5, 14], ["viruses", "OBSERVATION", 15, 22], ["bacteria", "OBSERVATION_MODIFIER", 27, 35], ["large", "OBSERVATION_MODIFIER", 229, 234], ["foreign genes", "OBSERVATION", 235, 248]]], ["The vectors should grow well and be easy to produce in large-scale operations.", [["The vectors", "TREATMENT", 0, 11], ["large-scale operations", "TREATMENT", 55, 77]]], ["The foreign proteins should be highly expressed from the vector to elicit the best immune response.", [["foreign proteins", "PROTEIN", 4, 20], ["The foreign proteins", "PROBLEM", 0, 20], ["foreign proteins", "OBSERVATION", 4, 20]]], ["Proteins from the vector should not elicit a strong immune response, as this may interfere with the induction of a response to the foreign proteins and also reduce the effectiveness of boosts after initial vaccination.", [["foreign proteins", "PROTEIN", 131, 147], ["the foreign proteins", "TREATMENT", 127, 147], ["initial vaccination", "TREATMENT", 198, 217]]], ["The expression of foreign proteins in the host should be transient and the vector must be fully cleared from the host once the adaptive immune response has commenced.", [["foreign proteins", "PROTEIN", 18, 34], ["foreign proteins in the host", "PROBLEM", 18, 46], ["foreign proteins", "OBSERVATION", 18, 34]]], ["Integration of DNA from the vector into the host genome must not occur, as this can disrupt host genes and possibly lead to the development of cancer.", [["cancer", "ANATOMY", 143, 149], ["cancer", "DISEASE", 143, 149], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["cancer", "CANCER", 143, 149], ["host genome", "DNA", 44, 55], ["host genes", "DNA", 92, 102], ["cancer", "PROBLEM", 143, 149], ["host genome", "OBSERVATION", 44, 55], ["cancer", "OBSERVATION", 143, 149]]], ["Humans should not have pre-existing antibodies to the vector, as this could prevent replication of the vector and subsequently prevent the induction of an immune response to the foreign proteins.", [["Humans", "ORGANISM", 0, 6], ["antibodies", "PROTEIN", 36, 46], ["foreign proteins", "PROTEIN", 178, 194], ["pre-existing antibodies to the vector", "TREATMENT", 23, 60], ["replication of the vector", "TREATMENT", 84, 109], ["the foreign proteins", "PROBLEM", 174, 194], ["foreign proteins", "OBSERVATION", 178, 194]]], ["Ideally, the vector should not cause disease symptoms in humans and should be safe even for immunocompromised individuals and young children.", [["humans", "ORGANISM", 57, 63], ["children", "ORGANISM", 132, 140], ["humans", "SPECIES", 57, 63], ["children", "SPECIES", 132, 140], ["humans", "SPECIES", 57, 63], ["the vector", "TREATMENT", 9, 19], ["disease symptoms", "PROBLEM", 37, 53]]], ["Additionally, recombinant vectors that do not require refrigeration would facilitate the distribution of the vaccine to developing nations.", [["recombinant vectors", "TREATMENT", 14, 33], ["refrigeration", "TREATMENT", 54, 67], ["the vaccine", "TREATMENT", 105, 116]]], ["Recombinant vectors that can be administered without needles would also aid distribution and enhance vaccination compliance (Babiuk and Tikoo 2000; Barouch and Nabel 2005; Souza et al. 2005; Barouch 2006; Li et al. 2007) .", [["Recombinant vectors", "TREATMENT", 0, 19], ["needles", "TREATMENT", 53, 60]]], ["Several viruses possess many, but not all, of the characteristics of a useful vector.Newcastle Disease Virus VectorsNewcastle disease virus (NDV) contains a nonsegmented, single-strand, negativesense RNA genome and belongs to the family Paramyxoviridae.", [["Newcastle disease", "DISEASE", 116, 133], ["Newcastle Disease Virus Vectors", "ORGANISM", 85, 116], ["Newcastle disease virus", "ORGANISM", 116, 139], ["NDV", "ORGANISM", 141, 144], ["nonsegmented, single-strand, negativesense RNA genome", "DNA", 157, 210], ["Newcastle disease virus", "SPECIES", 116, 139], ["NDV", "SPECIES", 141, 144], ["Newcastle Disease Virus VectorsNewcastle disease virus", "SPECIES", 85, 139], ["NDV", "SPECIES", 141, 144], ["Several viruses", "PROBLEM", 0, 15], ["Newcastle Disease Virus VectorsNewcastle disease virus", "PROBLEM", 85, 139], ["viruses", "OBSERVATION", 8, 15]]], ["NDV contains six genes that encode seven proteins: nucleocapsid protein (NP), phosphoprotein and V protein (P/V), matrix (M) protein, fusion (F) protein, hemagglutinin-neuraminidase (HN), and large polymerase (L) protein.", [["NDV", "ORGANISM", 0, 3], ["nucleocapsid protein (NP), phosphoprotein and V protein", "GENE_OR_GENE_PRODUCT", 51, 106], ["matrix (M)", "GENE_OR_GENE_PRODUCT", 114, 124], ["fusion (F)", "GENE_OR_GENE_PRODUCT", 134, 144], ["hemagglutinin-neuraminidase", "GENE_OR_GENE_PRODUCT", 154, 181], ["HN", "GENE_OR_GENE_PRODUCT", 183, 185], ["large polymerase (L)", "GENE_OR_GENE_PRODUCT", 192, 212], ["nucleocapsid protein", "PROTEIN", 51, 71], ["NP", "PROTEIN", 73, 75], ["phosphoprotein", "PROTEIN", 78, 92], ["V protein", "PROTEIN", 97, 106], ["P", "PROTEIN", 108, 109], ["V", "PROTEIN", 110, 111], ["matrix (M) protein", "PROTEIN", 114, 132], ["fusion (F) protein", "PROTEIN", 134, 152], ["hemagglutinin", "PROTEIN", 154, 167], ["neuraminidase", "PROTEIN", 168, 181], ["HN", "PROTEIN", 183, 185], ["large polymerase (L) protein", "PROTEIN", 192, 220], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV", "PROBLEM", 0, 3], ["nucleocapsid protein", "TEST", 51, 71], ["NP", "TEST", 73, 75], ["phosphoprotein", "TEST", 78, 92], ["V protein", "TEST", 97, 106], ["P/V), matrix (M) protein", "TEST", 108, 132], ["protein", "TEST", 145, 152], ["hemagglutinin", "TEST", 154, 167], ["large polymerase (L) protein", "PROBLEM", 192, 220], ["six genes", "OBSERVATION_MODIFIER", 13, 22]]], ["As the viral polymerase can disassociate from the viral genome after the transcription of each gene, expression levels of the proteins reduce in a sequential manner from the 3\u00a2 to the 5\u00a2 end of the genome.", [["genome", "CELLULAR_COMPONENT", 198, 204], ["viral polymerase", "PROTEIN", 7, 23], ["viral genome", "DNA", 50, 62], ["5\u00a2 end", "DNA", 184, 190], ["the viral polymerase", "PROBLEM", 3, 23], ["the viral genome", "PROBLEM", 46, 62], ["the proteins", "PROBLEM", 122, 134], ["viral polymerase", "OBSERVATION", 7, 23], ["viral genome", "OBSERVATION", 50, 62], ["genome", "OBSERVATION", 198, 204]]], ["Thus, the expression level of a foreign protein can be controlled by its position on the viral genome .", [["foreign protein", "PROTEIN", 32, 47], ["viral genome", "DNA", 89, 101], ["a foreign protein", "TREATMENT", 30, 47], ["viral genome", "OBSERVATION", 89, 101]]], ["NDV naturally infects avian species, and it is a highly contagious virus with a pathogenicity ranging from avirulent to high levels of mortality (Huang et al. 2003) .", [["NDV", "ORGANISM", 0, 3], ["avian", "ORGANISM", 22, 27], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV naturally infects avian species", "PROBLEM", 0, 35], ["a highly contagious virus", "PROBLEM", 47, 72], ["a pathogenicity", "PROBLEM", 78, 93], ["infects", "OBSERVATION_MODIFIER", 14, 21], ["avian species", "OBSERVATION", 22, 35], ["highly", "OBSERVATION_MODIFIER", 49, 55], ["contagious", "OBSERVATION_MODIFIER", 56, 66], ["virus", "OBSERVATION", 67, 72], ["high levels", "OBSERVATION_MODIFIER", 120, 131]]], ["One determinant of NDV pathogenicity is the cleavage site of the F protein, which is necessary for the fusion of the viral envelope to the cell membrane.", [["cell membrane", "ANATOMY", 139, 152], ["NDV", "ORGANISM", 19, 22], ["F protein", "GENE_OR_GENE_PRODUCT", 65, 74], ["cell membrane", "CELLULAR_COMPONENT", 139, 152], ["F protein", "PROTEIN", 65, 74], ["NDV", "SPECIES", 19, 22], ["NDV pathogenicity", "PROBLEM", 19, 36], ["the fusion", "TREATMENT", 99, 109], ["NDV", "OBSERVATION", 19, 22], ["fusion", "OBSERVATION", 103, 109], ["viral envelope", "OBSERVATION", 117, 131], ["cell membrane", "OBSERVATION", 139, 152]]], ["NDV strains containing an F protein cleavage site that has several basic amino acids is readily cleaved by numerous cellular proteases in a variety of tissues, leading to wide dissemination of the virus throughout the host organism and high virulence.", [["cellular", "ANATOMY", 116, 124], ["tissues", "ANATOMY", 151, 158], ["amino acids", "CHEMICAL", 73, 84], ["amino acids", "CHEMICAL", 73, 84], ["NDV", "ORGANISM", 0, 3], ["amino acids", "AMINO_ACID", 73, 84], ["cellular", "CELL", 116, 124], ["tissues", "TISSUE", 151, 158], ["F protein cleavage site", "DNA", 26, 49], ["cellular proteases", "PROTEIN", 116, 134], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV strains", "PROBLEM", 0, 11], ["an F protein cleavage site", "TREATMENT", 23, 49], ["several basic amino acids", "PROBLEM", 59, 84], ["numerous cellular proteases", "PROBLEM", 107, 134], ["the virus", "PROBLEM", 193, 202], ["high virulence", "PROBLEM", 236, 250], ["protein cleavage", "OBSERVATION", 28, 44], ["amino acids", "OBSERVATION", 73, 84], ["numerous", "OBSERVATION_MODIFIER", 107, 115], ["cellular proteases", "OBSERVATION", 116, 134], ["wide", "OBSERVATION_MODIFIER", 171, 175], ["dissemination", "OBSERVATION", 176, 189], ["virus", "OBSERVATION", 197, 202], ["host organism", "OBSERVATION", 218, 231], ["high", "OBSERVATION_MODIFIER", 236, 240], ["virulence", "OBSERVATION_MODIFIER", 241, 250]]], ["NDV strains containing an F protein cleavage site that contains fewer basic amino acids is only cleaved by a secreted protease found in the lung, and thus its tropism is limited to the lung, leading to lower pathogenicity (Panda et al. 2004) .", [["lung", "ANATOMY", 140, 144], ["lung", "ANATOMY", 185, 189], ["amino acids", "CHEMICAL", 76, 87], ["amino acids", "CHEMICAL", 76, 87], ["NDV", "ORGANISM", 0, 3], ["amino acids", "AMINO_ACID", 76, 87], ["lung", "ORGAN", 140, 144], ["lung", "ORGAN", 185, 189], ["F protein cleavage site", "DNA", 26, 49], ["secreted protease", "PROTEIN", 109, 126], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV strains", "PROBLEM", 0, 11], ["an F protein cleavage site", "TREATMENT", 23, 49], ["basic amino acids", "TEST", 70, 87], ["a secreted protease", "TEST", 107, 126], ["lower pathogenicity", "PROBLEM", 202, 221], ["F protein", "OBSERVATION_MODIFIER", 26, 35], ["cleavage site", "OBSERVATION", 36, 49], ["fewer", "OBSERVATION_MODIFIER", 64, 69], ["amino acids", "OBSERVATION", 76, 87], ["lung", "ANATOMY", 140, 144], ["lung", "ANATOMY", 185, 189], ["lower", "OBSERVATION_MODIFIER", 202, 207], ["pathogenicity", "OBSERVATION", 208, 221]]], ["The ability to easily adjust the pathogenicity of NDV is one of the reasons that NDV is an attractive recombinant vector.Newcastle Disease Virus VectorsNDV possesses many of the qualities of an ideal vector for use in humans, and several of its properties make it specifically suited as a recombinant vector for pandemic influenza.", [["NDV", "DISEASE", 50, 53], ["influenza", "DISEASE", 321, 330], ["NDV", "ORGANISM", 50, 53], ["NDV", "ORGANISM", 81, 84], ["Newcastle Disease Virus VectorsNDV", "ORGANISM", 121, 155], ["humans", "ORGANISM", 218, 224], ["humans", "SPECIES", 218, 224], ["NDV", "SPECIES", 50, 53], ["NDV", "SPECIES", 81, 84], ["Newcastle Disease Virus VectorsNDV", "SPECIES", 121, 155], ["humans", "SPECIES", 218, 224], ["NDV", "PROBLEM", 81, 84], ["Newcastle Disease Virus VectorsNDV", "PROBLEM", 121, 155], ["a recombinant vector", "TREATMENT", 287, 307], ["pandemic influenza", "PROBLEM", 312, 330]]], ["Since under natural conditions NDV infects only birds, humans do not have pre-existing immunity to NDV.", [["NDV", "ORGANISM", 31, 34], ["birds", "ORGANISM", 48, 53], ["humans", "ORGANISM", 55, 61], ["NDV", "ORGANISM", 99, 102], ["humans", "SPECIES", 55, 61], ["NDV", "SPECIES", 31, 34], ["humans", "SPECIES", 55, 61], ["NDV", "SPECIES", 99, 102]]], ["Pre-existing antibodies to the recombinant vector drastically reduce or completely eliminate the formation of immunity to the foreign protein expressed from the vector, and this is one of the major reasons that recombinant vectors are not effective.", [["antibodies", "PROTEIN", 13, 23], ["foreign protein", "PROTEIN", 126, 141], ["Pre-existing antibodies", "PROBLEM", 0, 23], ["the recombinant vector", "TREATMENT", 27, 49], ["recombinant vectors", "TREATMENT", 211, 230]]], ["The fact that birds are a major reservoir for both NDV and highly pathogenic avian influenza virus (HPAI) has led to the development of dual vaccines that can protect poultry against both diseases.Newcastle Disease Virus VectorsAn NDV virus expressing an influenza virus HA, rNDV/B1-HA, was first rescued in 2001 (Nakaya et al. 2001 ).", [["avian influenza virus", "DISEASE", 77, 98], ["HPAI", "DISEASE", 100, 104], ["birds", "ORGANISM", 14, 19], ["NDV", "ORGANISM", 51, 54], ["highly pathogenic", "ORGANISM", 59, 76], ["avian influenza virus", "ORGANISM", 77, 98], ["Newcastle Disease Virus VectorsAn NDV virus", "ORGANISM", 197, 240], ["influenza virus HA", "ORGANISM", 255, 273], ["B1", "PROTEIN", 280, 282], ["NDV", "SPECIES", 51, 54], ["avian influenza virus", "SPECIES", 77, 98], ["VectorsAn NDV virus", "SPECIES", 221, 240], ["influenza virus", "SPECIES", 255, 270], ["NDV", "SPECIES", 51, 54], ["avian influenza virus", "SPECIES", 77, 98], ["HPAI", "SPECIES", 100, 104], ["poultry", "SPECIES", 167, 174], ["Newcastle Disease Virus VectorsAn NDV virus", "SPECIES", 197, 240], ["a major reservoir", "TREATMENT", 24, 41], ["NDV", "PROBLEM", 51, 54], ["highly pathogenic avian influenza virus", "PROBLEM", 59, 98], ["dual vaccines", "TREATMENT", 136, 149], ["both diseases", "PROBLEM", 183, 196], ["Newcastle Disease Virus VectorsAn NDV virus", "PROBLEM", 197, 240], ["an influenza virus HA", "PROBLEM", 252, 273], ["HA", "PROBLEM", 283, 285], ["influenza virus", "OBSERVATION", 255, 270]]], ["The influenza virus HA gene from the A/WSN/33 (H1N1) virus had been inserted between the P and M genes of the Hitchner B1 strain, which is avirulent, and this virus has been used as a live vaccine in birds (Russell and Ezeifeka 1995) .", [["influenza virus HA", "ORGANISM", 4, 22], ["A/WSN/33 (H1N1) virus", "ORGANISM", 37, 58], ["Hitchner B1 strain", "ORGANISM", 110, 128], ["birds", "ORGANISM", 200, 205], ["influenza virus HA gene", "DNA", 4, 27], ["P and M genes", "DNA", 89, 102], ["influenza virus", "SPECIES", 4, 19], ["influenza virus", "SPECIES", 4, 19], ["A/WSN/33 (H1N1) virus", "SPECIES", 37, 58], ["Hitchner B1 strain", "SPECIES", 110, 128], ["The influenza virus HA gene", "PROBLEM", 0, 27], ["the A/WSN", "TEST", 33, 42], ["H1N1) virus", "PROBLEM", 47, 58], ["the Hitchner B1 strain", "PROBLEM", 106, 128], ["avirulent", "PROBLEM", 139, 148], ["this virus", "PROBLEM", 154, 164], ["a live vaccine", "TREATMENT", 182, 196], ["influenza virus", "OBSERVATION", 4, 19], ["B1 strain", "OBSERVATION", 119, 128]]], ["The genomic structure of a recombinant NDV is illustrated in Fig. 1 .", [["NDV", "ORGANISM", 39, 42], ["NDV", "SPECIES", 39, 42], ["NDV", "SPECIES", 39, 42], ["a recombinant NDV", "TREATMENT", 25, 42], ["genomic structure", "OBSERVATION", 4, 21], ["recombinant", "OBSERVATION_MODIFIER", 27, 38], ["NDV", "OBSERVATION", 39, 42]]], ["The influenza virus HA was confirmed to be incorporated into the viral envelope and to be cleaved.", [["influenza virus HA", "ORGANISM", 4, 22], ["influenza virus", "SPECIES", 4, 19], ["influenza virus", "SPECIES", 4, 19], ["The influenza virus HA", "PROBLEM", 0, 22], ["influenza virus", "OBSERVATION", 4, 19], ["viral envelope", "OBSERVATION", 65, 79]]], ["The rNDV/B1-HA showed no pathogenicity in embryonated chicken eggs, which are used to grow large stocks of both influenza virus and NDV for vaccines.", [["eggs", "ANATOMY", 62, 66], ["influenza virus", "DISEASE", 112, 127], ["rNDV", "GENE_OR_GENE_PRODUCT", 4, 8], ["B1-HA", "GENE_OR_GENE_PRODUCT", 9, 14], ["chicken", "ORGANISM", 54, 61], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 62, 66], ["influenza virus", "ORGANISM", 112, 127], ["NDV", "ORGANISM", 132, 135], ["rNDV", "PROTEIN", 4, 8], ["B1", "PROTEIN", 9, 11], ["HA", "PROTEIN", 12, 14], ["chicken", "SPECIES", 54, 61], ["influenza virus", "SPECIES", 112, 127], ["NDV", "SPECIES", 132, 135], ["chicken", "SPECIES", 54, 61], ["influenza virus", "SPECIES", 112, 127], ["NDV", "SPECIES", 132, 135], ["The rNDV/B1", "TEST", 0, 11], ["HA", "PROBLEM", 12, 14], ["pathogenicity", "PROBLEM", 25, 38], ["embryonated chicken eggs", "PROBLEM", 42, 66], ["both influenza virus", "PROBLEM", 107, 127], ["vaccines", "TREATMENT", 140, 148], ["no", "UNCERTAINTY", 22, 24], ["pathogenicity", "OBSERVATION", 25, 38], ["influenza virus", "OBSERVATION", 112, 127]]], ["Most importantly, vaccination of mice with rNDV/ B1-HA conferred complete protection against lethal challenge with A/WSN/33 influenza virus (Nakaya et al. 2001) .Newcastle Disease Virus VectorsRecently, NDV recombinant vectors expressing HA genes from HPAI strains have also been generated.", [["rNDV/ B1-HA", "CHEMICAL", 43, 54], ["mice", "ORGANISM", 33, 37], ["rNDV/ B1-HA", "ORGANISM", 43, 54], ["A/WSN/33 influenza virus", "ORGANISM", 115, 139], ["Newcastle Disease Virus", "ORGANISM", 162, 185], ["NDV", "ORGANISM", 203, 206], ["HA", "GENE_OR_GENE_PRODUCT", 238, 240], ["HPAI", "ORGANISM", 252, 256], ["B1", "PROTEIN", 49, 51], ["HA genes", "DNA", 238, 246], ["mice", "SPECIES", 33, 37], ["influenza virus", "SPECIES", 124, 139], ["NDV", "SPECIES", 203, 206], ["mice", "SPECIES", 33, 37], ["rNDV", "SPECIES", 43, 47], ["A/WSN/33 influenza virus", "SPECIES", 115, 139], ["NDV", "SPECIES", 203, 206], ["rNDV/ B1", "TREATMENT", 43, 51], ["HA", "PROBLEM", 52, 54], ["lethal challenge", "TREATMENT", 93, 109], ["A/WSN/33 influenza virus", "TREATMENT", 115, 139], ["Newcastle Disease Virus VectorsRecently", "PROBLEM", 162, 201], ["NDV recombinant vectors", "TREATMENT", 203, 226], ["HA genes from HPAI strains", "PROBLEM", 238, 264]]], ["NDVs expressing HAs from H5 and H7 influenza virus strains, which have both caused illness and death in humans working with infected birds, were designed to be dual vaccines to protect birds from HPAI and NDV (Park et al. 2006; Veits et al. 2006; Ge et al. 2007) .", [["illness", "DISEASE", 83, 90], ["death", "DISEASE", 95, 100], ["HPAI", "DISEASE", 196, 200], ["NDVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["HAs", "ORGANISM", 16, 19], ["H5 and H7 influenza virus", "ORGANISM", 25, 50], ["humans", "ORGANISM", 104, 110], ["birds", "ORGANISM", 133, 138], ["birds", "ORGANISM", 185, 190], ["HPAI", "ORGANISM", 196, 200], ["NDV", "ORGANISM", 205, 208], ["H7 influenza virus", "SPECIES", 32, 50], ["humans", "SPECIES", 104, 110], ["NDV", "SPECIES", 205, 208], ["H7 influenza virus", "SPECIES", 32, 50], ["humans", "SPECIES", 104, 110], ["HPAI", "SPECIES", 196, 200], ["NDV", "SPECIES", 205, 208], ["H5", "PROBLEM", 25, 27], ["H7 influenza virus strains", "PROBLEM", 32, 58], ["illness", "PROBLEM", 83, 90], ["death", "PROBLEM", 95, 100], ["dual vaccines", "TREATMENT", 160, 173]]], ["In order to enhance incorporation of H7 into the viral envelope, the ectodomain of H7 was fused to the transmembrane and cytoplasmic domains of the F gene and inserted into the NDV genome between Fig. 1 Rescue of a recombinant NDV vector expressing influenza virus HA protein.", [["transmembrane", "ANATOMY", 103, 116], ["cytoplasmic", "ANATOMY", 121, 132], ["H7", "CHEMICAL", 37, 39], ["H7", "GENE_OR_GENE_PRODUCT", 83, 85], ["transmembrane", "CELLULAR_COMPONENT", 103, 116], ["cytoplasmic", "ORGANISM_SUBSTANCE", 121, 132], ["F", "GENE_OR_GENE_PRODUCT", 148, 149], ["NDV", "ORGANISM", 177, 180], ["NDV", "ORGANISM", 227, 230], ["influenza virus HA", "ORGANISM", 249, 267], ["H7", "PROTEIN", 37, 39], ["ectodomain", "PROTEIN", 69, 79], ["H7", "PROTEIN", 83, 85], ["transmembrane and cytoplasmic domains", "PROTEIN", 103, 140], ["F gene", "DNA", 148, 154], ["NDV genome", "DNA", 177, 187], ["influenza virus HA protein", "PROTEIN", 249, 275], ["influenza virus", "SPECIES", 249, 264], ["NDV", "SPECIES", 177, 180], ["NDV", "SPECIES", 227, 230], ["influenza virus", "SPECIES", 249, 264], ["the viral envelope", "PROBLEM", 45, 63], ["the ectodomain of H7", "TREATMENT", 65, 85], ["the transmembrane and cytoplasmic domains of the F gene", "TREATMENT", 99, 154], ["a recombinant NDV vector", "TREATMENT", 213, 237], ["influenza virus HA protein", "PROBLEM", 249, 275], ["viral envelope", "OBSERVATION", 49, 63], ["NDV genome", "OBSERVATION", 177, 187], ["Fig", "OBSERVATION_MODIFIER", 196, 199]]], ["The HA gene was cloned between the P and the M gene in a plasmid containing the full-length NDV genome under the control of the T7 promoter that requires the T7 polymerase for expression.", [["plasmid", "ANATOMY", 57, 64], ["HA", "GENE_OR_GENE_PRODUCT", 4, 6], ["NDV", "ORGANISM", 92, 95], ["T7", "GENE_OR_GENE_PRODUCT", 128, 130], ["T7 polymerase", "GENE_OR_GENE_PRODUCT", 158, 171], ["HA gene", "DNA", 4, 11], ["P", "DNA", 35, 36], ["M gene", "DNA", 45, 51], ["full-length NDV genome", "DNA", 80, 102], ["T7 promoter", "DNA", 128, 139], ["T7 polymerase", "PROTEIN", 158, 171], ["NDV", "SPECIES", 92, 95], ["a plasmid", "TREATMENT", 55, 64], ["the full-length NDV genome", "TREATMENT", 76, 102], ["the T7 promoter", "TREATMENT", 124, 139], ["the T7 polymerase", "TREATMENT", 154, 171], ["T7", "ANATOMY", 128, 130]]], ["Cells were cotransfected with a plasmid containing the full-length NDV-HA genome as well as helper plasmids expressing NP, P, and L from a Pol II promoter.", [["Cells", "ANATOMY", 0, 5], ["plasmid", "ANATOMY", 32, 39], ["plasmids", "ANATOMY", 99, 107], ["Cells", "CELL", 0, 5], ["NDV", "ORGANISM", 67, 70], ["Pol II", "GENE_OR_GENE_PRODUCT", 139, 145], ["full-length NDV-HA genome", "DNA", 55, 80], ["helper plasmids", "DNA", 92, 107], ["NP, P, and L", "DNA", 119, 131], ["Pol II promoter", "DNA", 139, 154], ["a plasmid", "TREATMENT", 30, 39], ["the full-length NDV", "TREATMENT", 51, 70], ["HA genome", "TREATMENT", 71, 80], ["helper plasmids", "TREATMENT", 92, 107], ["a Pol II promoter", "TREATMENT", 137, 154]]], ["One hour prior to transfection, cells were infected with MVA-T7 vaccinia virus, which had been modified to express the T7 polymerase.", [["cells", "ANATOMY", 32, 37], ["cells", "CELL", 32, 37], ["MVA-T7 vaccinia virus", "ORGANISM", 57, 78], ["T7 polymerase", "PROTEIN", 119, 132], ["T7 vaccinia virus", "SPECIES", 61, 78], ["MVA-T7 vaccinia virus", "SPECIES", 57, 78], ["cells", "PROBLEM", 32, 37], ["MVA-T7 vaccinia virus", "PROBLEM", 57, 78], ["T7", "ANATOMY", 61, 63], ["T7", "ANATOMY", 119, 121]]], ["The resulting NDV virus expressed NDV F and HN, as well as influenza HA on the virion surface.", [["surface", "ANATOMY", 86, 93], ["NDV virus", "ORGANISM", 14, 23], ["NDV F", "ORGANISM", 34, 39], ["HN", "GENE_OR_GENE_PRODUCT", 44, 46], ["influenza HA", "ORGANISM", 59, 71], ["NDV", "SPECIES", 14, 17], ["NDV virus", "SPECIES", 14, 23], ["NDV", "SPECIES", 34, 37], ["The resulting NDV virus", "PROBLEM", 0, 23], ["HN", "PROBLEM", 44, 46], ["influenza HA", "PROBLEM", 59, 71], ["NDV virus", "OBSERVATION", 14, 23], ["influenza", "OBSERVATION", 59, 68], ["virion", "ANATOMY", 79, 85], ["surface", "ANATOMY_MODIFIER", 86, 93]]], ["Conformation of the rescue of NDV-HA virus was determined by sequence analysis, as described in Nakaya et al. (2001) the P and M genes.", [["NDV-HA virus", "ORGANISM", 30, 42], ["P and M genes", "DNA", 121, 134], ["NDV-HA virus", "SPECIES", 30, 42], ["NDV", "PROBLEM", 30, 33], ["HA virus", "PROBLEM", 34, 42], ["sequence analysis", "TEST", 61, 78]]], ["The virus was too attenuated to confer full protection after challenge with HPAI, so three basic amino acids were added to the F protein fusion site to enhance viral spread.", [["HPAI", "DISEASE", 76, 80], ["amino acids", "CHEMICAL", 97, 108], ["amino acids", "CHEMICAL", 97, 108], ["amino acids", "AMINO_ACID", 97, 108], ["F protein fusion site", "DNA", 127, 148], ["HPAI", "SPECIES", 76, 80], ["The virus", "PROBLEM", 0, 9], ["HPAI", "TREATMENT", 76, 80], ["three basic amino acids", "TREATMENT", 85, 108], ["the F protein fusion site", "TREATMENT", 123, 148], ["viral spread", "PROBLEM", 160, 172], ["virus", "OBSERVATION", 4, 9], ["viral spread", "OBSERVATION", 160, 172]]], ["The resulting virus was still highly attenuated compared to pathogenic strains of NDV, but it did induce 90% protection after stringent challenge with HPAI and 100% protection after challenge with NDV (Park et al. 2006) .", [["HPAI", "DISEASE", 151, 155], ["NDV", "ORGANISM", 82, 85], ["NDV", "ORGANISM", 197, 200], ["NDV", "SPECIES", 82, 85], ["NDV", "SPECIES", 82, 85], ["HPAI", "SPECIES", 151, 155], ["NDV", "SPECIES", 197, 200], ["The resulting virus", "PROBLEM", 0, 19], ["pathogenic strains of NDV", "PROBLEM", 60, 85], ["HPAI", "TREATMENT", 151, 155], ["virus", "OBSERVATION", 14, 19]]], ["H5 HAs were cloned into a different nonpathogenic NDV strain, La Sota, and used to vaccinate chickens.", [["H5 HAs", "ORGANISM", 0, 6], ["NDV", "ORGANISM", 50, 53], ["La Sota", "CELL", 62, 69], ["chickens", "ORGANISM", 93, 101], ["NDV", "SPECIES", 50, 53], ["chickens", "SPECIES", 93, 101], ["NDV", "SPECIES", 50, 53], ["chickens", "SPECIES", 93, 101], ["NDV", "OBSERVATION", 50, 53]]], ["Not only were the chickens fully protected after lethal challenge with HPAI and NDV, but the vaccine also prevented the chickens from shedding virus after challenge (Veits et al. 2006; Ge et al. 2007 ).Newcastle Disease Virus VectorsNDV has also been used as a recombinant vector for pathogens other than influenza virus.", [["HPAI", "DISEASE", 71, 75], ["VectorsNDV", "CHEMICAL", 226, 236], ["influenza virus", "DISEASE", 305, 320], ["chickens", "ORGANISM", 18, 26], ["HPAI", "ORGANISM", 71, 75], ["NDV", "ORGANISM", 80, 83], ["chickens", "ORGANISM", 120, 128], ["Newcastle Disease Virus VectorsNDV", "ORGANISM", 202, 236], ["influenza virus", "ORGANISM", 305, 320], ["chickens", "SPECIES", 18, 26], ["NDV", "SPECIES", 80, 83], ["chickens", "SPECIES", 120, 128], ["influenza virus", "SPECIES", 305, 320], ["chickens", "SPECIES", 18, 26], ["HPAI", "SPECIES", 71, 75], ["NDV", "SPECIES", 80, 83], ["chickens", "SPECIES", 120, 128], ["Newcastle Disease Virus VectorsNDV", "SPECIES", 202, 236], ["influenza virus", "SPECIES", 305, 320], ["lethal challenge", "TREATMENT", 49, 65], ["HPAI", "TREATMENT", 71, 75], ["NDV", "TREATMENT", 80, 83], ["the vaccine", "TREATMENT", 89, 100], ["shedding virus", "PROBLEM", 134, 148], ["Newcastle Disease Virus VectorsNDV", "PROBLEM", 202, 236], ["a recombinant vector", "TREATMENT", 259, 279], ["pathogens", "PROBLEM", 284, 293], ["influenza virus", "PROBLEM", 305, 320]]], ["Infectious bursal disease virus (IBDV) causes immunosuppression in poultry, which reduces the effectiveness of vaccines and leaves the animals especially susceptible to other infections.", [["Infectious bursal disease", "DISEASE", 0, 25], ["infections", "DISEASE", 175, 185], ["Infectious bursal disease virus", "ORGANISM", 0, 31], ["IBDV", "ORGANISM", 33, 37], ["Infectious bursal disease virus", "SPECIES", 0, 31], ["Infectious bursal disease virus", "SPECIES", 0, 31], ["IBDV", "SPECIES", 33, 37], ["poultry", "SPECIES", 67, 74], ["Infectious bursal disease virus", "PROBLEM", 0, 31], ["immunosuppression in poultry", "PROBLEM", 46, 74], ["vaccines", "TREATMENT", 111, 119], ["other infections", "PROBLEM", 169, 185], ["infections", "OBSERVATION", 175, 185]]], ["A recombinant NDV expressing the IBDV VP2 protein provided protection against IBDV and NDV in chickens .", [["NDV", "ORGANISM", 14, 17], ["IBDV", "ORGANISM", 33, 37], ["VP2", "ORGANISM", 38, 41], ["IBDV", "ORGANISM", 78, 82], ["NDV", "ORGANISM", 87, 90], ["chickens", "ORGANISM", 94, 102], ["IBDV VP2 protein", "PROTEIN", 33, 49], ["IBDV", "SPECIES", 33, 37], ["IBDV", "SPECIES", 78, 82], ["NDV", "SPECIES", 87, 90], ["chickens", "SPECIES", 94, 102], ["NDV", "SPECIES", 14, 17], ["IBDV", "SPECIES", 33, 37], ["IBDV", "SPECIES", 78, 82], ["NDV", "SPECIES", 87, 90], ["chickens", "SPECIES", 94, 102], ["A recombinant NDV", "TREATMENT", 0, 17], ["the IBDV VP2 protein", "TREATMENT", 29, 49], ["IBDV", "PROBLEM", 78, 82], ["NDV", "PROBLEM", 87, 90], ["NDV", "OBSERVATION", 14, 17]]], ["Another recombinant NDV was designed to prevent respiratory syncytial virus (RSV), which causes severe respiratory disease in infants and the elderly.", [["respiratory", "ANATOMY", 103, 114], ["respiratory syncytial virus (RSV)", "DISEASE", 48, 81], ["respiratory disease", "DISEASE", 103, 122], ["NDV", "ORGANISM", 20, 23], ["respiratory syncytial virus", "ORGANISM", 48, 75], ["RSV", "ORGANISM", 77, 80], ["infants", "ORGANISM", 126, 133], ["respiratory syncytial virus", "SPECIES", 48, 75], ["infants", "SPECIES", 126, 133], ["NDV", "SPECIES", 20, 23], ["respiratory syncytial virus", "SPECIES", 48, 75], ["RSV", "SPECIES", 77, 80], ["Another recombinant NDV", "TREATMENT", 0, 23], ["respiratory syncytial virus", "PROBLEM", 48, 75], ["severe respiratory disease in infants", "PROBLEM", 96, 133], ["NDV", "OBSERVATION", 20, 23], ["syncytial virus", "OBSERVATION", 60, 75], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["respiratory disease", "OBSERVATION", 103, 122]]], ["A recombinant NDV expressing RSV F protein protected mice against challenge with RSV (Martinez-Sobrido et al. 2006) .Newcastle Disease Virus VectorsRecombinant NDV vaccines for pathogens such as severe acute respiratory syndrome virus (SARS-CoV) and human parainfluenza virus type 3 (HPIV3) have been tested in primates.", [["acute respiratory syndrome virus", "DISEASE", 202, 234], ["SARS-CoV)", "DISEASE", 236, 245], ["NDV", "ORGANISM", 14, 17], ["RSV", "ORGANISM", 29, 32], ["F", "GENE_OR_GENE_PRODUCT", 33, 34], ["mice", "ORGANISM", 53, 57], ["RSV", "ORGANISM", 81, 84], ["Newcastle Disease Virus VectorsRecombinant NDV", "ORGANISM", 117, 163], ["severe acute respiratory syndrome virus", "ORGANISM", 195, 234], ["SARS-CoV", "ORGANISM", 236, 244], ["human", "ORGANISM", 250, 255], ["parainfluenza virus type 3", "ORGANISM", 256, 282], ["HPIV3", "GENE_OR_GENE_PRODUCT", 284, 289], ["primates", "ORGANISM", 311, 319], ["recombinant NDV expressing RSV F protein", "PROTEIN", 2, 42], ["mice", "SPECIES", 53, 57], ["NDV", "SPECIES", 160, 163], ["human", "SPECIES", 250, 255], ["parainfluenza virus", "SPECIES", 256, 275], ["NDV", "SPECIES", 14, 17], ["RSV", "SPECIES", 29, 32], ["mice", "SPECIES", 53, 57], ["RSV", "SPECIES", 81, 84], ["NDV", "SPECIES", 160, 163], ["severe acute respiratory syndrome virus", "SPECIES", 195, 234], ["SARS-CoV", "SPECIES", 236, 244], ["human parainfluenza virus", "SPECIES", 250, 275], ["HPIV3", "SPECIES", 284, 289], ["A recombinant NDV", "TREATMENT", 0, 17], ["RSV F protein", "TREATMENT", 29, 42], ["RSV (Martinez", "TREATMENT", 81, 94], ["Newcastle Disease Virus VectorsRecombinant NDV vaccines", "TREATMENT", 117, 172], ["pathogens", "PROBLEM", 177, 186], ["severe acute respiratory syndrome virus", "PROBLEM", 195, 234], ["human parainfluenza virus type", "PROBLEM", 250, 280], ["NDV", "OBSERVATION", 14, 17], ["severe", "OBSERVATION_MODIFIER", 195, 201], ["acute", "OBSERVATION_MODIFIER", 202, 207], ["respiratory syndrome", "OBSERVATION", 208, 228], ["parainfluenza virus", "OBSERVATION", 256, 275]]], ["SARS-CoV caused a worldwide outbreak in 2003 with a mortality rate of about 10%.", [["SARS-CoV", "DISEASE", 0, 8], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["a mortality rate", "TEST", 50, 66]]], ["Vaccination of African green monkeys with an NDV vector expressing SARS-CoV spike protein resulted in a dramatic reduction of viral replication after challenge with SARS-CoV (DiNapoli et al. 2007 ).", [["green monkeys", "ORGANISM", 23, 36], ["NDV", "ORGANISM", 45, 48], ["SARS-CoV", "ORGANISM", 67, 75], ["SARS-CoV", "ORGANISM", 165, 173], ["SARS-CoV spike protein", "PROTEIN", 67, 89], ["green monkeys", "SPECIES", 23, 36], ["African green monkeys", "SPECIES", 15, 36], ["NDV", "SPECIES", 45, 48], ["SARS-CoV", "SPECIES", 67, 75], ["SARS-CoV", "SPECIES", 165, 173], ["African green monkeys", "TREATMENT", 15, 36], ["an NDV vector", "TREATMENT", 42, 55], ["SARS", "PROBLEM", 67, 71], ["CoV spike protein", "PROBLEM", 72, 89], ["a dramatic reduction of viral replication", "TREATMENT", 102, 143], ["SARS", "PROBLEM", 165, 169], ["viral replication", "OBSERVATION", 126, 143]]], ["An NDV vector expressing HPIV3 HN protein induced levels of antibody comparable to natural infection with HPIV3 in African green monkeys (Bukreyev et al. 2005) .Newcastle Disease Virus VectorsOne limitation of NDV as a recombinant vector is that it can be difficult to grow NDVs with long foreign genes or multiple foreign genes inserted into the NDV genome.", [["infection", "DISEASE", 91, 100], ["HPIV3", "CHEMICAL", 106, 111], ["NDV", "ORGANISM", 3, 6], ["HPIV3 HN", "GENE_OR_GENE_PRODUCT", 25, 33], ["HPIV3", "SIMPLE_CHEMICAL", 106, 111], ["green monkeys", "ORGANISM", 123, 136], ["Newcastle Disease Virus", "ORGANISM", 161, 184], ["NDV", "ORGANISM", 210, 213], ["NDVs", "GENE_OR_GENE_PRODUCT", 274, 278], ["NDV", "ORGANISM", 347, 350], ["HPIV3 HN protein", "PROTEIN", 25, 41], ["long foreign genes", "DNA", 284, 302], ["foreign genes", "DNA", 315, 328], ["NDV genome", "DNA", 347, 357], ["green monkeys", "SPECIES", 123, 136], ["NDV", "SPECIES", 3, 6], ["HPIV3", "SPECIES", 25, 30], ["HPIV3", "SPECIES", 106, 111], ["African green monkeys", "SPECIES", 115, 136], ["NDV", "SPECIES", 210, 213], ["NDV", "SPECIES", 347, 350], ["An NDV vector", "TREATMENT", 0, 13], ["HPIV3 HN protein induced levels of antibody", "PROBLEM", 25, 68], ["natural infection", "PROBLEM", 83, 100], ["Newcastle Disease Virus Vectors", "PROBLEM", 161, 192], ["NDV", "PROBLEM", 210, 213], ["a recombinant vector", "TREATMENT", 217, 237], ["long foreign genes", "TREATMENT", 284, 302], ["multiple foreign genes", "TREATMENT", 306, 328], ["infection", "OBSERVATION", 91, 100], ["Virus Vectors", "OBSERVATION", 179, 192], ["NDV", "OBSERVATION", 210, 213], ["multiple", "OBSERVATION_MODIFIER", 306, 314], ["foreign genes", "OBSERVATION", 315, 328], ["NDV genome", "OBSERVATION", 347, 357]]], ["This shortcoming has recently been overcome by rescuing a recombinant NDV with a bisegmented genome.", [["NDV", "ORGANISM", 70, 73], ["bisegmented genome", "DNA", 81, 99], ["NDV", "SPECIES", 70, 73], ["a recombinant NDV", "TREATMENT", 56, 73]]], ["One segment contains the genes for NP, P, and L, while the other segment contains the genes for M, F, and HN.", [["HN", "GENE_OR_GENE_PRODUCT", 106, 108], ["NP", "DNA", 35, 37], ["P", "DNA", 39, 40], ["L", "DNA", 46, 47], ["NP", "TEST", 35, 37], ["segment", "ANATOMY_MODIFIER", 4, 11], ["genes", "OBSERVATION_MODIFIER", 25, 30], ["L", "ANATOMY_MODIFIER", 46, 47]]], ["A recombinant virus expressing GFP from the first segment and SARS-CoV spike protein from the second segment was rescued, demonstrating that NDV can be designed to express multiple foreign proteins and large proteins such as SARS-CoV spike protein ( Fig. 2) (Gao et al. 2008) .", [["GFP", "GENE_OR_GENE_PRODUCT", 31, 34], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["NDV", "ORGANISM", 141, 144], ["SARS-CoV spike protein", "GENE_OR_GENE_PRODUCT", 225, 247], ["GFP", "PROTEIN", 31, 34], ["SARS-CoV spike protein", "PROTEIN", 62, 84], ["foreign proteins", "PROTEIN", 181, 197], ["large proteins", "PROTEIN", 202, 216], ["SARS-CoV spike protein", "PROTEIN", 225, 247], ["SARS-CoV", "SPECIES", 62, 70], ["NDV", "SPECIES", 141, 144], ["SARS-CoV", "SPECIES", 225, 233], ["A recombinant virus expressing GFP", "PROBLEM", 0, 34], ["SARS", "PROBLEM", 62, 66], ["CoV spike protein", "PROBLEM", 67, 84], ["NDV", "PROBLEM", 141, 144], ["multiple foreign proteins", "PROBLEM", 172, 197], ["large proteins", "PROBLEM", 202, 216], ["SARS", "PROBLEM", 225, 229], ["CoV spike protein", "TEST", 230, 247], ["virus", "OBSERVATION", 14, 19], ["CoV spike", "OBSERVATION", 67, 76], ["multiple", "OBSERVATION_MODIFIER", 172, 180], ["foreign proteins", "OBSERVATION", 181, 197]]], ["Fig. 2 Expression of two foreign proteins from a bisegmented NDV virus.", [["NDV virus", "ORGANISM", 61, 70], ["foreign proteins", "PROTEIN", 25, 41], ["NDV virus", "SPECIES", 61, 70], ["NDV virus", "SPECIES", 61, 70], ["two foreign proteins", "PROBLEM", 21, 41], ["a bisegmented NDV virus", "PROBLEM", 47, 70], ["two", "OBSERVATION_MODIFIER", 21, 24], ["foreign proteins", "OBSERVATION", 25, 41], ["NDV virus", "OBSERVATION", 61, 70]]], ["The nonsegmented NDV genome was divided into two segments to allow the expression of two foreign proteins.", [["NDV", "ORGANISM", 17, 20], ["nonsegmented NDV genome", "DNA", 4, 27], ["foreign proteins", "PROTEIN", 89, 105], ["NDV", "SPECIES", 17, 20], ["NDV", "SPECIES", 17, 20], ["The nonsegmented NDV genome", "TREATMENT", 0, 27], ["two foreign proteins", "PROBLEM", 85, 105], ["NDV genome", "OBSERVATION", 17, 27], ["two", "OBSERVATION_MODIFIER", 85, 88], ["foreign proteins", "OBSERVATION", 89, 105]]], ["Segment 1 contains the M, F, and HN genes as well as the SARS-CoV spike gene.", [["Segment 1", "GENE_OR_GENE_PRODUCT", 0, 9], ["M, F", "GENE_OR_GENE_PRODUCT", 23, 27], ["HN", "GENE_OR_GENE_PRODUCT", 33, 35], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["Segment 1", "DNA", 0, 9], ["M, F, and HN genes", "DNA", 23, 41], ["SARS-CoV spike gene", "DNA", 57, 76], ["SARS-CoV", "SPECIES", 57, 65], ["the M, F, and HN genes", "PROBLEM", 19, 41], ["the SARS", "PROBLEM", 53, 61], ["HN genes", "ANATOMY", 33, 41], ["SARS", "OBSERVATION", 57, 61], ["CoV spike", "OBSERVATION", 62, 71]]], ["The 3\u00a2 and 5\u00a2 noncoding regions were added onto the ends of segment 1.", [["3\u00a2 and 5\u00a2 noncoding regions", "DNA", 4, 31], ["segment 1", "DNA", 60, 69], ["The 3\u00a2 and 5\u00a2 noncoding regions", "TREATMENT", 0, 31], ["ends", "ANATOMY_MODIFIER", 52, 56], ["segment 1", "ANATOMY_MODIFIER", 60, 69]]], ["Segment 2 contains NP, P, and L genes as well as GFP inserted between the P and L genes.", [["Segment 2", "GENE_OR_GENE_PRODUCT", 0, 9], ["NP", "GENE_OR_GENE_PRODUCT", 19, 21], ["GFP", "GENE_OR_GENE_PRODUCT", 49, 52], ["NP, P, and L genes", "DNA", 19, 37], ["GFP", "DNA", 49, 52], ["P and L genes", "DNA", 74, 87], ["NP, P, and L genes", "TREATMENT", 19, 37], ["NP", "OBSERVATION", 19, 21], ["L genes", "ANATOMY_MODIFIER", 30, 37], ["L", "ANATOMY_MODIFIER", 80, 81], ["genes", "ANATOMY", 82, 87]]], ["Figure adapted from Gao et al. (2008) Interestingly, NDV is being tested as a recombinant vector for not only infectious diseases, but also for cancer.", [["cancer", "ANATOMY", 144, 150], ["infectious diseases", "DISEASE", 110, 129], ["cancer", "DISEASE", 144, 150], ["NDV", "ORGANISM", 53, 56], ["cancer", "CANCER", 144, 150], ["NDV", "SPECIES", 53, 56], ["a recombinant vector", "TREATMENT", 76, 96], ["infectious diseases", "PROBLEM", 110, 129], ["cancer", "PROBLEM", 144, 150], ["cancer", "OBSERVATION", 144, 150]]], ["It had previously been observed that NDV replicates in human tumor cells much more readily than normal cells.", [["tumor cells", "ANATOMY", 61, 72], ["cells", "ANATOMY", 103, 108], ["tumor", "DISEASE", 61, 66], ["NDV", "ORGANISM", 37, 40], ["human", "ORGANISM", 55, 60], ["tumor cells", "CELL", 61, 72], ["cells", "CELL", 103, 108], ["human tumor cells", "CELL_TYPE", 55, 72], ["normal cells", "CELL_TYPE", 96, 108], ["human", "SPECIES", 55, 60], ["NDV", "SPECIES", 37, 40], ["human", "SPECIES", 55, 60], ["NDV", "PROBLEM", 37, 40], ["human tumor cells", "TEST", 55, 72], ["NDV", "OBSERVATION", 37, 40], ["tumor cells", "OBSERVATION", 61, 72]]], ["This is believed to occur because cancer cells often have mutations in the interferon pathway, a key host antiviral immune response, while normal cells have an intact interferon pathway.", [["cancer cells", "ANATOMY", 34, 46], ["cells", "ANATOMY", 146, 151], ["cancer", "DISEASE", 34, 40], ["cancer cells", "CELL", 34, 46], ["interferon", "GENE_OR_GENE_PRODUCT", 75, 85], ["cells", "CELL", 146, 151], ["interferon", "GENE_OR_GENE_PRODUCT", 167, 177], ["cancer cells", "CELL_TYPE", 34, 46], ["interferon", "PROTEIN", 75, 85], ["normal cells", "CELL_TYPE", 139, 151], ["interferon", "PROTEIN", 167, 177], ["cancer cells", "PROBLEM", 34, 46], ["mutations in the interferon pathway", "PROBLEM", 58, 93], ["an intact interferon pathway", "TREATMENT", 157, 185], ["believed to occur", "UNCERTAINTY", 8, 25], ["intact interferon", "OBSERVATION", 160, 177]]], ["Since NDV is very sensitive to the effects of interferon, it is rapidly eliminated from normal cells.", [["cells", "ANATOMY", 95, 100], ["NDV", "ORGANISM", 6, 9], ["interferon", "GENE_OR_GENE_PRODUCT", 46, 56], ["cells", "CELL", 95, 100], ["interferon", "PROTEIN", 46, 56], ["normal cells", "CELL_TYPE", 88, 100], ["NDV", "SPECIES", 6, 9], ["NDV", "PROBLEM", 6, 9], ["interferon", "TREATMENT", 46, 56], ["normal cells", "OBSERVATION", 88, 100]]], ["The cancer cells, however, are killed by NDV since they cannot mount an antiviral response.", [["cancer cells", "ANATOMY", 4, 16], ["cancer", "DISEASE", 4, 10], ["cancer cells", "CELL", 4, 16], ["NDV", "ORGANISM", 41, 44], ["cancer cells", "CELL_TYPE", 4, 16], ["NDV", "SPECIES", 41, 44], ["The cancer cells", "PROBLEM", 0, 16], ["cancer cells", "OBSERVATION", 4, 16], ["antiviral response", "OBSERVATION", 72, 90]]], ["An NDV vector expressing granulocyte/macrophage colonystimulating factor (GM-CSF), which has been shown to enhance immunity to tumors, stimulates antitumor activity in human cells better than NDV vector alone (Janke et al. 2007) .", [["tumors", "ANATOMY", 127, 133], ["antitumor", "ANATOMY", 146, 155], ["cells", "ANATOMY", 174, 179], ["tumors", "DISEASE", 127, 133], ["NDV", "ORGANISM", 3, 6], ["granulocyte/macrophage colonystimulating factor", "GENE_OR_GENE_PRODUCT", 25, 72], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 74, 80], ["tumors", "CANCER", 127, 133], ["antitumor", "CANCER", 146, 155], ["human", "ORGANISM", 168, 173], ["cells", "CELL", 174, 179], ["NDV", "ORGANISM", 192, 195], ["granulocyte/macrophage colonystimulating factor", "PROTEIN", 25, 72], ["GM", "PROTEIN", 74, 76], ["CSF", "PROTEIN", 77, 80], ["human cells", "CELL_TYPE", 168, 179], ["human", "SPECIES", 168, 173], ["NDV", "SPECIES", 3, 6], ["human", "SPECIES", 168, 173], ["NDV", "SPECIES", 192, 195], ["An NDV vector", "TEST", 0, 13], ["granulocyte", "TEST", 25, 36], ["macrophage colonystimulating factor", "PROBLEM", 37, 72], ["tumors", "PROBLEM", 127, 133], ["stimulates antitumor activity in human cells", "TREATMENT", 135, 179], ["NDV vector", "TREATMENT", 192, 202], ["macrophage", "OBSERVATION_MODIFIER", 37, 47], ["tumors", "OBSERVATION", 127, 133]]], ["A recombinant NDV vector expressing IL-2 reduced tumor volume and caused a higher remission rate of colon carcinoma tumors in mice compared to NDV alone (Vigil et al. 2007) .", [["tumor", "ANATOMY", 49, 54], ["colon carcinoma tumors", "ANATOMY", 100, 122], ["tumor", "DISEASE", 49, 54], ["colon carcinoma tumors", "DISEASE", 100, 122], ["NDV", "ORGANISM", 14, 17], ["IL-2", "GENE_OR_GENE_PRODUCT", 36, 40], ["tumor", "CANCER", 49, 54], ["colon carcinoma tumors", "CANCER", 100, 122], ["mice", "ORGANISM", 126, 130], ["NDV", "ORGANISM", 143, 146], ["IL-2", "PROTEIN", 36, 40], ["mice", "SPECIES", 126, 130], ["NDV", "SPECIES", 14, 17], ["mice", "SPECIES", 126, 130], ["NDV", "SPECIES", 143, 146], ["A recombinant NDV vector", "TREATMENT", 0, 24], ["reduced tumor volume", "PROBLEM", 41, 61], ["colon carcinoma tumors", "PROBLEM", 100, 122], ["tumor", "OBSERVATION", 49, 54], ["higher", "OBSERVATION_MODIFIER", 75, 81], ["colon", "ANATOMY", 100, 105], ["carcinoma", "OBSERVATION", 106, 115]]], ["A new approach involving the expression of tumor-related antibodies from the NDV genome also has promise for cancer therapy (Puhler et al. 2008) .", [["tumor", "ANATOMY", 43, 48], ["cancer", "ANATOMY", 109, 115], ["tumor", "DISEASE", 43, 48], ["cancer", "DISEASE", 109, 115], ["tumor", "CANCER", 43, 48], ["NDV", "ORGANISM", 77, 80], ["cancer", "CANCER", 109, 115], ["tumor-related antibodies", "PROTEIN", 43, 67], ["NDV genome", "DNA", 77, 87], ["NDV", "SPECIES", 77, 80], ["A new approach", "TREATMENT", 0, 14], ["tumor", "PROBLEM", 43, 48], ["related antibodies", "PROBLEM", 49, 67], ["the NDV genome", "PROBLEM", 73, 87], ["cancer therapy", "TREATMENT", 109, 123], ["new", "OBSERVATION_MODIFIER", 2, 5], ["tumor", "OBSERVATION", 43, 48], ["NDV genome", "OBSERVATION", 77, 87], ["cancer", "OBSERVATION", 109, 115]]], ["Additionally, the safety of NDV has already been demonstrated in humans (Freeman et al. 2006; Laurie et al. 2006 ).", [["NDV", "ORGANISM", 28, 31], ["humans", "ORGANISM", 65, 71], ["humans", "SPECIES", 65, 71], ["NDV", "SPECIES", 28, 31], ["humans", "SPECIES", 65, 71], ["NDV", "TREATMENT", 28, 31]]], ["Thus, NDV shows promise of being a valuable recombinant vector in both humans and birds.Vesicular Stomatitis Virus VectorsVesicular stomatitis virus (VSV) contains a nonsegmented, single-strand, negativesense RNA genome and belongs to the family Rhabdoviridae.", [["VectorsVesicular stomatitis", "DISEASE", 115, 142], ["NDV", "ORGANISM", 6, 9], ["humans", "ORGANISM", 71, 77], ["birds", "ORGANISM", 82, 87], ["Vesicular Stomatitis Virus VectorsVesicular stomatitis virus", "ORGANISM", 88, 148], ["VSV", "ORGANISM", 150, 153], ["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 246, 259], ["nonsegmented, single-strand, negativesense RNA genome", "DNA", 166, 219], ["humans", "SPECIES", 71, 77], ["VectorsVesicular stomatitis virus", "SPECIES", 115, 148], ["NDV", "SPECIES", 6, 9], ["humans", "SPECIES", 71, 77], ["Vesicular Stomatitis Virus VectorsVesicular stomatitis virus", "SPECIES", 88, 148], ["VSV", "SPECIES", 150, 153], ["NDV", "PROBLEM", 6, 9], ["Vesicular Stomatitis Virus VectorsVesicular stomatitis virus", "PROBLEM", 88, 148], ["Rhabdoviridae", "TREATMENT", 246, 259], ["Stomatitis Virus", "OBSERVATION", 98, 114], ["VectorsVesicular stomatitis virus", "OBSERVATION", 115, 148]]], ["The VSV genome is organized similarly to NDV except that VSV encodes a protein responsible for both fusion and attachment, glycoprotein (G), whereas NDV encodes two separate proteins for these functions, F and HN.", [["VSV", "ORGANISM", 4, 7], ["NDV", "ORGANISM", 41, 44], ["VSV", "ORGANISM", 57, 60], ["glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 123, 139], ["NDV", "ORGANISM", 149, 152], ["HN", "GENE_OR_GENE_PRODUCT", 210, 212], ["VSV genome", "DNA", 4, 14], ["glycoprotein (G)", "PROTEIN", 123, 139], ["NDV", "SPECIES", 41, 44], ["VSV", "SPECIES", 4, 7], ["NDV", "SPECIES", 41, 44], ["VSV", "SPECIES", 57, 60], ["NDV", "SPECIES", 149, 152], ["both fusion and attachment, glycoprotein (G)", "TREATMENT", 95, 139], ["VSV genome", "OBSERVATION", 4, 14]]], ["VSV normally infects horses, cattle, and swine, where it causes vesicular lesions on the mouth, nose, teats, and hooves.", [["vesicular lesions", "ANATOMY", 64, 81], ["mouth", "ANATOMY", 89, 94], ["nose", "ANATOMY", 96, 100], ["teats", "ANATOMY", 102, 107], ["vesicular lesions on the mouth", "DISEASE", 64, 94], ["VSV", "ORGANISM", 0, 3], ["horses", "ORGANISM_SUBDIVISION", 21, 27], ["vesicular lesions", "PATHOLOGICAL_FORMATION", 64, 81], ["mouth", "ORGANISM_SUBDIVISION", 89, 94], ["nose", "ORGANISM_SUBDIVISION", 96, 100], ["hooves", "ORGANISM_SUBDIVISION", 113, 119], ["VSV", "SPECIES", 0, 3], ["horses", "SPECIES", 21, 27], ["cattle", "SPECIES", 29, 35], ["swine", "SPECIES", 41, 46], ["VSV", "SPECIES", 0, 3], ["cattle", "SPECIES", 29, 35], ["swine", "SPECIES", 41, 46], ["vesicular lesions on the mouth, nose, teats, and hooves", "PROBLEM", 64, 119], ["infects", "OBSERVATION_MODIFIER", 13, 20], ["vesicular", "OBSERVATION_MODIFIER", 64, 73], ["lesions", "OBSERVATION", 74, 81], ["mouth", "ANATOMY", 89, 94], ["nose", "ANATOMY", 96, 100], ["teats", "ANATOMY", 102, 107]]], ["Infection is usually cleared within two weeks without complications.", [["Infection", "PROBLEM", 0, 9], ["complications", "PROBLEM", 54, 67]]], ["In nature, VSV is spread primarily by arthropod vectors such as sand flies (Lutzomyia shannoni) and black flies (Simulium vittatum), though transmission by animal-to-animal contact has been reported (Letchworth et al. 1999; Stallknecht et al. 2001; Rodriguez 2002) .", [["VSV", "ORGANISM", 11, 14], ["sand flies", "ORGANISM", 64, 74], ["Lutzomyia shannoni", "ORGANISM", 76, 94], ["black flies", "ORGANISM", 100, 111], ["Simulium vittatum", "ORGANISM", 113, 130], ["Lutzomyia shannoni", "SPECIES", 76, 94], ["Simulium vittatum", "SPECIES", 113, 130], ["VSV", "SPECIES", 11, 14], ["Lutzomyia shannoni", "SPECIES", 76, 94], ["black flies", "SPECIES", 100, 111], ["Simulium vittatum", "SPECIES", 113, 130], ["VSV", "PROBLEM", 11, 14], ["black flies", "PROBLEM", 100, 111], ["VSV", "OBSERVATION", 11, 14]]], ["VSV is considered a good vaccine vector candidate since humans do not have pre-existing antibodies that would interfere with the induction of an immune response to a foreign protein expressed from the virus.Vesicular Stomatitis Virus VectorsA recombinant VSV expressing the HA of WSN influenza virus strain was rescued and subsequently shown to confer protection in mice after challenge with WSN virus (Kretzschmar et al. 1997; Roberts et al. 1998) .", [["VSV", "ORGANISM", 0, 3], ["humans", "ORGANISM", 56, 62], ["Vesicular Stomatitis Virus VectorsA recombinant VSV", "ORGANISM", 207, 258], ["HA", "GENE_OR_GENE_PRODUCT", 274, 276], ["WSN influenza virus", "ORGANISM", 280, 299], ["mice", "ORGANISM", 366, 370], ["WSN virus", "ORGANISM", 392, 401], ["pre-existing antibodies", "PROTEIN", 75, 98], ["foreign protein", "PROTEIN", 166, 181], ["humans", "SPECIES", 56, 62], ["WSN influenza virus", "SPECIES", 280, 299], ["mice", "SPECIES", 366, 370], ["VSV", "SPECIES", 0, 3], ["humans", "SPECIES", 56, 62], ["VSV", "SPECIES", 255, 258], ["WSN influenza virus", "SPECIES", 280, 299], ["mice", "SPECIES", 366, 370], ["WSN virus", "SPECIES", 392, 401], ["pre-existing antibodies", "PROBLEM", 75, 98], ["a foreign protein", "PROBLEM", 164, 181], ["the virus", "PROBLEM", 197, 206], ["Vesicular Stomatitis Virus", "PROBLEM", 207, 233], ["WSN influenza virus strain", "PROBLEM", 280, 306], ["Stomatitis", "OBSERVATION", 217, 227]]], ["VSV expressing HA from A/Hong Kong/156/97, a highly pathogenic H5N1 virus, was shown to elicit neutralizing antibodies in mice and confer protection after challenge with A/Hong Kong/156/97 virus (Fig. 3) .", [["VSV", "ORGANISM", 0, 3], ["HA", "GENE_OR_GENE_PRODUCT", 15, 17], ["A/Hong Kong/156/97", "ORGANISM", 23, 41], ["H5N1 virus", "ORGANISM", 63, 73], ["mice", "ORGANISM", 122, 126], ["A/Hong Kong/156/97 virus", "ORGANISM", 170, 194], ["neutralizing antibodies", "PROTEIN", 95, 118], ["H5N1 virus", "SPECIES", 63, 73], ["mice", "SPECIES", 122, 126], ["VSV", "SPECIES", 0, 3], ["A/Hong Kong/156/97", "SPECIES", 23, 41], ["H5N1 virus", "SPECIES", 63, 73], ["mice", "SPECIES", 122, 126], ["Hong Kong/156/97 virus", "SPECIES", 172, 194], ["HA", "PROBLEM", 15, 17], ["a highly pathogenic H5N1 virus", "PROBLEM", 43, 73], ["neutralizing antibodies", "TREATMENT", 95, 118], ["H5N1 virus", "OBSERVATION", 63, 73]]], ["Interestingly, this recombinant vector induced cross-reactive neutralizing antibodies to distantly related H5 viruses.", [["H5 viruses", "ORGANISM", 107, 117], ["cross-reactive neutralizing antibodies", "PROTEIN", 47, 85], ["H5 viruses", "SPECIES", 107, 117], ["this recombinant vector", "TREATMENT", 15, 38], ["cross-reactive neutralizing antibodies", "PROBLEM", 47, 85], ["H5 viruses", "PROBLEM", 107, 117], ["neutralizing antibodies", "OBSERVATION", 62, 85], ["H5 viruses", "OBSERVATION", 107, 117]]], ["Long-term protection was also achieved with this vector, as mice were fully protected after 7.5 months between vaccination and challenge (Schwartz et al. 2007) .", [["mice", "ORGANISM", 60, 64], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["Long-term protection", "TREATMENT", 0, 20], ["this vector", "TREATMENT", 44, 55], ["vaccination", "TREATMENT", 111, 122], ["-term protection", "OBSERVATION_MODIFIER", 4, 20]]], ["These experiments demonstrate that VSV may be a suitable recombinant vector for influenza virus HA proteins.Vesicular Stomatitis Virus VectorsRecombinant VSV vectors expressing various viral and bacterial proteins of pathogens have also been tested in animal models.", [["VSV", "ORGANISM", 35, 38], ["influenza virus HA", "ORGANISM", 80, 98], ["Vesicular Stomatitis Virus VectorsRecombinant VSV", "ORGANISM", 108, 157], ["influenza virus HA proteins", "PROTEIN", 80, 107], ["viral and bacterial proteins", "PROTEIN", 185, 213], ["influenza virus", "SPECIES", 80, 95], ["VSV", "SPECIES", 35, 38], ["influenza virus", "SPECIES", 80, 95], ["VSV", "SPECIES", 154, 157], ["VSV", "PROBLEM", 35, 38], ["a suitable recombinant vector", "TREATMENT", 46, 75], ["influenza virus HA proteins", "PROBLEM", 80, 107], ["Vesicular Stomatitis Virus VectorsRecombinant VSV vectors", "TREATMENT", 108, 165], ["various viral and bacterial proteins of pathogens", "PROBLEM", 177, 226], ["Stomatitis", "OBSERVATION", 118, 128]]], ["VSV vectors expressing the Yersinia pestis lcrV gene provided protection in mice from lethal pulmonary challenge with Yersinia pestis (Palin et al. 2007 ).", [["pulmonary", "ANATOMY", 93, 102], ["Yersinia pestis", "DISEASE", 118, 133], ["VSV", "ORGANISM", 0, 3], ["Yersinia pestis", "ORGANISM", 27, 42], ["lcrV", "GENE_OR_GENE_PRODUCT", 43, 47], ["mice", "ORGANISM", 76, 80], ["pulmonary", "ORGAN", 93, 102], ["Yersinia pestis", "ORGANISM", 118, 133], ["Yersinia pestis lcrV gene", "DNA", 27, 52], ["Yersinia pestis lcrV", "SPECIES", 27, 47], ["mice", "SPECIES", 76, 80], ["Yersinia pestis", "SPECIES", 118, 133], ["VSV", "SPECIES", 0, 3], ["Yersinia pestis", "SPECIES", 27, 42], ["mice", "SPECIES", 76, 80], ["Yersinia pestis", "SPECIES", 118, 133], ["VSV vectors", "TREATMENT", 0, 11], ["the Yersinia pestis lcrV gene", "TREATMENT", 23, 52], ["lethal pulmonary challenge", "TREATMENT", 86, 112], ["Yersinia pestis", "PROBLEM", 118, 133], ["pulmonary", "ANATOMY", 93, 102]]], ["Vaccination with a recombinant VSV expressing SARS spike protein provided protection against challenge with SARS in both young and aged mice (Kapadia et al. 2005; Vogel et al. 2007) .", [["SARS", "DISEASE", 108, 112], ["VSV", "ORGANISM", 31, 34], ["SARS spike protein", "GENE_OR_GENE_PRODUCT", 46, 64], ["mice", "ORGANISM", 136, 140], ["SARS spike protein", "PROTEIN", 46, 64], ["mice", "SPECIES", 136, 140], ["VSV", "SPECIES", 31, 34], ["mice", "SPECIES", 136, 140], ["Vaccination", "TREATMENT", 0, 11], ["a recombinant VSV", "TREATMENT", 17, 34], ["SARS spike protein", "PROBLEM", 46, 64]]], ["VSV vectors are also currently being tested as vaccines and therapeutic agents for HIV Schnell et al. 1997; Haglund et al. 2000; Rose et al. 2001; Ramsburg et al. 2004; Publicover et al. 2005; Okuma et al. 2006; Cooper et al. 2008) .", [["VSV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 83, 86], ["VSV", "SPECIES", 0, 3], ["HIV", "SPECIES", 83, 86], ["VSV vectors", "TREATMENT", 0, 11], ["vaccines", "TREATMENT", 47, 55], ["therapeutic agents", "TREATMENT", 60, 78], ["HIV Schnell et al", "TREATMENT", 83, 100]]], ["Recombinant VSV vectors have been developed for many other viruses, such as herpes simplex virus type 2, Borna disease virus, Marburg virus, and papillomaviruses.", [["herpes simplex virus", "DISEASE", 76, 96], ["Borna disease", "DISEASE", 105, 118], ["Marburg virus, and papillomaviruses", "DISEASE", 126, 161], ["VSV", "ORGANISM", 12, 15], ["herpes simplex virus type 2", "ORGANISM", 76, 103], ["Borna disease virus", "ORGANISM", 105, 124], ["Marburg virus", "ORGANISM", 126, 139], ["papillomaviruses", "ORGANISM", 145, 161], ["herpes simplex virus", "SPECIES", 76, 96], ["Borna disease virus", "SPECIES", 105, 124], ["Marburg virus", "SPECIES", 126, 139], ["VSV", "SPECIES", 12, 15], ["herpes simplex virus type 2", "SPECIES", 76, 103], ["Borna disease virus", "SPECIES", 105, 124], ["Marburg virus", "SPECIES", 126, 139], ["Recombinant VSV vectors", "TREATMENT", 0, 23], ["many other viruses", "PROBLEM", 48, 66], ["herpes simplex virus type 2", "PROBLEM", 76, 103], ["Borna disease virus", "PROBLEM", 105, 124], ["Marburg virus", "PROBLEM", 126, 139], ["papillomaviruses", "PROBLEM", 145, 161], ["viruses", "OBSERVATION", 59, 66], ["Borna disease", "OBSERVATION", 105, 118]]], ["(Daddario-DiCaprio et al. 2006; Natuk et al. 2006; Brandsma et al. 2007a,b; Perez et al. 2007) .Vesicular Stomatitis Virus VectorsOne limitation of VSV as a recombinant vector is that it does appear to cause some pathogenicity in humans.", [["Vesicular Stomatitis Virus", "ORGANISM", 96, 122], ["VSV", "ORGANISM", 148, 151], ["humans", "ORGANISM", 230, 236], ["humans", "SPECIES", 230, 236], ["VSV", "SPECIES", 148, 151], ["humans", "SPECIES", 230, 236], ["Vesicular Stomatitis Virus Vectors", "PROBLEM", 96, 130], ["VSV", "PROBLEM", 148, 151], ["a recombinant vector", "TREATMENT", 155, 175], ["some pathogenicity in humans", "PROBLEM", 208, 236], ["Stomatitis", "OBSERVATION", 106, 116], ["Virus Vectors", "OBSERVATION", 117, 130], ["VSV", "OBSERVATION", 148, 151], ["pathogenicity", "OBSERVATION", 213, 226]]], ["Though humans are rarely infected, animal handlers have been exposed to VSV and show symptoms of disease ranging from asymptomatic to fever with myalgia that resolves within a week.", [["fever", "DISEASE", 134, 139], ["myalgia", "DISEASE", 145, 152], ["humans", "ORGANISM", 7, 13], ["VSV", "ORGANISM", 72, 75], ["humans", "SPECIES", 7, 13], ["humans", "SPECIES", 7, 13], ["VSV", "SPECIES", 72, 75], ["symptoms", "PROBLEM", 85, 93], ["disease", "PROBLEM", 97, 104], ["fever", "PROBLEM", 134, 139], ["myalgia", "PROBLEM", 145, 152], ["infected", "OBSERVATION", 25, 33]]], ["Mouse studies of VSV infection demonstrate that the virus can replicate in the olfactory nerve soon after intranasal infection and can then cross the blood-brain barrier.", [["olfactory nerve", "ANATOMY", 79, 94], ["blood-brain barrier", "ANATOMY", 150, 169], ["VSV infection", "DISEASE", 17, 30], ["infection", "DISEASE", 117, 126], ["Mouse", "ORGANISM", 0, 5], ["VSV", "ORGANISM", 17, 20], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 79, 94], ["blood-", "MULTI-TISSUE_STRUCTURE", 150, 156], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 156, 169], ["Mouse", "SPECIES", 0, 5], ["VSV", "SPECIES", 17, 20], ["Mouse studies", "TEST", 0, 13], ["VSV infection", "PROBLEM", 17, 30], ["the virus", "PROBLEM", 48, 57], ["intranasal infection", "PROBLEM", 106, 126], ["VSV infection", "OBSERVATION", 17, 30], ["olfactory nerve", "ANATOMY", 79, 94], ["infection", "OBSERVATION", 117, 126], ["brain", "ANATOMY", 156, 161]]], ["The virus then spreads to many areas of the brain, resulting in neuropathology, hind-limb paralysis, and death (Huneycutt et al. 1994; Bi et al. 1995; Plakhov et al. 1995) .", [["brain", "ANATOMY", 44, 49], ["hind-limb", "ANATOMY", 80, 89], ["neuropathology", "DISEASE", 64, 78], ["paralysis", "DISEASE", 90, 99], ["death", "DISEASE", 105, 110], ["brain", "ORGAN", 44, 49], ["hind-", "ORGANISM_SUBDIVISION", 80, 85], ["limb", "ORGANISM_SUBDIVISION", 85, 89], ["The virus", "PROBLEM", 0, 9], ["neuropathology", "PROBLEM", 64, 78], ["hind-limb paralysis", "PROBLEM", 80, 99], ["death", "PROBLEM", 105, 110], ["virus", "OBSERVATION", 4, 9], ["brain", "ANATOMY", 44, 49], ["neuropathology", "OBSERVATION", 64, 78], ["hind", "ANATOMY", 80, 84], ["limb", "ANATOMY", 85, 89], ["paralysis", "OBSERVATION", 90, 99]]], ["VSV infection was also analyzed in nonhuman primates, and it is critical to determine the safety of vectors in this model prior to human use.", [["VSV infection", "DISEASE", 0, 13], ["VSV", "ORGANISM", 0, 3], ["nonhuman", "ORGANISM", 35, 43], ["primates", "ORGANISM", 44, 52], ["human", "ORGANISM", 131, 136], ["VSV", "SPECIES", 0, 3], ["human", "SPECIES", 131, 136], ["VSV", "SPECIES", 0, 3], ["human", "SPECIES", 131, 136], ["VSV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["Macaques inoculated with VSV intranasally shed virus in nasal washes for the first day after infection, but the virus did not cause viremia or enter the central nervous system.", [["nasal", "ANATOMY", 56, 61], ["central nervous system", "ANATOMY", 153, 175], ["infection", "DISEASE", 93, 102], ["viremia", "DISEASE", 132, 139], ["VSV", "ORGANISM", 25, 28], ["nasal", "ORGANISM_SUBDIVISION", 56, 61], ["central nervous system", "ANATOMICAL_SYSTEM", 153, 175], ["VSV", "SPECIES", 25, 28], ["VSV intranasally shed virus", "SPECIES", 25, 52], ["VSV intranasally", "TREATMENT", 25, 41], ["nasal washes", "TREATMENT", 56, 68], ["infection", "PROBLEM", 93, 102], ["the virus", "PROBLEM", 108, 117], ["viremia", "PROBLEM", 132, 139], ["nasal", "ANATOMY", 56, 61], ["washes", "OBSERVATION", 62, 68], ["infection", "OBSERVATION", 93, 102], ["viremia", "OBSERVATION", 132, 139], ["central", "ANATOMY_MODIFIER", 153, 160], ["nervous system", "ANATOMY", 161, 175]]], ["However, when macaques were injected with VSV directly into the brain with an intrathalamic injection, the virus spread and caused severe disease symptoms ).Vesicular Stomatitis Virus VectorsIn order for VSV to be used as a recombinant vector in humans, the virus must be attenuated so that disease symptoms are eliminated.", [["brain", "ANATOMY", 64, 69], ["macaques", "ORGANISM", 14, 22], ["VSV", "ORGANISM", 42, 45], ["brain", "ORGAN", 64, 69], ["Vesicular Stomatitis Virus", "ORGANISM", 157, 183], ["VSV", "ORGANISM", 204, 207], ["humans", "ORGANISM", 246, 252], ["macaques", "SPECIES", 14, 22], ["humans", "SPECIES", 246, 252], ["VSV", "SPECIES", 42, 45], ["VSV", "SPECIES", 204, 207], ["humans", "SPECIES", 246, 252], ["VSV", "TREATMENT", 42, 45], ["an intrathalamic injection", "TREATMENT", 75, 101], ["the virus spread", "PROBLEM", 103, 119], ["severe disease symptoms", "PROBLEM", 131, 154], ["Vesicular Stomatitis Virus Vectors", "PROBLEM", 157, 191], ["VSV", "TREATMENT", 204, 207], ["a recombinant vector", "TREATMENT", 222, 242], ["the virus", "PROBLEM", 254, 263], ["disease symptoms", "PROBLEM", 291, 307], ["brain", "ANATOMY", 64, 69], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["disease", "OBSERVATION", 138, 145], ["Stomatitis", "OBSERVATION", 167, 177], ["Virus Vectors", "OBSERVATION", 178, 191]]], ["Fortunately, much has already been discovered about the mechanisms of VSV pathogenicity, and so attenuated VSV vectors can be rationally designed.", [["VSV", "ORGANISM", 70, 73], ["VSV", "ORGANISM", 107, 110], ["VSV", "SPECIES", 70, 73], ["VSV", "SPECIES", 107, 110], ["VSV pathogenicity", "PROBLEM", 70, 87], ["attenuated VSV vectors", "TREATMENT", 96, 118], ["VSV pathogenicity", "OBSERVATION", 70, 87]]], ["Insertion of the HIV Gag protein into the VSV genome attenuated the virus sufficiently so that it did not cause pathogenesis in macaques, though additional viral attenuation may be necessary for human trials ).", [["HIV", "ORGANISM", 17, 20], ["Gag", "GENE_OR_GENE_PRODUCT", 21, 24], ["VSV", "ORGANISM", 42, 45], ["macaques", "ORGANISM", 128, 136], ["human", "ORGANISM", 195, 200], ["HIV Gag protein", "PROTEIN", 17, 32], ["VSV genome", "DNA", 42, 52], ["human", "SPECIES", 195, 200], ["HIV", "SPECIES", 17, 20], ["VSV", "SPECIES", 42, 45], ["human", "SPECIES", 195, 200], ["the HIV Gag protein", "TREATMENT", 13, 32], ["the virus", "PROBLEM", 64, 73], ["pathogenesis in macaques", "PROBLEM", 112, 136], ["additional viral attenuation", "PROBLEM", 145, 173], ["human trials", "TREATMENT", 195, 207]]], ["Truncations of the cytoplasmic region of the G protein had been shown to attenuate VSV growth and pathogenesis in mice (Roberts et al. 1998) .", [["cytoplasmic", "ANATOMY", 19, 30], ["cytoplasmic", "ORGANISM_SUBSTANCE", 19, 30], ["G protein", "GENE_OR_GENE_PRODUCT", 45, 54], ["VSV", "ORGANISM", 83, 86], ["mice", "ORGANISM", 114, 118], ["cytoplasmic region", "PROTEIN", 19, 37], ["G protein", "PROTEIN", 45, 54], ["mice", "SPECIES", 114, 118], ["VSV", "SPECIES", 83, 86], ["mice", "SPECIES", 114, 118], ["the G protein", "TEST", 41, 54], ["cytoplasmic", "OBSERVATION_MODIFIER", 19, 30]]], ["A recombinant vector containing a G protein deletion and expressing HIV Env protein elicited CD8 + T cell responses comparable to wtVSV expressing Env protein (Publicover et al. 2004) .Vesicular Stomatitis Virus VectorsAnother strategy for attenuating VSV expressing HIV proteins includes placing gag at the beginning of the genome, which results in a reduction of the expression of the VSV proteins and a reduction of viral replication.", [["CD8 + T cell", "ANATOMY", 93, 105], ["G", "GENE_OR_GENE_PRODUCT", 34, 35], ["HIV Env", "ORGANISM", 68, 75], ["CD8", "GENE_OR_GENE_PRODUCT", 93, 96], ["wtVSV", "ORGANISM", 130, 135], ["Env", "ORGANISM", 147, 150], ["Vesicular Stomatitis Virus", "ORGANISM", 185, 211], ["VSV", "ORGANISM", 252, 255], ["HIV", "ORGANISM", 267, 270], ["gag", "GENE_OR_GENE_PRODUCT", 297, 300], ["VSV", "ORGANISM", 387, 390], ["G protein deletion", "DNA", 34, 52], ["HIV Env protein", "PROTEIN", 68, 83], ["CD8", "PROTEIN", 93, 96], ["wtVSV", "PROTEIN", 130, 135], ["Env protein", "PROTEIN", 147, 158], ["HIV proteins", "PROTEIN", 267, 279], ["VSV proteins", "PROTEIN", 387, 399], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 267, 270], ["HIV", "SPECIES", 68, 71], ["wtVSV", "SPECIES", 130, 135], ["VSV", "SPECIES", 252, 255], ["HIV", "SPECIES", 267, 270], ["VSV", "SPECIES", 387, 390], ["A recombinant vector", "TREATMENT", 0, 20], ["a G protein deletion", "PROBLEM", 32, 52], ["HIV Env protein", "TEST", 68, 83], ["CD8", "TEST", 93, 96], ["T cell responses", "TEST", 99, 115], ["Env protein", "TEST", 147, 158], ["Vesicular Stomatitis Virus Vectors", "TREATMENT", 185, 219], ["attenuating VSV", "TREATMENT", 240, 255], ["HIV proteins", "PROBLEM", 267, 279], ["placing gag", "PROBLEM", 289, 300], ["the VSV proteins", "TREATMENT", 383, 399], ["viral replication", "TREATMENT", 419, 436], ["Stomatitis", "OBSERVATION", 195, 205], ["viral replication", "OBSERVATION", 419, 436]]], ["Also, the N gene was moved to a further downstream position, which reduces N protein expression and viral replication.", [["N gene", "DNA", 10, 16], ["N protein", "PROTEIN", 75, 84], ["N protein expression", "TREATMENT", 75, 95], ["viral replication", "TREATMENT", 100, 117], ["protein expression", "OBSERVATION", 77, 95], ["viral replication", "OBSERVATION", 100, 117]]], ["The M protein, which has been shown to inhibit the interferon response and induce apoptosis, has also been mutated to reduce VSV pathogenesis Cooper et al. 2008) .", [["M protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["VSV", "ORGANISM", 125, 128], ["M protein", "PROTEIN", 4, 13], ["interferon", "PROTEIN", 51, 61], ["The M protein", "TEST", 0, 13], ["apoptosis", "PROBLEM", 82, 91]]], ["Applying a combination of these alterations to recombinant VSV vectors expressing Gag protein resulted in a drastic reduction in pathogenesis in mice but still induced a strong immune response to Gag (Cooper et al. 2008) .", [["VSV", "ORGANISM", 59, 62], ["Gag", "GENE_OR_GENE_PRODUCT", 82, 85], ["mice", "ORGANISM", 145, 149], ["Gag", "GENE_OR_GENE_PRODUCT", 196, 199], ["Gag protein", "PROTEIN", 82, 93], ["mice", "SPECIES", 145, 149], ["VSV", "SPECIES", 59, 62], ["mice", "SPECIES", 145, 149], ["these alterations", "TREATMENT", 26, 43], ["recombinant VSV vectors", "TREATMENT", 47, 70], ["Gag protein", "PROBLEM", 82, 93], ["a drastic reduction", "TREATMENT", 106, 125], ["pathogenesis in mice", "PROBLEM", 129, 149], ["drastic", "OBSERVATION_MODIFIER", 108, 115], ["reduction", "OBSERVATION_MODIFIER", 116, 125]]], ["VSV vector replication and pathogenesis can also be eliminated by using VSV mutants that can only complete one cycle of replication.", [["VSV", "ORGANISM", 0, 3], ["VSV", "ORGANISM", 72, 75], ["VSV", "SPECIES", 0, 3], ["VSV", "SPECIES", 0, 3], ["VSV", "SPECIES", 72, 75], ["VSV vector replication", "TREATMENT", 0, 22], ["pathogenesis", "PROBLEM", 27, 39], ["VSV mutants", "TREATMENT", 72, 83], ["replication", "TREATMENT", 120, 131]]], ["This is achieved by eliminating the VSV G protein from the genome.", [["VSV G protein", "GENE_OR_GENE_PRODUCT", 36, 49], ["VSV G protein", "PROTEIN", 36, 49], ["VSV", "SPECIES", 36, 39], ["the VSV G protein", "TREATMENT", 32, 49]]], ["Since VSV G protein, but not the G gene, is necessary for viral growth, the vector can be grown readily in cell lines that constitutively express VSV G so that G protein can be incorporated into the viral envelope.", [["cell lines", "ANATOMY", 107, 117], ["VSV", "ORGANISM", 6, 9], ["G protein", "GENE_OR_GENE_PRODUCT", 10, 19], ["G", "GENE_OR_GENE_PRODUCT", 33, 34], ["cell lines", "CELL", 107, 117], ["VSV G", "GENE_OR_GENE_PRODUCT", 146, 151], ["G protein", "GENE_OR_GENE_PRODUCT", 160, 169], ["G protein", "PROTEIN", 10, 19], ["G gene", "DNA", 33, 39], ["cell lines", "CELL_LINE", 107, 117], ["VSV G", "PROTEIN", 146, 151], ["G protein", "PROTEIN", 160, 169], ["VSV", "SPECIES", 6, 9], ["VSV", "SPECIES", 146, 149], ["G protein", "TEST", 10, 19], ["viral growth", "PROBLEM", 58, 70], ["the vector", "TREATMENT", 72, 82], ["VSV G", "PROBLEM", 146, 151], ["G protein", "PROBLEM", 160, 169], ["cell lines", "OBSERVATION", 107, 117], ["viral envelope", "OBSERVATION", 199, 213]]], ["In animals, the single-cycle VSV vectors can enter and infect cells and express the viral and foreign proteins in its genome, but viral assembly cannot occur because the G protein is not synthesized.", [["cells", "ANATOMY", 62, 67], ["VSV", "ORGANISM", 29, 32], ["cells", "CELL", 62, 67], ["G protein", "GENE_OR_GENE_PRODUCT", 170, 179], ["viral and foreign proteins", "PROTEIN", 84, 110], ["G protein", "PROTEIN", 170, 179], ["VSV", "SPECIES", 29, 32], ["the single-cycle VSV vectors", "TREATMENT", 12, 40], ["infect cells", "PROBLEM", 55, 67], ["the viral and foreign proteins in its genome", "PROBLEM", 80, 124], ["the G protein", "TEST", 166, 179], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["foreign proteins", "OBSERVATION", 94, 110]]], ["A VSV single-cycle vector expressing HIV Env was demonstrated to produce an immune response to Env that was similar to the response elicited by replicating VSV vectors expressing Env (Publicover et al. 2005) .", [["VSV", "ORGANISM", 2, 5], ["HIV Env", "ORGANISM", 37, 44], ["Env", "GENE_OR_GENE_PRODUCT", 95, 98], ["VSV", "ORGANISM", 156, 159], ["Env", "GENE_OR_GENE_PRODUCT", 179, 182], ["HIV Env", "PROTEIN", 37, 44], ["Env", "PROTEIN", 95, 98], ["Env", "PROTEIN", 179, 182], ["HIV", "SPECIES", 37, 40], ["VSV", "SPECIES", 2, 5], ["HIV", "SPECIES", 37, 40], ["VSV", "SPECIES", 156, 159], ["A VSV single-cycle vector", "TREATMENT", 0, 25], ["HIV Env", "PROBLEM", 37, 44]]], ["VSV vectors with attenuating mutations are being investigated carefully so that they can be safely administered to humans without side effects.Vesicular Stomatitis Virus VectorsSimilar to NDV, VSV is also being analyzed as a therapeutic cancer agent based on the observation that VSV replicates and induces apoptosis in cancer cells more readily than normal cells (Barber 2004) .", [["cancer", "ANATOMY", 237, 243], ["cancer cells", "ANATOMY", 320, 332], ["cells", "ANATOMY", 358, 363], ["cancer", "DISEASE", 237, 243], ["cancer", "DISEASE", 320, 326], ["VSV", "ORGANISM", 0, 3], ["humans", "ORGANISM", 115, 121], ["Vesicular Stomatitis Virus", "ORGANISM", 143, 169], ["NDV", "ORGANISM", 188, 191], ["VSV", "ORGANISM", 193, 196], ["cancer", "CANCER", 237, 243], ["VSV", "ORGANISM", 280, 283], ["cancer cells", "CELL", 320, 332], ["cells", "CELL", 358, 363], ["cancer cells", "CELL_TYPE", 320, 332], ["normal cells", "CELL_TYPE", 351, 363], ["humans", "SPECIES", 115, 121], ["NDV", "SPECIES", 188, 191], ["VSV", "SPECIES", 0, 3], ["humans", "SPECIES", 115, 121], ["NDV", "SPECIES", 188, 191], ["VSV", "SPECIES", 193, 196], ["VSV", "SPECIES", 280, 283], ["VSV vectors", "TREATMENT", 0, 11], ["attenuating mutations", "PROBLEM", 17, 38], ["side effects", "PROBLEM", 130, 142], ["Vesicular Stomatitis Virus VectorsSimilar", "PROBLEM", 143, 184], ["VSV", "PROBLEM", 193, 196], ["a therapeutic cancer agent", "TREATMENT", 223, 249], ["VSV replicates", "TREATMENT", 280, 294], ["apoptosis in cancer cells", "PROBLEM", 307, 332], ["Stomatitis", "OBSERVATION", 153, 163], ["cancer", "OBSERVATION", 237, 243], ["cancer cells", "OBSERVATION", 320, 332]]], ["VSV is also very sensitive to the effects of interferon, and tumor cells without an intact interferon pathway are rapidly killed by VSV.", [["tumor cells", "ANATOMY", 61, 72], ["tumor", "DISEASE", 61, 66], ["VSV", "ORGANISM", 0, 3], ["interferon", "GENE_OR_GENE_PRODUCT", 45, 55], ["tumor cells", "CELL", 61, 72], ["interferon", "GENE_OR_GENE_PRODUCT", 91, 101], ["VSV", "ORGANISM", 132, 135], ["interferon", "PROTEIN", 45, 55], ["tumor cells", "CELL_TYPE", 61, 72], ["interferon", "PROTEIN", 91, 101], ["VSV", "SPECIES", 0, 3], ["VSV", "SPECIES", 132, 135], ["interferon", "TREATMENT", 45, 55], ["tumor cells", "PROBLEM", 61, 72], ["an intact interferon pathway", "PROBLEM", 81, 109], ["tumor cells", "OBSERVATION", 61, 72], ["intact", "OBSERVATION_MODIFIER", 84, 90], ["interferon", "OBSERVATION", 91, 101]]], ["VSV vectors expressing the cytokine IL-12 or the chemokine inhibitor equine herpes virus-1 glycoprotein were able to enhance tumor reduction of squamous cell carcinoma and hepatocellular carcinoma, respectively, in mice (Shin et al. 2007; Altomonte et al. 2008) .", [["tumor", "ANATOMY", 125, 130], ["squamous cell carcinoma", "ANATOMY", 144, 167], ["hepatocellular carcinoma", "ANATOMY", 172, 196], ["tumor", "DISEASE", 125, 130], ["squamous cell carcinoma", "DISEASE", 144, 167], ["hepatocellular carcinoma", "DISEASE", 172, 196], ["VSV", "ORGANISM", 0, 3], ["IL-12", "GENE_OR_GENE_PRODUCT", 36, 41], ["equine herpes virus-1", "ORGANISM", 69, 90], ["tumor", "CANCER", 125, 130], ["squamous cell carcinoma", "CANCER", 144, 167], ["hepatocellular carcinoma", "CANCER", 172, 196], ["mice", "ORGANISM", 215, 219], ["cytokine IL-12", "PROTEIN", 27, 41], ["chemokine", "PROTEIN", 49, 58], ["equine herpes virus-1 glycoprotein", "PROTEIN", 69, 103], ["equine herpes virus-1", "SPECIES", 69, 90], ["mice", "SPECIES", 215, 219], ["VSV", "SPECIES", 0, 3], ["equine herpes virus-1", "SPECIES", 69, 90], ["mice", "SPECIES", 215, 219], ["VSV vectors", "TREATMENT", 0, 11], ["the cytokine IL", "TEST", 23, 38], ["the chemokine inhibitor", "TREATMENT", 45, 68], ["herpes virus", "PROBLEM", 76, 88], ["1 glycoprotein", "TREATMENT", 89, 103], ["tumor reduction", "TREATMENT", 125, 140], ["squamous cell carcinoma", "PROBLEM", 144, 167], ["hepatocellular carcinoma", "PROBLEM", 172, 196], ["tumor", "OBSERVATION", 125, 130], ["squamous cell carcinoma", "OBSERVATION", 144, 167], ["hepatocellular carcinoma", "OBSERVATION", 172, 196], ["Shin", "ANATOMY", 221, 225]]], ["Thus, VSV vectors show the potential to function as vaccines for infectious diseases as well as cancer.Influenza Virus VectorsThere has been recent interest in using influenza virus itself as a recombinant vector to protect against highly virulent influenza virus strains as well as other pathogens.", [["cancer", "ANATOMY", 96, 102], ["infectious diseases", "DISEASE", 65, 84], ["cancer", "DISEASE", 96, 102], ["influenza virus", "DISEASE", 248, 263], ["VSV", "ORGANISM", 6, 9], ["cancer", "CANCER", 96, 102], ["Influenza Virus", "ORGANISM", 103, 118], ["influenza virus", "ORGANISM", 166, 181], ["influenza virus", "ORGANISM", 248, 263], ["Influenza", "SPECIES", 103, 112], ["influenza virus", "SPECIES", 166, 181], ["virulent influenza virus", "SPECIES", 239, 263], ["VSV", "SPECIES", 6, 9], ["influenza virus", "SPECIES", 166, 181], ["VSV vectors", "TREATMENT", 6, 17], ["vaccines", "TREATMENT", 52, 60], ["infectious diseases", "PROBLEM", 65, 84], ["cancer", "PROBLEM", 96, 102], ["Influenza Virus Vectors", "TREATMENT", 103, 126], ["influenza virus", "TREATMENT", 166, 181], ["a recombinant vector", "TREATMENT", 192, 212], ["highly virulent influenza virus strains", "PROBLEM", 232, 271], ["other pathogens", "PROBLEM", 283, 298], ["cancer", "OBSERVATION", 96, 102]]], ["Influenza viruses need to be highly attenuated for use as a vector, and several strategies for attenuating influenza viruses have been successful.", [["Influenza viruses", "DISEASE", 0, 17], ["influenza viruses", "DISEASE", 107, 124], ["Influenza viruses", "ORGANISM", 0, 17], ["influenza viruses", "ORGANISM", 107, 124], ["Influenza viruses", "PROBLEM", 0, 17], ["a vector", "TREATMENT", 58, 66], ["attenuating influenza viruses", "PROBLEM", 95, 124]]], ["An attenuated cold-adapted strain was generated by growing influenza virus at 25\u00b0C in primary chick kidney cells, and is currently licensed for use in humans (Cox et al. 1988 ).", [["kidney cells", "ANATOMY", 100, 112], ["influenza", "DISEASE", 59, 68], ["influenza virus", "ORGANISM", 59, 74], ["C", "GENE_OR_GENE_PRODUCT", 81, 82], ["chick", "ORGANISM", 94, 99], ["kidney cells", "CELL", 100, 112], ["humans", "ORGANISM", 151, 157], ["primary chick kidney cells", "CELL_TYPE", 86, 112], ["influenza virus", "SPECIES", 59, 74], ["chick", "SPECIES", 94, 99], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 151, 157], ["An attenuated cold-adapted strain", "PROBLEM", 0, 33], ["growing influenza virus", "PROBLEM", 51, 74], ["C in primary chick kidney cells", "PROBLEM", 81, 112], ["chick kidney cells", "OBSERVATION", 94, 112]]], ["An attenuated cold-adapted strain that was generated in embryonated chicken eggs grown at low temperatures is also being used in horses (Youngner et al. 2001) .", [["chicken", "ORGANISM", 68, 75], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 76, 80], ["chicken", "SPECIES", 68, 75], ["chicken", "SPECIES", 68, 75], ["An attenuated cold-adapted strain", "PROBLEM", 0, 33], ["embryonated chicken eggs", "TREATMENT", 56, 80], ["attenuated", "OBSERVATION_MODIFIER", 3, 13], ["cold", "OBSERVATION", 14, 18], ["low temperatures", "OBSERVATION_MODIFIER", 90, 106]]], ["Reduction of virulence is also observed by influenza viruses containing deletions of the NS1 protein, the viral protein responsible for inhibiting the innate interferon response (Garcia-Sastre et al. 1998; Talon et al. 2000) .", [["influenza viruses", "ORGANISM", 43, 60], ["NS1", "GENE_OR_GENE_PRODUCT", 89, 92], ["NS1 protein", "PROTEIN", 89, 100], ["viral protein", "PROTEIN", 106, 119], ["interferon", "PROTEIN", 158, 168], ["virulence", "PROBLEM", 13, 22], ["influenza viruses", "PROBLEM", 43, 60], ["the NS1 protein", "TEST", 85, 100], ["the viral protein", "TEST", 102, 119], ["the innate interferon response", "TREATMENT", 147, 177], ["virulence", "OBSERVATION", 13, 22], ["influenza viruses", "OBSERVATION", 43, 60]]], ["Influenza virus vaccines containing deletions of the M2 gene, which are necessary for virus uncoating, are currently being tested (Watanabe et al. 2007 ).", [["Influenza virus", "ORGANISM", 0, 15], ["M2", "GENE_OR_GENE_PRODUCT", 53, 55], ["M2 gene", "DNA", 53, 60], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus vaccines", "TREATMENT", 0, 24], ["deletions of the M2 gene", "TREATMENT", 36, 60], ["virus uncoating", "PROBLEM", 86, 101]]], ["Thus, there are likely many ways to sufficiently attenuate influenza virus.Influenza Virus VectorsSeveral influenza virus vectors have shown promising results in animal models.", [["influenza", "DISEASE", 59, 68], ["influenza virus", "ORGANISM", 59, 74], ["Influenza Virus VectorsSeveral influenza virus", "ORGANISM", 75, 121], ["Influenza Virus", "SPECIES", 75, 90], ["VectorsSeveral influenza virus", "SPECIES", 91, 121], ["Influenza Virus VectorsSeveral influenza virus", "SPECIES", 75, 121], ["influenza virus", "PROBLEM", 59, 74], ["Influenza Virus VectorsSeveral influenza virus vectors", "PROBLEM", 75, 129], ["influenza", "OBSERVATION", 59, 68]]], ["A recombinant influenza virus containing the NDV HN ectodomain in place of the influenza virus NA ectodomain administered in ovo provided protection in chickens against both influenza virus and NDV after a lethal challenge (Fig. 4) (Steel et al. 2008) .", [["NA", "CHEMICAL", 95, 97], ["influenza virus", "DISEASE", 174, 189], ["recombinant influenza virus", "ORGANISM", 2, 29], ["NDV HN", "ORGANISM", 45, 51], ["influenza virus NA", "ORGANISM", 79, 97], ["chickens", "ORGANISM", 152, 160], ["influenza virus", "ORGANISM", 174, 189], ["NDV", "ORGANISM", 194, 197], ["NDV HN ectodomain", "PROTEIN", 45, 62], ["influenza virus NA ectodomain", "PROTEIN", 79, 108], ["influenza virus", "SPECIES", 14, 29], ["influenza virus NA", "SPECIES", 79, 97], ["chickens", "SPECIES", 152, 160], ["influenza virus", "SPECIES", 174, 189], ["NDV", "SPECIES", 194, 197], ["NDV", "SPECIES", 45, 48], ["chickens", "SPECIES", 152, 160], ["NDV", "SPECIES", 194, 197], ["A recombinant influenza virus", "TREATMENT", 0, 29], ["the NDV HN ectodomain", "TREATMENT", 41, 62], ["the influenza virus NA ectodomain", "TREATMENT", 75, 108], ["protection", "TREATMENT", 138, 148], ["chickens", "TREATMENT", 152, 160], ["both influenza virus", "TREATMENT", 169, 189], ["NDV", "TREATMENT", 194, 197], ["a lethal challenge", "TREATMENT", 204, 222], ["influenza virus", "OBSERVATION", 14, 29], ["influenza virus", "OBSERVATION", 174, 189]]], ["Millions of people die each year after infection with Mycobacterium tuberculosis, and an effective vaccine is urgently needed.", [["infection", "DISEASE", 39, 48], ["Mycobacterium tuberculosis", "DISEASE", 54, 80], ["people", "ORGANISM", 12, 18], ["Mycobacterium tuberculosis", "ORGANISM", 54, 80], ["people", "SPECIES", 12, 18], ["Mycobacterium tuberculosis", "SPECIES", 54, 80], ["Mycobacterium tuberculosis", "SPECIES", 54, 80], ["infection", "PROBLEM", 39, 48], ["Mycobacterium tuberculosis", "PROBLEM", 54, 80], ["an effective vaccine", "TREATMENT", 86, 106], ["Mycobacterium tuberculosis", "OBSERVATION", 54, 80]]], ["Vaccination with influenza virus that expresses a truncated NS1 protein and the ESAT-6 protein of Mycobacterium tuberculosis from the NS gene segment provides protection in mice and guinea pigs from lethal challenge with the bacteria Stukova et al. 2006) .", [["Mycobacterium tuberculosis", "DISEASE", 98, 124], ["influenza virus", "ORGANISM", 17, 32], ["NS1", "GENE_OR_GENE_PRODUCT", 60, 63], ["ESAT-6", "GENE_OR_GENE_PRODUCT", 80, 86], ["Mycobacterium tuberculosis", "GENE_OR_GENE_PRODUCT", 98, 124], ["mice", "ORGANISM", 173, 177], ["guinea pigs", "ORGANISM", 182, 193], ["truncated NS1 protein", "PROTEIN", 50, 71], ["ESAT-6 protein", "PROTEIN", 80, 94], ["NS gene segment", "DNA", 134, 149], ["influenza virus", "SPECIES", 17, 32], ["Mycobacterium tuberculosis", "SPECIES", 98, 124], ["mice", "SPECIES", 173, 177], ["guinea pigs", "SPECIES", 182, 193], ["influenza virus", "SPECIES", 17, 32], ["Mycobacterium tuberculosis", "SPECIES", 98, 124], ["mice", "SPECIES", 173, 177], ["pigs", "SPECIES", 189, 193], ["Vaccination", "TREATMENT", 0, 11], ["influenza virus", "PROBLEM", 17, 32], ["a truncated NS1 protein", "PROBLEM", 48, 71], ["the ESAT", "TEST", 76, 84], ["Mycobacterium tuberculosis", "PROBLEM", 98, 124], ["the NS gene segment", "TREATMENT", 130, 149], ["lethal challenge", "TREATMENT", 199, 215], ["Mycobacterium tuberculosis", "OBSERVATION", 98, 124]]], ["Recombinant influenza viruses expressing portions of Bacillus anthracis proteins fused to the influenza virus HA protein elicited antibodies against both Bacillus anthracis and influenza virus (Li et al. 2005) .", [["Recombinant influenza viruses", "ORGANISM", 0, 29], ["Bacillus anthracis", "ORGANISM", 53, 71], ["influenza virus", "ORGANISM", 94, 109], ["HA", "ORGANISM", 110, 112], ["Bacillus anthracis", "ORGANISM", 154, 172], ["influenza virus", "ORGANISM", 177, 192], ["Bacillus anthracis proteins", "PROTEIN", 53, 80], ["influenza virus HA protein", "PROTEIN", 94, 120], ["antibodies", "PROTEIN", 130, 140], ["Bacillus anthracis", "SPECIES", 53, 71], ["influenza virus", "SPECIES", 94, 109], ["Bacillus anthracis", "SPECIES", 154, 172], ["influenza virus", "SPECIES", 177, 192], ["Bacillus anthracis", "SPECIES", 53, 71], ["influenza virus", "SPECIES", 94, 109], ["Bacillus anthracis", "SPECIES", 154, 172], ["Recombinant influenza viruses", "PROBLEM", 0, 29], ["Bacillus anthracis proteins", "PROBLEM", 53, 80], ["the influenza virus HA protein elicited antibodies", "PROBLEM", 90, 140], ["both Bacillus anthracis", "PROBLEM", 149, 172], ["influenza virus", "PROBLEM", 177, 192], ["influenza viruses", "OBSERVATION", 12, 29], ["influenza virus", "OBSERVATION", 94, 109]]], ["Protection in mice was achieved after vaccination with an influenza virus expressing Chlamydia trachomatis epitopes in the NA protein (He et al. 2007 ).", [["Chlamydia trachomatis", "DISEASE", 85, 106], ["mice", "ORGANISM", 14, 18], ["influenza virus", "ORGANISM", 58, 73], ["Chlamydia trachomatis", "ORGANISM", 85, 106], ["Chlamydia trachomatis epitopes", "PROTEIN", 85, 115], ["NA protein", "PROTEIN", 123, 133], ["mice", "SPECIES", 14, 18], ["Chlamydia trachomatis", "SPECIES", 85, 106], ["mice", "SPECIES", 14, 18], ["Chlamydia trachomatis", "SPECIES", 85, 106], ["Protection in mice", "TREATMENT", 0, 18], ["vaccination", "TREATMENT", 38, 49], ["an influenza virus", "PROBLEM", 55, 73], ["Chlamydia trachomatis epitopes", "PROBLEM", 85, 115]]], ["Mice vaccinated with an influenza virus expressing an epitope of Pseudomonas aeruginosa, which is the leading cause of mortality in cystic fibrosis patients, were fully protected after challenge (Gilleland et al. 2000) .", [["cystic fibrosis", "DISEASE", 132, 147], ["Mice", "ORGANISM", 0, 4], ["influenza virus", "ORGANISM", 24, 39], ["Pseudomonas aeruginosa", "ORGANISM", 65, 87], ["patients", "ORGANISM", 148, 156], ["Mice", "SPECIES", 0, 4], ["influenza virus", "SPECIES", 24, 39], ["Pseudomonas aeruginosa", "SPECIES", 65, 87], ["patients", "SPECIES", 148, 156], ["influenza virus", "SPECIES", 24, 39], ["Pseudomonas aeruginosa", "SPECIES", 65, 87], ["Mice vaccinated", "TREATMENT", 0, 15], ["an influenza virus", "PROBLEM", 21, 39], ["Pseudomonas aeruginosa", "PROBLEM", 65, 87], ["cystic fibrosis", "PROBLEM", 132, 147], ["Pseudomonas aeruginosa", "OBSERVATION", 65, 87], ["leading cause of", "UNCERTAINTY", 102, 118], ["mortality", "OBSERVATION_MODIFIER", 119, 128], ["cystic", "OBSERVATION_MODIFIER", 132, 138], ["fibrosis", "OBSERVATION", 139, 147]]], ["Chimeric influenza viruses have been developed to express HIV epitopes.", [["influenza viruses", "DISEASE", 9, 26], ["Chimeric influenza viruses", "ORGANISM", 0, 26], ["HIV", "ORGANISM", 58, 61], ["HIV epitopes", "PROTEIN", 58, 70], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 58, 61], ["Chimeric influenza viruses", "PROBLEM", 0, 26], ["HIV epitopes", "PROBLEM", 58, 70]]], ["After intranasal administration, these vectors induce a long-lasting mucosal antibody response in not only the respiratory tract, but also the genital tract (Li et al. 1993; Muster et al. 1994 Muster et al. , 1995 Palese et al. 1997; Gonzalo et al. 1999; Gherardi et al. 2003; Nakaya et al. 2003) .", [["mucosal", "ANATOMY", 69, 76], ["respiratory tract", "ANATOMY", 111, 128], ["genital tract", "ANATOMY", 143, 156], ["respiratory tract", "ORGANISM_SUBDIVISION", 111, 128], ["genital tract", "ORGANISM_SUBDIVISION", 143, 156], ["intranasal administration", "TREATMENT", 6, 31], ["these vectors", "TREATMENT", 33, 46], ["a long-lasting mucosal antibody response", "PROBLEM", 54, 94], ["antibody response", "OBSERVATION", 77, 94], ["respiratory tract", "ANATOMY", 111, 128], ["genital tract", "ANATOMY", 143, 156]]], ["The encouraging results obtained using influenza virus vectors thus far demonstrate the need for further research in this field.Influenza Virus VectorsWhile the live cold-adapted influenza virus vaccine has been successfully administered to millions of individuals, safety must be carefully considered in the .", [["influenza virus", "DISEASE", 179, 194], ["influenza virus", "ORGANISM", 39, 54], ["Influenza Virus", "ORGANISM", 128, 143], ["influenza virus", "ORGANISM", 179, 194], ["influenza virus", "SPECIES", 39, 54], ["Influenza Virus", "SPECIES", 128, 143], ["influenza virus vaccine", "SPECIES", 179, 202], ["influenza virus", "SPECIES", 39, 54], ["influenza virus vectors", "TREATMENT", 39, 62], ["Influenza Virus VectorsWhile", "TREATMENT", 128, 156], ["influenza virus vaccine", "TREATMENT", 179, 202]]], ["Cells were transfected with the 12 plasmids and a recombinant virus expressing NDV HN was rescued, as described in Steel et al. (2008) development of future live-attenuated influenza virus vaccines.", [["Cells", "ANATOMY", 0, 5], ["plasmids", "ANATOMY", 35, 43], ["Cells", "CELL", 0, 5], ["NDV HN", "ORGANISM", 79, 85], ["influenza virus", "ORGANISM", 173, 188], ["12 plasmids", "DNA", 32, 43], ["influenza virus", "SPECIES", 173, 188], ["NDV", "SPECIES", 79, 82], ["Cells", "TEST", 0, 5], ["the 12 plasmids", "TREATMENT", 28, 43], ["a recombinant virus", "TREATMENT", 48, 67], ["future live-attenuated influenza virus vaccines", "TREATMENT", 150, 197]]], ["Live-attenuated influenza virus vaccines must be designed so that a pathogenic virus could not result from reassortment of the vaccine with a circulating influenza virus strain.", [["influenza virus", "DISEASE", 154, 169], ["Live-attenuated influenza virus", "ORGANISM", 0, 31], ["influenza virus", "ORGANISM", 154, 169], ["influenza virus", "SPECIES", 16, 31], ["influenza virus", "SPECIES", 154, 169], ["Live-attenuated influenza virus vaccines", "TREATMENT", 0, 40], ["a pathogenic virus", "PROBLEM", 66, 84], ["the vaccine", "TREATMENT", 123, 134], ["a circulating influenza virus strain", "PROBLEM", 140, 176]]], ["This issue was addressed for the cold-adapted vaccine by demonstrating that three internal genes contained attenuating mutations, making it unlikely that reassortment would lead to a virulent viral strain (Cox et al. 1986 (Cox et al. , 1988 Jin et al. 2003) .", [["the cold-adapted vaccine", "TREATMENT", 29, 53], ["attenuating mutations", "PROBLEM", 107, 128], ["a virulent viral strain", "PROBLEM", 181, 204]]], ["The issue of vector-mediated immunity is a concern for most live vaccines, but influenza virus rapidly evolves due to antigen drift.", [["influenza", "DISEASE", 79, 88], ["influenza virus", "ORGANISM", 79, 94], ["antigen", "GENE_OR_GENE_PRODUCT", 118, 125], ["influenza virus", "SPECIES", 79, 94], ["most live vaccines", "TREATMENT", 55, 73], ["influenza virus", "PROBLEM", 79, 94], ["antigen drift", "PROBLEM", 118, 131], ["antigen drift", "OBSERVATION", 118, 131]]], ["Live-attenuated influenza virus vaccines, like the cold-adapted vaccine, must be reformulated each year to reflect the newly emerged strains.", [["Live-attenuated influenza virus", "ORGANISM", 0, 31], ["influenza virus", "SPECIES", 16, 31], ["influenza virus vaccines", "TREATMENT", 16, 40], ["the cold-adapted vaccine", "TREATMENT", 47, 71], ["the newly emerged strains", "PROBLEM", 115, 140]]], ["Just as people can be infected multiple times with different strains of influenza virus, a recombinant vector based on influenza virus could be repeatedly administered if it was designed using different antigenic variants of influenza virus.Adenovirus VectorsAdenoviruses are nonenveloped DNA viruses that have been thoroughly explored for their potential use as recombinant vaccine vectors.", [["influenza", "DISEASE", 72, 81], ["influenza virus", "DISEASE", 225, 240], ["people", "ORGANISM", 8, 14], ["influenza virus", "ORGANISM", 72, 87], ["influenza virus", "ORGANISM", 119, 134], ["influenza virus", "ORGANISM", 225, 240], ["Adenovirus VectorsAdenoviruses", "ORGANISM", 241, 271], ["DNA", "CELLULAR_COMPONENT", 289, 292], ["people", "SPECIES", 8, 14], ["influenza virus", "SPECIES", 72, 87], ["influenza virus", "SPECIES", 72, 87], ["influenza virus", "SPECIES", 119, 134], ["Adenovirus", "SPECIES", 241, 251], ["influenza virus", "PROBLEM", 72, 87], ["a recombinant vector", "TREATMENT", 89, 109], ["influenza virus", "PROBLEM", 119, 134], ["influenza virus", "PROBLEM", 225, 240], ["Adenovirus VectorsAdenoviruses", "PROBLEM", 241, 271], ["DNA viruses", "PROBLEM", 289, 300], ["recombinant vaccine vectors", "TREATMENT", 363, 390], ["infected", "OBSERVATION", 22, 30], ["influenza virus", "OBSERVATION", 72, 87], ["influenza virus", "OBSERVATION", 225, 240]]], ["Adenoviruses were originally identified as one of the causes of acute respiratory infections.", [["respiratory", "ANATOMY", 70, 81], ["respiratory infections", "DISEASE", 70, 92], ["Adenoviruses", "PROBLEM", 0, 12], ["acute respiratory infections", "PROBLEM", 64, 92], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory", "ANATOMY", 70, 81], ["infections", "OBSERVATION", 82, 92]]], ["Infection with adenoviruses has also been associated with conjunctivitis and gastroenteritis in infants.", [["conjunctivitis", "DISEASE", 58, 72], ["gastroenteritis", "DISEASE", 77, 92], ["adenoviruses", "ORGANISM", 15, 27], ["infants", "ORGANISM", 96, 103], ["infants", "SPECIES", 96, 103], ["Infection", "PROBLEM", 0, 9], ["adenoviruses", "PROBLEM", 15, 27], ["conjunctivitis", "PROBLEM", 58, 72], ["gastroenteritis in infants", "PROBLEM", 77, 103], ["adenoviruses", "OBSERVATION", 15, 27], ["associated with", "UNCERTAINTY", 42, 57], ["conjunctivitis", "OBSERVATION", 58, 72], ["gastroenteritis", "OBSERVATION", 77, 92]]], ["While adenovirus infection usually results in mild disease symptoms that are promptly resolved, adenovirus infection of immunocompromised individuals can result in severe disease symptoms, such as pneumonia, encephalitis, and even death (Krilov 2005) .", [["adenovirus infection", "DISEASE", 6, 26], ["adenovirus infection", "DISEASE", 96, 116], ["pneumonia", "DISEASE", 197, 206], ["encephalitis", "DISEASE", 208, 220], ["death", "DISEASE", 231, 236], ["adenovirus", "ORGANISM", 6, 16], ["adenovirus", "ORGANISM", 96, 106], ["adenovirus", "SPECIES", 6, 16], ["adenovirus", "SPECIES", 96, 106], ["adenovirus infection", "PROBLEM", 6, 26], ["mild disease symptoms", "PROBLEM", 46, 67], ["adenovirus infection of immunocompromised individuals", "PROBLEM", 96, 149], ["severe disease symptoms", "PROBLEM", 164, 187], ["pneumonia", "PROBLEM", 197, 206], ["encephalitis", "PROBLEM", 208, 220], ["infection", "OBSERVATION", 17, 26], ["mild", "OBSERVATION_MODIFIER", 46, 50], ["disease", "OBSERVATION", 51, 58], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["disease", "OBSERVATION", 171, 178], ["pneumonia", "OBSERVATION", 197, 206], ["encephalitis", "OBSERVATION", 208, 220]]], ["Adenovirus is often chosen as a recombinant vaccine vector to express foreign proteins because a live vaccine was administered to US military personal for over two decades with no incidence of significant side effects (Souza et al. 2005) .", [["Adenovirus", "ORGANISM", 0, 10], ["foreign proteins", "PROTEIN", 70, 86], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus", "PROBLEM", 0, 10], ["a recombinant vaccine vector", "TREATMENT", 30, 58], ["foreign proteins", "PROBLEM", 70, 86], ["a live vaccine", "TREATMENT", 95, 109], ["significant side effects", "PROBLEM", 193, 217]]], ["This oral vaccine consisted of the two most prevalent strains of adenovirus among military personal, Ad4 and Ad7, contained in a capsule coated to prevent the release of the viruses until they reached the intestines (Howell et al. 1998; Lichtenstein and Wold 2004) .", [["oral", "ANATOMY", 5, 9], ["capsule", "ANATOMY", 129, 136], ["intestines", "ANATOMY", 205, 215], ["Ad7", "CHEMICAL", 109, 112], ["oral", "ORGANISM_SUBDIVISION", 5, 9], ["adenovirus", "ORGANISM", 65, 75], ["Ad4", "SIMPLE_CHEMICAL", 101, 104], ["Ad7", "SIMPLE_CHEMICAL", 109, 112], ["intestines", "ORGAN", 205, 215], ["adenovirus", "SPECIES", 65, 75], ["This oral vaccine", "TREATMENT", 0, 17], ["adenovirus", "PROBLEM", 65, 75], ["a capsule coated", "TREATMENT", 127, 143], ["the viruses", "PROBLEM", 170, 181], ["viruses", "OBSERVATION", 174, 181], ["intestines", "ANATOMY", 205, 215]]], ["Because of its potential to cause illness, many of the adenovirus vectors currently being developed and tested are replication defective and cannot spread cell-to-cell.", [["cell", "ANATOMY", 155, 159], ["cell", "ANATOMY", 163, 167], ["adenovirus", "ORGANISM", 55, 65], ["cell", "CELL", 155, 159], ["cell", "CELL", 163, 167], ["adenovirus", "SPECIES", 55, 65], ["illness", "PROBLEM", 34, 41], ["the adenovirus vectors", "TREATMENT", 51, 73], ["replication defective", "PROBLEM", 115, 136]]], ["Replication-defective vectors often have deletions of the E1 portion of the viral genome, since this region is necessary for the initiation of viral replication (Souza et al. 2005) .Adenovirus VectorsIn addition to its extensive record as a military vaccine, adenovirus offers several advantages as a recombinant vaccine vector.", [["Adenovirus", "ORGANISM", 182, 192], ["adenovirus", "ORGANISM", 259, 269], ["E1 portion", "DNA", 58, 68], ["viral genome", "DNA", 76, 88], ["Adenovirus", "SPECIES", 182, 192], ["adenovirus", "SPECIES", 259, 269], ["Replication-defective vectors", "TREATMENT", 0, 29], ["deletions of the E1 portion", "PROBLEM", 41, 68], ["the viral genome", "PROBLEM", 72, 88], ["viral replication", "TREATMENT", 143, 160], ["Adenovirus VectorsIn", "TREATMENT", 182, 202], ["a military vaccine", "TREATMENT", 239, 257], ["adenovirus", "TREATMENT", 259, 269], ["a recombinant vaccine vector", "TREATMENT", 299, 327], ["defective vectors", "OBSERVATION", 12, 29], ["viral genome", "OBSERVATION", 76, 88]]], ["The viral genome is relatively easy to manipulate and the virus grows to high titers.", [["viral genome", "DNA", 4, 16], ["The viral genome", "PROBLEM", 0, 16], ["the virus", "PROBLEM", 54, 63], ["high titers", "PROBLEM", 73, 84], ["viral genome", "OBSERVATION", 4, 16]]], ["Adenovirus can by lyophilized, after which it does not need refrigeration (Souza et al. 2005) .", [["Adenovirus", "ORGANISM", 0, 10], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus", "PROBLEM", 0, 10]]], ["Because of these reasons, adenovirus has been one of the most popular recombinant vectors, and pharmaceutical companies have chosen to test adenovirus vectors in clinical trials.Adenovirus VectorsSeveral groups have demonstrated that recombinant adenovirus vectors expressing influenza virus proteins can protect animals after challenge.", [["adenovirus", "ORGANISM", 26, 36], ["adenovirus", "ORGANISM", 140, 150], ["Adenovirus", "ORGANISM", 178, 188], ["adenovirus", "ORGANISM", 246, 256], ["influenza virus", "ORGANISM", 276, 291], ["influenza virus proteins", "PROTEIN", 276, 300], ["influenza virus", "SPECIES", 276, 291], ["adenovirus", "SPECIES", 26, 36], ["adenovirus", "SPECIES", 140, 150], ["Adenovirus", "SPECIES", 178, 188], ["adenovirus", "SPECIES", 246, 256], ["influenza virus", "SPECIES", 276, 291], ["adenovirus", "PROBLEM", 26, 36], ["pharmaceutical companies", "TREATMENT", 95, 119], ["Adenovirus VectorsSeveral groups", "TREATMENT", 178, 210], ["recombinant adenovirus vectors", "TREATMENT", 234, 264], ["influenza virus proteins", "PROBLEM", 276, 300]]], ["Adenovirus vectors expressing HA and NP of an H3N2 swine influenza virus fully protected swine after a lethal challenge (Wesley et al. 2004) .", [["influenza virus", "DISEASE", 57, 72], ["Adenovirus", "ORGANISM", 0, 10], ["HA", "GENE_OR_GENE_PRODUCT", 30, 32], ["H3N2 swine influenza virus", "ORGANISM", 46, 72], ["swine", "ORGANISM", 89, 94], ["H3N2 swine influenza virus", "SPECIES", 46, 72], ["swine", "SPECIES", 89, 94], ["Adenovirus", "SPECIES", 0, 10], ["H3N2 swine influenza virus", "SPECIES", 46, 72], ["swine", "SPECIES", 89, 94], ["Adenovirus vectors", "TREATMENT", 0, 18], ["HA", "PROBLEM", 30, 32], ["an H3N2 swine influenza virus", "PROBLEM", 43, 72], ["a lethal challenge", "TREATMENT", 101, 119]]], ["A recombinant adenovirus vector expressing HA of HPAI H5N1 induced both cellular and humoral immunity in mice, and the vaccine was completely protective in both mice and chickens after lethal challenge (Gao et al. 2006 ).", [["cellular", "ANATOMY", 72, 80], ["H5N1", "DISEASE", 54, 58], ["adenovirus", "ORGANISM", 14, 24], ["HA", "GENE_OR_GENE_PRODUCT", 43, 45], ["HPAI H5N1", "ORGANISM", 49, 58], ["cellular", "CELL", 72, 80], ["mice", "ORGANISM", 105, 109], ["mice", "ORGANISM", 161, 165], ["chickens", "ORGANISM", 170, 178], ["HPAI H5N1", "SPECIES", 49, 58], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 161, 165], ["chickens", "SPECIES", 170, 178], ["adenovirus", "SPECIES", 14, 24], ["HPAI H5N1", "SPECIES", 49, 58], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 161, 165], ["chickens", "SPECIES", 170, 178], ["A recombinant adenovirus vector", "TREATMENT", 0, 31], ["HPAI H5N1", "TREATMENT", 49, 58], ["the vaccine", "TREATMENT", 115, 126], ["humoral immunity", "OBSERVATION", 85, 101]]], ["An adenovirus vector expressing HA from a H9N2 strain that was used to vaccinate chickens in ovo provided complete protection against lethal challenge with an H5N2 strain and partial protection against an H5N1 strain (Toro et al. 2007 ).", [["adenovirus", "ORGANISM", 3, 13], ["HA", "GENE_OR_GENE_PRODUCT", 32, 34], ["H9N2", "ORGANISM", 42, 46], ["chickens", "ORGANISM", 81, 89], ["HA", "PROTEIN", 32, 34], ["chickens", "SPECIES", 81, 89], ["adenovirus", "SPECIES", 3, 13], ["chickens", "SPECIES", 81, 89], ["ovo", "SPECIES", 93, 96], ["An adenovirus vector", "TREATMENT", 0, 20], ["HA", "PROBLEM", 32, 34], ["a H9N2 strain", "PROBLEM", 40, 53], ["vaccinate chickens", "TREATMENT", 71, 89], ["lethal challenge", "TREATMENT", 134, 150], ["an H5N2 strain", "TREATMENT", 156, 170], ["partial protection", "TREATMENT", 175, 193], ["an H5N1 strain", "PROBLEM", 202, 216], ["adenovirus", "OBSERVATION", 3, 13], ["H5N2", "OBSERVATION", 159, 163], ["H5N1", "OBSERVATION", 205, 209]]], ["Long-lasting immunity after vaccination with adenovirus vector expressing HA from an H5N1 virus provides protection after lethal challenge for at least one year (Hoelscher et al. 2007) .Adenovirus VectorsAdenovirus vectors are currently being examined as possible vaccines for a variety of viruses.", [["adenovirus", "ORGANISM", 45, 55], ["HA", "GENE_OR_GENE_PRODUCT", 74, 76], ["H5N1 virus", "ORGANISM", 85, 95], ["Adenovirus VectorsAdenovirus", "ORGANISM", 186, 214], ["H5N1 virus", "SPECIES", 85, 95], ["adenovirus", "SPECIES", 45, 55], ["H5N1 virus", "SPECIES", 85, 95], ["Adenovirus", "SPECIES", 186, 196], ["vaccination", "TREATMENT", 28, 39], ["adenovirus vector", "TREATMENT", 45, 62], ["HA", "PROBLEM", 74, 76], ["an H5N1 virus", "TREATMENT", 82, 95], ["lethal challenge", "TREATMENT", 122, 138], ["Adenovirus VectorsAdenovirus vectors", "TREATMENT", 186, 222], ["vaccines", "TREATMENT", 264, 272], ["a variety of viruses", "PROBLEM", 277, 297], ["viruses", "OBSERVATION", 290, 297]]], ["Adenovirus vectors, which have been shown to prevent disease after challenge, include those expressing herpes simplex virus and measles virus H, N, and F proteins (McDermott et al. 1989; Fooks et al. 1998; Sharpe et al. 2002) .", [["herpes simplex virus", "DISEASE", 103, 123], ["Adenovirus", "ORGANISM", 0, 10], ["herpes simplex virus", "ORGANISM", 103, 123], ["measles virus H", "ORGANISM", 128, 143], ["measles virus H, N, and F proteins", "PROTEIN", 128, 162], ["herpes simplex virus", "SPECIES", 103, 123], ["measles virus", "SPECIES", 128, 141], ["Adenovirus", "SPECIES", 0, 10], ["herpes simplex virus", "SPECIES", 103, 123], ["measles virus", "SPECIES", 128, 141], ["Adenovirus vectors", "TREATMENT", 0, 18], ["disease", "PROBLEM", 53, 60], ["those expressing herpes simplex virus", "PROBLEM", 86, 123], ["measles virus H", "TEST", 128, 143]]], ["Perhaps the most famous adenovirus vector is the Merck-sponsored HIV vaccine V520 that recently went into clinical trials.", [["adenovirus", "ORGANISM", 24, 34], ["HIV", "ORGANISM", 65, 68], ["HIV", "SPECIES", 65, 68], ["HIV", "SPECIES", 65, 68], ["the Merck-sponsored HIV vaccine", "TREATMENT", 45, 76]]], ["The vaccine consisted of adenovirus vectors containing HIV nef, gag, and pol genes (Steinbrook 2007; Sekaly 2008) .", [["adenovirus", "ORGANISM", 25, 35], ["HIV", "ORGANISM", 55, 58], ["gag", "GENE_OR_GENE_PRODUCT", 64, 67], ["pol", "GENE_OR_GENE_PRODUCT", 73, 76], ["HIV nef, gag, and pol genes", "DNA", 55, 82], ["HIV", "SPECIES", 55, 58], ["adenovirus", "SPECIES", 25, 35], ["HIV", "SPECIES", 55, 58], ["The vaccine", "TREATMENT", 0, 11], ["adenovirus vectors", "TREATMENT", 25, 43]]], ["The vaccine was administered as three injections at zero, two, and six months.", [["The vaccine", "TREATMENT", 0, 11]]], ["The clinical trials were halted early because it became clear that not only was the vaccine failing to prevent HIV infection, but the individuals given the vaccine also had a higher rate of HIV infection than those given the placebo (Sekaly 2008).", [["HIV infection", "DISEASE", 111, 124], ["HIV infection", "DISEASE", 190, 203], ["HIV", "ORGANISM", 111, 114], ["individuals", "ORGANISM", 134, 145], ["HIV", "ORGANISM", 190, 193], ["HIV", "SPECIES", 111, 114], ["HIV", "SPECIES", 111, 114], ["HIV", "SPECIES", 190, 193], ["the vaccine", "TREATMENT", 80, 91], ["HIV infection", "PROBLEM", 111, 124], ["the individuals", "PROBLEM", 130, 145], ["the vaccine", "TREATMENT", 152, 163], ["HIV infection", "PROBLEM", 190, 203], ["infection", "OBSERVATION", 115, 124], ["infection", "OBSERVATION", 194, 203]]], ["This devastating failure necessitates a thorough analysis of what went wrong so that it will not be repeated in future trials.", [["This devastating failure", "PROBLEM", 0, 24], ["a thorough analysis", "TEST", 38, 57], ["devastating", "OBSERVATION_MODIFIER", 5, 16], ["failure", "OBSERVATION", 17, 24]]], ["It is clear that a major problem is that many people have been exposed to the Ad5 strain used as the vaccine vector.", [["people", "ORGANISM", 46, 52], ["Ad5", "ORGANISM", 78, 81], ["people", "SPECIES", 46, 52], ["Ad5", "SPECIES", 78, 81], ["the Ad5 strain", "TREATMENT", 74, 88], ["the vaccine vector", "TREATMENT", 97, 115], ["clear", "OBSERVATION", 6, 11]]], ["About half of the individuals in western countries have antibodies to Ad5, and about 95% of people in developing countries have antibodies.", [["individuals", "ORGANISM", 18, 29], ["Ad5", "ORGANISM", 70, 73], ["people", "ORGANISM", 92, 98], ["antibodies", "PROTEIN", 56, 66], ["antibodies", "PROTEIN", 128, 138], ["people", "SPECIES", 92, 98], ["Ad5", "SPECIES", 70, 73], ["antibodies", "PROBLEM", 128, 138]]], ["The presence of pre-existing antibodies likely led to a rapid memory immune response that prevented the development of an immune response to the HIV proteins expressed from the vectors.", [["HIV", "ORGANISM", 145, 148], ["pre-existing antibodies", "PROTEIN", 16, 39], ["HIV proteins", "PROTEIN", 145, 157], ["HIV", "SPECIES", 145, 148], ["pre-existing antibodies", "PROBLEM", 16, 39], ["a rapid memory immune response", "PROBLEM", 54, 84], ["an immune response", "PROBLEM", 119, 137], ["the HIV proteins", "PROBLEM", 141, 157], ["antibodies", "OBSERVATION", 29, 39], ["rapid", "OBSERVATION_MODIFIER", 56, 61], ["memory immune response", "OBSERVATION", 62, 84], ["immune response", "OBSERVATION", 122, 137]]], ["What was unexpected and is not yet fully explained is that individuals that had been previously exposed to adenovirus before the vaccinations were more susceptible to HIV infection.", [["HIV infection", "DISEASE", 167, 180], ["individuals", "ORGANISM", 59, 70], ["adenovirus", "ORGANISM", 107, 117], ["HIV", "ORGANISM", 167, 170], ["HIV", "SPECIES", 167, 170], ["adenovirus", "SPECIES", 107, 117], ["HIV", "SPECIES", 167, 170], ["adenovirus", "TREATMENT", 107, 117], ["the vaccinations", "TREATMENT", 125, 141], ["HIV infection", "PROBLEM", 167, 180], ["infection", "OBSERVATION", 171, 180]]], ["Other researchers have been testing less common strains of adenovirus to use as vectors in hopes of circumventing the pre-existing immunity problems (Hofmann et al. 1999; Reddy et al. 1999; Farina et al. 2001) .Adenovirus VectorsSurprisingly, this was not the first time that adenovirus vectors have unexpectedly harmed clinical trial participants.", [["adenovirus", "ORGANISM", 59, 69], ["Adenovirus", "ORGANISM", 211, 221], ["adenovirus", "ORGANISM", 276, 286], ["participants", "SPECIES", 335, 347], ["adenovirus", "SPECIES", 59, 69], ["Adenovirus", "SPECIES", 211, 221], ["adenovirus", "SPECIES", 276, 286], ["adenovirus", "PROBLEM", 59, 69], ["the pre-existing immunity problems", "PROBLEM", 114, 148], ["adenovirus vectors", "TREATMENT", 276, 294]]], ["Adenovirus vectors have been used in gene therapy trials as well as for therapy against cancer, and it was during a gene therapy trial that a participant died of an inflammatory response after receiving a high dose of vector (3.8 \u00d7 10 13 virus particles) (Lehrman 1999; Marshall 1999) .", [["cancer", "ANATOMY", 88, 94], ["cancer", "DISEASE", 88, 94], ["Adenovirus", "ORGANISM", 0, 10], ["cancer", "CANCER", 88, 94], ["participant", "SPECIES", 142, 153], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus vectors", "TREATMENT", 0, 18], ["gene therapy trials", "TREATMENT", 37, 56], ["therapy", "TREATMENT", 72, 79], ["cancer", "PROBLEM", 88, 94], ["a gene therapy trial", "TREATMENT", 114, 134], ["an inflammatory response", "PROBLEM", 162, 186], ["a high dose of vector", "TREATMENT", 203, 224], ["inflammatory", "OBSERVATION", 165, 177]]], ["Another disadvantage of using this vector is that the adenovirus genome is DNA, and there is a risk that viral DNA may disrupt host genes and possibly cause cancer.", [["cancer", "ANATOMY", 157, 163], ["cancer", "DISEASE", 157, 163], ["adenovirus", "ORGANISM", 54, 64], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["cancer", "CANCER", 157, 163], ["adenovirus genome", "DNA", 54, 71], ["viral DNA", "DNA", 105, 114], ["host genes", "DNA", 127, 137], ["adenovirus", "SPECIES", 54, 64], ["this vector", "TREATMENT", 30, 41], ["the adenovirus genome", "PROBLEM", 50, 71], ["viral DNA", "PROBLEM", 105, 114], ["cancer", "PROBLEM", 157, 163], ["possibly cause", "UNCERTAINTY", 142, 156], ["cancer", "OBSERVATION", 157, 163]]], ["Some adenovirus strains can cause cancer in laboratory animals (Trentin et al. 1962) .", [["cancer", "ANATOMY", 34, 40], ["cancer", "DISEASE", 34, 40], ["adenovirus", "ORGANISM", 5, 15], ["cancer", "CANCER", 34, 40], ["Some adenovirus strains", "PROBLEM", 0, 23], ["cancer in laboratory animals", "PROBLEM", 34, 62], ["adenovirus strains", "OBSERVATION", 5, 23]]], ["Even though adenoviruses have not been shown to cause human cancer, it is possible that some cancer cases may arise after the vaccination of a large population.", [["cancer", "ANATOMY", 60, 66], ["cancer", "ANATOMY", 93, 99], ["cancer", "DISEASE", 60, 66], ["cancer", "DISEASE", 93, 99], ["adenoviruses", "ORGANISM", 12, 24], ["human", "ORGANISM", 54, 59], ["cancer", "CANCER", 60, 66], ["cancer", "CANCER", 93, 99], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["adenoviruses", "PROBLEM", 12, 24], ["human cancer", "PROBLEM", 54, 66], ["some cancer cases", "PROBLEM", 88, 105], ["a large population", "TREATMENT", 141, 159], ["adenoviruses", "OBSERVATION", 12, 24], ["cancer", "OBSERVATION", 60, 66], ["cancer", "OBSERVATION", 93, 99], ["large", "OBSERVATION_MODIFIER", 143, 148], ["population", "OBSERVATION", 149, 159]]], ["In light of the fiascos involving this vector, it is difficult to foresee high enthusiasm for adenovirus vectors in the future when other vectors seem more promising.Venezuelan Equine Encephalitis Virus VectorsVenezuelan equine encephalitis virus (VEE) is an RNA virus that primarily infects equines in Central and South America.", [["Equine Encephalitis", "DISEASE", 177, 196], ["Venezuelan equine encephalitis", "DISEASE", 210, 240], ["VEE", "DISEASE", 248, 251], ["adenovirus", "ORGANISM", 94, 104], ["Venezuelan", "ORGANISM", 166, 176], ["Equine Encephalitis Virus Vectors", "ORGANISM", 177, 210], ["Venezuelan equine encephalitis virus", "ORGANISM", 210, 246], ["VEE", "ORGANISM", 248, 251], ["Venezuelan equine encephalitis virus", "SPECIES", 210, 246], ["adenovirus", "SPECIES", 94, 104], ["Venezuelan Equine Encephalitis Virus Vectors", "SPECIES", 166, 210], ["Venezuelan equine encephalitis virus", "SPECIES", 210, 246], ["VEE", "SPECIES", 248, 251], ["this vector", "TREATMENT", 34, 45], ["adenovirus vectors", "TREATMENT", 94, 112], ["Venezuelan Equine Encephalitis Virus Vectors", "TREATMENT", 166, 210], ["Venezuelan equine encephalitis virus", "PROBLEM", 210, 246], ["an RNA virus", "PROBLEM", 256, 268], ["RNA virus", "OBSERVATION", 259, 268], ["Central", "ANATOMY_MODIFIER", 303, 310]]], ["In contrast to adenovirus, most humans do not have pre-existing antibodies to VEE that could interfere with the vaccine (Davis et al. 1996) .", [["VEE", "DISEASE", 78, 81], ["adenovirus", "ORGANISM", 15, 25], ["humans", "ORGANISM", 32, 38], ["VEE", "ORGANISM", 78, 81], ["pre-existing antibodies", "PROTEIN", 51, 74], ["humans", "SPECIES", 32, 38], ["adenovirus", "SPECIES", 15, 25], ["humans", "SPECIES", 32, 38], ["VEE", "SPECIES", 78, 81], ["adenovirus", "TREATMENT", 15, 25], ["pre-existing antibodies to VEE", "PROBLEM", 51, 81]]], ["Like VSV, VEE is transmitted by insects.", [["VEE", "DISEASE", 10, 13], ["VSV", "ORGANISM", 5, 8], ["VEE", "ORGANISM", 10, 13], ["VSV", "SPECIES", 5, 8], ["VEE", "SPECIES", 10, 13], ["VSV", "OBSERVATION", 5, 8]]], ["Strains of VEE range in pathogenicity from avirulent to causing acute encephalitis and death in equines.", [["VEE", "DISEASE", 11, 14], ["encephalitis", "DISEASE", 70, 82], ["death", "DISEASE", 87, 92], ["VEE", "ORGANISM", 11, 14], ["equines", "CANCER", 96, 103], ["VEE", "SPECIES", 11, 14], ["VEE range", "PROBLEM", 11, 20], ["pathogenicity", "PROBLEM", 24, 37], ["avirulent", "PROBLEM", 43, 52], ["acute encephalitis", "PROBLEM", 64, 82], ["death in equines", "PROBLEM", 87, 103], ["VEE range", "OBSERVATION", 11, 20], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["encephalitis", "OBSERVATION", 70, 82]]], ["Humans can be infected as well and usually only develop mild symptoms, but human deaths have occurred (Weaver et al. 2004 ).", [["deaths", "DISEASE", 81, 87], ["Humans", "ORGANISM", 0, 6], ["human", "ORGANISM", 75, 80], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["mild symptoms", "PROBLEM", 56, 69], ["human deaths", "PROBLEM", 75, 87], ["infected", "OBSERVATION", 14, 22], ["mild", "OBSERVATION_MODIFIER", 56, 60], ["symptoms", "OBSERVATION", 61, 69]]], ["Thus, VEE must be highly attenuated in order to be used as a vaccine vector.", [["VEE", "DISEASE", 6, 9], ["VEE", "ORGANISM", 6, 9], ["VEE", "SPECIES", 6, 9], ["VEE", "PROBLEM", 6, 9], ["a vaccine vector", "TREATMENT", 59, 75]]], ["Many of the VEE vaccines being tested use a viral replicon particle (VRP) that is capable of infecting cells but cannot spread throughout the host.", [["cells", "ANATOMY", 103, 108], ["VRP", "CHEMICAL", 69, 72], ["VEE", "ORGANISM", 12, 15], ["VRP", "ORGANISM", 69, 72], ["cells", "CELL", 103, 108], ["VEE", "SPECIES", 12, 15], ["the VEE vaccines", "TREATMENT", 8, 24], ["a viral replicon particle", "TREATMENT", 42, 67], ["infecting cells", "PROBLEM", 93, 108], ["infecting cells", "OBSERVATION", 93, 108]]], ["Foreign proteins are expressed at high levels from the VRP vectors.", [["Foreign proteins", "PROTEIN", 0, 16], ["Foreign proteins", "PROBLEM", 0, 16], ["high levels", "OBSERVATION_MODIFIER", 34, 45]]], ["One major advantage of using this vector it that the VEE targets antigen-presenting cells in the draining lymph node, so the foreign antigen is presented directly to the site where the adaptive immune response begins (Davis et al. 1996 Charles et al. 1997) .", [["antigen-presenting cells", "ANATOMY", 65, 89], ["lymph node", "ANATOMY", 106, 116], ["site", "ANATOMY", 170, 174], ["VEE", "ORGANISM", 53, 56], ["antigen", "GENE_OR_GENE_PRODUCT", 65, 72], ["cells", "CELL", 84, 89], ["lymph node", "MULTI-TISSUE_STRUCTURE", 106, 116], ["foreign antigen", "GENE_OR_GENE_PRODUCT", 125, 140], ["antigen-presenting cells", "CELL_TYPE", 65, 89], ["VEE", "SPECIES", 53, 56], ["this vector", "TREATMENT", 29, 40], ["the VEE targets antigen", "TEST", 49, 72], ["the draining lymph node", "PROBLEM", 93, 116], ["the foreign antigen", "PROBLEM", 121, 140], ["draining", "OBSERVATION_MODIFIER", 97, 105], ["lymph node", "OBSERVATION", 106, 116]]], ["Another advantage is that VEE vaccines can also induce an IgA mucosal immune response, even after subcutaneous injection of the vaccine (Charles et al. 1997) .", [["mucosal", "ANATOMY", 62, 69], ["subcutaneous", "ANATOMY", 98, 110], ["VEE", "ORGANISM", 26, 29], ["IgA", "GENE_OR_GENE_PRODUCT", 58, 61], ["IgA", "PROTEIN", 58, 61], ["VEE", "SPECIES", 26, 29], ["VEE vaccines", "TREATMENT", 26, 38], ["subcutaneous injection of the vaccine", "TREATMENT", 98, 135]]], ["Since many pathogens, including HIV, initially invade mucosal surfaces, the induction of mucosal immunity by a vaccine is highly desirable.", [["mucosal surfaces", "ANATOMY", 54, 70], ["mucosal", "ANATOMY", 89, 96], ["HIV", "ORGANISM", 32, 35], ["mucosal surfaces", "TISSUE", 54, 70], ["mucosal", "MULTI-TISSUE_STRUCTURE", 89, 96], ["HIV", "SPECIES", 32, 35], ["HIV", "SPECIES", 32, 35], ["many pathogens", "PROBLEM", 6, 20], ["HIV", "PROBLEM", 32, 35], ["mucosal immunity", "TREATMENT", 89, 105], ["a vaccine", "TREATMENT", 109, 118], ["many", "OBSERVATION_MODIFIER", 6, 10], ["pathogens", "OBSERVATION", 11, 20]]], ["VEE VRPs expressing HA from an H5N1 influenza virus were used to successfully protect two-week-old chickens from lethal challenge (Fig. 5) (Schultz-Cherry et al. 2000) .", [["VEE", "ORGANISM", 0, 3], ["VRPs", "GENE_OR_GENE_PRODUCT", 4, 8], ["HA", "GENE_OR_GENE_PRODUCT", 20, 22], ["H5N1 influenza virus", "ORGANISM", 31, 51], ["chickens", "ORGANISM", 99, 107], ["VEE VRPs", "PROTEIN", 0, 8], ["H5N1 influenza virus", "SPECIES", 31, 51], ["chickens", "SPECIES", 99, 107], ["VEE", "SPECIES", 0, 3], ["H5N1 influenza virus", "SPECIES", 31, 51], ["chickens", "SPECIES", 99, 107], ["HA", "PROBLEM", 20, 22], ["an H5N1 influenza virus", "PROBLEM", 28, 51], ["lethal challenge", "TREATMENT", 113, 129]]], ["VEE vaccines have also been developed for many other agents, including SIV, HIV, Lassa virus, Norwalk virus, Borrelia burgdorferi (the causative agent of Lyme disease), SARS-CoV, cowpox virus, dengue virus, and RSV (Caley et al. 1997 (Caley et al. , 1999 Pushko et al. 1997; Davis et al. 2000; Baric et al. 2002; Harrington et al. 2002; Gipson et al. 2003; Johnston et al. 2005; Deming et al. 2006; Cecil et al. 2007; Mok et al. 2007; Thornburg et al. 2007; White et al. 2007) .", [["VEE", "DISEASE", 0, 3], ["SIV, HIV, Lassa virus", "DISEASE", 71, 92], ["Borrelia burgdorferi", "DISEASE", 109, 129], ["Lyme disease", "DISEASE", 154, 166], ["SARS-CoV, cowpox virus", "DISEASE", 169, 191], ["dengue", "DISEASE", 193, 199], ["RSV", "DISEASE", 211, 214], ["VEE", "ORGANISM", 0, 3], ["SIV", "ORGANISM", 71, 74], ["HIV", "ORGANISM", 76, 79], ["Lassa virus", "ORGANISM", 81, 92], ["Norwalk virus", "ORGANISM", 94, 107], ["Borrelia burgdorferi", "ORGANISM", 109, 129], ["SARS-CoV", "ORGANISM", 169, 177], ["cowpox virus", "ORGANISM", 179, 191], ["dengue virus", "ORGANISM", 193, 205], ["RSV", "ORGANISM", 211, 214], ["HIV", "SPECIES", 76, 79], ["Lassa virus", "SPECIES", 81, 92], ["Norwalk virus", "SPECIES", 94, 107], ["Borrelia burgdorferi", "SPECIES", 109, 129], ["cowpox virus", "SPECIES", 179, 191], ["dengue virus", "SPECIES", 193, 205], ["RSV", "SPECIES", 211, 214], ["VEE", "SPECIES", 0, 3], ["SIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 76, 79], ["Lassa virus", "SPECIES", 81, 92], ["Norwalk virus", "SPECIES", 94, 107], ["Borrelia burgdorferi", "SPECIES", 109, 129], ["SARS-CoV", "SPECIES", 169, 177], ["cowpox virus", "SPECIES", 179, 191], ["dengue virus", "SPECIES", 193, 205], ["RSV", "SPECIES", 211, 214], ["VEE vaccines", "TREATMENT", 0, 12], ["SIV", "PROBLEM", 71, 74], ["HIV", "PROBLEM", 76, 79], ["Lassa virus", "PROBLEM", 81, 92], ["Norwalk virus", "PROBLEM", 94, 107], ["Borrelia burgdorferi", "PROBLEM", 109, 129], ["Lyme disease)", "PROBLEM", 154, 167], ["SARS", "PROBLEM", 169, 173], ["CoV", "PROBLEM", 174, 177], ["cowpox virus", "PROBLEM", 179, 191], ["dengue virus", "PROBLEM", 193, 205], ["RSV", "PROBLEM", 211, 214], ["cowpox virus", "OBSERVATION", 179, 191]]], ["Further testing will determine whether VEE vaccine vectors are safe and efficacious in humans.Poxvirus VectorsPoxviruses, DNA viruses with large genomes, have been studied as recombinant vectors after the successful eradication of smallpox using vaccinia virus.", [["smallpox", "DISEASE", 231, 239], ["VEE", "ORGANISM", 39, 42], ["humans", "ORGANISM", 87, 93], ["Poxvirus VectorsPoxviruses", "ORGANISM", 94, 120], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["vaccinia virus", "ORGANISM", 246, 260], ["humans", "SPECIES", 87, 93], ["VEE", "SPECIES", 39, 42], ["humans", "SPECIES", 87, 93], ["vaccinia virus", "SPECIES", 246, 260], ["Further testing", "TEST", 0, 15], ["VEE vaccine vectors", "TREATMENT", 39, 58], ["Poxvirus VectorsPoxviruses", "TREATMENT", 94, 120], ["DNA viruses", "PROBLEM", 122, 133], ["large genomes", "PROBLEM", 139, 152], ["recombinant vectors", "TREATMENT", 175, 194], ["smallpox", "TREATMENT", 231, 239], ["vaccinia virus", "TREATMENT", 246, 260], ["DNA viruses", "OBSERVATION", 122, 133], ["large", "OBSERVATION_MODIFIER", 139, 144], ["genomes", "OBSERVATION", 145, 152]]], ["Vaccinia viruses possess several properties of an ideal vector (Panicali et al. 1983 ): they are easy and inexpensive to manufacture, can be lyophilized, can accommodate large inserts of foreign DNA, and can induce both mucosal and systemic immunity after oral administration (Gherardi and Esteban 2005; Souza et al. 2005) .", [["mucosal", "ANATOMY", 220, 227], ["oral", "ANATOMY", 256, 260], ["Vaccinia viruses", "ORGANISM", 0, 16], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["mucosal", "PATHOLOGICAL_FORMATION", 220, 227], ["oral", "ORGANISM_SUBDIVISION", 256, 260], ["Vaccinia viruses", "SPECIES", 0, 16], ["Vaccinia viruses", "TREATMENT", 0, 16], ["foreign DNA", "PROBLEM", 187, 198], ["oral administration", "TREATMENT", 256, 275], ["several properties", "OBSERVATION_MODIFIER", 25, 43], ["large", "OBSERVATION_MODIFIER", 170, 175], ["foreign DNA", "OBSERVATION", 187, 198], ["mucosal", "ANATOMY", 220, 227]]], ["A major drawback of vaccinia vectors is that a large segment of the population has pre-existing immunity to vaccinia from the smallpox eradication program, which would interfere with the induction of an immune response to a foreign protein expressed from vaccinia virus.", [["vaccinia", "DISEASE", 108, 116], ["smallpox", "DISEASE", 126, 134], ["vaccinia", "ORGANISM", 20, 28], ["vaccinia", "ORGANISM", 108, 116], ["vaccinia virus", "ORGANISM", 255, 269], ["foreign protein", "PROTEIN", 224, 239], ["vaccinia", "SPECIES", 20, 28], ["vaccinia virus", "SPECIES", 255, 269], ["A major drawback of vaccinia vectors", "TREATMENT", 0, 36], ["vaccinia", "TREATMENT", 108, 116], ["the smallpox eradication program", "TREATMENT", 122, 154], ["a foreign protein", "TREATMENT", 222, 239], ["vaccinia virus", "PROBLEM", 255, 269], ["vaccinia", "OBSERVATION", 20, 28], ["large", "OBSERVATION_MODIFIER", 47, 52], ["segment", "OBSERVATION_MODIFIER", 53, 60], ["vaccinia virus", "OBSERVATION", 255, 269]]], ["To overcome this, similar poxviruses from other species that do not cross-react with vaccinia virus, such as canarypox virus and fowlpox virus, are currently being tested Bublot et al. 2006 ).", [["vaccinia virus", "DISEASE", 85, 99], ["vaccinia virus", "ORGANISM", 85, 99], ["canarypox virus", "ORGANISM", 109, 124], ["fowlpox virus", "ORGANISM", 129, 142], ["vaccinia virus", "SPECIES", 85, 99], ["canarypox virus", "SPECIES", 109, 124], ["vaccinia virus", "SPECIES", 85, 99], ["canarypox virus", "SPECIES", 109, 124], ["fowlpox virus", "SPECIES", 129, 142], ["similar poxviruses", "PROBLEM", 18, 36], ["other species", "PROBLEM", 42, 55], ["vaccinia virus", "PROBLEM", 85, 99], ["canarypox virus", "TREATMENT", 109, 124], ["fowlpox virus", "TREATMENT", 129, 142]]], ["However, it appears that these recombinant vectors induce a weaker immune response to foreign proteins compared to recombinant vaccinia vectors (Zhang et al. 2007) .", [["vaccinia", "ORGANISM", 127, 135], ["foreign proteins", "PROTEIN", 86, 102], ["these recombinant vectors", "TREATMENT", 25, 50], ["a weaker immune response", "PROBLEM", 58, 82], ["foreign proteins", "PROBLEM", 86, 102], ["recombinant vaccinia vectors", "TREATMENT", 115, 143]]], ["A canarypox vaccine encoding HIV gp120 failed phase 2 clinical trials in humans since it failed to elicit a strong cellular immune response (Russell et al. 2007) .", [["cellular", "ANATOMY", 115, 123], ["HIV gp120", "DISEASE", 29, 38], ["HIV", "ORGANISM", 29, 32], ["humans", "ORGANISM", 73, 79], ["cellular", "CELL", 115, 123], ["HIV gp120", "PROTEIN", 29, 38], ["HIV", "SPECIES", 29, 32], ["humans", "SPECIES", 73, 79], ["HIV", "SPECIES", 29, 32], ["humans", "SPECIES", 73, 79], ["A canarypox vaccine", "TREATMENT", 0, 19]]], ["Also, vaccinees can spread vaccinia virus to other individuals, which is especially dangerous for immunocompromised individuals.", [["vaccinia virus", "ORGANISM", 27, 41], ["vaccinia virus", "SPECIES", 27, 41], ["vaccinees", "TREATMENT", 6, 15], ["vaccinia virus", "PROBLEM", 27, 41], ["immunocompromised individuals", "PROBLEM", 98, 127]]], ["To address this, replication-defective attenuated vaccinia viruses, such as the Ankara strain, are being evaluated for recombinant vector potential, though these attenuated strains do Pushko et al. (1997) cross-react with vaccinia virus, making it less likely that they will ultimately be successful (Souza et al. 2005) .Live Attenuated Measles Viruses as Recombinant VectorsAnother strategy involves altering currently licensed vaccines-such as the live attenuated measles virus vaccine-to express foreign proteins, in the hope that there would be a strong immune response to both measles virus and a foreign protein (Zuniga et al. 2007 ).", [["Attenuated Measles Viruses", "DISEASE", 326, 352], ["measles virus", "DISEASE", 582, 595], ["vaccinia viruses", "ORGANISM", 50, 66], ["Ankara strain", "ORGANISM", 80, 93], ["vaccinia virus", "ORGANISM", 222, 236], ["measles virus", "ORGANISM", 466, 479], ["measles virus", "ORGANISM", 582, 595], ["foreign proteins", "PROTEIN", 499, 515], ["foreign protein", "PROTEIN", 602, 617], ["measles virus vaccine", "SPECIES", 466, 487], ["measles virus", "SPECIES", 582, 595], ["vaccinia viruses", "SPECIES", 50, 66], ["vaccinia virus", "SPECIES", 222, 236], ["measles virus", "SPECIES", 466, 479], ["measles virus", "SPECIES", 582, 595], ["defective attenuated vaccinia viruses", "PROBLEM", 29, 66], ["the Ankara strain", "PROBLEM", 76, 93], ["these attenuated strains", "PROBLEM", 156, 180], ["vaccinia virus", "PROBLEM", 222, 236], ["Live Attenuated Measles Viruses", "TREATMENT", 321, 352], ["Recombinant Vectors", "TREATMENT", 356, 375], ["licensed vaccines", "TREATMENT", 420, 437], ["the live attenuated measles virus vaccine", "TREATMENT", 446, 487], ["foreign proteins", "PROBLEM", 499, 515], ["both measles virus", "PROBLEM", 577, 595], ["attenuated", "OBSERVATION_MODIFIER", 39, 49], ["vaccinia viruses", "OBSERVATION", 50, 66]]], ["The measles virus vaccine is highly efficacious in infants and has an excellent safety record.", [["measles virus", "ORGANISM", 4, 17], ["infants", "ORGANISM", 51, 58], ["measles virus vaccine", "SPECIES", 4, 25], ["infants", "SPECIES", 51, 58], ["measles virus", "SPECIES", 4, 17], ["The measles virus vaccine", "TREATMENT", 0, 25]]], ["A measles virus vector expressing West Nile virus glycoprotein protected mice against a lethal challenge with West Nile virus (Despres et al. 2005) .", [["measles virus", "ORGANISM", 2, 15], ["West Nile virus glycoprotein", "ORGANISM", 34, 62], ["mice", "ORGANISM", 73, 77], ["West Nile virus", "ORGANISM", 110, 125], ["West Nile virus glycoprotein", "PROTEIN", 34, 62], ["A measles virus", "SPECIES", 0, 15], ["West Nile virus", "SPECIES", 34, 49], ["mice", "SPECIES", 73, 77], ["West Nile virus", "SPECIES", 110, 125], ["measles virus", "SPECIES", 2, 15], ["West Nile virus", "SPECIES", 34, 49], ["mice", "SPECIES", 73, 77], ["West Nile virus", "SPECIES", 110, 125], ["A measles virus vector", "TREATMENT", 0, 22], ["West Nile virus glycoprotein", "TREATMENT", 34, 62], ["a lethal challenge", "TREATMENT", 86, 104]]], ["The only disadvantage of this vector is that most of the human population has already been vaccinated and has pre-existing immunity to measles virus.", [["measles virus", "DISEASE", 135, 148], ["human", "ORGANISM", 57, 62], ["measles virus", "ORGANISM", 135, 148], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["measles virus", "SPECIES", 135, 148], ["this vector", "TREATMENT", 25, 36], ["the human population", "PROBLEM", 53, 73], ["measles virus", "PROBLEM", 135, 148]]], ["However, mice and macaques were vaccinated with the measles virus vaccine, and after 12 months were vaccinated with the measles virus vaccine expressing HIV gp140.", [["mice", "ORGANISM", 9, 13], ["macaques", "ORGANISM", 18, 26], ["measles virus", "ORGANISM", 52, 65], ["measles virus", "ORGANISM", 120, 133], ["HIV gp140", "ORGANISM", 153, 162], ["HIV gp140", "PROTEIN", 153, 162], ["mice", "SPECIES", 9, 13], ["macaques", "SPECIES", 18, 26], ["measles virus vaccine", "SPECIES", 52, 73], ["measles virus vaccine", "SPECIES", 120, 141], ["HIV", "SPECIES", 153, 156], ["mice", "SPECIES", 9, 13], ["measles virus", "SPECIES", 52, 65], ["measles virus", "SPECIES", 120, 133], ["HIV", "SPECIES", 153, 156], ["mice and macaques", "TREATMENT", 9, 26], ["the measles virus vaccine", "TREATMENT", 48, 73], ["the measles virus vaccine", "TREATMENT", 116, 141]]], ["The animals developed antibody titers to HIV that were similar to the antibody titers in na\u00efve animals (Lorin et al. 2004) .", [["animals", "ORGANISM", 4, 11], ["HIV", "ORGANISM", 41, 44], ["HIV", "SPECIES", 41, 44], ["HIV", "SPECIES", 41, 44], ["antibody titers", "PROBLEM", 22, 37], ["HIV", "PROBLEM", 41, 44], ["the antibody titers", "TEST", 66, 85], ["antibody titers", "OBSERVATION", 22, 37]]], ["While more work is required to substantiate these results in order to recommend using this vector in humans with pre-existing measles virus immunity, at the very least this is a promising method for vaccinating na\u00efve infants against both measles virus and another pathogen.Other Recombinant VectorsA current vaccine strategy under development is the use of bacteria as delivery vehicles of foreign antigens.", [["measles virus immunity", "DISEASE", 126, 148], ["measles virus", "DISEASE", 238, 251], ["humans", "ORGANISM", 101, 107], ["measles virus", "ORGANISM", 126, 139], ["infants", "ORGANISM", 217, 224], ["measles virus", "ORGANISM", 238, 251], ["foreign antigens", "PROTEIN", 390, 406], ["humans", "SPECIES", 101, 107], ["infants", "SPECIES", 217, 224], ["measles virus", "SPECIES", 238, 251], ["humans", "SPECIES", 101, 107], ["measles virus", "SPECIES", 126, 139], ["measles virus", "SPECIES", 238, 251], ["this vector", "TREATMENT", 86, 97], ["pre-existing measles virus immunity", "TREATMENT", 113, 148], ["vaccinating na\u00efve infants", "TREATMENT", 199, 224], ["both measles virus", "PROBLEM", 233, 251], ["another pathogen", "PROBLEM", 256, 272], ["Other Recombinant VectorsA current vaccine", "TREATMENT", 273, 315], ["bacteria", "PROBLEM", 357, 365], ["foreign antigens", "PROBLEM", 390, 406], ["foreign antigens", "OBSERVATION", 390, 406]]], ["Attenuated strains of intracellular bacteria such as Salmonella enterica serovar Typhimurium and Listeria monocytogenes are being engineered as recombinant vectors (Schoen et al. 2004; Cheminay and Hensel 2008; Schoen et al. 2008) .", [["intracellular", "ANATOMY", 22, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["Salmonella enterica serovar Typhimurium", "ORGANISM", 53, 92], ["Listeria monocytogenes", "ORGANISM", 97, 119], ["Salmonella", "SPECIES", 53, 63], ["enterica serovar Typhimurium", "SPECIES", 64, 92], ["Listeria monocytogenes", "SPECIES", 97, 119], ["Salmonella enterica serovar Typhimurium", "SPECIES", 53, 92], ["Listeria monocytogenes", "SPECIES", 97, 119], ["Attenuated strains", "PROBLEM", 0, 18], ["intracellular bacteria", "PROBLEM", 22, 44], ["Salmonella enterica serovar Typhimurium", "PROBLEM", 53, 92], ["Listeria monocytogenes", "PROBLEM", 97, 119], ["intracellular bacteria", "OBSERVATION", 22, 44], ["serovar Typhimurium", "OBSERVATION", 73, 92], ["Listeria monocytogenes", "OBSERVATION", 97, 119]]], ["While intracellular, the bacteria remain in a membranebound vesicle inside the host cell, which prevents foreign proteins expressed by bacteria from entering the host cytosol, a necessary step for antigens to be presented to the immune system.", [["intracellular", "ANATOMY", 6, 19], ["membranebound vesicle", "ANATOMY", 46, 67], ["cell", "ANATOMY", 84, 88], ["cytosol", "ANATOMY", 167, 174], ["immune system", "ANATOMY", 229, 242], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 19], ["membranebound vesicle", "CELLULAR_COMPONENT", 46, 67], ["host cell", "CELL", 79, 88], ["cytosol", "CELLULAR_COMPONENT", 167, 174], ["foreign proteins", "PROTEIN", 105, 121], ["antigens", "PROTEIN", 197, 205], ["the bacteria", "PROBLEM", 21, 33], ["a membranebound vesicle", "PROBLEM", 44, 67], ["foreign proteins", "PROBLEM", 105, 121], ["bacteria", "PROBLEM", 135, 143], ["bacteria", "OBSERVATION_MODIFIER", 25, 33], ["membranebound vesicle", "OBSERVATION", 46, 67], ["host cell", "OBSERVATION", 79, 88], ["foreign proteins", "OBSERVATION", 105, 121], ["bacteria", "OBSERVATION_MODIFIER", 135, 143]]], ["Two mechanisms of antigen delivery to combat this problem have been tested in bacterial vectors.", [["antigen delivery", "TREATMENT", 18, 34], ["this problem", "PROBLEM", 45, 57]]], ["One involves synthesis of the foreign protein inside the bacteria and release of the foreign protein into the human cell by the bacterial type III secretory pathway (Panthel et al. 2008) .", [["cell", "ANATOMY", 116, 120], ["human", "ORGANISM", 110, 115], ["cell", "CELL", 116, 120], ["bacterial type III", "GENE_OR_GENE_PRODUCT", 128, 146], ["foreign protein", "PROTEIN", 30, 45], ["foreign protein", "PROTEIN", 85, 100], ["human cell", "CELL_TYPE", 110, 120], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["the foreign protein inside the bacteria", "PROBLEM", 26, 65], ["the foreign protein", "PROBLEM", 81, 100], ["foreign protein", "OBSERVATION", 30, 45], ["bacteria", "OBSERVATION_MODIFIER", 57, 65], ["foreign protein", "OBSERVATION", 85, 100], ["human cell", "OBSERVATION", 110, 120], ["bacterial", "OBSERVATION_MODIFIER", 128, 137]]], ["Because proteins must be unfolded prior to being secreted, foreign proteins with high stability cannot be completely unfolded and are unable to exit the bacterial cell.", [["cell", "ANATOMY", 163, 167], ["cell", "CELL", 163, 167], ["foreign proteins", "PROTEIN", 59, 75], ["bacterial cell", "CELL_TYPE", 153, 167], ["foreign proteins", "PROBLEM", 59, 75], ["unfolded", "OBSERVATION", 25, 33], ["high stability", "OBSERVATION_MODIFIER", 81, 95], ["unfolded", "OBSERVATION", 117, 125], ["bacterial cell", "OBSERVATION", 153, 167]]], ["It has been demonstrated that the removal of small stabilizing domains in HIV proteins can allow these large foreign proteins to be secreted by the type III pathway (Chen et al. 2006 ).", [["HIV", "ORGANISM", 74, 77], ["small stabilizing domains", "PROTEIN", 45, 70], ["HIV proteins", "PROTEIN", 74, 86], ["HIV", "SPECIES", 74, 77], ["the removal", "TREATMENT", 30, 41], ["small stabilizing domains in HIV proteins", "PROBLEM", 45, 86], ["these large foreign proteins", "PROBLEM", 97, 125], ["small", "OBSERVATION_MODIFIER", 45, 50], ["stabilizing", "OBSERVATION", 51, 62], ["large", "OBSERVATION_MODIFIER", 103, 108], ["foreign proteins", "OBSERVATION", 109, 125]]], ["However, the complexity of the bacterial genome and the difficulty of secreting foreign proteins will limit the use of this system.Other Recombinant VectorsAnother mechanism of antigen delivery by bacterial vectors involves the release of DNA encoding a foreign protein into the host cell, essentially a DNA vaccine delivered by a live bacterial organism.", [["cell", "ANATOMY", 284, 288], ["antigen", "GENE_OR_GENE_PRODUCT", 177, 184], ["DNA", "CELLULAR_COMPONENT", 239, 242], ["host cell", "CELL", 279, 288], ["DNA", "CELLULAR_COMPONENT", 304, 307], ["bacterial genome", "DNA", 31, 47], ["foreign proteins", "PROTEIN", 80, 96], ["foreign protein", "PROTEIN", 254, 269], ["host cell", "CELL_TYPE", 279, 288], ["the bacterial genome", "PROBLEM", 27, 47], ["secreting foreign proteins", "PROBLEM", 70, 96], ["this system", "TREATMENT", 119, 130], ["Other Recombinant VectorsAnother mechanism of antigen delivery", "TREATMENT", 131, 193], ["bacterial vectors", "TREATMENT", 197, 214], ["DNA", "PROBLEM", 239, 242], ["a foreign protein into the host cell", "PROBLEM", 252, 288], ["a DNA vaccine", "TREATMENT", 302, 315], ["a live bacterial organism", "PROBLEM", 329, 354], ["complexity", "OBSERVATION_MODIFIER", 13, 23], ["bacterial genome", "OBSERVATION", 31, 47], ["host cell", "OBSERVATION", 279, 288]]], ["This strategy includes transforming bacteria with a naked DNA vector that encodes a foreign gene.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["naked DNA vector", "DNA", 52, 68], ["foreign gene", "DNA", 84, 96], ["transforming bacteria", "PROBLEM", 23, 44], ["a naked DNA vector", "TREATMENT", 50, 68], ["foreign gene", "OBSERVATION", 84, 96]]], ["Bacteria that target antigenpresenting cells, such as Listeria monocytogenes that targets dendritic cells, must be used for this technique.", [["antigenpresenting cells", "ANATOMY", 21, 44], ["dendritic cells", "ANATOMY", 90, 105], ["antigenpresenting cells", "CELL", 21, 44], ["Listeria monocytogenes", "ORGANISM", 54, 76], ["dendritic cells", "CELL", 90, 105], ["antigenpresenting cells", "CELL_TYPE", 21, 44], ["dendritic cells", "CELL_TYPE", 90, 105], ["Listeria monocytogenes", "SPECIES", 54, 76], ["Listeria monocytogenes", "SPECIES", 54, 76], ["Bacteria", "PROBLEM", 0, 8], ["target antigenpresenting cells", "PROBLEM", 14, 44], ["Listeria monocytogenes", "PROBLEM", 54, 76], ["dendritic cells", "PROBLEM", 90, 105], ["this technique", "TEST", 124, 138], ["antigenpresenting cells", "OBSERVATION", 21, 44], ["Listeria monocytogenes", "OBSERVATION", 54, 76], ["dendritic cells", "OBSERVATION", 90, 105]]], ["The chosen bacteria have to be highly attenuated and designed to lyse upon host cell entry.", [["cell", "ANATOMY", 80, 84], ["host cell", "CELL", 75, 84], ["The chosen bacteria", "PROBLEM", 0, 19], ["bacteria", "OBSERVATION", 11, 19], ["host cell entry", "OBSERVATION", 75, 90]]], ["Once the bacteria are lysed, the DNA vector enters the cytosol and then transports to the nucleus, where it is transcribed.", [["cytosol", "ANATOMY", 55, 62], ["nucleus", "ANATOMY", 90, 97], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["cytosol", "CELLULAR_COMPONENT", 55, 62], ["nucleus", "CELLULAR_COMPONENT", 90, 97], ["DNA vector", "DNA", 33, 43], ["the bacteria", "PROBLEM", 5, 17], ["the DNA vector", "TEST", 29, 43], ["lysed", "OBSERVATION", 22, 27], ["nucleus", "ANATOMY", 90, 97]]], ["After being translated in the cytoplasm, the antigens can be processed to be presented on both MHC I and MHC II molecules in order to stimulate humoral and cellular immunity (Mollenkopf et al. 2001; Weiss 2003; Schoen et al. 2008 ).", [["cytoplasm", "ANATOMY", 30, 39], ["cellular", "ANATOMY", 156, 164], ["cytoplasm", "ORGANISM_SUBSTANCE", 30, 39], ["MHC I", "GENE_OR_GENE_PRODUCT", 95, 100], ["MHC II", "GENE_OR_GENE_PRODUCT", 105, 111], ["cellular", "CELL", 156, 164], ["antigens", "PROTEIN", 45, 53], ["MHC I", "PROTEIN", 95, 100], ["MHC II molecules", "PROTEIN", 105, 121]]], ["While this method shows promise, as with viral vectors, pre-existing immunity to bacterial vectors does appear to inhibit the production of an immune response to foreign proteins (Sevil Domenech et al. 2007) .Other Recombinant VectorsA new area of recombinant vector research has been focusing on using transgenic plants as delivery vectors.", [["foreign proteins", "PROTEIN", 162, 178], ["this method", "TEST", 6, 17], ["viral vectors", "TREATMENT", 41, 54], ["pre-existing immunity to bacterial vectors", "TREATMENT", 56, 98], ["foreign proteins", "PROBLEM", 162, 178], ["Other Recombinant Vectors", "TREATMENT", 209, 234], ["recombinant vector research", "TREATMENT", 248, 275], ["transgenic plants", "TREATMENT", 303, 320], ["delivery vectors", "TREATMENT", 324, 340], ["new", "OBSERVATION_MODIFIER", 236, 239], ["area", "OBSERVATION_MODIFIER", 240, 244], ["recombinant vector", "OBSERVATION", 248, 266]]], ["Plants are safe and inexpensive vectors, can easily be grown in large quantities, are stable at room temperature, and can be designed to express many antigens (Webster et al. 2005) .", [["antigens", "PROTEIN", 150, 158], ["inexpensive vectors", "TREATMENT", 20, 39], ["stable", "OBSERVATION_MODIFIER", 86, 92]]], ["Expression of HIV antigens in plants has been reported, and these vaccine vectors are currently being evaluated for their efficacy (Yusibov et al. 1997; Marusic et al. 2001 ).ConclusionsThe growing interest in using recombinant vectors as vaccines for influenza virus and other dangerous pathogens reflects the reality that these vaccines have substantial advantages over most other types of vaccines.", [["influenza virus", "DISEASE", 252, 267], ["HIV antigens", "GENE_OR_GENE_PRODUCT", 14, 26], ["influenza virus", "ORGANISM", 252, 267], ["HIV antigens", "PROTEIN", 14, 26], ["influenza virus", "SPECIES", 252, 267], ["HIV", "SPECIES", 14, 17], ["influenza virus", "SPECIES", 252, 267], ["HIV antigens", "PROBLEM", 14, 26], ["these vaccine vectors", "TREATMENT", 60, 81], ["recombinant vectors", "TREATMENT", 216, 235], ["vaccines", "TREATMENT", 239, 247], ["influenza virus", "PROBLEM", 252, 267], ["other dangerous pathogens", "PROBLEM", 272, 297], ["these vaccines", "TREATMENT", 324, 338], ["vaccines", "TREATMENT", 392, 400], ["HIV", "OBSERVATION", 14, 17], ["growing", "OBSERVATION_MODIFIER", 190, 197]]], ["While some recombinant vectors appear to be more encouraging than others, ideally it is hoped that several different vectors will ultimately be used to vaccinate against different diseases.", [["some recombinant vectors", "TREATMENT", 6, 30], ["several different vectors", "TREATMENT", 99, 124], ["different diseases", "PROBLEM", 170, 188]]], ["An important hurdle to overcome in the development of recombinant vectors is the problem of pre-existing immunity to many of the vectors being tested.", [["recombinant vectors", "TREATMENT", 54, 73]]], ["The issue of pre-existing immunity must also be addressed for recombinant viruses that humans currently do not have immunity against.", [["humans", "ORGANISM", 87, 93], ["humans", "SPECIES", 87, 93], ["humans", "SPECIES", 87, 93], ["recombinant viruses", "PROBLEM", 62, 81]]], ["This is because people have to be vaccinated multiple times for influenza virus, as the viral HA protein mutates.", [["influenza", "DISEASE", 64, 73], ["people", "ORGANISM", 16, 22], ["influenza virus", "ORGANISM", 64, 79], ["viral HA protein", "PROTEIN", 88, 104], ["people", "SPECIES", 16, 22], ["influenza virus", "SPECIES", 64, 79], ["influenza virus", "PROBLEM", 64, 79], ["the viral HA protein mutates", "PROBLEM", 84, 112]]], ["If a strong immune response is generated against the vector after the first vaccination, the vector may not be able to replicate sufficiently after successive administrations.", [["the first vaccination", "TREATMENT", 66, 87], ["the vector", "TREATMENT", 89, 99]]], ["This would prevent the formation of an immune response to the mutated HAs, leaving the individual vulnerable to infection with the altered influenza viruses.", [["infection", "DISEASE", 112, 121], ["influenza viruses", "DISEASE", 139, 156], ["influenza viruses", "ORGANISM", 139, 156], ["the mutated HAs", "PROBLEM", 58, 73], ["infection", "PROBLEM", 112, 121], ["the altered influenza viruses", "PROBLEM", 127, 156], ["infection", "OBSERVATION", 112, 121], ["altered", "OBSERVATION_MODIFIER", 131, 138], ["influenza viruses", "OBSERVATION", 139, 156]]], ["This is being addressed for VSV by the generation of vectors that express different serotypes of VSV G protein that do not cross-react.", [["VSV", "ORGANISM", 28, 31], ["VSV G protein", "GENE_OR_GENE_PRODUCT", 97, 110], ["VSV G protein", "PROTEIN", 97, 110], ["VSV", "SPECIES", 28, 31], ["VSV", "SPECIES", 97, 100], ["VSV", "PROBLEM", 28, 31], ["the generation of vectors", "TREATMENT", 35, 60], ["VSV G protein", "TEST", 97, 110]]], ["Recombinant VSV vectors expressing HIV Env elicit a strong immune response to Env, and subsequent vaccination with different VSV vectors expressing HIV Env and other G proteins can be used to boost the initial immune response .", [["VSV", "ORGANISM", 12, 15], ["HIV Env", "ORGANISM", 35, 42], ["Env", "GENE_OR_GENE_PRODUCT", 78, 81], ["VSV", "ORGANISM", 125, 128], ["HIV Env", "ORGANISM", 148, 155], ["G proteins", "GENE_OR_GENE_PRODUCT", 166, 176], ["HIV Env", "PROTEIN", 35, 42], ["Env", "PROTEIN", 78, 81], ["HIV Env", "PROTEIN", 148, 155], ["G proteins", "PROTEIN", 166, 176], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 148, 151], ["VSV", "SPECIES", 12, 15], ["HIV", "SPECIES", 35, 38], ["VSV", "SPECIES", 125, 128], ["HIV", "SPECIES", 148, 151], ["Recombinant VSV vectors", "TREATMENT", 0, 23], ["subsequent vaccination", "TREATMENT", 87, 109], ["different VSV vectors", "TREATMENT", 115, 136], ["HIV Env", "TREATMENT", 148, 155], ["other G proteins", "TREATMENT", 160, 176]]], ["Further work in this area is needed to overcome this limitation of recombinant vectors.", [["recombinant vectors", "TREATMENT", 67, 86]]], ["A comparison of the viral vectors is shown in Table 1 .", [["viral vectors", "DNA", 20, 33], ["the viral vectors", "TREATMENT", 16, 33], ["viral vectors", "OBSERVATION", 20, 33]]], ["Overall, recombinant vectors provide a Zuniga et al. (2007) safe and effective mechanism for eliciting humoral and cellular immunity to the most dangerous pathogens on the planet.", [["cellular", "ANATOMY", 115, 123], ["cellular", "CELL", 115, 123]]]], "0a5e7650d8ff6d24c2ee42d666a3c46aeef596ae": [["With this in mind, we take here a network dynamics approach, and analyse the spatiotemporal propagation patterns of both the commodities and the pathogens (Fig. 1b) .", [["a network dynamics approach", "TREATMENT", 32, 59]]], ["We find that while the disease impacts the majority of nodes uniformly, maximum commodity flow optimization naturally yields a highly uneven spread, conflicting a concurrent and homogeneous global demand with an extremely heterogeneous supply pattern.", [["the disease", "PROBLEM", 19, 30], ["a highly uneven spread", "PROBLEM", 125, 147], ["homogeneous global demand", "PROBLEM", 178, 203], ["an extremely heterogeneous supply pattern", "PROBLEM", 209, 250], ["disease", "OBSERVATION", 23, 30], ["majority", "OBSERVATION_MODIFIER", 43, 51], ["nodes", "OBSERVATION", 55, 60], ["maximum", "OBSERVATION_MODIFIER", 72, 79], ["highly", "OBSERVATION_MODIFIER", 127, 133], ["uneven", "OBSERVATION_MODIFIER", 134, 140], ["spread", "OBSERVATION_MODIFIER", 141, 147], ["homogeneous", "OBSERVATION_MODIFIER", 178, 189], ["global demand", "OBSERVATION", 190, 203], ["extremely", "OBSERVATION_MODIFIER", 212, 221], ["heterogeneous", "OBSERVATION_MODIFIER", 222, 235], ["supply pattern", "OBSERVATION", 236, 250]]], ["As a result, not only does maximum flow not guarantee optimal mitigation, it is, in fact, counterproductive, indeed, generating a desirable volume of available therapeutics, but at the same time a highly undesirable spreading pattern.", [["highly", "OBSERVATION_MODIFIER", 197, 203], ["undesirable", "OBSERVATION_MODIFIER", 204, 215]]], ["We, therefore, introduce an equality criterion to the optimization, that prioritizes dissemination sequences with homogeneous spreading patterns (Fig. 1c) .", [["dissemination sequences", "TEST", 85, 108]]], ["This ensures that the therapeutic flow is not just rapid, but also properly disseminated, generating supply patterns that are compatible with demand.", [["the therapeutic flow", "TEST", 18, 38], ["therapeutic", "OBSERVATION_MODIFIER", 22, 33], ["flow", "OBSERVATION", 34, 38], ["disseminated", "OBSERVATION", 76, 88], ["compatible with", "UNCERTAINTY", 126, 141]]], ["The resulting dissemination, we find, is orders of magnitude more efficient, achieving higher mitigation levels even under extremely prohibitive shipping constraints.MITIGATION VIA MAXIMUM-FLOWTo examine our response to a global epidemic, we consider different epidemiological scenarios, from mildly contagious to extremely virulent, in which a disease spreads globally via air-travel, under the susceptible-infected-recovered (SIR) epidemic model 13, 14, 33 (Box I).", [["a global epidemic", "PROBLEM", 220, 237], ["different epidemiological scenarios", "PROBLEM", 251, 286], ["mildly contagious", "PROBLEM", 293, 310], ["extremely virulent", "PROBLEM", 314, 332], ["a disease spreads", "PROBLEM", 343, 360], ["epidemic model", "TEST", 433, 447], ["dissemination", "OBSERVATION", 14, 27], ["mildly", "OBSERVATION_MODIFIER", 293, 299]]], ["We used empirical data on human aviation to evaluate the flux of passengers between = 1,292 local populations (nodes), each with individuals ( = 1, \u2026 , ), and quantified the impact of the epidemic through its global coverageMITIGATION VIA MAXIMUM-FLOWwhere ( ) is the fraction of recovered individuals in and \u03a9 = \u2211 =1 represents the global population.", [["nodes", "ANATOMY", 111, 116], ["human", "ORGANISM", 26, 31], ["nodes", "MULTI-TISSUE_STRUCTURE", 111, 116], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["individuals", "TEST", 129, 140], ["nodes", "OBSERVATION", 111, 116], ["global", "OBSERVATION_MODIFIER", 209, 215], ["MAXIMUM", "OBSERVATION_MODIFIER", 239, 246], ["recovered", "OBSERVATION_MODIFIER", 280, 289], ["individuals", "OBSERVATION", 290, 301], ["global", "OBSERVATION_MODIFIER", 333, 339], ["population", "OBSERVATION", 340, 350]]], ["Hence, ( ) in (1) captures the fraction of impacted individuals worldwide.", [["impacted individuals worldwide", "PROBLEM", 43, 73], ["impacted", "OBSERVATION_MODIFIER", 43, 51], ["individuals", "OBSERVATION", 52, 63]]], ["In Fig. 2a we show the unmitigated ( ) under three different scenarios: extremely contagious, where ( \u2192 \u221e) \u2192 1 (dark red), medium ( ( \u2192 \u221e) \u2248 0.5, red) and mild ( ( \u2192 \u221e) \u2248 0.3, light red).MITIGATION VIA MAXIMUM-FLOWFollowing the initial outbreak at = 0, we define the response time R as the time required to begin the distribution of a therapy.", [["extremely contagious", "PROBLEM", 72, 92], ["medium", "TEST", 123, 129], ["a therapy", "TREATMENT", 333, 342], ["mild", "OBSERVATION_MODIFIER", 155, 159], ["MAXIMUM", "OBSERVATION_MODIFIER", 202, 209]]], ["This therapy can be in the form of a vaccine, designed to prevent the infection of susceptible individuals, or a drug, facilitating the recovery of infected individuals.", [["infection", "DISEASE", 70, 79], ["This therapy", "TREATMENT", 0, 12], ["a vaccine", "TREATMENT", 35, 44], ["the infection of susceptible individuals", "PROBLEM", 66, 106], ["infected individuals", "PROBLEM", 148, 168], ["infection", "OBSERVATION", 70, 79], ["infected", "OBSERVATION", 148, 156]]], ["As we consider a scenario in which the disease is rapidly spreading, and hence many individuals may already be infected, we focus below on the dissemination of drugs, which remain relevant at all stages of the spread 34, 35 .MITIGATION VIA MAXIMUM-FLOWExamining the efficiency of dissemination, rather than production, we assume that the therapeutic is already stockpiled in sufficient quantities at a specific source node .", [["node", "ANATOMY", 418, 422], ["individuals", "ORGANISM", 84, 95], ["node", "MULTI-TISSUE_STRUCTURE", 418, 422], ["the disease", "PROBLEM", 35, 46], ["drugs", "TREATMENT", 160, 165], ["dissemination", "PROBLEM", 280, 293], ["disease", "OBSERVATION", 39, 46], ["rapidly", "OBSERVATION_MODIFIER", 50, 57], ["spreading", "OBSERVATION_MODIFIER", 58, 67], ["infected", "OBSERVATION", 111, 119], ["dissemination", "OBSERVATION", 280, 293], ["node", "OBSERVATION", 418, 422]]], ["Therefore, the main challenge is to optimally distribute it via the air-transportation network to all destinations.", [["main", "OBSERVATION_MODIFIER", 15, 19]]], ["The network is characterized by the carrying capacities that quantify the daily volume of drugs that can be shipped through each air-route \u2192 , i.e. = \u2190 .", [["the carrying capacities", "PROBLEM", 32, 55], ["drugs", "TREATMENT", 90, 95]]], ["The challenge is, therefore, to obtain the optimal shipping sequence from to all other nodes, under the constraints imposed by .MITIGATION VIA MAXIMUM-FLOWMax-flow mitigation (Fig. 2a-c) .", [["the optimal shipping sequence", "TEST", 39, 68], ["MAXIMUM-FLOWMax-flow mitigation", "TREATMENT", 143, 174], ["nodes", "OBSERVATION", 87, 92], ["MAXIMUM", "OBSERVATION_MODIFIER", 143, 150], ["flow mitigation", "OBSERVATION", 159, 174]]], ["In the maximum flow dissemination strategy we seek to maximize the daily volume of drug doses spreading from to the rest of the network.", [["the maximum flow dissemination strategy", "TREATMENT", 3, 42], ["the daily volume of drug doses", "TREATMENT", 63, 93], ["maximum", "OBSERVATION_MODIFIER", 7, 14], ["flow", "OBSERVATION_MODIFIER", 15, 19]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprintMITIGATION VIA MAXIMUM-FLOWcaptures the net daily outflow of drugs from .", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprintMITIGATION", "TREATMENT", 330, 356], ["the net daily outflow of drugs", "TREATMENT", 382, 412], ["med", "ANATOMY", 102, 105]]], ["(2), by maximizing \u2192 ( ), i.e. the outflow from the source, we seek to enhance the total volume of drugs introduced into the network in each day.", [["the total volume of drugs", "TREATMENT", 79, 104], ["outflow", "ANATOMY_MODIFIER", 35, 42]]], ["This maximization is subject to two constraints:MITIGATION VIA MAXIMUM-FLOWThe first constraint (4) ensures that the daily flux along each route \u2192 is within the bounds of the route carrying capacity .", [["the daily flux", "TREATMENT", 113, 127]]], ["The second constraint (5) restricts nodes from accumulating doses in excess of their remaining demand at time .", [["nodes", "MULTI-TISSUE_STRUCTURE", 36, 41], ["restricts nodes", "PROBLEM", 26, 41], ["nodes", "OBSERVATION", 36, 41]]], ["At = 0 we set (0) to be proportional to each node's population , then update these demands daily according to 's supply, as ( + 1) = ( ) \u2212 \u2190 ( ) \u2022 (ii) Impact based.", [["node", "ANATOMY", 45, 49], ["node", "ANATOMY", 45, 49]]], ["Setting (0) according to the projected number of infected individuals at \u2022 (iii) Urgency based.", [["infected individuals", "PROBLEM", 49, 69], ["Urgency", "PROBLEM", 81, 88], ["infected", "OBSERVATION", 49, 57]]], ["Updating ( + 1) dynamically based on 's supply gap at , such that highly impacted (or undersupplied) nodes are prioritized.", [["nodes", "MULTI-TISSUE_STRUCTURE", 101, 106], ["dynamically based on 's supply gap", "PROBLEM", 16, 50], ["highly impacted (or undersupplied) nodes", "PROBLEM", 66, 106], ["highly", "OBSERVATION_MODIFIER", 66, 72], ["impacted", "OBSERVATION_MODIFIER", 73, 81], ["nodes", "OBSERVATION", 101, 106]]], ["While (i) is simplest, it is also inefficient, tending to over-estimate the actual demand at ; (iii), on the other hand, is highly complex, relying on real-time tracking and updating of the demands, but, in some cases, benefits, by design, from a high level of congruency with the spread of the pathogens.", [["the pathogens", "PROBLEM", 291, 304], ["highly", "OBSERVATION_MODIFIER", 124, 130], ["complex", "OBSERVATION", 131, 138]]], ["An expanded discussion of these three strategies appears in Supplementary Section 2.4.MITIGATION VIA MAXIMUM-FLOWNetwork capacity.", [["MAXIMUM-FLOWNetwork capacity", "TEST", 101, 129]]], ["Applying (2) -(5), the maximal dissemination rate one can achieve is restricted by the out-degree of the source node, = \u2211 =1MITIGATION VIA MAXIMUM-FLOW, representing an upper-bound on the volume of drugs that can be introduced into the network per day.", [["the maximal dissemination rate", "TREATMENT", 19, 49], ["the volume of drugs", "TREATMENT", 184, 203], ["node", "OBSERVATION", 112, 116], ["FLOW", "OBSERVATION", 147, 151], ["upper", "ANATOMY_MODIFIER", 169, 174]]], ["We, therefore, define the network's normalized capacity with respect to each source as In Fig. 2b ,c we present the evolution of the epidemic at four selected time-points.", [["the epidemic", "PROBLEM", 129, 141]]], ["At = 0 we simulate an outbreak (red) at Burundi (BJM), emulating the 2013 Ebola, which originated in Africa 36, 37 , then track its spread through air-travel, setting \u211b 0 = 2.", [["Ebola", "DISEASE", 74, 79], ["an outbreak (red) at Burundi (BJM)", "PROBLEM", 19, 53]]], ["The node infection levels and the epidemic fluxes, i.e. the daily volume of infected passengers on each route, are represented by red color depth.", [["node", "ANATOMY", 4, 8], ["infection", "DISEASE", 9, 18], ["node", "MULTI-TISSUE_STRUCTURE", 4, 8], ["The node infection levels", "PROBLEM", 0, 25], ["the epidemic fluxes", "PROBLEM", 30, 49], ["red color depth", "TEST", 130, 145], ["node", "ANATOMY", 4, 8], ["infection", "OBSERVATION", 9, 18], ["epidemic", "OBSERVATION_MODIFIER", 34, 42], ["fluxes", "OBSERVATION_MODIFIER", 43, 49], ["infected", "OBSERVATION", 76, 84], ["red color", "OBSERVATION", 130, 139], ["depth", "OBSERVATION_MODIFIER", 140, 145]]], ["Drug dissemination via max-flow optimization (blue) begins at R = 57 days in Osaka (ITM), using blue color depth to signify the availability/flux of drugs in each node/route.", [["node", "ANATOMY", 163, 167], ["Drug dissemination", "PROBLEM", 0, 18], ["max-flow optimization (blue", "TREATMENT", 23, 50], ["drugs", "TREATMENT", 149, 154], ["flow optimization", "OBSERVATION", 27, 44], ["node", "ANATOMY", 163, 167]]], ["(6) to = 10 \u22122 , a dissemination capability of 1% of the global demand per day, and assign demands ( ) using the impact based strategy.", [["the impact based strategy", "TREATMENT", 109, 134]]], ["We find, through the long-term prevalence of infections (Fig. 2c, red) , that under these conditions, mitigation falls short.", [["infections", "DISEASE", 45, 55], ["infections", "PROBLEM", 45, 55], ["infections", "OBSERVATION", 45, 55]]], ["Indeed, in Fig. 2e -g we observe that the coverage ( ) in (1) is only slightly affected by our max-flow mitigation (red vs. yellow), illustrating the failure to effectively suppress the epidemic.MITIGATION VIA MAXIMUM-FLOW.", [["FLOW", "PROTEIN", 218, 222], ["the failure", "PROBLEM", 146, 157], ["the epidemic", "PROBLEM", 182, 194], ["failure", "OBSERVATION", 150, 157], ["MAXIMUM", "OBSERVATION_MODIFIER", 210, 217], ["FLOW", "OBSERVATION", 218, 222]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintMITIGATION VIA MAXIMUM-FLOWThe copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["For a more systematic assessment of our dissemination strategy, we track the mitigation efficiency via 15MITIGATION VIA MAXIMUM-FLOWwhere \u221e ( ) is the long term coverage, i.e. ( \u2192 \u221e), of the epidemic under mitigation with network capacity = .", [["a more systematic assessment", "TEST", 4, 32], ["our dissemination strategy", "TREATMENT", 36, 62], ["the long term coverage", "TREATMENT", 147, 169]]], ["In case mitigation is effective we expect \u221e ( ) \u226a \u221e (0), a significant reduction in the disease coverage, which translates to \u2192 1.", [["a significant reduction in the disease coverage", "PROBLEM", 57, 104], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["reduction", "OBSERVATION_MODIFIER", 71, 80], ["disease", "OBSERVATION", 88, 95]]], ["Conversely, a failed mitigation leaves infection levels almost unchanged, leading in (7) to \u2192 0.", [["infection", "DISEASE", 39, 48], ["a failed mitigation leaves infection levels", "PROBLEM", 12, 55], ["infection", "OBSERVATION", 39, 48], ["unchanged", "OBSERVATION_MODIFIER", 63, 72]]], ["Testing vs. under maximum flow dissemination, we find that for a broad range of levels the epidemic is almost unaffected, a consistently inefficient mitigation in which \u226a 1 (Fig. 1h, yellow) .", [["Testing", "TEST", 0, 7], ["maximum flow dissemination", "PROBLEM", 18, 44], ["maximum", "OBSERVATION_MODIFIER", 18, 25], ["flow dissemination", "OBSERVATION", 26, 44]]], ["Effective mitigation is only achieved around \u2273 0.1, a limit in which is capable of shipping doses in the order of the entire global demand in few days.", [["shipping doses", "TREATMENT", 83, 97]]], ["Such optimal conditions are not only unlikely, but mainly, they indicate the inefficiency of this dissemination strategy, requiring an extreme volume of therapeutics shipped in a highly constrained timeframe in order to achieve a measurable impact on the epidemic.MITIGATION VIA MAXIMUM-FLOWIt seems, therefore, that the max-flow optimization strategy is inadequate for the containment of a globally spreading epidemic.", [["this dissemination strategy", "PROBLEM", 93, 120], ["an extreme volume of therapeutics", "TREATMENT", 132, 165], ["the max-flow optimization strategy", "TREATMENT", 317, 351], ["a globally spreading epidemic", "PROBLEM", 389, 418], ["not only unlikely", "UNCERTAINTY", 28, 45], ["globally", "OBSERVATION_MODIFIER", 391, 399], ["spreading", "OBSERVATION_MODIFIER", 400, 409], ["epidemic", "OBSERVATION", 410, 418]]], ["In Supplementary Section 2 we analyze the population and urgency based strategies, observing similar challenges.The roots of the max-flow inefficiencyOur mitigation is, in its essence, a spreading competition between the therapeutics and the pathogens, both progressing along the same underlying network, i.e. air-transportation 19 .", [["roots", "ANATOMY", 116, 121], ["roots", "ORGAN", 116, 121], ["the population", "TREATMENT", 38, 52], ["urgency based strategies", "TREATMENT", 57, 81], ["the pathogens", "PROBLEM", 238, 251], ["roots", "ANATOMY_MODIFIER", 116, 121], ["max", "ANATOMY", 129, 132], ["flow inefficiency", "OBSERVATION", 133, 150]]], ["It seems, therefore, that winning this competition is a matter of shipping capacity: we must generate sufficient therapeutic fluxes to outrun the spread of the disease, namely we must increase .", [["the disease", "PROBLEM", 156, 167], ["disease", "OBSERVATION", 160, 167]]], ["However, the analysis above indicates, that there is an intrinsic deficiency in the spread of therapeutics, that cannot be easily compensated by simply increasing shipping rates.", [["the analysis", "TEST", 9, 21], ["an intrinsic deficiency", "PROBLEM", 53, 76], ["simply increasing shipping rates", "PROBLEM", 145, 177], ["intrinsic deficiency", "OBSERVATION", 56, 76], ["increasing", "OBSERVATION_MODIFIER", 152, 162], ["shipping", "OBSERVATION", 163, 171]]], ["Next, we show that the two competing processes -viruses vs. therapeutics -indeed, lead to fundamentally different spreading patterns, in which the viruses benefit from an intrinsic advantage.", [["viruses", "PROBLEM", 48, 55], ["therapeutics", "TREATMENT", 60, 72], ["fundamentally different spreading patterns", "PROBLEM", 90, 132], ["an intrinsic advantage", "TREATMENT", 168, 190], ["viruses", "OBSERVATION", 48, 55], ["spreading", "OBSERVATION_MODIFIER", 114, 123]]], ["Viruses spread via diffusion coupled with local SIR dynamics, as captured by Eqs.", [["Viruses spread via diffusion", "PROBLEM", 0, 28]]], ["(15) in Box I. In this process, upon penetration of node , the viruses reproduce locally through SIR, until reaching peak infection at = P .", [["node", "ANATOMY", 52, 56], ["infection", "DISEASE", 122, 131], ["node", "MULTI-TISSUE_STRUCTURE", 52, 56], ["node", "PROBLEM", 52, 56], ["peak infection", "PROBLEM", 117, 131], ["node", "OBSERVATION", 52, 56], ["infection", "OBSERVATION", 122, 131]]], ["In a network environment, since the majority of nodes are at the mean distance from the initial outbreak, we find that after a limited propagation time, most nodes reach peak infection approximately simultaneously.", [["nodes", "ANATOMY", 48, 53], ["nodes", "ANATOMY", 158, 163], ["infection", "DISEASE", 175, 184], ["nodes", "MULTI-TISSUE_STRUCTURE", 48, 53], ["nodes", "MULTI-TISSUE_STRUCTURE", 158, 163], ["peak infection", "PROBLEM", 170, 184], ["nodes", "OBSERVATION", 48, 53], ["nodes", "OBSERVATION", 158, 163], ["peak", "OBSERVATION_MODIFIER", 170, 174], ["infection", "OBSERVATION", 175, 184]]], ["We track this via the infection ratePropagation of pathogenscapturing the average speed by which the pathogens propagate to .", [["infection", "DISEASE", 22, 31], ["infection", "OBSERVATION", 22, 31]]], ["In Fig. 3c we show ( ), the probability density for a randomly selected node to have \u2208 ( , + d ).", [["node", "ANATOMY", 72, 76], ["node", "MULTI-TISSUE_STRUCTURE", 72, 76], ["a randomly selected node", "PROBLEM", 52, 76], ["node", "OBSERVATION", 72, 76]]], ["Indeed, we find that follows a bounded distribution, where the majority of nodes are infected at a similar rate, and hence their peak infection occurs at roughly at the same time.", [["nodes", "ANATOMY", 75, 80], ["infection", "DISEASE", 134, 143], ["nodes", "MULTI-TISSUE_STRUCTURE", 75, 80], ["nodes", "PROBLEM", 75, 80], ["infected", "PROBLEM", 85, 93], ["their peak infection", "PROBLEM", 123, 143], ["nodes", "OBSERVATION", 75, 80], ["infected", "OBSERVATION", 85, 93], ["peak", "OBSERVATION_MODIFIER", 129, 133], ["infection", "OBSERVATION", 134, 143]]], ["Such uniform propagation patterns lead to a simultaneous global peak infection, and, as a consequence, to a concurrent global demand for therapeutics.", [["infection", "DISEASE", 69, 78], ["a simultaneous global peak infection", "PROBLEM", 42, 78], ["simultaneous", "OBSERVATION_MODIFIER", 44, 56], ["global", "OBSERVATION_MODIFIER", 57, 63], ["peak", "OBSERVATION_MODIFIER", 64, 68], ["infection", "OBSERVATION", 69, 78]]], ["The dynamics of commodity flow, as provided by Eqs.", [["commodity flow", "OBSERVATION", 16, 30]]], ["(2) -(5) are fundamentally different.", [["(2) -(5)", "SIMPLE_CHEMICAL", 0, 8], ["fundamentally different", "OBSERVATION_MODIFIER", 13, 36]]], ["The therapeutics flow from a single source node , and undergo dilution as they disperse across the exponentially growing number of .", [["node", "ANATOMY", 43, 47], ["The therapeutics flow", "TREATMENT", 0, 21], ["a single source node", "TREATMENT", 27, 47], ["dilution", "TREATMENT", 62, 70], ["node", "OBSERVATION", 43, 47], ["exponentially", "OBSERVATION_MODIFIER", 99, 112], ["growing", "OBSERVATION_MODIFIER", 113, 120], ["number", "OBSERVATION_MODIFIER", 121, 127]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDissemination of therapeuticsThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprint pathways 38, 39 .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105], ["therapeutics", "OBSERVATION_MODIFIER", 225, 237]]], ["Such flow patterns naturally lead to a highly heterogeneous supply pattern across all nodes.", [["Such flow patterns", "PROBLEM", 0, 18], ["a highly heterogeneous supply pattern across all nodes", "PROBLEM", 37, 91], ["flow", "OBSERVATION", 5, 9], ["highly", "OBSERVATION_MODIFIER", 39, 45], ["heterogeneous", "OBSERVATION_MODIFIER", 46, 59], ["supply pattern", "OBSERVATION", 60, 74], ["all nodes", "OBSERVATION", 82, 91]]], ["To observe this we consider the therapeutic supply time Th for node to fill its therapeutic demand, and its consequent supply rateDissemination of therapeuticswhere \u0394 = Th \u2212 R , is the elapsed time from initial dissemination ( R ) to 's final supply ( Th ).", [["node", "ANATOMY", 63, 67], ["node", "MULTI-TISSUE_STRUCTURE", 63, 67], ["Th \u2212 R", "GENE_OR_GENE_PRODUCT", 169, 175], ["node", "PROBLEM", 63, 67], ["node", "OBSERVATION", 63, 67]]], ["This rate quantifies how rapidly receives treatment.", [["treatment", "TREATMENT", 42, 51]]], ["Hence, in contrast to the homogeneity of the epidemic spread, supply is extremely heterogeneous, with a vast majority of undersupplied nodes (small , shaded 80%), and a selected privileged minority of well-treated destinations (large ).Dissemination of therapeuticsTogether, this combination of homogeneous demand and heterogeneous supply, a consequence of the naturally occurring spreading patterns of pathogens versus commodities, creates a crucial gap in our ability to effectively mitigate a global pandemic.", [["nodes", "ANATOMY", 135, 140], ["undersupplied nodes", "MULTI-TISSUE_STRUCTURE", 121, 140], ["the epidemic spread", "PROBLEM", 41, 60], ["undersupplied nodes", "PROBLEM", 121, 140], ["homogeneous demand", "PROBLEM", 295, 313], ["pathogens", "PROBLEM", 403, 412], ["a crucial gap", "PROBLEM", 441, 454], ["a global pandemic", "PROBLEM", 494, 511], ["epidemic", "OBSERVATION_MODIFIER", 45, 53], ["spread", "OBSERVATION", 54, 60], ["extremely", "OBSERVATION_MODIFIER", 72, 81], ["heterogeneous", "OBSERVATION_MODIFIER", 82, 95], ["vast", "OBSERVATION_MODIFIER", 104, 108], ["majority", "OBSERVATION_MODIFIER", 109, 117], ["undersupplied", "OBSERVATION_MODIFIER", 121, 134], ["nodes", "OBSERVATION", 135, 140], ["small", "OBSERVATION_MODIFIER", 142, 147], ["large", "OBSERVATION_MODIFIER", 228, 233], ["therapeutics", "OBSERVATION_MODIFIER", 253, 265], ["homogeneous", "OBSERVATION_MODIFIER", 295, 306], ["demand", "OBSERVATION_MODIFIER", 307, 313], ["heterogeneous", "OBSERVATION_MODIFIER", 318, 331], ["supply", "OBSERVATION_MODIFIER", 332, 338], ["pathogens", "OBSERVATION_MODIFIER", 403, 412], ["crucial", "OBSERVATION_MODIFIER", 443, 450], ["gap", "OBSERVATION_MODIFIER", 451, 454], ["global", "OBSERVATION_MODIFIER", 496, 502], ["pandemic", "OBSERVATION", 503, 511]]], ["To understand this, consider ideal flow conditions, where \u2329 \u232a > \u2329 \u232a, namely that, on average, dissemination is more rapid than the viral propagation.", [["the viral propagation", "PROBLEM", 127, 148], ["viral propagation", "OBSERVATION", 131, 148]]], ["Still, the fat-tailed nature of ( ) vs. the bounded form of ( ) indicates that while most nodes have \u2248 \u2329 \u232a, when it comes to supply, the typical node has < \u2329 \u232a.", [["nodes", "ANATOMY", 90, 95], ["node", "ANATOMY", 145, 149], ["node", "MULTI-TISSUE_STRUCTURE", 145, 149], ["nodes", "OBSERVATION", 90, 95], ["typical", "OBSERVATION_MODIFIER", 137, 144], ["node", "OBSERVATION", 145, 149]]], ["Indeed, in a scale-free distribution the majority of entries are below the mean.", [["free", "OBSERVATION_MODIFIER", 19, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36], ["majority", "OBSERVATION_MODIFIER", 41, 49]]], ["This is illustrated in Fig. 3 , where we show that 80% of nodes are within a 20% margin of \u2329 \u232a, i.e. they are all impacted within a narrow time window around the mean (Fig. 3b, shaded) .", [["nodes", "ANATOMY", 58, 63], ["nodes", "MULTI-TISSUE_STRUCTURE", 58, 63], ["nodes", "PROBLEM", 58, 63], ["nodes", "OBSERVATION", 58, 63], ["all", "OBSERVATION_MODIFIER", 110, 113], ["impacted", "OBSERVATION", 114, 122], ["narrow", "OBSERVATION_MODIFIER", 132, 138]]], ["Hence we are confronted with a reality in which almost all nodes require treatment, and yet only a small minority receives sufficient, and at times, even superfluous, supply.Dissemination of therapeuticsThis uneven distribution ( ) directly impacts our mitigation efficiency.", [["nodes", "ANATOMY", 59, 64], ["nodes", "MULTI-TISSUE_STRUCTURE", 59, 64], ["treatment", "TREATMENT", 73, 82], ["nodes", "OBSERVATION", 59, 64], ["small", "OBSERVATION_MODIFIER", 99, 104], ["minority", "OBSERVATION", 105, 113], ["therapeutics", "OBSERVATION_MODIFIER", 191, 203], ["uneven", "OBSERVATION_MODIFIER", 208, 214], ["distribution", "OBSERVATION_MODIFIER", 215, 227], ["mitigation efficiency", "OBSERVATION", 253, 274]]], ["To observe this, consider the local efficiencyDissemination of therapeuticswhere ,\u221e ( ) = ( \u2192 \u221e) under mitigation with capacity = .", [["\u2192 \u221e", "SIMPLE_CHEMICAL", 92, 95], ["the local efficiency", "PROBLEM", 26, 46]]], ["Hence, while in (7) captures the global mitigation efficiency, focuses specifically on the effect observed at .", [["the global mitigation efficiency", "PROBLEM", 29, 61], ["global", "OBSERVATION_MODIFIER", 33, 39], ["mitigation efficiency", "OBSERVATION", 40, 61]]], ["In Fig. 3e we show vs. .", [["vs", "TEST", 19, 21]]], ["As predicted, we observe that is a crucial determinant of mitigation efficiency.", [["mitigation efficiency", "PROBLEM", 58, 79], ["mitigation efficiency", "OBSERVATION", 58, 79]]], ["Indeed, nodes with low (shaded), by far the majority of nodes according to the power-law structure of ( ), exhibit an almost vanishing .", [["nodes", "ANATOMY", 8, 13], ["nodes", "OBSERVATION", 8, 13], ["low", "OBSERVATION_MODIFIER", 19, 22], ["nodes", "OBSERVATION", 56, 61]]], ["This illustrates, once again, the flaw of max-flow: most nodes, the deprived 80%, have \u2192 0, while a small minority benefit from \u2192 1.Dissemination of therapeuticsTaken together, our analysis shows that the common approach of maximizing flow is insufficient, as it treats the mean flow, but not its distribution.", [["nodes", "ANATOMY", 57, 62], ["most nodes", "PROBLEM", 52, 62], ["our analysis", "TEST", 177, 189], ["most nodes", "OBSERVATION", 52, 62], ["small", "OBSERVATION_MODIFIER", 100, 105], ["minority", "OBSERVATION", 106, 114], ["therapeutics", "OBSERVATION_MODIFIER", 149, 161], ["common", "OBSERVATION_MODIFIER", 205, 211], ["maximizing", "OBSERVATION_MODIFIER", 224, 234], ["flow", "OBSERVATION", 235, 239], ["mean flow", "OBSERVATION", 274, 283]]], ["Most essentially, it disregards the interplay with the competing flow of the pathogens.", [["the pathogens", "PROBLEM", 73, 86], ["pathogens", "OBSERVATION", 77, 86]]], ["When confronting these two spreading processes, we observe that the main challenge is rooted in equality ( ( )) rather than in quantity (\u2329 \u232a), namely not the volume of the outflux, \u2192 ( ), but rather the way this volume distributes across the network.", [["main", "OBSERVATION_MODIFIER", 68, 72]]], ["Hence, below we complement our optimization for max-flow with an additional requirement, seeking supply homogeneity.OPTIMIZING FOR HOMOGENEITYEgalitarian mitigation (Fig. 1c) .", [["an additional requirement", "TREATMENT", 62, 87], ["HOMOGENEITYEgalitarian mitigation", "TREATMENT", 131, 164]]], ["(2) -(5) is designed to increase the volume of drugs introduced into the network, but as we have shown, it leads to an extremely sub-.", [["the volume of drugs", "TREATMENT", 33, 52]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintOPTIMIZING FOR HOMOGENEITYThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprint optimal dispersion pattern.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["In addition to constrains (4) and (5) above, we now also requireOPTIMIZING FOR HOMOGENEITYandOPTIMIZING FOR HOMOGENEITYforcing, at each step, to supply, at the least, a fraction ( ) of every node's current demand.", [["node", "ANATOMY", 191, 195], ["node", "MULTI-TISSUE_STRUCTURE", 191, 195], ["HOMOGENEITYandOPTIMIZING", "TREATMENT", 79, 103], ["HOMOGENEITYforcing", "TREATMENT", 108, 126], ["node", "OBSERVATION", 191, 195]]], ["This strategy seeks to maximize flow, but at the same time favors solutions that supply all nodes simultaneously.", [["nodes", "OBSERVATION", 92, 97]]], ["Indeed, constraint (12) prohibits shipping sequences that at any step supply exclusively a subset of the nodes.", [["nodes", "ANATOMY", 105, 110], ["shipping sequences", "DNA", 34, 52], ["shipping sequences", "TEST", 34, 52], ["nodes", "OBSERVATION", 105, 110]]], ["This additional constraint may, in general, lead to a diminished net flow, however, thanks to its egalitarian nature, we find that it dramatically enhances mitigation efficiency.OPTIMIZING FOR HOMOGENEITYTo observe this, we revisit the epidemic spread of Fig. 2 , leaving all conditions unchanged, except that now, instead of the max-flow optimization of (2) -(5) we mitigate the disease via the egalitarian strategy of (11) - (13) .", [["(11) - (13)", "SIMPLE_CHEMICAL", 420, 431], ["a diminished net flow", "PROBLEM", 52, 73], ["the disease", "PROBLEM", 376, 387], ["diminished", "OBSERVATION_MODIFIER", 54, 64], ["net flow", "OBSERVATION", 65, 73], ["mitigation efficiency", "OBSERVATION", 156, 177], ["unchanged", "OBSERVATION_MODIFIER", 287, 296], ["disease", "OBSERVATION", 380, 387]]], ["The results are striking: egalitarian drug dissemination practically eliminates the epidemic, as observed by the dominance of blue nodes/links at > R (Fig. 2d) .", [["blue nodes", "MULTI-TISSUE_STRUCTURE", 126, 136], ["egalitarian drug dissemination", "PROBLEM", 26, 56], ["blue nodes", "PROBLEM", 126, 136], ["blue nodes", "OBSERVATION", 126, 136]]], ["Indeed, compared to the \u223c 30% reduction in ( \u2192 \u221e) afforded by max-flow, egalitarian achieves, under the same capacity , a \u223c 95% reduction, representing a practically perfect mitigation (Fig. 2g) .OPTIMIZING FOR HOMOGENEITYA systematic comparison of the two mitigation strategies consistently supports the crucial role of dissemination homogeneity.", [["a \u223c 95% reduction", "TREATMENT", 120, 137], ["the two mitigation strategies", "TREATMENT", 249, 278], ["dissemination homogeneity", "OBSERVATION", 321, 346]]], ["In Fig. 2h we show the efficiency in (7) vs. under egalitarian dissemination (green).", [["egalitarian dissemination", "OBSERVATION", 51, 76]]], ["We find that approaches 80% already at \u223c 10 \u22123 , representing an extreme case of supply deficiency.", [["supply deficiency", "PROBLEM", 81, 98], ["supply deficiency", "OBSERVATION", 81, 98]]], ["A similar under max-flow was only observed for \u223c 10 \u22121 (yellow), a two order of magnitude advantage for egalitarian.", [["flow", "OBSERVATION", 20, 24]]], ["A crucial factor impacting our mitigation efficiency, is the response time R , required to identify the threat and initiate a response.", [["A crucial factor", "PROBLEM", 0, 16], ["mitigation efficiency", "OBSERVATION", 31, 52]]], ["To observe this, in Fig. 2i we present vs. R for both max-flow (yellow) and egalitarian (green) mitigation.", [["R", "GENE_OR_GENE_PRODUCT", 43, 44], ["egalitarian (green) mitigation", "PROBLEM", 76, 106]]], ["In Fig. 2j we further show that the egalitarian advantage is consistently maintained for a range of contagion levels \u211b 0 .OPTIMIZING FOR HOMOGENEITYHence, examined against a series of potential challenges, from the disease parameters (\u211b 0 ) to the performance level of our response ( R , ), we find that egalitarian allows enhanced mitigation, in some cases, by a dramatic margin.", [["contagion levels", "TEST", 100, 116], ["the disease parameters", "TEST", 211, 233], ["dramatic", "OBSERVATION_MODIFIER", 364, 372], ["margin", "OBSERVATION_MODIFIER", 373, 379]]], ["This, again, is thanks to egalitarian's homogeneous dissemination patterns, which, under the price of a potentially diminished supply rate, afford us a more desirable supply distribution, and consequently, an optimized mitigation.OPTIMIZING FOR HOMOGENEITY.", [["a potentially diminished supply rate", "PROBLEM", 102, 138], ["homogeneous", "OBSERVATION_MODIFIER", 40, 51], ["dissemination", "OBSERVATION", 52, 65], ["diminished", "OBSERVATION", 116, 126]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintOPTIMIZING FOR HOMOGENEITYThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprintThe roots of the egalitarian advantageThe efficiency of egalitarian mitigation may seem, at first glance, implausibly high.", [["roots", "ANATOMY", 375, 380], ["CC", "CHEMICAL", 0, 2], ["roots", "ORGAN", 375, 380], ["medRxiv", "TREATMENT", 355, 362], ["egalitarian mitigation", "TREATMENT", 427, 449], ["med", "ANATOMY", 102, 105], ["roots", "ANATOMY_MODIFIER", 375, 380], ["efficiency", "OBSERVATION_MODIFIER", 413, 423], ["egalitarian mitigation", "OBSERVATION", 427, 449]]], ["This represents an extreme scenario, in which we require an order of 10 3 days to supply the global demand, a time scale that by far exceeds the final spread of the epidemic.", [["a time scale", "TREATMENT", 108, 120], ["extreme", "OBSERVATION_MODIFIER", 19, 26], ["scenario", "OBSERVATION", 27, 35]]], ["Such extraordinary efficiency is rooted in the fact that even a tiny influx of drugs introduced at an early enough stage of the epidemic can dramatically impact its future development.The roots of the egalitarian advantageTo understand this, consider a node at the early stage of the spread, when ( ) \u226a 1.", [["roots", "ANATOMY", 188, 193], ["node", "ANATOMY", 253, 257], ["roots", "ORGAN", 188, 193], ["Such extraordinary efficiency", "PROBLEM", 0, 29], ["a tiny influx of drugs", "PROBLEM", 62, 84], ["a node", "PROBLEM", 251, 257], ["extraordinary", "OBSERVATION_MODIFIER", 5, 18], ["efficiency", "OBSERVATION", 19, 29], ["tiny", "OBSERVATION_MODIFIER", 64, 68], ["influx of drugs", "OBSERVATION", 69, 84], ["roots", "ANATOMY_MODIFIER", 188, 193], ["node", "OBSERVATION", 253, 257]]], ["As time advances, this small seed of infections reproduces until reaches its final infection levels ( \u2192 \u221e).", [["infections", "DISEASE", 37, 47], ["infection", "DISEASE", 83, 92], ["infections", "PROBLEM", 37, 47], ["small", "OBSERVATION_MODIFIER", 23, 28], ["seed", "OBSERVATION_MODIFIER", 29, 33], ["infections", "OBSERVATION", 37, 47], ["infection", "OBSERVATION", 83, 92]]], ["Suppressing this seed when it is small is, therefore, the optimal strategy, allowing us, with a tiny supply of therapeutics, to eliminate not just the current ( ), but also terminate its potential future reproduction.", [["small", "OBSERVATION_MODIFIER", 33, 38], ["tiny", "OBSERVATION_MODIFIER", 96, 100]]], ["Hence, maintaining a continuous influx of therapeutics, even at a very low rate, keeps ( ) subdued, never allowing the local infections to reach their potential coverage.", [["infections", "DISEASE", 125, 135], ["a continuous influx of therapeutics", "TREATMENT", 19, 54], ["the local infections", "PROBLEM", 115, 135], ["infections", "OBSERVATION", 125, 135]]], ["Egalitarian mitigation is precisely designed to provide such supply patterns: instead of rapidly supplying a select group of nodes at a time, it favors a slow influx that is spread evenly across all nodes, starting from the get-go at = R .The roots of the egalitarian advantageIn contrast, max-flow generates a similar (or even higher) total flux, but spreads it out sequentiallyfew nodes receive all their supply early on, and are hence successfully treated, while the majority fill their demand at a much later time, when ( ) is already harder to contain.", [["roots", "ANATOMY", 243, 248], ["sequentiallyfew nodes", "ANATOMY", 367, 388], ["roots", "ORGAN", 243, 248], ["sequentiallyfew nodes", "MULTI-TISSUE_STRUCTURE", 367, 388], ["Egalitarian mitigation", "TREATMENT", 0, 22], ["a slow influx", "PROBLEM", 152, 165], ["sequentiallyfew nodes", "PROBLEM", 367, 388], ["nodes", "OBSERVATION", 125, 130], ["slow", "OBSERVATION_MODIFIER", 154, 158], ["influx", "OBSERVATION", 159, 165], ["nodes", "OBSERVATION", 199, 204], ["nodes", "OBSERVATION", 383, 388]]], ["To observe this, we revisit the simulated mitigation of Fig. 2 , this time focusing on a pair of specific nodes (Fig. 4a) : SDJ which is among the few early supplied nodes ( SDJ = 0.2, red), and CGQ, a typical node, which represents the majority destinations, which receive their supply later on ( CGQ = 3 \u00d7 10 \u22123 , Color).", [["nodes", "ANATOMY", 166, 171], ["node", "ANATOMY", 210, 214], ["nodes", "MULTI-TISSUE_STRUCTURE", 166, 171], ["node", "MULTI-TISSUE_STRUCTURE", 210, 214], ["SDJ", "TEST", 174, 177], ["a typical node", "PROBLEM", 200, 214], ["CGQ", "TEST", 298, 301], ["nodes", "OBSERVATION", 106, 111], ["few", "OBSERVATION_MODIFIER", 147, 150], ["early", "OBSERVATION_MODIFIER", 151, 156], ["nodes", "OBSERVATION", 166, 171], ["typical", "OBSERVATION_MODIFIER", 202, 209], ["node", "OBSERVATION", 210, 214], ["majority", "OBSERVATION_MODIFIER", 237, 245]]], ["In Fig. 4b,c we show the drug availability ( ) in both nodes (blue), together with their unmitigated (red) vs. mitigated (yellow) disease coverage.", [["nodes", "ANATOMY", 55, 60], ["mitigated (yellow) disease coverage", "PROBLEM", 111, 146], ["nodes", "ANATOMY", 55, 60]]], ["Indeed, we find that early supply is crucial, with SDJ benefiting from an almost perfect mitigation, and CGQ being almost unaffected by the late arriving drugs.The roots of the egalitarian advantageUnder egalitarian mitigation the supply pattern is fundamentally different: indeed, as per the equality constraint, both nodes settle for the slower rate SDJ \u2248 CGQ \u2248 10 \u22123 .", [["roots", "ANATOMY", 164, 169], ["CGQ", "SIMPLE_CHEMICAL", 105, 108], ["roots", "ORGAN", 164, 169], ["SDJ", "PROBLEM", 51, 54], ["the slower rate", "TEST", 336, 351], ["roots", "ANATOMY_MODIFIER", 164, 169], ["egalitarian mitigation", "OBSERVATION", 204, 226], ["supply pattern", "OBSERVATION", 231, 245], ["fundamentally", "OBSERVATION_MODIFIER", 249, 262], ["different", "OBSERVATION_MODIFIER", 263, 272], ["nodes", "OBSERVATION", 319, 324]]], ["Hence, egalitarian provides no overall rate advantage, and, in fact, disadvantages the high rate SDJ.", [["the high rate SDJ", "PROBLEM", 83, 100]]], ["However, now, instead of ( ) remaining idle and then, in due time, receiving a sharp supply boost, it is continuously supplied from the outset at R (Fig. 4 d,e) , a direct consequence of the homogeneity constraint of (11) -(13).", [["a sharp supply boost", "TREATMENT", 77, 97], ["the homogeneity constraint", "TEST", 187, 213]]], ["The advantage is that now both SDJ and CGQ receive treatment early on, mitigating the disease while it is still small, and thus suppressing its potential to grow.", [["CGQ", "CHEMICAL", 39, 42], ["SDJ", "CHEMICAL", 31, 34], ["CGQ", "CHEMICAL", 39, 42], ["CGQ", "SIMPLE_CHEMICAL", 39, 42], ["treatment", "TREATMENT", 51, 60], ["the disease", "PROBLEM", 82, 93], ["disease", "OBSERVATION", 86, 93], ["small", "OBSERVATION_MODIFIER", 112, 117]]], ["This is because its simultaneous, even if slow, supply, affords early treatment for all nodes, overcoming ( ) while it is still at its embryonic stage.Mitigation under restricted supplyA crucial implication of the above analysis touches on the global resources required for mitigation 40, 41 .", [["nodes", "ANATOMY", 88, 93], ["embryonic", "ANATOMY", 135, 144], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 135, 144], ["early treatment", "TREATMENT", 64, 79], ["all nodes", "PROBLEM", 84, 93], ["nodes", "OBSERVATION", 88, 93]]], ["Clearly, running the max-flow/egalitarian algorithm until all demands are filled will inevitably cost a total of \u223c \u03a9 drug units, supplied at a time-scale of \u223c \u03a9/ days.", [["the max-flow/egalitarian algorithm", "TREATMENT", 17, 51], ["drug units", "TREATMENT", 117, 127]]], ["However, since egalitarian begins supplying all nodes while ( ) is still small, it has the potential to overcome the pandemic even before all initial demands (0) are completely satiated.", [["nodes", "ANATOMY", 48, 53], ["all", "OBSERVATION_MODIFIER", 44, 47], ["nodes", "OBSERVATION", 48, 53], ["small", "OBSERVATION_MODIFIER", 73, 78]]], ["We then measured the efficiency (7), in function of the total resource consumption .", [["efficiency", "OBSERVATION_MODIFIER", 21, 31]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprint(which was not certified by peer review) preprintEquation (14) quantifies the total outflux of therapeutics from as a fraction of the global demand \u03a9, throughout the mitigation period, = 0 to .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105], ["global demand", "OBSERVATION", 478, 491]]], ["The greater is ( ), the more therapeutic resources that are consumed.", [["greater", "OBSERVATION_MODIFIER", 4, 11]]], ["As predicted we find in Fig. 4g that egalitarian, not only provides a higher mitigation efficiency, but achieves this in a fraction of the resources.", [["a higher mitigation efficiency", "PROBLEM", 68, 98]]], ["For max-flow (green) we observe a linear gain with , reaching peak efficiency only around \u2192 1, i.e. when supply fills all demands.", [["a linear gain", "PROBLEM", 32, 45], ["peak efficiency", "OBSERVATION", 62, 77]]], ["Egalitarian, in contrast, thanks to its simultaneous treatment of all nodes, suppresses the epidemic at an early stage, when it is still manageable, with limited supply, therefore enabling mitigation of above 90% (grey dashed line) with total consumption as low as \u223c 0.1, i.e. a mere 10% of the global demand.DISCUSSIONCommodity flow problems are at the heart of many crucial applications, from communications to supply chains, seeking to optimize a network's capacity to distribute information or goods [20] [21] [22] [23] [24] [25] [42] [43] [44] .DISCUSSIONMost often the target optimization function, e.g., max-flow, arises naturally from the purpose of the distribution.", [["nodes", "ANATOMY", 70, 75], ["heart", "ANATOMY", 354, 359], ["[20] [21] [22] [23] [24] [25] [42] [43] [44]", "CHEMICAL", 504, 548], ["heart", "ORGAN", 354, 359], ["[21] [22] [23] [24] [25] [42] [43] [44]", "SIMPLE_CHEMICAL", 509, 548], ["all nodes", "PROBLEM", 66, 75], ["grey dashed line", "TREATMENT", 214, 230], ["total consumption", "TEST", 237, 254], ["flow problems", "PROBLEM", 329, 342], ["nodes", "OBSERVATION", 70, 75], ["early stage", "OBSERVATION_MODIFIER", 107, 118], ["heart", "ANATOMY", 354, 359]]], ["However, in the context of disease mitigation, the optimization is a consequence not just of the dissemination scheme, but also of its interplay with the viral spread.", [["disease mitigation", "PROBLEM", 27, 45], ["the dissemination scheme", "PROBLEM", 93, 117], ["the viral spread", "PROBLEM", 150, 166], ["disease", "OBSERVATION", 27, 34], ["viral spread", "OBSERVATION", 154, 166]]], ["Indeed, our true goal is not just distribution efficiency in and of itself, but rather mitigation efficiency.", [["mitigation efficiency", "OBSERVATION", 87, 108]]], ["Hence, to assess a dissemination protocol we must couple it with the spread of the epidemic, and observe its effectiveness in terms of the actual observed reduction in infection levels.", [["infection", "DISEASE", 168, 177], ["a dissemination protocol", "TREATMENT", 17, 41], ["infection levels", "PROBLEM", 168, 184], ["infection", "OBSERVATION", 168, 177]]], ["Here we have shown that the na\u00efve approach of maximizing the commodity flow fails this test, indeed, providing rapid supply, but at the same time a highly inefficient mitigation.", [["this test", "TEST", 82, 91]]], ["On the other hand -optimizing for homogeneity dramatically improves mitigation efficiency.DISCUSSIONOur findings are relevant in case the epidemic spreads globally -a scenario averted in many recent pandemics, but experienced quite severely during COVID-19.", [["COVID", "TEST", 248, 253], ["mitigation efficiency", "OBSERVATION", 68, 89], ["pandemics", "OBSERVATION", 199, 208]]], ["In such scenario, the peak infection occurs approximately simultaneously at logarithmic time-scales, due to the short network paths 27, 45 .", [["infection", "DISEASE", 27, 36], ["the peak infection", "PROBLEM", 18, 36], ["peak", "OBSERVATION_MODIFIER", 22, 26], ["infection", "OBSERVATION", 27, 36]]], ["Our egalitarian protocol, by spreading simultaneously, albeit slowly, to all nodes outlines the most effective strategy, catching the disease at its early stage in all locations.", [["Our egalitarian protocol", "TREATMENT", 0, 24], ["catching the disease", "PROBLEM", 121, 141], ["nodes", "OBSERVATION", 77, 82], ["disease", "OBSERVATION", 134, 141], ["early stage", "OBSERVATION_MODIFIER", 149, 160]]], ["Otherwise, social distancing measures must be employed to delay the viral spread and keep it at manageable levels until egalitarian dissemination can be instigated [46] [47] [48] [49] [50] [51] [52] .DISCUSSIONIn this regard, the recent successes in epidemic forecasting 53 are key: first, predict whether the pathogens will spread globally, then instigate egalitarian dissemination.", [["[46] [47] [48] [49] [50] [51]", "CHEMICAL", 164, 193], ["[46] [47] [48] [49] [50] [51", "SIMPLE_CHEMICAL", 164, 192], ["the viral spread", "PROBLEM", 64, 80], ["the pathogens", "PROBLEM", 306, 319], ["egalitarian dissemination", "PROBLEM", 357, 382]]], ["Of course, a false alarm might result in a waste of resources, however our analysis indicates that early intervention allows mitigation with relatively small amount of doses, hence we believe that the potential gain by far outweighs the risk.DISCUSSIONBattling a global spread, it is crucial to appropriately set the demands ( ), which determine how much supply will be shipped to each node.", [["node", "ANATOMY", 386, 390], ["node", "MULTI-TISSUE_STRUCTURE", 386, 390], ["a false alarm", "PROBLEM", 11, 24], ["our analysis", "TEST", 71, 83], ["early intervention", "TREATMENT", 99, 117], ["a global spread", "PROBLEM", 261, 276], ["global", "OBSERVATION_MODIFIER", 263, 269], ["spread", "OBSERVATION", 270, 276], ["node", "OBSERVATION", 386, 390]]], ["On the side of caution, the natural tendency is to overestimate these demands, i.e. generate redundancy.", [["caution", "TREATMENT", 15, 22], ["redundancy", "OBSERVATION", 93, 103]]], ["However, in the face of a virulent epidemic, where the distribution network is stretched to its maximal capacity, such strategy may over-allocate resources to some destinations, while depriving others.", [["a virulent epidemic", "PROBLEM", 24, 43], ["virulent", "OBSERVATION_MODIFIER", 26, 34], ["epidemic", "OBSERVATION", 35, 43]]], ["On the other hand, fine-tuning the demands to meet the exact supply gap of each node, as we do, for example in our urgency-based strategy, is highly complex, not always practical, and, if inaccurate, may lead to undersupply in some destinations.", [["node", "ANATOMY", 80, 84], ["node", "MULTI-TISSUE_STRUCTURE", 80, 84], ["node", "OBSERVATION", 80, 84]]], ["Our egalitarian optimization addresses this trade-off quite naturally, by simultaneously supplying all nodes.", [["nodes", "OBSERVATION", 103, 108]]], ["To understand this consider two nodes and .", [["nodes", "OBSERVATION", 32, 37]]], ["Under max-flow, supply will be .", [["flow", "OBSERVATION", 10, 14]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprint typically sequential, e.g., and then .", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 328, 335], ["med", "ANATOMY", 102, 105]]], ["Under these conditions, overestimating ( ) will lead to the shipment of more drugs to , thus wrongly delaying the treatment of .", [["the treatment", "TREATMENT", 110, 123]]], ["In contrast, such discrepancy under egalitarian, will have no bearing on , as both nodes are simultaneously supplied from the start.", [["nodes", "ANATOMY", 83, 88], ["nodes", "MULTI-TISSUE_STRUCTURE", 83, 88], ["nodes", "OBSERVATION", 83, 88]]], ["This makes egalitarian highly robust against the specific assignment of ( ), allowing us to design a simple dissemination protocol, free of the need to accurately tailor and fine-tune all demands.(which was not certified by peer review) preprintOur analysis focuses solely on the mitigation efficiency, yet its conclusions touch upon the ethics of resource allocation -here, prioritizing the even distribution of drugs in a global emergency.", [["a simple dissemination protocol", "TREATMENT", 99, 130], ["Our analysis", "TEST", 245, 257]]], ["While often one is confronted with a clash of values in such cases, here we find it encouraging that efficiency and equality are, in fact, compatible -representing a case in which scientific results go hand in hand with moral directives.(which was not certified by peer review) preprintAuthor contribution.", [["hand", "ANATOMY", 202, 206], ["hand", "ANATOMY", 210, 214], ["hand", "ORGANISM_SUBDIVISION", 202, 206], ["hand", "ORGANISM_SUBDIVISION", 210, 214]]], ["AH analyzed the data and conducted the numerical simulations, AH, BB and RC lead the analytical derivations, and IB and SE advised on the biological applicability.", [["SE", "DISEASE", 120, 122], ["the data", "TEST", 12, 20], ["the numerical simulations", "TEST", 35, 60], ["AH", "PROBLEM", 62, 64], ["BB", "TREATMENT", 66, 68], ["RC lead", "TREATMENT", 73, 80]]], ["BB was the lead writer.Competing interests.", [["BB", "MULTI-TISSUE_STRUCTURE", 0, 2]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprintBox I. Modeling the mitigation of a global epidemicIn a network of coupled nodes = 1, \u2026 , , each with a population of individuals, we use the SIR model to track the fraction of who are susceptible ( ), infected ( ) or removed ( ), where the infected are divided as = T + U , among the treated (T) individuals, who have been provided a therapeutic and the untreated (U) individuals, who have not yet gained access to it.", [["CC", "CHEMICAL", 0, 2], ["T + U", "GENE_OR_GENE_PRODUCT", 611, 616], ["coupled nodes", "PROBLEM", 411, 424], ["the SIR model", "TREATMENT", 482, 495], ["med", "ANATOMY", 102, 105], ["nodes", "OBSERVATION", 419, 424], ["infected", "OBSERVATION_MODIFIER", 546, 554], ["infected", "OBSERVATION", 585, 593]]], ["Sec.", [["Sec", "CHEMICAL", 0, 3]]], ["1)Box I. Modeling the mitigation of a global epidemicwhere is the infection rate, is the mortality/recovery rate of the untreated individuals and > is the recovery rate under treatment.", [["infection", "DISEASE", 66, 75], ["a global epidemicwhere", "PROBLEM", 36, 58], ["the infection rate", "PROBLEM", 62, 80], ["treatment", "TREATMENT", 175, 184], ["global", "OBSERVATION_MODIFIER", 38, 44], ["epidemicwhere", "OBSERVATION", 45, 58], ["infection", "OBSERVATION", 66, 75]]], ["The epidemic reproduction number \u211b 0 = / captures the level of contagion of the (untreated) disease.", [["the (untreated) disease", "PROBLEM", 76, 99], ["epidemic", "OBSERVATION_MODIFIER", 4, 12]]], ["The therapeutic consumption rate ( ) depends on the availability of the therapeutic ( ) in , asBox I. Modeling the mitigation of a global epidemicHence ( ) increases linearly with ( ) as long as the demand (denominator) exceeds the supply, and saturates to unity when has excess quantities of the therapeutic, avoiding over consumption (Supp.", [["excess quantities", "PROBLEM", 272, 289], ["Supp", "TREATMENT", 337, 341]]], ["Sec.", [["Sec", "CHEMICAL", 0, 3]]], ["(3), or egalitarian flow, as in Eq.", [["egalitarian flow", "TEST", 8, 24], ["egalitarian flow", "OBSERVATION", 8, 24]]], ["(11) .Box I. Modeling the mitigation of a global epidemicIn (15) we introduce an invasion threshold through the sigmoidal functionBox I. Modeling the mitigation of a global epidemicwhich activates the local SIR dynamics only when the local infection levels = U + T exceed .", [["infection", "DISEASE", 240, 249], ["U + T", "GENE_OR_GENE_PRODUCT", 259, 264], ["a global epidemicIn", "TREATMENT", 40, 59], ["an invasion threshold", "TREATMENT", 78, 99], ["the local infection levels", "PROBLEM", 230, 256], ["invasion", "OBSERVATION", 81, 89], ["infection", "OBSERVATION", 240, 249]]], ["The diffusion of individuals between nodes is mediated by , derived from the empirical international air-travel network (Supp.", [["nodes", "ANATOMY", 37, 42], ["nodes", "MULTI-TISSUE_STRUCTURE", 37, 42], ["air-travel network", "MULTI-TISSUE_STRUCTURE", 101, 119], ["nodes", "OBSERVATION", 37, 42]]], ["Sec.", [["Sec", "CHEMICAL", 0, 3]]], ["2.1).Box I. Modeling the mitigation of a global epidemic.", [["a global epidemic", "PROBLEM", 39, 56], ["global", "OBSERVATION_MODIFIER", 41, 47], ["epidemic", "OBSERVATION", 48, 56]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. , and hence the rates by which all nodes are supplied.", [["nodes", "ANATOMY", 194, 199], ["CC", "CHEMICAL", 0, 2], ["nodes", "MULTI-TISSUE_STRUCTURE", 194, 199], ["med", "ANATOMY", 102, 105], ["nodes", "OBSERVATION", 194, 199]]], ["Under max-flow the goal is to achieve the highest net outflow of commodities from , i.e. maximize \u2192 ( ).", [["the highest net outflow of commodities", "TREATMENT", 38, 76]]], ["Here, nodes were supplies within two days, a net flow \u2192 (1) = 9 in day 1 and \u2192 ( ) = 8, in day 2. (b) During an epidemic, however, the goal is to achieve optimal mitigation, not just optimal commodity flow.", [["nodes", "ANATOMY", 6, 11], ["a net flow \u2192", "TEST", 43, 55], ["nodes", "OBSERVATION", 6, 11]]], ["This requires us to consider the interplay between our dissemination and the spread of the epidemic.", [["epidemic", "OBSERVATION_MODIFIER", 91, 99]]], ["Each node's demand is determined by its infection levels ( ( ), red), leading us to seek the shipping sequence which best adresses the anticiated spread of infections -aiming for supply ( ( ), blue) that is most compatible with demand. (c) We find that the optimal strategy is to design an egalitarian flow, in which supply is homogeneously spread across all destinations.", [["node", "ANATOMY", 5, 9], ["infection", "DISEASE", 40, 49], ["infections", "DISEASE", 156, 166], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["Each node's demand", "PROBLEM", 0, 18], ["its infection levels", "PROBLEM", 36, 56], ["the shipping sequence", "TEST", 89, 110], ["infections", "PROBLEM", 156, 166], ["an egalitarian flow", "TEST", 287, 306], ["node", "OBSERVATION", 5, 9], ["infection", "OBSERVATION", 40, 49], ["infections", "OBSERVATION", 156, 166], ["most compatible with", "UNCERTAINTY", 207, 227], ["egalitarian", "OBSERVATION_MODIFIER", 290, 301], ["flow", "OBSERVATION", 302, 306], ["homogeneously", "OBSERVATION_MODIFIER", 327, 340], ["spread", "OBSERVATION_MODIFIER", 341, 347]]], ["Using the same network as in (a), our egalitarian strategy yields an even shipping sequence, in which nodes are supplied concurrently at roughly equal rates.", [["nodes", "ANATOMY", 102, 107], ["nodes", "MULTI-TISSUE_STRUCTURE", 102, 107], ["nodes", "OBSERVATION", 102, 107]]], ["For example, instead of fully supplying node in = 1 and only then shipping to at = 2, as done under max-flow in panel (a), our egalitarian algorithm favors the shipping sequence where and are simulataneasly supplied at equal rates.", [["node", "ANATOMY", 40, 44], ["shipping sequence", "DNA", 160, 177], ["fully supplying node", "PROBLEM", 24, 44], ["our egalitarian algorithm", "TEST", 123, 148], ["node", "OBSERVATION", 40, 44]]], ["Under global demand, we show, such egalitarian supply is orders of magnitude more effective in terms of mitigation and resource disposal.Box I. Modeling the mitigation of a global epidemic.", [["resource disposal", "TREATMENT", 119, 136], ["a global epidemic", "PROBLEM", 171, 188], ["global demand", "OBSERVATION", 6, 19], ["global", "OBSERVATION_MODIFIER", 173, 179], ["epidemic", "OBSERVATION", 180, 188]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintBox I. Modeling the mitigation of a global epidemicThe copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105], ["global", "OBSERVATION_MODIFIER", 244, 250], ["epidemic", "OBSERVATION_MODIFIER", 251, 259]]], ["The bounded form of ( ) indicates the homogeneous nature of the pathogen spread.", [["the pathogen spread", "PROBLEM", 60, 79], ["homogeneous", "OBSERVATION_MODIFIER", 38, 49], ["pathogen spread", "OBSERVATION", 64, 79]]], ["Indeed, we find that 80% of the nodes are impacted wthin a small margin around the average (shaded area). (c) Using max-flow we track the availability of the therapeutics ( ) at all destinations (node size/blue color depth).", [["nodes", "ANATOMY", 32, 37], ["node", "ANATOMY", 196, 200], ["nodes", "MULTI-TISSUE_STRUCTURE", 32, 37], ["node", "MULTI-TISSUE_STRUCTURE", 196, 200], ["the therapeutics", "TREATMENT", 154, 170], ["nodes", "OBSERVATION", 32, 37], ["impacted", "OBSERVATION_MODIFIER", 42, 50], ["small", "OBSERVATION_MODIFIER", 59, 64], ["margin", "OBSERVATION_MODIFIER", 65, 71], ["average", "OBSERVATION_MODIFIER", 83, 90], ["shaded", "OBSERVATION_MODIFIER", 92, 98], ["area", "OBSERVATION_MODIFIER", 99, 103], ["node", "ANATOMY", 196, 200], ["size", "OBSERVATION_MODIFIER", 201, 205], ["blue color", "OBSERVATION", 206, 216]]], ["In contrast to the pathogens, the therapeutics naturally spread extremely unevenly, with a small minority of early supplied nodes (large, dark blue), coexisting alogside a majority of delayed destinations (small, light blue). (d) The supply rate distribution ( ) as obtained via maxflow (circles).", [["nodes", "ANATOMY", 124, 129], ["nodes", "MULTI-TISSUE_STRUCTURE", 124, 129], ["early supplied nodes (large, dark blue", "PROBLEM", 109, 147], ["delayed destinations (small, light blue)", "PROBLEM", 184, 224], ["pathogens", "OBSERVATION", 19, 28], ["small", "OBSERVATION_MODIFIER", 91, 96], ["minority", "OBSERVATION_MODIFIER", 97, 105], ["early", "OBSERVATION_MODIFIER", 109, 114], ["supplied", "OBSERVATION_MODIFIER", 115, 123], ["nodes", "OBSERVATION", 124, 129], ["large", "OBSERVATION_MODIFIER", 131, 136], ["dark blue", "OBSERVATION_MODIFIER", 138, 147], ["majority", "OBSERVATION_MODIFIER", 172, 180], ["delayed", "OBSERVATION_MODIFIER", 184, 191], ["small", "OBSERVATION_MODIFIER", 206, 211]]], ["This captures an extremely heterogeneous dissemination pattern, in which 80% of the nodes are supplied at a below average rate (shaded area).", [["nodes", "ANATOMY", 84, 89], ["nodes", "MULTI-TISSUE_STRUCTURE", 84, 89], ["an extremely heterogeneous dissemination pattern", "PROBLEM", 14, 62], ["extremely", "OBSERVATION_MODIFIER", 17, 26], ["heterogeneous", "OBSERVATION_MODIFIER", 27, 40], ["dissemination", "OBSERVATION", 41, 54], ["nodes", "OBSERVATION", 84, 89]]], ["Hence, max-flow confronts a homogeneous demand ( ( ), red) with an extremely uneven supply ( ( ), blue). (e) The local efficiency vs. supply rate as obtained via max-flow dissemination.", [["The local efficiency", "PROBLEM", 109, 129], ["supply rate", "TEST", 134, 145], ["flow dissemination", "OBSERVATION", 166, 184]]], ["Therefore, the fat-tailed nature of ( ), in which the majority of nodes have a small (80%, shaded) creates an intrinsic mitigation defficiency, in which most destinations experience insufficient supply.", [["nodes", "ANATOMY", 66, 71], ["nodes", "MULTI-TISSUE_STRUCTURE", 66, 71], ["an intrinsic mitigation defficiency", "PROBLEM", 107, 142], ["majority", "OBSERVATION_MODIFIER", 54, 62], ["nodes", "OBSERVATION", 66, 71], ["small", "OBSERVATION_MODIFIER", 79, 84], ["intrinsic mitigation defficiency", "OBSERVATION", 110, 142]]], ["Rather, is is rooted in the patterns of spread of the existing supply, which are fundamentally incongruent with those of the pathogens.Box I. Modeling the mitigation of a global epidemic.", [["the pathogens", "PROBLEM", 121, 134], ["a global epidemic", "PROBLEM", 169, 186], ["rooted", "OBSERVATION_MODIFIER", 14, 20], ["pathogens", "OBSERVATION", 125, 134], ["global", "OBSERVATION_MODIFIER", 171, 177], ["epidemic", "OBSERVATION", 178, 186]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ( ) vs. at CGQ (blue) as obtained under max-flow dissemination.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105], ["flow dissemination", "OBSERVATION", 203, 221]]], ["Due to the sequential nature of this dissemination scheme, the therapeutic reaches CGQ too late, and consequently its infection level ( ) remains high, both without (red) and under the effect of max-flow mitigation (yellow). (c) In contrast, SDJ is among the first to fill its demand, hence the sharp rise in ( ) at an early stage (blue).", [["infection", "DISEASE", 118, 127], ["this dissemination scheme", "PROBLEM", 32, 57], ["its infection level", "PROBLEM", 114, 133], ["the sharp rise", "PROBLEM", 291, 305], ["infection", "OBSERVATION", 118, 127], ["sharp", "OBSERVATION_MODIFIER", 295, 300], ["rise", "OBSERVATION_MODIFIER", 301, 305]]], ["As a result this node benefits from highly efficienct mitigation, with ( \u2192 \u221e) reduced dramatically from 80% (unmitigated, red) to a mere 15% (mitigated, yellow).", [["node", "ANATOMY", 17, 21], ["node", "MULTI-TISSUE_STRUCTURE", 17, 21], ["node", "OBSERVATION", 17, 21], ["reduced", "OBSERVATION_MODIFIER", 78, 85], ["dramatically", "OBSERVATION_MODIFIER", 86, 98]]], ["The challenge is that while CGQ is representative of the majority of destinations, the highly benefited SDJ belongs to a select minoroty under the max-flow framework. (d)-(e) Egalitarian generates a homogeneous supply pattern, hence now both CGQ and SDJ share a similar (low) supply rate of \u223c 10 \u22123 .", [["CGQ", "CHEMICAL", 242, 245], ["(d)-(e) Egalitarian", "CHEMICAL", 167, 186], ["SDJ", "CANCER", 104, 107], ["SDJ", "SIMPLE_CHEMICAL", 250, 253], ["homogeneous", "OBSERVATION_MODIFIER", 199, 210], ["supply pattern", "OBSERVATION", 211, 225]]], ["Despite that they both benefit from a near perfect mitigation (unmitigated -red; mitigated -green).", [["red", "PROBLEM", 76, 79]]], ["Indeed, even SDJ, who is now, under egalitarian, experiencing a dramtic drop in its supply rate, from 0.2 to 10 \u22123 , continues to benefit from highly efficient mitigation.", [["a dramtic drop", "PROBLEM", 62, 76]]], ["Hence, the simulataneous, albeit uniformly slow, treatment afforded via egalitarian, not only benefits the max-flow deprived majority, but also continues to effectively treat its superflous minority. (f) The global consumption ( ) vs. , approaching unity, i.e. all demands are filled, when \u2192 \u221e. (g) Global mitigation efficiency vs. the volume of disseminated therapeutics .", [["Global mitigation efficiency", "PROBLEM", 299, 327], ["disseminated therapeutics", "TREATMENT", 346, 371], ["disseminated", "OBSERVATION", 346, 358]]], ["In contrast, egalitarian has \u223c 1 already at \u223c 0.1, achieving, thanks to its concurrent supply patterns, an almost perfect mitigation with only 10% of the resources.Box I. Modeling the mitigation of a global epidemic.", [["a global epidemic", "PROBLEM", 198, 215], ["global", "OBSERVATION_MODIFIER", 200, 206], ["epidemic", "OBSERVATION", 207, 215]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintBox I. Modeling the mitigation of a global epidemicThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprintFIGURES -FULL SIZE.", [["CC", "CHEMICAL", 0, 2], ["FULL SIZE", "DNA", 405, 414], ["med", "ANATOMY", 102, 105], ["global", "OBSERVATION_MODIFIER", 244, 250], ["epidemic", "OBSERVATION_MODIFIER", 251, 259], ["FULL SIZE", "OBSERVATION_MODIFIER", 405, 414]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintFIGURES -FULL SIZEThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194506 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 347, 354], ["med", "ANATOMY", 102, 105]]]], "16b2a1456de279536882b5a220f7de14c2e17366": [["IntroductionAngiotensin (Ang)-converting enzyme 2 (ACE2) has been implicated in a number of physiologic and patho-physiologic processes.", [["IntroductionAngiotensin", "CHEMICAL", 0, 23], ["Ang", "CHEMICAL", 25, 28], ["IntroductionAngiotensin (Ang)-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 0, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["IntroductionAngiotensin (Ang)-converting enzyme 2", "PROTEIN", 0, 49], ["ACE2", "PROTEIN", 51, 55], ["IntroductionAngiotensin (Ang)", "TREATMENT", 0, 29], ["physiologic processes", "OBSERVATION", 114, 135]]], ["It is a novel homologue of ACE and a component of the counterregulatory axis of ACE.", [["ACE", "GENE_OR_GENE_PRODUCT", 27, 30], ["ACE", "GENE_OR_GENE_PRODUCT", 80, 83], ["ACE", "PROTEIN", 27, 30], ["ACE", "PROTEIN", 80, 83], ["ACE", "TREATMENT", 27, 30], ["ACE", "TREATMENT", 80, 83]]], ["It is a monocarboxypeptidase, and it generates Ang-(1-7), another component of the renin-angiotensin system (RAS), which attenuates the vasoconstrictive, proliferative, fibrotic, and inflammatory effects of Ang II [1] .", [["Ang-(1-7)", "CHEMICAL", 47, 56], ["angiotensin", "CHEMICAL", 89, 100], ["Ang II", "CHEMICAL", 207, 213], ["monocarboxypeptidase", "GENE_OR_GENE_PRODUCT", 8, 28], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 47, 55], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 83, 107], ["RAS", "GENE_OR_GENE_PRODUCT", 109, 112], ["Ang II", "GENE_OR_GENE_PRODUCT", 207, 213], ["renin", "PROTEIN", 83, 88], ["the renin-angiotensin system", "TREATMENT", 79, 107], ["the vasoconstrictive, proliferative, fibrotic", "PROBLEM", 132, 177], ["vasoconstrictive", "OBSERVATION_MODIFIER", 136, 152], ["proliferative", "OBSERVATION_MODIFIER", 154, 167], ["fibrotic", "OBSERVATION_MODIFIER", 169, 177], ["inflammatory", "OBSERVATION_MODIFIER", 183, 195]]], ["ACE2 cleaves a single residue from its substrate, Ang I, generating Ang-(1-9) and a single residue from another preferred substrate, Ang II, to generate Ang- (1) (2) (3) (4) (5) (6) (7) .", [["Ang", "CHEMICAL", 50, 53], ["Ang-(1-9", "CHEMICAL", 68, 76], ["Ang II", "CHEMICAL", 133, 139], ["Ang", "CHEMICAL", 153, 156], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang I", "GENE_OR_GENE_PRODUCT", 50, 55], ["Ang II", "GENE_OR_GENE_PRODUCT", 133, 139], ["Ang- (1) (2) (3) (4) (5) (6) (7)", "SIMPLE_CHEMICAL", 153, 185], ["ACE2", "PROTEIN", 0, 4], ["Ang I", "PROTEIN", 50, 55], ["Ang II", "PROTEIN", 133, 139], ["ACE2", "TREATMENT", 0, 4], ["a single residue", "PROBLEM", 13, 29], ["Ang", "TEST", 68, 71], ["a single residue", "PROBLEM", 82, 98]]], ["ACE2 also cleaves other peptide substrates such as des-arg-bradykinin, neurotensin, and kinetensin.", [["bradykinin", "CHEMICAL", 59, 69], ["neurotensin", "CHEMICAL", 71, 82], ["kinetensin", "CHEMICAL", 88, 98], ["bradykinin", "CHEMICAL", 59, 69], ["neurotensin", "CHEMICAL", 71, 82], ["kinetensin", "CHEMICAL", 88, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["des-arg-bradykinin", "GENE_OR_GENE_PRODUCT", 51, 69], ["neurotensin", "GENE_OR_GENE_PRODUCT", 71, 82], ["kinetensin", "SIMPLE_CHEMICAL", 88, 98], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["other peptide substrates", "TREATMENT", 18, 42], ["des-arg-bradykinin", "TREATMENT", 51, 69], ["neurotensin", "TREATMENT", 71, 82], ["kinetensin", "TREATMENT", 88, 98]]], ["ACE2 plays a pertinent role in the vasoprotective axis of the RAS, ACE2-Ang-(1-7)-Mas, as it counterbalances the vasoconstrictive, proliferative, and fibrotic actions of the ACE-Ang II-Ang II type 1 receptor (AT 1 R) axis [2\u2022\u2022] .IntroductionACE2 is abundantly expressed in many cell types in the lung, such as Clara cells, type I and II alveolar epithelial cells, macrophages, endothelium, smooth muscle cells (SMCs) of blood vessels, and bronchial epithelia [3] .", [["cell", "ANATOMY", 278, 282], ["lung", "ANATOMY", 296, 300], ["Clara cells", "ANATOMY", 310, 321], ["alveolar epithelial cells", "ANATOMY", 337, 362], ["macrophages", "ANATOMY", 364, 375], ["endothelium", "ANATOMY", 377, 388], ["smooth muscle cells", "ANATOMY", 390, 409], ["SMCs", "ANATOMY", 411, 415], ["blood vessels", "ANATOMY", 420, 433], ["bronchial epithelia", "ANATOMY", 439, 458], ["Ang", "CHEMICAL", 72, 75], ["Ang II", "CHEMICAL", 178, 184], ["Ang II", "CHEMICAL", 185, 191], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAS", "GENE_OR_GENE_PRODUCT", 62, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["Ang-(1-7)-Mas", "GENE_OR_GENE_PRODUCT", 72, 85], ["ACE-Ang II-Ang II type 1 receptor", "GENE_OR_GENE_PRODUCT", 174, 207], ["AT 1 R", "GENE_OR_GENE_PRODUCT", 209, 215], ["IntroductionACE2", "GENE_OR_GENE_PRODUCT", 229, 245], ["cell", "CELL", 278, 282], ["lung", "ORGAN", 296, 300], ["Clara cells", "CELL", 310, 321], ["type I", "GENE_OR_GENE_PRODUCT", 323, 329], ["alveolar epithelial cells", "CELL", 337, 362], ["macrophages", "CELL", 364, 375], ["endothelium", "CELL", 377, 388], ["smooth muscle cells", "CELL", 390, 409], ["SMCs", "CELL", 411, 415], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 420, 433], ["bronchial epithelia", "TISSUE", 439, 458], ["ACE2", "PROTEIN", 0, 4], ["RAS", "PROTEIN", 62, 65], ["ACE2", "PROTEIN", 67, 71], ["ACE", "PROTEIN", 174, 177], ["Ang II", "PROTEIN", 178, 184], ["Ang II type 1 receptor", "PROTEIN", 185, 207], ["IntroductionACE2", "PROTEIN", 229, 245], ["Clara cells", "CELL_TYPE", 310, 321], ["type I and II alveolar epithelial cells", "CELL_TYPE", 323, 362], ["macrophages", "CELL_TYPE", 364, 375], ["smooth muscle cells", "CELL_TYPE", 390, 409], ["SMCs", "CELL_TYPE", 411, 415], ["ACE2", "TEST", 67, 71], ["Ang", "TEST", 72, 75], ["the ACE", "TEST", 170, 177], ["Clara cells", "PROBLEM", 310, 321], ["type I and II alveolar epithelial cells", "PROBLEM", 323, 362], ["macrophages", "PROBLEM", 364, 375], ["bronchial epithelia", "PROBLEM", 439, 458], ["vasoconstrictive", "OBSERVATION", 113, 129], ["fibrotic", "OBSERVATION", 150, 158], ["many cell types", "OBSERVATION", 273, 288], ["lung", "ANATOMY", 296, 300], ["Clara cells", "OBSERVATION", 310, 321], ["alveolar", "ANATOMY_MODIFIER", 337, 345], ["epithelial cells", "OBSERVATION", 346, 362], ["macrophages", "OBSERVATION", 364, 375], ["endothelium", "ANATOMY_MODIFIER", 377, 388], ["smooth muscle cells", "OBSERVATION", 390, 409], ["blood vessels", "ANATOMY", 420, 433], ["bronchial", "ANATOMY", 439, 448], ["epithelia", "ANATOMY_MODIFIER", 449, 458]]], ["Because the RAS components are widely expressed in the lung, the activation of pulmonary ACE2 could influence the pathogenesis of lung injury and serve as a novel therapeutic target in pulmonary arterial hypertension (PAH).IntroductionPAH is a chronic disease of diverse etiology.", [["lung", "ANATOMY", 55, 59], ["pulmonary", "ANATOMY", 79, 88], ["lung", "ANATOMY", 130, 134], ["pulmonary arterial", "ANATOMY", 185, 203], ["lung injury", "DISEASE", 130, 141], ["pulmonary arterial hypertension", "DISEASE", 185, 216], ["PAH", "DISEASE", 218, 221], ["IntroductionPAH", "DISEASE", 223, 238], ["RAS", "GENE_OR_GENE_PRODUCT", 12, 15], ["lung", "ORGAN", 55, 59], ["pulmonary", "ORGAN", 79, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["lung", "ORGAN", 130, 134], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 185, 203], ["RAS components", "PROTEIN", 12, 26], ["pulmonary ACE2", "PROTEIN", 79, 93], ["the RAS components", "PROBLEM", 8, 26], ["pulmonary ACE2", "PROBLEM", 79, 93], ["lung injury", "PROBLEM", 130, 141], ["pulmonary arterial hypertension", "PROBLEM", 185, 216], ["a chronic disease", "PROBLEM", 242, 259], ["widely", "OBSERVATION_MODIFIER", 31, 37], ["lung", "ANATOMY", 55, 59], ["pulmonary ACE2", "ANATOMY", 79, 93], ["lung", "ANATOMY", 130, 134], ["injury", "OBSERVATION", 135, 141], ["pulmonary arterial", "ANATOMY", 185, 203], ["hypertension", "OBSERVATION", 204, 216], ["chronic", "OBSERVATION_MODIFIER", 244, 251], ["disease", "OBSERVATION", 252, 259], ["diverse", "OBSERVATION_MODIFIER", 263, 270]]], ["Although targeted treatment, pleiotropic drug approaches, and novel progenitor-cell therapy provide symptomatic relief and prolong survival, PAH remains a fatal disease with no cure.", [["progenitor-cell", "ANATOMY", 68, 83], ["PAH", "CHEMICAL", 141, 144], ["PAH", "CHEMICAL", 141, 144], ["progenitor-cell", "CELL", 68, 83], ["targeted treatment", "TREATMENT", 9, 27], ["pleiotropic drug approaches", "TREATMENT", 29, 56], ["novel progenitor-cell therapy", "TREATMENT", 62, 91], ["symptomatic relief", "TREATMENT", 100, 118], ["prolong survival", "TREATMENT", 123, 139], ["a fatal disease", "PROBLEM", 153, 168], ["fatal disease", "OBSERVATION", 155, 168]]], ["Without proper therapy, chronic vasoconstriction, inflammation, and in situ thrombosis promote increased pulmonary vascular remodeling (PVR).", [["pulmonary vascular", "ANATOMY", 105, 123], ["inflammation", "DISEASE", 50, 62], ["thrombosis", "DISEASE", 76, 86], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 105, 123], ["proper therapy", "TREATMENT", 8, 22], ["chronic vasoconstriction", "PROBLEM", 24, 48], ["inflammation", "PROBLEM", 50, 62], ["situ thrombosis", "PROBLEM", 71, 86], ["increased pulmonary vascular remodeling", "PROBLEM", 95, 134], ["therapy", "OBSERVATION", 15, 22], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["vasoconstriction", "OBSERVATION", 32, 48], ["inflammation", "OBSERVATION", 50, 62], ["situ", "OBSERVATION_MODIFIER", 71, 75], ["thrombosis", "OBSERVATION", 76, 86], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["pulmonary vascular", "ANATOMY", 105, 123], ["remodeling", "OBSERVATION", 124, 134], ["PVR", "OBSERVATION", 136, 139]]], ["Clinically, PAH is characterized by increased mean pulmonary arterial pressure (>25 mm Hg at rest) and persistent elevation of pulmonary vascular resistance, which leads to the main cause of death in these patients, right-sided heart failure [4] .IntroductionPAH can be heritable, and predisposing genetic and environmental risk factors may lead to an imbalance in counterregulatory mechanisms associated with pulmonary vascular remodeling, such as vasoconstriction/vasodilatation, proliferation/antiproliferation, and prothrombogenics/ antithrombogenics.", [["pulmonary arterial", "ANATOMY", 51, 69], ["pulmonary vascular", "ANATOMY", 127, 145], ["heart", "ANATOMY", 228, 233], ["pulmonary vascular", "ANATOMY", 410, 428], ["PAH", "CHEMICAL", 12, 15], ["death", "DISEASE", 191, 196], ["heart failure", "DISEASE", 228, 241], ["IntroductionPAH", "CHEMICAL", 247, 262], ["PAH", "CHEMICAL", 12, 15], ["Hg", "CHEMICAL", 87, 89], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 51, 69], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 127, 145], ["patients", "ORGANISM", 206, 214], ["heart", "ORGAN", 228, 233], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 410, 428], ["patients", "SPECIES", 206, 214], ["increased mean pulmonary arterial pressure", "PROBLEM", 36, 78], ["persistent elevation of pulmonary vascular resistance", "PROBLEM", 103, 156], ["death", "PROBLEM", 191, 196], ["right-sided heart failure", "PROBLEM", 216, 241], ["IntroductionPAH", "TREATMENT", 247, 262], ["predisposing genetic and environmental risk factors", "PROBLEM", 285, 336], ["an imbalance in counterregulatory mechanisms", "PROBLEM", 349, 393], ["pulmonary vascular remodeling", "PROBLEM", 410, 439], ["vasoconstriction", "PROBLEM", 449, 465], ["vasodilatation", "PROBLEM", 466, 480], ["proliferation", "PROBLEM", 482, 495], ["antiproliferation", "TREATMENT", 496, 513], ["prothrombogenics", "TREATMENT", 519, 535], ["antithrombogenics", "TREATMENT", 537, 554], ["PAH", "OBSERVATION", 12, 15], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["mean", "OBSERVATION_MODIFIER", 46, 50], ["pulmonary arterial", "ANATOMY", 51, 69], ["pressure", "OBSERVATION_MODIFIER", 70, 78], ["persistent", "OBSERVATION_MODIFIER", 103, 113], ["elevation", "OBSERVATION_MODIFIER", 114, 123], ["pulmonary vascular", "ANATOMY", 127, 145], ["resistance", "OBSERVATION", 146, 156], ["main", "OBSERVATION_MODIFIER", 177, 181], ["death", "OBSERVATION", 191, 196], ["right", "ANATOMY_MODIFIER", 216, 221], ["sided", "ANATOMY_MODIFIER", 222, 227], ["heart", "ANATOMY", 228, 233], ["failure", "OBSERVATION", 234, 241], ["pulmonary", "ANATOMY_MODIFIER", 410, 419], ["vascular", "ANATOMY", 420, 428], ["remodeling", "OBSERVATION", 429, 439]]], ["These imbalances initiate a cascade of pathophysiologic events in the lungs leading to PAH [5\u2022\u2022] ; the exact pathogenesis of the disease is still unknown.", [["lungs", "ANATOMY", 70, 75], ["PAH", "CHEMICAL", 87, 90], ["PAH", "CHEMICAL", 87, 90], ["lungs", "ORGAN", 70, 75], ["PAH", "SIMPLE_CHEMICAL", 87, 90], ["pathophysiologic events in the lungs", "PROBLEM", 39, 75], ["PAH", "PROBLEM", 87, 90], ["the disease", "PROBLEM", 125, 136], ["lungs", "ANATOMY", 70, 75], ["PAH", "OBSERVATION", 87, 90], ["disease", "OBSERVATION", 129, 136]]], ["Based upon the concept of homeostatic imbalance and multifactorial pathobiology, the mainstay of PAH treatment includes vasodilators, anticoagulants, calcium channel blockers, and endothelin receptor antagonists.IntroductionThe renin-angiotensin system (RAS) is a well-recognized player in endothelial dysfunction and vascular remodeling, but the precise involvement of this system's members in the lung pathophysiology of PAH remains elusive.", [["endothelial", "ANATOMY", 290, 301], ["vascular", "ANATOMY", 318, 326], ["lung", "ANATOMY", 399, 403], ["PAH", "CHEMICAL", 97, 100], ["calcium", "CHEMICAL", 150, 157], ["PAH", "DISEASE", 423, 426], ["PAH", "CHEMICAL", 97, 100], ["calcium", "CHEMICAL", 150, 157], ["PAH", "CHEMICAL", 423, 426], ["PAH", "SIMPLE_CHEMICAL", 97, 100], ["calcium channel blockers", "SIMPLE_CHEMICAL", 150, 174], ["endothelin receptor antagonists", "GENE_OR_GENE_PRODUCT", 180, 211], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 228, 252], ["RAS", "GENE_OR_GENE_PRODUCT", 254, 257], ["endothelial", "CELL", 290, 301], ["vascular", "MULTI-TISSUE_STRUCTURE", 318, 326], ["lung", "ORGAN", 399, 403], ["PAH", "SIMPLE_CHEMICAL", 423, 426], ["homeostatic imbalance", "PROBLEM", 26, 47], ["PAH treatment", "TREATMENT", 97, 110], ["vasodilators", "TREATMENT", 120, 132], ["anticoagulants", "TREATMENT", 134, 148], ["calcium channel blockers", "TREATMENT", 150, 174], ["endothelin receptor antagonists", "TREATMENT", 180, 211], ["The renin-angiotensin system", "TREATMENT", 224, 252], ["endothelial dysfunction", "PROBLEM", 290, 313], ["vascular remodeling", "PROBLEM", 318, 337], ["PAH", "PROBLEM", 423, 426], ["homeostatic imbalance", "OBSERVATION", 26, 47], ["PAH", "OBSERVATION", 97, 100], ["endothelial", "ANATOMY", 290, 301], ["dysfunction", "OBSERVATION", 302, 313], ["vascular", "ANATOMY", 318, 326], ["remodeling", "OBSERVATION", 327, 337], ["lung", "ANATOMY", 399, 403], ["PAH", "OBSERVATION", 423, 426]]], ["Thus, the discovery of ACE2 and the emerging counterregulatory concept of RAS is of great significance [4] .", [["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["RAS", "GENE_OR_GENE_PRODUCT", 74, 77], ["ACE2", "PROTEIN", 23, 27], ["RAS", "PROTEIN", 74, 77], ["ACE2", "PROBLEM", 23, 27]]], ["The ACE-Ang II-AT 1 R axis promotes vasoconstriction, proliferation, and fibrosis, whereas the ACE2-Ang-(1-7)-Mas axis protects lungs.", [["lungs", "ANATOMY", 128, 133], ["Ang", "CHEMICAL", 8, 11], ["fibrosis", "DISEASE", 73, 81], ["Ang-(1-7)", "CHEMICAL", 100, 109], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 4, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 100, 108], ["Mas", "GENE_OR_GENE_PRODUCT", 110, 113], ["lungs", "ORGAN", 128, 133], ["ACE", "PROTEIN", 4, 7], ["Ang II", "PROTEIN", 8, 14], ["ACE2", "PROTEIN", 95, 99], ["The ACE", "TEST", 0, 7], ["vasoconstriction", "PROBLEM", 36, 52], ["proliferation", "PROBLEM", 54, 67], ["fibrosis", "PROBLEM", 73, 81], ["the ACE2", "TEST", 91, 99], ["Ang", "TEST", 100, 103], ["vasoconstriction", "OBSERVATION", 36, 52], ["proliferation", "OBSERVATION", 54, 67], ["fibrosis", "OBSERVATION", 73, 81], ["lungs", "ANATOMY", 128, 133]]], ["The ACE2-Ang-(1-7)-Mas axis intrinsically induces vasoprotective actions by counterregulating the ACE-Ang II-AT 1 R axis.", [["Ang", "CHEMICAL", 9, 12], ["Ang", "CHEMICAL", 102, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 9, 17], ["Mas", "GENE_OR_GENE_PRODUCT", 19, 22], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 98, 115], ["ACE2", "PROTEIN", 4, 8], ["ACE", "PROTEIN", 98, 101], ["Ang II", "PROTEIN", 102, 108], ["The ACE2", "TEST", 0, 8], ["Ang", "TEST", 9, 12], ["vasoprotective actions", "TREATMENT", 50, 72], ["the ACE", "TEST", 94, 101]]], ["This review focuses on the vasoprotective axis of the RAS as a potential target for therapeutic intervention in PAH.", [["PAH", "DISEASE", 112, 115], ["PAH", "CHEMICAL", 112, 115], ["RAS", "GENE_OR_GENE_PRODUCT", 54, 57], ["PAH", "SIMPLE_CHEMICAL", 112, 115], ["therapeutic intervention", "TREATMENT", 84, 108], ["PAH", "PROBLEM", 112, 115], ["PAH", "OBSERVATION", 112, 115]]], ["A conceptual breakthrough is urgently needed to develop a novel strategy for therapeutic intervention and management of PAH.", [["PAH", "DISEASE", 120, 123], ["PAH", "CHEMICAL", 120, 123], ["PAH", "SIMPLE_CHEMICAL", 120, 123], ["A conceptual breakthrough", "PROBLEM", 0, 25], ["a novel strategy", "TREATMENT", 56, 72], ["therapeutic intervention", "TREATMENT", 77, 101], ["management", "TREATMENT", 106, 116], ["PAH", "PROBLEM", 120, 123], ["PAH", "OBSERVATION", 120, 123]]], ["Research establishing a role for ACE2 in lung pathophysiology is emerging.The Role of the RAS in Pulmonary Arterial HypertensionPAH is a chronic disease of diverse etiology, clinically characterized by increased pulmonary vascular resistance.", [["lung", "ANATOMY", 41, 45], ["Pulmonary Arterial", "ANATOMY", 97, 115], ["pulmonary vascular", "ANATOMY", 212, 230], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["lung", "ORGAN", 41, 45], ["Pulmonary Arterial", "MULTI-TISSUE_STRUCTURE", 97, 115], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 212, 230], ["ACE2", "PROTEIN", 33, 37], ["RAS", "PROTEIN", 90, 93], ["ACE2 in lung pathophysiology", "PROBLEM", 33, 61], ["a chronic disease", "PROBLEM", 135, 152], ["increased pulmonary vascular resistance", "PROBLEM", 202, 241], ["lung", "ANATOMY", 41, 45], ["RAS", "OBSERVATION", 90, 93], ["Pulmonary Arterial", "ANATOMY", 97, 115], ["chronic", "OBSERVATION_MODIFIER", 137, 144], ["disease", "OBSERVATION", 145, 152], ["diverse", "OBSERVATION_MODIFIER", 156, 163], ["increased", "OBSERVATION_MODIFIER", 202, 211], ["pulmonary vascular", "ANATOMY", 212, 230], ["resistance", "OBSERVATION", 231, 241]]], ["Table 1 outlines the current classification of all forms of pulmonary hypertension (PH) [6\u2022\u2022] .", [["pulmonary", "ANATOMY", 60, 69], ["pulmonary hypertension", "DISEASE", 60, 82], ["PH", "DISEASE", 84, 86], ["pulmonary", "ORGAN", 60, 69], ["pulmonary hypertension", "PROBLEM", 60, 82], ["pulmonary", "ANATOMY", 60, 69], ["hypertension", "OBSERVATION", 70, 82]]], ["Genetic mutations influence PAH development, and in the year 2000, mutations of the gene encoding bone morphogenetic protein receptor type II (BMPR-II), a transforming growth factor (TGF)-\u03b2 superfamily receptor, were identified as the primary genetic mutation in some patients with PAH [7] .The Role of the RAS in Pulmonary Arterial HypertensionPAH patients are often characterized by remodeling of small distal pulmonary arteries resulting in medial hypertrophy, intimal proliferation, adventitial thickening with moderate inflammatory infiltrates, plexiform lesions, and thrombotic lesions.", [["Pulmonary Arterial", "ANATOMY", 314, 332], ["distal pulmonary arteries", "ANATOMY", 405, 430], ["medial", "ANATOMY", 444, 450], ["intimal", "ANATOMY", 464, 471], ["adventitial", "ANATOMY", 487, 498], ["plexiform lesions", "ANATOMY", 550, 567], ["thrombotic lesions", "ANATOMY", 573, 591], ["PAH", "CHEMICAL", 28, 31], ["PAH", "CHEMICAL", 282, 285], ["hypertrophy", "DISEASE", 451, 462], ["plexiform lesions", "DISEASE", 550, 567], ["thrombotic lesions", "DISEASE", 573, 591], ["PAH", "CHEMICAL", 28, 31], ["PAH", "CHEMICAL", 282, 285], ["PAH", "PATHOLOGICAL_FORMATION", 28, 31], ["bone morphogenetic protein receptor type II", "GENE_OR_GENE_PRODUCT", 98, 141], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 143, 150], ["transforming growth factor (TGF)-\u03b2", "GENE_OR_GENE_PRODUCT", 155, 189], ["patients", "ORGANISM", 268, 276], ["RAS", "GENE_OR_GENE_PRODUCT", 307, 310], ["patients", "ORGANISM", 349, 357], ["pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 412, 430], ["intimal", "TISSUE", 464, 471], ["adventitial", "TISSUE", 487, 498], ["plexiform lesions", "PATHOLOGICAL_FORMATION", 550, 567], ["thrombotic lesions", "PATHOLOGICAL_FORMATION", 573, 591], ["bone morphogenetic protein receptor type II (BMPR-II", "PROTEIN", 98, 150], ["transforming growth factor (TGF)-\u03b2 superfamily receptor", "PROTEIN", 155, 210], ["RAS", "PROTEIN", 307, 310], ["patients", "SPECIES", 268, 276], ["patients", "SPECIES", 349, 357], ["Genetic mutations", "PROBLEM", 0, 17], ["a transforming growth factor", "PROBLEM", 153, 181], ["the primary genetic mutation", "PROBLEM", 231, 259], ["remodeling of small distal pulmonary arteries", "PROBLEM", 385, 430], ["medial hypertrophy", "PROBLEM", 444, 462], ["intimal proliferation", "PROBLEM", 464, 485], ["adventitial thickening", "PROBLEM", 487, 509], ["moderate inflammatory infiltrates", "PROBLEM", 515, 548], ["plexiform lesions", "PROBLEM", 550, 567], ["thrombotic lesions", "PROBLEM", 573, 591], ["bone", "ANATOMY", 98, 102], ["RAS", "OBSERVATION", 307, 310], ["Pulmonary Arterial", "ANATOMY", 314, 332], ["remodeling", "OBSERVATION", 385, 395], ["small", "OBSERVATION_MODIFIER", 399, 404], ["distal", "ANATOMY_MODIFIER", 405, 411], ["pulmonary arteries", "ANATOMY", 412, 430], ["medial", "ANATOMY_MODIFIER", 444, 450], ["hypertrophy", "OBSERVATION", 451, 462], ["intimal", "OBSERVATION_MODIFIER", 464, 471], ["proliferation", "OBSERVATION_MODIFIER", 472, 485], ["adventitial", "OBSERVATION_MODIFIER", 487, 498], ["thickening", "OBSERVATION", 499, 509], ["moderate", "OBSERVATION_MODIFIER", 515, 523], ["inflammatory", "OBSERVATION_MODIFIER", 524, 536], ["infiltrates", "OBSERVATION", 537, 548], ["plexiform", "OBSERVATION_MODIFIER", 550, 559], ["lesions", "OBSERVATION", 560, 567], ["thrombotic", "OBSERVATION_MODIFIER", 573, 583], ["lesions", "OBSERVATION", 584, 591]]], ["This remodeling causes increased pulmonary vascular resistance resulting in a mean pulmonary arterial pressure greater than 25 mm Hg at rest.", [["pulmonary vascular", "ANATOMY", 33, 51], ["pulmonary arterial", "ANATOMY", 83, 101], ["Hg", "CHEMICAL", 130, 132], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 33, 51], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 83, 101], ["increased pulmonary vascular resistance", "PROBLEM", 23, 62], ["a mean pulmonary arterial pressure", "TEST", 76, 110], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["pulmonary vascular", "ANATOMY", 33, 51], ["resistance", "OBSERVATION", 52, 62], ["pulmonary arterial", "ANATOMY", 83, 101], ["pressure", "OBSERVATION_MODIFIER", 102, 110]]], ["Persistent elevation of pulmonary vascular resistance leads to right heart failure and death [6\u2022\u2022] .", [["pulmonary vascular", "ANATOMY", 24, 42], ["right heart", "ANATOMY", 63, 74], ["heart failure", "DISEASE", 69, 82], ["death", "DISEASE", 87, 92], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 24, 42], ["heart", "ORGAN", 69, 74], ["Persistent elevation of pulmonary vascular resistance", "PROBLEM", 0, 53], ["right heart failure", "PROBLEM", 63, 82], ["death", "PROBLEM", 87, 92], ["elevation", "OBSERVATION", 11, 20], ["pulmonary vascular", "ANATOMY", 24, 42], ["resistance", "OBSERVATION", 43, 53], ["right", "ANATOMY_MODIFIER", 63, 68], ["heart", "ANATOMY", 69, 74], ["failure", "OBSERVATION", 75, 82]]], ["PAH is a consequence of vascular effector imbalance, perturbations in the homeostasis of vasoconstrictors and vasodilators, growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic factors [8] .", [["vascular", "ANATOMY", 24, 32], ["PAH", "CHEMICAL", 0, 3], ["PAH", "CHEMICAL", 0, 3], ["PAH", "SIMPLE_CHEMICAL", 0, 3], ["vascular", "MULTI-TISSUE_STRUCTURE", 24, 32], ["mitogenic factors", "PROTEIN", 146, 163], ["prothrombotic factors", "PROTEIN", 188, 209], ["vascular effector imbalance", "PROBLEM", 24, 51], ["vasoconstrictors", "TREATMENT", 89, 105], ["vasodilators", "TREATMENT", 110, 122], ["growth inhibitors", "TREATMENT", 124, 141], ["mitogenic factors", "PROBLEM", 146, 163], ["antithrombotic and prothrombotic factors", "PROBLEM", 169, 209], ["vascular", "ANATOMY", 24, 32], ["effector imbalance", "OBSERVATION", 33, 51]]], ["As a result of these findings, vasodilator, anticoagulant, antiplatelet, anti-inflammatory, and vascular remodeling therapies have been used for PAH treatment.", [["vascular", "ANATOMY", 96, 104], ["PAH", "CHEMICAL", 145, 148], ["PAH", "CHEMICAL", 145, 148], ["vascular", "MULTI-TISSUE_STRUCTURE", 96, 104], ["PAH", "SIMPLE_CHEMICAL", 145, 148], ["vasodilator", "TREATMENT", 31, 42], ["anticoagulant", "TREATMENT", 44, 57], ["antiplatelet", "TREATMENT", 59, 71], ["anti-inflammatory", "TREATMENT", 73, 90], ["vascular remodeling therapies", "TREATMENT", 96, 125], ["PAH treatment", "TREATMENT", 145, 158], ["vascular", "ANATOMY", 96, 104]]], ["Before current intervention strategies, life expectancy for adults with idiopathic PAH was less than 3 years from diagnosis; for children, it was less than 10 months [9] .", [["idiopathic PAH", "DISEASE", 72, 86], ["PAH", "CHEMICAL", 83, 86], ["children", "ORGANISM", 129, 137], ["children", "SPECIES", 129, 137], ["current intervention strategies", "TREATMENT", 7, 38], ["idiopathic PAH", "PROBLEM", 72, 86]]], ["There are complex strategies for treating PAH patients that include both supportive and specific drug therapy.", [["PAH", "DISEASE", 42, 45], ["PAH", "CHEMICAL", 42, 45], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["treating PAH patients", "TREATMENT", 33, 54], ["specific drug therapy", "TREATMENT", 88, 109], ["complex", "OBSERVATION_MODIFIER", 10, 17]]], ["Specific drug therapy often falls into three categories: vasodilators, calcium channel blockers, and endothelin receptor antagonists.", [["calcium", "CHEMICAL", 71, 78], ["calcium", "CHEMICAL", 71, 78], ["calcium channel blockers", "SIMPLE_CHEMICAL", 71, 95], ["endothelin receptor antagonists", "GENE_OR_GENE_PRODUCT", 101, 132], ["Specific drug therapy", "TREATMENT", 0, 21], ["vasodilators", "TREATMENT", 57, 69], ["calcium channel blockers", "TREATMENT", 71, 95], ["endothelin receptor antagonists", "TREATMENT", 101, 132]]], ["The latest clinical trials have strategically targeted remodeling, including the testing of antiproliferative drugs in advanced human PAH.The Role of the RAS in Pulmonary Arterial HypertensionBoth clinical and animal data suggest that intervention strategies that attenuate the actions of the ACE-Ang II-AT 1 R axis (i.e., angiotensin receptor blockers and/or ACE inhibitor therapy) and activate the ACE2-Ang-(1-7)-Mas axis (i.e., ACE2 activation or ACE2 viral transfer) are effective in attenuating and preventing maladaptive vascular remodeling associated with PAH.", [["Pulmonary Arterial", "ANATOMY", 161, 179], ["vascular", "ANATOMY", 527, 535], ["PAH", "DISEASE", 134, 137], ["Ang II", "CHEMICAL", 297, 303], ["angiotensin", "CHEMICAL", 323, 334], ["ACE inhibitor", "CHEMICAL", 360, 373], ["Ang", "CHEMICAL", 405, 408], ["PAH", "CHEMICAL", 563, 566], ["PAH", "CHEMICAL", 134, 137], ["PAH", "CHEMICAL", 563, 566], ["human", "ORGANISM", 128, 133], ["PAH", "CANCER", 134, 137], ["Pulmonary Arterial", "MULTI-TISSUE_STRUCTURE", 161, 179], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 293, 310], ["angiotensin receptor blockers", "GENE_OR_GENE_PRODUCT", 323, 352], ["ACE", "GENE_OR_GENE_PRODUCT", 360, 363], ["ACE2", "GENE_OR_GENE_PRODUCT", 400, 404], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 405, 413], ["Mas", "GENE_OR_GENE_PRODUCT", 415, 418], ["ACE2", "GENE_OR_GENE_PRODUCT", 431, 435], ["ACE2", "GENE_OR_GENE_PRODUCT", 450, 454], ["vascular", "MULTI-TISSUE_STRUCTURE", 527, 535], ["PAH", "SIMPLE_CHEMICAL", 563, 566], ["ACE2", "PROTEIN", 400, 404], ["ACE2", "PROTEIN", 431, 435], ["ACE2", "PROTEIN", 450, 454], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["antiproliferative drugs", "TREATMENT", 92, 115], ["advanced human PAH", "PROBLEM", 119, 137], ["intervention strategies", "TREATMENT", 235, 258], ["the ACE-Ang II", "TREATMENT", 289, 303], ["angiotensin receptor blockers", "TREATMENT", 323, 352], ["ACE inhibitor therapy", "TREATMENT", 360, 381], ["the ACE2", "TEST", 396, 404], ["Ang", "TEST", 405, 408], ["ACE2 activation", "TREATMENT", 431, 446], ["ACE2 viral transfer", "TREATMENT", 450, 469], ["maladaptive vascular remodeling", "PROBLEM", 515, 546], ["PAH", "PROBLEM", 563, 566], ["PAH", "OBSERVATION", 134, 137], ["Pulmonary Arterial", "ANATOMY", 161, 179], ["vascular", "ANATOMY", 527, 535], ["PAH", "OBSERVATION", 563, 566]]], ["Because limiting AngII bioactivity remains the cornerstone of cardiovascular therapeutics, it is plausible that the same approach may be valid in pulmonary diseases [10] .", [["cardiovascular", "ANATOMY", 62, 76], ["pulmonary", "ANATOMY", 146, 155], ["AngII", "CHEMICAL", 17, 22], ["pulmonary diseases", "DISEASE", 146, 164], ["AngII", "GENE_OR_GENE_PRODUCT", 17, 22], ["cardiovascular", "ANATOMICAL_SYSTEM", 62, 76], ["pulmonary", "ORGAN", 146, 155], ["cardiovascular therapeutics", "TREATMENT", 62, 89], ["pulmonary diseases", "PROBLEM", 146, 164], ["pulmonary", "ANATOMY", 146, 155], ["diseases", "OBSERVATION", 156, 164]]], ["Pulmonary vascular fibrosis, hypertrophy, and vascular smooth muscle migration are regressed with ACE2.", [["Pulmonary vascular", "ANATOMY", 0, 18], ["vascular smooth muscle", "ANATOMY", 46, 68], ["fibrosis", "DISEASE", 19, 27], ["hypertrophy", "DISEASE", 29, 40], ["Pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 0, 18], ["vascular smooth muscle", "TISSUE", 46, 68], ["ACE2", "GENE_OR_GENE_PRODUCT", 98, 102], ["ACE2", "PROTEIN", 98, 102], ["Pulmonary vascular fibrosis", "PROBLEM", 0, 27], ["hypertrophy", "PROBLEM", 29, 40], ["vascular smooth muscle migration", "PROBLEM", 46, 78], ["ACE2", "PROBLEM", 98, 102], ["vascular", "ANATOMY", 10, 18], ["fibrosis", "OBSERVATION", 19, 27], ["hypertrophy", "OBSERVATION", 29, 40], ["vascular", "ANATOMY", 46, 54], ["smooth muscle migration", "OBSERVATION", 55, 78]]], ["Thus, its discovery and role in lung pathophysiology are of great importance.ACE2 and Its Role in Lung DiseasesACE2 was initially discovered as a receptor for severe acute respiratory syndrome (SARS) coronavirus and because of its sequence homology to ACE, the research community began to determine its localization and study its role in most model systems.", [["lung", "ANATOMY", 32, 36], ["Lung", "ANATOMY", 98, 102], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 166, 211], ["lung", "ORGAN", 32, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["Its", "GENE_OR_GENE_PRODUCT", 86, 89], ["Lung DiseasesACE2", "CANCER", 98, 115], ["ACE", "GENE_OR_GENE_PRODUCT", 252, 255], ["ACE2", "PROTEIN", 77, 81], ["Its", "PROTEIN", 86, 89], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 159, 211], ["ACE2", "TREATMENT", 77, 81], ["severe acute respiratory syndrome", "PROBLEM", 159, 192], ["SARS) coronavirus", "PROBLEM", 194, 211], ["lung", "ANATOMY", 32, 36], ["Lung", "ANATOMY", 98, 102], ["DiseasesACE2", "OBSERVATION", 103, 115], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["respiratory syndrome", "OBSERVATION", 172, 192]]], ["It is a type I transmembrane protein, which contains a single metalloproteinase active site [3] .", [["type I transmembrane protein", "PROTEIN", 8, 36], ["metalloproteinase active site", "PROTEIN", 62, 91], ["a type I transmembrane protein", "PROBLEM", 6, 36], ["a single metalloproteinase active site", "TREATMENT", 53, 91]]], ["ACE2 has been localized to human heart, kidney, coronary arteries, arterioles, vasa vasorum, testis, gastrointestinal tract, and lung.", [["heart", "ANATOMY", 33, 38], ["kidney", "ANATOMY", 40, 46], ["coronary arteries", "ANATOMY", 48, 65], ["arterioles", "ANATOMY", 67, 77], ["vasa vasorum", "ANATOMY", 79, 91], ["testis", "ANATOMY", 93, 99], ["gastrointestinal tract", "ANATOMY", 101, 123], ["lung", "ANATOMY", 129, 133], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 27, 32], ["heart", "ORGAN", 33, 38], ["kidney", "ORGAN", 40, 46], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 48, 65], ["arterioles", "MULTI-TISSUE_STRUCTURE", 67, 77], ["vasa vasorum", "MULTI-TISSUE_STRUCTURE", 79, 91], ["testis", "ORGAN", 93, 99], ["gastrointestinal tract", "ORGAN", 101, 123], ["lung", "ORGAN", 129, 133], ["ACE2", "PROTEIN", 0, 4], ["human", "SPECIES", 27, 32], ["vasa vasorum", "SPECIES", 79, 91], ["human", "SPECIES", 27, 32], ["vasa vasorum", "SPECIES", 79, 91], ["ACE2", "TREATMENT", 0, 4], ["human", "ANATOMY_MODIFIER", 27, 32], ["heart", "ANATOMY", 33, 38], ["kidney", "ANATOMY", 40, 46], ["coronary arteries", "ANATOMY", 48, 65], ["arterioles", "ANATOMY_MODIFIER", 67, 77], ["vasa vasorum", "ANATOMY", 79, 91], ["testis", "ANATOMY", 93, 99], ["gastrointestinal tract", "ANATOMY", 101, 123], ["lung", "ANATOMY", 129, 133]]], ["ACE2 is abundantly expressed in many cell types in the lung such as Clara cells, type I and II alveolar epithelial cells, macrophages, endothelium, SMCs, and bronchial epithelia.", [["cell", "ANATOMY", 37, 41], ["lung", "ANATOMY", 55, 59], ["Clara cells", "ANATOMY", 68, 79], ["alveolar epithelial cells", "ANATOMY", 95, 120], ["macrophages", "ANATOMY", 122, 133], ["endothelium", "ANATOMY", 135, 146], ["SMCs", "ANATOMY", 148, 152], ["bronchial epithelia", "ANATOMY", 158, 177], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 37, 41], ["lung", "ORGAN", 55, 59], ["Clara cells", "CELL", 68, 79], ["type I", "GENE_OR_GENE_PRODUCT", 81, 87], ["alveolar epithelial cells", "CELL", 95, 120], ["macrophages", "CELL", 122, 133], ["endothelium", "TISSUE", 135, 146], ["SMCs", "CELL", 148, 152], ["bronchial epithelia", "TISSUE", 158, 177], ["ACE2", "PROTEIN", 0, 4], ["Clara cells", "CELL_TYPE", 68, 79], ["type I and II alveolar epithelial cells", "CELL_TYPE", 81, 120], ["macrophages", "CELL_TYPE", 122, 133], ["SMCs", "CELL_TYPE", 148, 152], ["Clara cells", "PROBLEM", 68, 79], ["type I and II alveolar epithelial cells", "PROBLEM", 81, 120], ["macrophages", "PROBLEM", 122, 133], ["endothelium", "PROBLEM", 135, 146], ["SMCs", "PROBLEM", 148, 152], ["bronchial epithelia", "PROBLEM", 158, 177], ["many cell types", "OBSERVATION", 32, 47], ["lung", "ANATOMY", 55, 59], ["Clara cells", "OBSERVATION", 68, 79], ["alveolar", "ANATOMY_MODIFIER", 95, 103], ["epithelial cells", "OBSERVATION", 104, 120], ["macrophages", "OBSERVATION", 122, 133], ["endothelium", "ANATOMY_MODIFIER", 135, 146], ["SMCs", "ANATOMY", 148, 152], ["bronchial", "ANATOMY", 158, 167], ["epithelia", "ANATOMY_MODIFIER", 168, 177]]], ["ACE2 is localized to endothelial cells, and expression is enhanced in the walls of newly muscularized pulmonary arteries [11] .", [["endothelial cells", "ANATOMY", 21, 38], ["walls", "ANATOMY", 74, 79], ["pulmonary arteries", "ANATOMY", 102, 120], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["endothelial cells", "CELL", 21, 38], ["pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 102, 120], ["ACE2", "PROTEIN", 0, 4], ["endothelial cells", "CELL_TYPE", 21, 38], ["ACE2", "PROBLEM", 0, 4], ["endothelial cells", "OBSERVATION", 21, 38], ["enhanced", "OBSERVATION_MODIFIER", 58, 66], ["walls", "ANATOMY_MODIFIER", 74, 79], ["newly", "ANATOMY_MODIFIER", 83, 88], ["muscularized", "ANATOMY_MODIFIER", 89, 101], ["pulmonary arteries", "ANATOMY", 102, 120]]], ["These data illustrate that ACE2, like ACE, is localized to the lung, the vasculature, and more specifically, to the endothelium, and thus exists as a potential therapeutic target.", [["lung", "ANATOMY", 63, 67], ["vasculature", "ANATOMY", 73, 84], ["endothelium", "ANATOMY", 116, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["ACE", "GENE_OR_GENE_PRODUCT", 38, 41], ["lung", "ORGAN", 63, 67], ["vasculature", "MULTI-TISSUE_STRUCTURE", 73, 84], ["endothelium", "TISSUE", 116, 127], ["ACE2", "PROTEIN", 27, 31], ["ACE", "PROTEIN", 38, 41], ["ACE2", "PROBLEM", 27, 31], ["lung", "ANATOMY", 63, 67], ["vasculature", "ANATOMY", 73, 84], ["endothelium", "ANATOMY", 116, 127]]], ["The literature also strongly supports a RAS imbalance in pulmonary disease and lung injury.ACE2 in Lung InjuryACE2 limits vasoproliferative, fibrotic, and hypertrophic actions of the RAS during lung injury.", [["pulmonary", "ANATOMY", 57, 66], ["lung", "ANATOMY", 79, 83], ["Lung", "ANATOMY", 99, 103], ["lung", "ANATOMY", 194, 198], ["pulmonary disease", "DISEASE", 57, 74], ["lung injury", "DISEASE", 79, 90], ["lung injury", "DISEASE", 194, 205], ["RAS", "GENE_OR_GENE_PRODUCT", 40, 43], ["pulmonary", "ORGAN", 57, 66], ["lung", "ORGAN", 79, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["Lung", "ORGAN", 99, 103], ["RAS", "GENE_OR_GENE_PRODUCT", 183, 186], ["lung", "ORGAN", 194, 198], ["ACE2", "PROTEIN", 91, 95], ["a RAS imbalance", "PROBLEM", 38, 53], ["pulmonary disease", "PROBLEM", 57, 74], ["lung injury", "PROBLEM", 79, 90], ["ACE2", "TEST", 91, 95], ["Lung InjuryACE2", "TEST", 99, 114], ["fibrotic", "PROBLEM", 141, 149], ["hypertrophic actions", "PROBLEM", 155, 175], ["the RAS during lung injury", "PROBLEM", 179, 205], ["pulmonary", "ANATOMY", 57, 66], ["disease", "OBSERVATION", 67, 74], ["lung", "ANATOMY", 79, 83], ["injury", "OBSERVATION", 84, 90], ["Lung", "ANATOMY", 99, 103], ["InjuryACE2", "OBSERVATION", 104, 114], ["fibrotic", "OBSERVATION_MODIFIER", 141, 149], ["hypertrophic", "OBSERVATION_MODIFIER", 155, 167], ["lung", "ANATOMY", 194, 198], ["injury", "OBSERVATION", 199, 205]]], ["Both animal and human pulmonary studies reveal that a RAS imbalance may play an important role in pulmonary disease progression.", [["pulmonary", "ANATOMY", 22, 31], ["pulmonary", "ANATOMY", 98, 107], ["pulmonary disease", "DISEASE", 98, 115], ["human", "ORGANISM", 16, 21], ["pulmonary", "ORGAN", 22, 31], ["RAS", "GENE_OR_GENE_PRODUCT", 54, 57], ["pulmonary", "ORGAN", 98, 107], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["Both animal and human pulmonary studies", "TEST", 0, 39], ["a RAS imbalance", "PROBLEM", 52, 67], ["pulmonary disease progression", "PROBLEM", 98, 127], ["pulmonary", "ANATOMY", 22, 31], ["pulmonary", "ANATOMY", 98, 107], ["disease", "OBSERVATION", 108, 115]]], ["In three different models of acute respiratory distress syndrome (ARDS), ACE2 knockout mice have severe lung disease, elevated serum and tissue Ang II levels, and increased collagen deposition.", [["respiratory", "ANATOMY", 35, 46], ["lung", "ANATOMY", 104, 108], ["serum", "ANATOMY", 127, 132], ["tissue", "ANATOMY", 137, 143], ["acute respiratory distress syndrome", "DISEASE", 29, 64], ["ARDS", "DISEASE", 66, 70], ["lung disease", "DISEASE", 104, 116], ["Ang", "CHEMICAL", 144, 147], ["ACE2", "GENE_OR_GENE_PRODUCT", 73, 77], ["mice", "ORGANISM", 87, 91], ["lung", "ORGAN", 104, 108], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["tissue", "TISSUE", 137, 143], ["Ang II", "GENE_OR_GENE_PRODUCT", 144, 150], ["collagen", "GENE_OR_GENE_PRODUCT", 173, 181], ["ACE2", "PROTEIN", 73, 77], ["Ang II", "PROTEIN", 144, 150], ["collagen", "PROTEIN", 173, 181], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 87, 91], ["acute respiratory distress syndrome", "PROBLEM", 29, 64], ["ARDS", "PROBLEM", 66, 70], ["ACE2 knockout mice", "PROBLEM", 73, 91], ["severe lung disease", "PROBLEM", 97, 116], ["elevated serum and tissue Ang II levels", "PROBLEM", 118, 157], ["increased collagen deposition", "PROBLEM", 163, 192], ["three different", "OBSERVATION_MODIFIER", 3, 18], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["respiratory distress syndrome", "OBSERVATION", 35, 64], ["ARDS", "OBSERVATION", 66, 70], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["lung", "ANATOMY", 104, 108], ["disease", "OBSERVATION", 109, 116], ["elevated", "OBSERVATION_MODIFIER", 118, 126], ["serum", "OBSERVATION_MODIFIER", 127, 132], ["increased", "OBSERVATION_MODIFIER", 163, 172], ["collagen deposition", "OBSERVATION", 173, 192]]], ["This loss of ACE in acute lung injury leads to leaky pulmonary blood vessels through AT 1 a receptor stimulation [12] .", [["lung", "ANATOMY", 26, 30], ["pulmonary blood vessels", "ANATOMY", 53, 76], ["lung injury", "DISEASE", 26, 37], ["ACE", "GENE_OR_GENE_PRODUCT", 13, 16], ["lung", "ORGAN", 26, 30], ["pulmonary blood vessels", "MULTI-TISSUE_STRUCTURE", 53, 76], ["AT 1", "GENE_OR_GENE_PRODUCT", 85, 89], ["ACE", "PROTEIN", 13, 16], ["ACE in acute lung injury", "PROBLEM", 13, 37], ["leaky pulmonary blood vessels", "PROBLEM", 47, 76], ["a receptor stimulation", "TREATMENT", 90, 112], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["lung", "ANATOMY", 26, 30], ["injury", "OBSERVATION", 31, 37], ["leaky", "OBSERVATION", 47, 52], ["pulmonary", "ANATOMY_MODIFIER", 53, 62], ["blood vessels", "ANATOMY", 63, 76]]], ["In a lung injury model induced by acid aspiration or sepsis, ACE2 deletion worsens the injury.", [["lung", "ANATOMY", 5, 9], ["lung injury", "DISEASE", 5, 16], ["sepsis", "DISEASE", 53, 59], ["lung", "ORGAN", 5, 9], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["ACE2", "PROTEIN", 61, 65], ["a lung injury", "PROBLEM", 3, 16], ["acid aspiration", "PROBLEM", 34, 49], ["sepsis", "PROBLEM", 53, 59], ["ACE2 deletion", "PROBLEM", 61, 74], ["the injury", "PROBLEM", 83, 93], ["lung", "ANATOMY", 5, 9], ["injury", "OBSERVATION", 10, 16], ["acid", "OBSERVATION_MODIFIER", 34, 38], ["aspiration", "OBSERVATION", 39, 49], ["sepsis", "OBSERVATION", 53, 59], ["injury", "OBSERVATION", 87, 93]]], ["Aortas from ACE2-deficient mice exhibit impaired endothelium-dependent vasodilation [10] .", [["Aortas", "ANATOMY", 0, 6], ["endothelium", "ANATOMY", 49, 60], ["Aortas", "GENE_OR_GENE_PRODUCT", 0, 6], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["mice", "ORGANISM", 27, 31], ["endothelium", "TISSUE", 49, 60], ["ACE2", "PROTEIN", 12, 16], ["mice", "SPECIES", 27, 31], ["Aortas", "TEST", 0, 6], ["ACE2", "TEST", 12, 16], ["impaired endothelium", "PROBLEM", 40, 60], ["dependent vasodilation", "PROBLEM", 61, 83], ["impaired", "OBSERVATION_MODIFIER", 40, 48], ["endothelium", "OBSERVATION", 49, 60]]], ["This RAS imbalance is further supported by literature revealing that severe lung failure on an ACE2 knockout background was rescued by ACE inactivation [12] .ACE2 in Lung InjuryThe RAS imbalance is also evident in animal models of PH.", [["lung", "ANATOMY", 76, 80], ["Lung", "ANATOMY", 166, 170], ["lung failure", "DISEASE", 76, 88], ["Lung Injury", "DISEASE", 166, 177], ["PH", "DISEASE", 231, 233], ["RAS", "GENE_OR_GENE_PRODUCT", 5, 8], ["lung", "ORGAN", 76, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["ACE", "GENE_OR_GENE_PRODUCT", 135, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 158, 162], ["Lung", "ORGAN", 166, 170], ["RAS", "GENE_OR_GENE_PRODUCT", 181, 184], ["ACE2", "PROTEIN", 95, 99], ["ACE", "PROTEIN", 135, 138], ["ACE2", "PROTEIN", 158, 162], ["This RAS imbalance", "PROBLEM", 0, 18], ["severe lung failure", "PROBLEM", 69, 88], ["ACE inactivation", "PROBLEM", 135, 151], ["ACE2 in Lung Injury", "PROBLEM", 158, 177], ["The RAS imbalance", "PROBLEM", 177, 194], ["imbalance", "OBSERVATION", 9, 18], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["lung", "ANATOMY", 76, 80], ["failure", "OBSERVATION", 81, 88], ["Lung", "ANATOMY", 166, 170], ["Injury", "OBSERVATION", 171, 177], ["imbalance", "OBSERVATION", 185, 194]]], ["Bleomycin-induced PH and pulmonary fibrosis are associated with decreased ACE2 activity.", [["pulmonary", "ANATOMY", 25, 34], ["Bleomycin", "CHEMICAL", 0, 9], ["PH", "DISEASE", 18, 20], ["fibrosis", "DISEASE", 35, 43], ["Bleomycin", "CHEMICAL", 0, 9], ["Bleomycin", "SIMPLE_CHEMICAL", 0, 9], ["pulmonary", "ORGAN", 25, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["ACE2", "PROTEIN", 74, 78], ["Bleomycin", "TREATMENT", 0, 9], ["induced PH", "PROBLEM", 10, 20], ["pulmonary fibrosis", "PROBLEM", 25, 43], ["decreased ACE2 activity", "PROBLEM", 64, 87], ["induced PH", "OBSERVATION", 10, 20], ["pulmonary", "ANATOMY", 25, 34], ["fibrosis", "OBSERVATION", 35, 43], ["decreased", "OBSERVATION_MODIFIER", 64, 73], ["ACE2 activity", "OBSERVATION", 74, 87]]], ["ACE2 is upregulated in response to hypoxia and illustrates a protective effect in severe acute lung failure.", [["lung", "ANATOMY", 95, 99], ["hypoxia", "DISEASE", 35, 42], ["acute lung failure", "DISEASE", 89, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung", "ORGAN", 95, 99], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["hypoxia", "PROBLEM", 35, 42], ["severe acute lung failure", "PROBLEM", 82, 107], ["upregulated", "OBSERVATION_MODIFIER", 8, 19], ["hypoxia", "OBSERVATION", 35, 42], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["lung", "ANATOMY", 95, 99], ["failure", "OBSERVATION", 100, 107]]], ["Activation of a key transcriptional factor during hypoxia, HIF \u00c0 1 a , increased ACE and decreased ACE2 [13] .", [["hypoxia", "DISEASE", 50, 57], ["HIF \u00c0 1", "GENE_OR_GENE_PRODUCT", 59, 66], ["ACE", "GENE_OR_GENE_PRODUCT", 81, 84], ["ACE2 [13]", "GENE_OR_GENE_PRODUCT", 99, 108], ["transcriptional factor", "PROTEIN", 20, 42], ["HIF", "PROTEIN", 59, 62], ["ACE", "PROTEIN", 81, 84], ["ACE2", "PROTEIN", 99, 103], ["hypoxia", "PROBLEM", 50, 57], ["increased ACE", "TREATMENT", 71, 84], ["decreased ACE2", "PROBLEM", 89, 103]]], ["Lenti-ACE2 tracheal injections prevent and partially reverse PH in a monocrotaline (MCT) model of PH [14] .ACE2 in Lung InjuryTargeting ACE2 may have additional beneficial effects, unlike the blockade of ACE and AT 1 Rs.", [["tracheal", "ANATOMY", 11, 19], ["Lung", "ANATOMY", 115, 119], ["PH", "DISEASE", 61, 63], ["monocrotaline", "CHEMICAL", 69, 82], ["PH", "DISEASE", 98, 100], ["monocrotaline", "CHEMICAL", 69, 82], ["tracheal", "MULTI-TISSUE_STRUCTURE", 11, 19], ["monocrotaline", "SIMPLE_CHEMICAL", 69, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 107, 111], ["Lung", "ORGAN", 115, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 136, 140], ["ACE", "GENE_OR_GENE_PRODUCT", 204, 207], ["AT 1 Rs", "GENE_OR_GENE_PRODUCT", 212, 219], ["ACE2", "PROTEIN", 107, 111], ["ACE2", "PROTEIN", 136, 140], ["ACE", "PROTEIN", 204, 207], ["AT 1 Rs", "PROTEIN", 212, 219], ["Lenti-ACE2 tracheal injections", "TREATMENT", 0, 30], ["ACE2 in Lung InjuryTargeting ACE2", "TREATMENT", 107, 140], ["the blockade of ACE", "TREATMENT", 188, 207], ["tracheal", "ANATOMY", 11, 19], ["Lung", "ANATOMY", 115, 119]]], ["Targeting ACE2 in PH is a novel strategy (Fig. 1) , as ACE2 is a multifunctional enzyme with pleiotropic effects.", [["PH", "DISEASE", 18, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACE2", "PROTEIN", 10, 14], ["ACE2", "PROTEIN", 55, 59], ["pleiotropic effects", "PROBLEM", 93, 112]]], ["It not only gives protection by degradation of Ang II, but it also produces the vasodilatory peptide, Ang-(1-7).ACE2 in Lung InjuryIn animal models, the literature also strongly supports pharmacologic treatment of lung disease with ACE2.", [["Lung", "ANATOMY", 120, 124], ["lung", "ANATOMY", 214, 218], ["Ang II", "CHEMICAL", 47, 53], ["Ang-(1-7", "CHEMICAL", 102, 110], ["Lung Injury", "DISEASE", 120, 131], ["lung disease", "DISEASE", 214, 226], ["Ang II", "GENE_OR_GENE_PRODUCT", 47, 53], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 102, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["Lung", "ORGAN", 120, 124], ["lung", "ORGAN", 214, 218], ["ACE2", "GENE_OR_GENE_PRODUCT", 232, 236], ["Ang II", "PROTEIN", 47, 53], ["ACE2", "PROTEIN", 112, 116], ["ACE2", "PROTEIN", 232, 236], ["the vasodilatory peptide", "TEST", 76, 100], ["Ang", "TEST", 102, 105], ["ACE2 in Lung Injury", "PROBLEM", 112, 131], ["pharmacologic treatment", "TREATMENT", 187, 210], ["lung disease", "PROBLEM", 214, 226], ["ACE2", "PROBLEM", 232, 236], ["Lung", "ANATOMY", 120, 124], ["Injury", "OBSERVATION", 125, 131], ["lung", "ANATOMY", 214, 218], ["disease", "OBSERVATION", 219, 226]]], ["Because PVR occurs in PAH, studies that prevent, limit, or regress PVR are important for progress in the field.", [["PAH", "DISEASE", 22, 25], ["PAH", "CHEMICAL", 22, 25], ["PVR", "GENE_OR_GENE_PRODUCT", 8, 11], ["PVR", "PROBLEM", 8, 11], ["PVR", "OBSERVATION", 8, 11], ["PAH", "OBSERVATION", 22, 25], ["PVR", "OBSERVATION", 67, 70]]], ["In a sepsis-induced ACE2 knockout model of acute lung injury, treatment with recombinant human ACE2 protein provided direct protection [12] .", [["lung", "ANATOMY", 49, 53], ["sepsis", "DISEASE", 5, 11], ["acute lung injury", "DISEASE", 43, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["lung", "ORGAN", 49, 53], ["human", "ORGANISM", 89, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["ACE2", "PROTEIN", 20, 24], ["recombinant human ACE2 protein", "PROTEIN", 77, 107], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["a sepsis", "PROBLEM", 3, 11], ["acute lung injury", "PROBLEM", 43, 60], ["recombinant human ACE2 protein", "TREATMENT", 77, 107], ["sepsis", "OBSERVATION", 5, 11], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["lung", "ANATOMY", 49, 53], ["injury", "OBSERVATION", 54, 60]]], ["This study also suggests that Ang II, ACE, and AT 1 a receptor promote lung injury, whereas ACE2 and AT 2 receptor protect against lung injury.", [["lung", "ANATOMY", 71, 75], ["lung", "ANATOMY", 131, 135], ["Ang II", "CHEMICAL", 30, 36], ["lung injury", "DISEASE", 71, 82], ["lung injury", "DISEASE", 131, 142], ["Ang II", "GENE_OR_GENE_PRODUCT", 30, 36], ["ACE", "GENE_OR_GENE_PRODUCT", 38, 41], ["AT 1", "GENE_OR_GENE_PRODUCT", 47, 51], ["lung", "ORGAN", 71, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["AT 2 receptor", "GENE_OR_GENE_PRODUCT", 101, 114], ["lung", "ORGAN", 131, 135], ["Ang II", "PROTEIN", 30, 36], ["ACE", "PROTEIN", 38, 41], ["AT 1", "PROTEIN", 47, 51], ["ACE2", "PROTEIN", 92, 96], ["AT 2 receptor", "PROTEIN", 101, 114], ["This study", "TEST", 0, 10], ["ACE", "TREATMENT", 38, 41], ["lung injury", "PROBLEM", 71, 82], ["ACE2", "TEST", 92, 96], ["lung injury", "PROBLEM", 131, 142], ["lung", "ANATOMY", 71, 75], ["injury", "OBSERVATION", 76, 82], ["lung", "ANATOMY", 131, 135], ["injury", "OBSERVATION", 136, 142]]], ["ACE2 overexpression improves endothelial cell migration and tube formation [10] .", [["endothelial cell", "ANATOMY", 29, 45], ["tube", "ANATOMY", 60, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["endothelial cell", "CELL", 29, 45], ["tube", "TISSUE", 60, 64], ["ACE2", "PROTEIN", 0, 4], ["ACE2 overexpression", "TREATMENT", 0, 19], ["endothelial cell migration", "TREATMENT", 29, 55], ["tube formation", "TREATMENT", 60, 74], ["endothelial cell migration", "OBSERVATION", 29, 55], ["tube formation", "OBSERVATION", 60, 74]]], ["We have demonstrated in MCT-treated mice that pulmonary ACE2 overexpression via lentiviral vector both prevents and reverses the increases in right ventricular systolic pressure, significantly attenuates and partially reverses muscularization of pulmonary vessel, and increases the AT 2 R:AT 1 R mRNA ratio [14] .", [["pulmonary", "ANATOMY", 46, 55], ["right ventricular", "ANATOMY", 142, 159], ["pulmonary vessel", "ANATOMY", 246, 262], ["MCT", "CHEMICAL", 24, 27], ["MCT", "SIMPLE_CHEMICAL", 24, 27], ["mice", "ORGANISM", 36, 40], ["pulmonary", "ORGAN", 46, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["lentiviral", "ORGANISM", 80, 90], ["ventricular", "ORGAN", 148, 159], ["pulmonary vessel", "MULTI-TISSUE_STRUCTURE", 246, 262], ["AT 2 R", "GENE_OR_GENE_PRODUCT", 282, 288], ["AT 1 R", "GENE_OR_GENE_PRODUCT", 289, 295], ["ACE2", "PROTEIN", 56, 60], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["pulmonary ACE2 overexpression", "TREATMENT", 46, 75], ["lentiviral vector", "TREATMENT", 80, 97], ["right ventricular systolic pressure", "TEST", 142, 177], ["mRNA ratio", "TEST", 296, 306], ["pulmonary ACE2", "ANATOMY", 46, 60], ["lentiviral vector", "OBSERVATION", 80, 97], ["increases", "OBSERVATION_MODIFIER", 129, 138], ["right ventricular", "ANATOMY", 142, 159], ["systolic pressure", "OBSERVATION", 160, 177], ["pulmonary vessel", "ANATOMY", 246, 262], ["increases", "OBSERVATION_MODIFIER", 268, 277]]], ["Our studies further reveal that activation of endogenous ACE2 by XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one) prevents pulmonary vascular remodeling in PH develop- Fig. 1 Targeting the ACE2/ Ang-(1-7)/Mas axis prevents and reverses pulmonary vascular pathology of pulmonary arterial hypertension.", [["pulmonary vascular", "ANATOMY", 183, 201], ["pulmonary vascular", "ANATOMY", 296, 314], ["pulmonary arterial", "ANATOMY", 328, 346], ["XNT", "CHEMICAL", 65, 68], ["1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one", "CHEMICAL", 70, 172], ["Ang", "CHEMICAL", 255, 258], ["pulmonary arterial hypertension", "DISEASE", 328, 359], ["XNT", "CHEMICAL", 65, 68], ["1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one", "CHEMICAL", 70, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["XNT", "SIMPLE_CHEMICAL", 65, 68], ["1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one", "SIMPLE_CHEMICAL", 70, 172], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 183, 201], ["ACE2", "GENE_OR_GENE_PRODUCT", 249, 253], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 255, 263], ["Mas", "GENE_OR_GENE_PRODUCT", 265, 268], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 296, 314], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 328, 346], ["endogenous ACE2", "PROTEIN", 46, 61], ["ACE2", "PROTEIN", 249, 253], ["Our studies", "TEST", 0, 11], ["endogenous ACE2 by XNT", "TREATMENT", 46, 68], ["[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)", "TREATMENT", 72, 120], ["methylphenyl) sulfonyl oxy]", "TREATMENT", 127, 154], ["xanthene", "TREATMENT", 158, 166], ["pulmonary vascular remodeling", "PROBLEM", 183, 212], ["the ACE2", "TEST", 245, 253], ["Ang", "TEST", 255, 258], ["pulmonary vascular pathology", "PROBLEM", 296, 324], ["pulmonary arterial hypertension", "PROBLEM", 328, 359], ["pulmonary", "ANATOMY", 183, 192], ["vascular", "ANATOMY", 193, 201], ["remodeling", "OBSERVATION", 202, 212], ["Ang", "ANATOMY", 255, 258], ["pulmonary vascular", "ANATOMY", 296, 314], ["pathology", "OBSERVATION", 315, 324], ["pulmonary arterial", "ANATOMY", 328, 346], ["hypertension", "OBSERVATION", 347, 359]]], ["ACEangiotensin-converting enzyme; Ang II-angiotensin II; AT 1 Rangiotensin II type 1 receptor; AT 2 R-angiotensin II type 2 receptor; BMPR-II-bone morphogenetic protein receptor type II; ERK1/2-extracellular signal-regulated protein kinase 1/2; NO-nitric oxide; TGF-\u03b2-transforming growth factor \u03b2 ment [2\u2022\u2022] .", [["ACEangiotensin", "CHEMICAL", 0, 14], ["Ang II", "CHEMICAL", 34, 40], ["angiotensin II", "CHEMICAL", 41, 55], ["angiotensin II", "CHEMICAL", 102, 116], ["NO", "CHEMICAL", 245, 247], ["nitric oxide", "CHEMICAL", 248, 260], ["NO-nitric oxide", "CHEMICAL", 245, 260], ["ACEangiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 0, 32], ["Ang II-angiotensin II", "GENE_OR_GENE_PRODUCT", 34, 55], ["AT 1 Rangiotensin II type 1 receptor", "GENE_OR_GENE_PRODUCT", 57, 93], ["AT 2 R-angiotensin II type 2 receptor", "GENE_OR_GENE_PRODUCT", 95, 132], ["BMPR-II-bone morphogenetic protein receptor type II", "GENE_OR_GENE_PRODUCT", 134, 185], ["ERK1/2-extracellular signal-regulated protein kinase 1/2", "GENE_OR_GENE_PRODUCT", 187, 243], ["NO-nitric oxide", "SIMPLE_CHEMICAL", 245, 260], ["TGF-\u03b2-transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 262, 296], ["ACEangiotensin-converting enzyme", "PROTEIN", 0, 32], ["Ang II", "PROTEIN", 34, 40], ["angiotensin II; AT 1 Rangiotensin II type 1 receptor", "PROTEIN", 41, 93], ["AT 2 R-angiotensin II type 2 receptor", "PROTEIN", 95, 132], ["BMPR-II-bone morphogenetic protein receptor type II", "PROTEIN", 134, 185], ["ERK1/2-extracellular signal-regulated protein kinase 1/2", "PROTEIN", 187, 243], ["TGF-\u03b2-transforming growth factor \u03b2", "PROTEIN", 262, 296], ["ACEangiotensin", "TEST", 0, 14], ["enzyme", "TEST", 26, 32], ["Ang II-angiotensin II", "TREATMENT", 34, 55], ["receptor", "TEST", 85, 93], ["angiotensin II type", "TREATMENT", 102, 121], ["receptor", "TEST", 124, 132], ["BMPR", "TEST", 134, 138], ["bone morphogenetic protein", "TEST", 142, 168], ["ERK1", "TEST", 187, 191], ["extracellular signal", "TEST", 194, 214], ["protein kinase", "TEST", 225, 239], ["nitric oxide", "TREATMENT", 248, 260], ["TGF", "TEST", 262, 265], ["bone", "ANATOMY", 142, 146]]], ["XNT reversed cardiac hypertrophy, ventricular fibrosis, and renal interstitial fibrosis; prevented an increase in right ventricular systolic pressure (RVSP) and right ventricular hypertrophy; and attenuated vascular wall thickening and pulmonary fibrosis.", [["cardiac", "ANATOMY", 13, 20], ["ventricular", "ANATOMY", 34, 45], ["renal interstitial", "ANATOMY", 60, 78], ["right ventricular", "ANATOMY", 114, 131], ["right ventricular", "ANATOMY", 161, 178], ["vascular wall", "ANATOMY", 207, 220], ["pulmonary", "ANATOMY", 236, 245], ["XNT", "CHEMICAL", 0, 3], ["cardiac hypertrophy", "DISEASE", 13, 32], ["ventricular fibrosis", "DISEASE", 34, 54], ["fibrosis", "DISEASE", 79, 87], ["ventricular hypertrophy", "DISEASE", 167, 190], ["fibrosis", "DISEASE", 246, 254], ["XNT", "SIMPLE_CHEMICAL", 0, 3], ["cardiac", "ORGAN", 13, 20], ["ventricular", "MULTI-TISSUE_STRUCTURE", 34, 45], ["renal interstitial", "MULTI-TISSUE_STRUCTURE", 60, 78], ["ventricular", "MULTI-TISSUE_STRUCTURE", 120, 131], ["ventricular", "MULTI-TISSUE_STRUCTURE", 167, 178], ["vascular wall", "TISSUE", 207, 220], ["pulmonary", "ORGAN", 236, 245], ["XNT reversed cardiac hypertrophy", "PROBLEM", 0, 32], ["ventricular fibrosis", "PROBLEM", 34, 54], ["renal interstitial fibrosis", "PROBLEM", 60, 87], ["right ventricular systolic pressure", "TEST", 114, 149], ["RVSP", "TEST", 151, 155], ["right ventricular hypertrophy", "PROBLEM", 161, 190], ["attenuated vascular wall thickening", "PROBLEM", 196, 231], ["pulmonary fibrosis", "PROBLEM", 236, 254], ["cardiac", "ANATOMY", 13, 20], ["hypertrophy", "OBSERVATION", 21, 32], ["ventricular", "ANATOMY", 34, 45], ["fibrosis", "OBSERVATION", 46, 54], ["renal", "ANATOMY", 60, 65], ["interstitial", "ANATOMY_MODIFIER", 66, 78], ["fibrosis", "OBSERVATION", 79, 87], ["increase", "OBSERVATION_MODIFIER", 102, 110], ["right ventricular", "ANATOMY", 114, 131], ["systolic pressure", "OBSERVATION", 132, 149], ["RVSP", "OBSERVATION", 151, 155], ["right ventricular", "ANATOMY", 161, 178], ["hypertrophy", "OBSERVATION", 179, 190], ["attenuated", "OBSERVATION_MODIFIER", 196, 206], ["vascular", "ANATOMY", 207, 215], ["wall", "ANATOMY_MODIFIER", 216, 220], ["thickening", "OBSERVATION", 221, 231], ["pulmonary", "ANATOMY", 236, 245], ["fibrosis", "OBSERVATION", 246, 254]]], ["XNT decreased proinflammatory cytokine levels, increased anti-inflammatory cytokine levels, and increased ACE2 activity.", [["XNT", "SIMPLE_CHEMICAL", 0, 3], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["proinflammatory cytokine", "PROTEIN", 14, 38], ["cytokine", "PROTEIN", 75, 83], ["ACE2", "PROTEIN", 106, 110], ["XNT decreased proinflammatory cytokine levels", "PROBLEM", 0, 45], ["increased anti-inflammatory cytokine levels", "PROBLEM", 47, 90], ["increased ACE2 activity", "PROBLEM", 96, 119], ["decreased", "OBSERVATION_MODIFIER", 4, 13], ["proinflammatory cytokine levels", "OBSERVATION", 14, 45], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["anti-inflammatory cytokine levels", "OBSERVATION", 57, 90], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["ACE2 activity", "OBSERVATION", 106, 119]]], ["XNT had no adverse effects on systemic blood pressure.", [["blood", "ANATOMY", 39, 44], ["XNT", "CHEMICAL", 0, 3], ["XNT", "SIMPLE_CHEMICAL", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["adverse effects", "PROBLEM", 11, 26], ["systemic blood pressure", "TEST", 30, 53], ["no", "UNCERTAINTY", 8, 10], ["adverse effects", "OBSERVATION", 11, 26]]], ["These effects are inhibited by an Ang-(1-7) antagonist, A779, demonstrating that ACE2 may produce beneficial effects via Ang-(1-7) [2\u2022\u2022].", [["Ang", "CHEMICAL", 34, 37], ["A779", "CHEMICAL", 56, 60], ["Ang", "CHEMICAL", 121, 124], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 34, 42], ["A779", "SIMPLE_CHEMICAL", 56, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["1-7) [2\u2022\u2022", "SIMPLE_CHEMICAL", 126, 135], ["ACE2", "PROTEIN", 81, 85], ["an Ang", "TEST", 31, 37], ["antagonist", "TREATMENT", 44, 54], ["ACE2", "TEST", 81, 85], ["Ang", "TEST", 121, 124]]], ["Interestingly, ACE2 overexpression in the smooth muscle of spontaneously hypertensive stroke prone rats (SHRSP) resulted in increased aortic ACE2 activity, Ang-(1-7), and Ang II and improved vascular function [15] .", [["smooth muscle", "ANATOMY", 42, 55], ["aortic", "ANATOMY", 134, 140], ["vascular", "ANATOMY", 191, 199], ["hypertensive stroke", "DISEASE", 73, 92], ["Ang-(1-7)", "CHEMICAL", 156, 165], ["Ang II", "CHEMICAL", 171, 177], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["smooth muscle", "TISSUE", 42, 55], ["rats", "ORGANISM", 99, 103], ["aortic", "MULTI-TISSUE_STRUCTURE", 134, 140], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 156, 164], ["Ang II", "GENE_OR_GENE_PRODUCT", 171, 177], ["vascular", "MULTI-TISSUE_STRUCTURE", 191, 199], ["ACE2", "PROTEIN", 15, 19], ["ACE2", "PROTEIN", 141, 145], ["Ang II", "PROTEIN", 171, 177], ["rats", "SPECIES", 99, 103], ["ACE2 overexpression", "PROBLEM", 15, 34], ["spontaneously hypertensive stroke prone rats", "PROBLEM", 59, 103], ["increased aortic ACE2 activity", "PROBLEM", 124, 154], ["Ang", "TEST", 156, 159], ["ACE2 overexpression", "OBSERVATION", 15, 34], ["smooth muscle", "ANATOMY", 42, 55], ["spontaneously", "OBSERVATION_MODIFIER", 59, 72], ["hypertensive", "OBSERVATION", 73, 85], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["aortic", "ANATOMY", 134, 140], ["ACE2 activity", "OBSERVATION", 141, 154], ["vascular", "ANATOMY", 191, 199]]], ["Mas agonists, AVE0991, CGEM856, CGEM857, confer endothelium-dependent relaxation effects.ACE2 in Lung InjuryChronic and sustained imbalances that favor the ACE-Ang II-AT 1 R axis may promote the progression of lung disease.", [["endothelium", "ANATOMY", 48, 59], ["Lung", "ANATOMY", 97, 101], ["lung", "ANATOMY", 210, 214], ["AVE0991", "CHEMICAL", 14, 21], ["CGEM856", "CHEMICAL", 23, 30], ["CGEM857", "CHEMICAL", 32, 39], ["Lung Injury", "DISEASE", 97, 108], ["Ang II", "CHEMICAL", 160, 166], ["lung disease", "DISEASE", 210, 222], ["AVE0991", "CHEMICAL", 14, 21], ["CGEM856", "CHEMICAL", 23, 30], ["Mas", "GENE_OR_GENE_PRODUCT", 0, 3], ["AVE0991", "SIMPLE_CHEMICAL", 14, 21], ["CGEM856", "SIMPLE_CHEMICAL", 23, 30], ["CGEM857", "SIMPLE_CHEMICAL", 32, 39], ["endothelium", "TISSUE", 48, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["Lung", "ORGAN", 97, 101], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 156, 173], ["lung", "ORGAN", 210, 214], ["ACE2", "PROTEIN", 89, 93], ["ACE", "PROTEIN", 156, 159], ["Ang II", "PROTEIN", 160, 166], ["dependent relaxation effects", "PROBLEM", 60, 88], ["ACE2 in Lung Injury", "PROBLEM", 89, 108], ["Chronic and sustained imbalances", "PROBLEM", 108, 140], ["the ACE", "TEST", 152, 159], ["lung disease", "PROBLEM", 210, 222], ["dependent", "OBSERVATION_MODIFIER", 60, 69], ["relaxation effects", "OBSERVATION", 70, 88], ["Lung", "ANATOMY", 97, 101], ["Injury", "OBSERVATION", 102, 108], ["sustained", "OBSERVATION_MODIFIER", 120, 129], ["imbalances", "OBSERVATION", 130, 140], ["progression", "OBSERVATION_MODIFIER", 195, 206], ["lung", "ANATOMY", 210, 214], ["disease", "OBSERVATION", 215, 222]]], ["We believe that the beneficial effects of the system involve a shift from the vasoconstrictive, proliferative, and fibrotic axes to the vasoprotective axis of the RAS, and thus targeting the RAS in PH should be revisited, with ACE2 as the therapeutic target.", [["PH", "DISEASE", 198, 200], ["RAS", "GENE_OR_GENE_PRODUCT", 163, 166], ["RAS", "GENE_OR_GENE_PRODUCT", 191, 194], ["ACE2", "GENE_OR_GENE_PRODUCT", 227, 231], ["RAS", "PROTEIN", 191, 194], ["ACE2", "PROTEIN", 227, 231], ["fibrotic axes", "PROBLEM", 115, 128], ["the RAS in PH", "PROBLEM", 187, 200], ["ACE2", "TREATMENT", 227, 231], ["vasoconstrictive", "OBSERVATION_MODIFIER", 78, 94], ["proliferative", "OBSERVATION_MODIFIER", 96, 109], ["fibrotic", "OBSERVATION", 115, 123], ["vasoprotective axis", "OBSERVATION_MODIFIER", 136, 155]]], ["Unlike ACE inhibitors and angiotensin-receptor blockers (ARBs), ACE2 is an endogenous regulator of the RAS.", [["angiotensin-receptor blockers", "CHEMICAL", 26, 55], ["ACE", "GENE_OR_GENE_PRODUCT", 7, 10], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 26, 55], ["ARBs", "SIMPLE_CHEMICAL", 57, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 64, 68], ["RAS", "GENE_OR_GENE_PRODUCT", 103, 106], ["ACE2", "PROTEIN", 64, 68], ["RAS", "PROTEIN", 103, 106], ["ACE inhibitors", "TREATMENT", 7, 21], ["angiotensin-receptor blockers", "TREATMENT", 26, 55], ["ARBs", "TREATMENT", 57, 61], ["ACE2", "TREATMENT", 64, 68]]], ["Therapy with ACE inhibitors and ARBs indirectly increases ACE2 and Ang-(1-7), but ACE2 activation would directly increase the enzyme to promote beneficial effects.", [["ACE inhibitors", "CHEMICAL", 13, 27], ["ARBs", "CHEMICAL", 32, 36], ["Ang-(1-7", "CHEMICAL", 67, 75], ["ACE", "GENE_OR_GENE_PRODUCT", 13, 16], ["ARBs", "SIMPLE_CHEMICAL", 32, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 67, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["ACE2", "PROTEIN", 58, 62], ["ACE2", "PROTEIN", 82, 86], ["Therapy", "TREATMENT", 0, 7], ["ACE inhibitors", "TREATMENT", 13, 27], ["ARBs", "TREATMENT", 32, 36], ["ACE2", "TEST", 58, 62], ["Ang", "TEST", 67, 70], ["ACE2 activation", "TREATMENT", 82, 97], ["the enzyme", "TREATMENT", 122, 132]]], ["Like ACE inhibitor and ARB therapy, ACE2 activation attenuates remodeling and fibro-sis and affects the vascular relaxation properties of the endothelium.", [["vascular", "ANATOMY", 104, 112], ["endothelium", "ANATOMY", 142, 153], ["ACE inhibitor", "CHEMICAL", 5, 18], ["ARB", "CHEMICAL", 23, 26], ["ACE", "GENE_OR_GENE_PRODUCT", 5, 8], ["ARB", "SIMPLE_CHEMICAL", 23, 26], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["vascular", "MULTI-TISSUE_STRUCTURE", 104, 112], ["endothelium", "TISSUE", 142, 153], ["ACE2", "PROTEIN", 36, 40], ["ACE inhibitor", "TREATMENT", 5, 18], ["ARB therapy", "TREATMENT", 23, 34], ["ACE2 activation attenuates remodeling", "TREATMENT", 36, 73], ["vascular", "ANATOMY", 104, 112], ["relaxation properties", "OBSERVATION", 113, 134], ["endothelium", "ANATOMY", 142, 153]]], ["RAS intervention studies in PH are inconclusive, and the role of the ACE2-Ang-(1-7)-Mas axis activation in PH has not been confirmed with clinical trials.RAS Intervention and Pulmonary Hypertension:The Controversy of ACE Inhibitor/ARB Therapy It is evident that benchside pharmacologic inhibition of the RAS has translated to the bedside in the treatment of patients with hypertension, congestive heart failure, left ventricular dysfunction, pulmonary and systemic edema, diabetic nephropathy, cirrhosis of the liver, and scleroderma [16] .", [["Pulmonary", "ANATOMY", 175, 184], ["heart", "ANATOMY", 397, 402], ["left ventricular", "ANATOMY", 412, 428], ["pulmonary", "ANATOMY", 442, 451], ["liver", "ANATOMY", 511, 516], ["PH", "DISEASE", 28, 30], ["Ang-(1-7)", "CHEMICAL", 74, 83], ["PH", "DISEASE", 107, 109], ["Pulmonary Hypertension", "DISEASE", 175, 197], ["ARB", "CHEMICAL", 231, 234], ["hypertension", "DISEASE", 372, 384], ["congestive heart failure", "DISEASE", 386, 410], ["left ventricular dysfunction", "DISEASE", 412, 440], ["pulmonary and systemic edema", "DISEASE", 442, 470], ["diabetic nephropathy", "DISEASE", 472, 492], ["cirrhosis of the liver", "DISEASE", 494, 516], ["scleroderma", "DISEASE", 522, 533], ["ACE2", "GENE_OR_GENE_PRODUCT", 69, 73], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 74, 82], ["Mas", "GENE_OR_GENE_PRODUCT", 84, 87], ["ACE Inhibitor", "GENE_OR_GENE_PRODUCT", 217, 230], ["ARB", "SIMPLE_CHEMICAL", 231, 234], ["RAS", "GENE_OR_GENE_PRODUCT", 304, 307], ["patients", "ORGANISM", 358, 366], ["heart", "ORGAN", 397, 402], ["ventricular", "MULTI-TISSUE_STRUCTURE", 417, 428], ["pulmonary", "ORGAN", 442, 451], ["edema", "PATHOLOGICAL_FORMATION", 465, 470], ["liver", "ORGAN", 511, 516], ["ACE2", "PROTEIN", 69, 73], ["RAS", "PROTEIN", 304, 307], ["patients", "SPECIES", 358, 366], ["RAS intervention studies", "TEST", 0, 24], ["PH", "TEST", 28, 30], ["the ACE2", "TEST", 65, 73], ["Ang", "TEST", 74, 77], ["Mas axis activation in PH", "PROBLEM", 84, 109], ["RAS Intervention", "TREATMENT", 154, 170], ["Pulmonary Hypertension", "PROBLEM", 175, 197], ["ACE Inhibitor", "TREATMENT", 217, 230], ["ARB Therapy", "TREATMENT", 231, 242], ["hypertension", "PROBLEM", 372, 384], ["congestive heart failure", "PROBLEM", 386, 410], ["left ventricular dysfunction", "PROBLEM", 412, 440], ["pulmonary and systemic edema", "PROBLEM", 442, 470], ["diabetic nephropathy", "PROBLEM", 472, 492], ["cirrhosis of the liver", "PROBLEM", 494, 516], ["scleroderma", "PROBLEM", 522, 533], ["Pulmonary", "ANATOMY", 175, 184], ["Hypertension", "OBSERVATION", 185, 197], ["hypertension", "OBSERVATION", 372, 384], ["congestive", "OBSERVATION_MODIFIER", 386, 396], ["heart", "ANATOMY", 397, 402], ["failure", "OBSERVATION", 403, 410], ["left ventricular", "ANATOMY", 412, 428], ["dysfunction", "OBSERVATION", 429, 440], ["pulmonary", "ANATOMY", 442, 451], ["systemic", "OBSERVATION_MODIFIER", 456, 464], ["edema", "OBSERVATION", 465, 470], ["diabetic", "OBSERVATION_MODIFIER", 472, 480], ["nephropathy", "OBSERVATION", 481, 492], ["cirrhosis", "OBSERVATION", 494, 503], ["liver", "ANATOMY", 511, 516], ["scleroderma", "OBSERVATION", 522, 533]]], ["Although there is evidence in both clinical and animal studies supporting the contention that the RAS is involved in the development and progression of PAH, the use of ACE inhibitors in PAH remains controversial ( Table 2) .RAS Therapy in Animal Models of Pulmonary HypertensionEnalapril, another ACE inhibitor, was given concomitantly with MCT in a chronic PAH rat model fed a highcholesterol diet [17] .", [["Pulmonary", "ANATOMY", 256, 265], ["PAH", "DISEASE", 152, 155], ["ACE inhibitors", "CHEMICAL", 168, 182], ["PAH", "DISEASE", 186, 189], ["Pulmonary Hypertension", "DISEASE", 256, 278], ["Enalapril", "CHEMICAL", 278, 287], ["ACE inhibitor", "CHEMICAL", 297, 310], ["MCT", "CHEMICAL", 341, 344], ["PAH", "CHEMICAL", 358, 361], ["highcholesterol", "CHEMICAL", 378, 393], ["PAH", "CHEMICAL", 152, 155], ["PAH", "CHEMICAL", 186, 189], ["Enalapril", "CHEMICAL", 278, 287], ["PAH", "CHEMICAL", 358, 361], ["highcholesterol", "CHEMICAL", 378, 393], ["RAS", "GENE_OR_GENE_PRODUCT", 98, 101], ["ACE", "GENE_OR_GENE_PRODUCT", 168, 171], ["PAH", "SIMPLE_CHEMICAL", 186, 189], ["Pulmonary", "ORGAN", 256, 265], ["Enalapril", "SIMPLE_CHEMICAL", 278, 287], ["ACE", "GENE_OR_GENE_PRODUCT", 297, 300], ["MCT", "SIMPLE_CHEMICAL", 341, 344], ["rat", "ORGANISM", 362, 365], ["RAS", "PROTEIN", 98, 101], ["rat", "SPECIES", 362, 365], ["animal studies", "TEST", 48, 62], ["PAH", "PROBLEM", 152, 155], ["ACE inhibitors", "TREATMENT", 168, 182], ["RAS Therapy", "TREATMENT", 224, 235], ["Pulmonary Hypertension", "PROBLEM", 256, 278], ["Enalapril", "TREATMENT", 278, 287], ["another ACE inhibitor", "TREATMENT", 289, 310], ["MCT", "TREATMENT", 341, 344], ["a chronic PAH rat model", "TREATMENT", 348, 371], ["a highcholesterol diet", "TREATMENT", 376, 398], ["progression", "OBSERVATION_MODIFIER", 137, 148], ["PAH", "OBSERVATION", 152, 155], ["Pulmonary", "ANATOMY", 256, 265], ["Hypertension", "OBSERVATION", 266, 278]]], ["This therapeutic intervention attenuated the development of PAH while preserving the expression of endothelial nitric oxide synthase (eNOS), demonstrating a role for RAS and NO in the development of PAH.", [["PAH", "CHEMICAL", 60, 63], ["nitric oxide", "CHEMICAL", 111, 123], ["NO", "CHEMICAL", 174, 176], ["PAH", "DISEASE", 199, 202], ["PAH", "CHEMICAL", 60, 63], ["nitric oxide", "CHEMICAL", 111, 123], ["NO", "CHEMICAL", 174, 176], ["PAH", "CHEMICAL", 199, 202], ["PAH", "SIMPLE_CHEMICAL", 60, 63], ["endothelial nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 99, 132], ["eNOS", "GENE_OR_GENE_PRODUCT", 134, 138], ["RAS", "GENE_OR_GENE_PRODUCT", 166, 169], ["NO", "SIMPLE_CHEMICAL", 174, 176], ["PAH", "SIMPLE_CHEMICAL", 199, 202], ["endothelial nitric oxide synthase", "PROTEIN", 99, 132], ["eNOS", "PROTEIN", 134, 138], ["RAS", "PROTEIN", 166, 169], ["This therapeutic intervention", "TREATMENT", 0, 29], ["PAH", "PROBLEM", 60, 63], ["endothelial nitric oxide synthase", "TREATMENT", 99, 132], ["RAS", "PROBLEM", 166, 169], ["PAH", "PROBLEM", 199, 202], ["PAH", "OBSERVATION", 60, 63], ["PAH", "OBSERVATION", 199, 202]]], ["In a hypoxic rat model of PAH, the dose- In addition to blocking ACE and angiotensin receptors of the ACE-Ang II-AT 1 R axis, these inhibitors increase ACE2 and Ang-(1-7) expression levels in rats and humans [25] .", [["PAH", "CHEMICAL", 26, 29], ["angiotensin", "CHEMICAL", 73, 84], ["Ang", "CHEMICAL", 106, 109], ["Ang-(1-7", "CHEMICAL", 161, 169], ["PAH", "CHEMICAL", 26, 29], ["rat", "ORGANISM", 13, 16], ["PAH", "SIMPLE_CHEMICAL", 26, 29], ["ACE", "GENE_OR_GENE_PRODUCT", 65, 68], ["angiotensin receptors", "GENE_OR_GENE_PRODUCT", 73, 94], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 102, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 161, 169], ["rats", "ORGANISM", 192, 196], ["humans", "ORGANISM", 201, 207], ["ACE", "PROTEIN", 65, 68], ["angiotensin receptors", "PROTEIN", 73, 94], ["ACE", "PROTEIN", 102, 105], ["Ang II", "PROTEIN", 106, 112], ["ACE2", "PROTEIN", 152, 156], ["rat", "SPECIES", 13, 16], ["rats", "SPECIES", 192, 196], ["humans", "SPECIES", 201, 207], ["humans", "SPECIES", 201, 207], ["blocking ACE", "TREATMENT", 56, 68], ["angiotensin receptors", "TREATMENT", 73, 94], ["the ACE", "TEST", 98, 105], ["these inhibitors", "TREATMENT", 126, 142], ["ACE2", "TEST", 152, 156], ["Ang", "TEST", 161, 164], ["expression levels", "TEST", 171, 188], ["hypoxic rat", "OBSERVATION", 5, 16], ["PAH", "OBSERVATION", 26, 29]]], ["In patients with primary PH, higher cardiac ACE2 activity and Ang-(1-7) levels provide cardioprotection; and in patients with pulmonary fibrosis, ACE2 expression is decreased [26] .", [["cardiac", "ANATOMY", 36, 43], ["pulmonary", "ANATOMY", 126, 135], ["primary PH", "DISEASE", 17, 27], ["Ang-(1-7)", "CHEMICAL", 62, 71], ["pulmonary fibrosis", "DISEASE", 126, 144], ["patients", "ORGANISM", 3, 11], ["cardiac", "ORGAN", 36, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 62, 70], ["patients", "ORGANISM", 112, 120], ["pulmonary", "ORGAN", 126, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 146, 150], ["ACE2", "PROTEIN", 44, 48], ["ACE2", "PROTEIN", 146, 150], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 112, 120], ["primary PH", "PROBLEM", 17, 27], ["higher cardiac ACE2 activity", "PROBLEM", 29, 57], ["Ang", "TEST", 62, 65], ["cardioprotection", "TREATMENT", 87, 103], ["pulmonary fibrosis", "PROBLEM", 126, 144], ["ACE2 expression", "TEST", 146, 161], ["cardiac", "ANATOMY", 36, 43], ["ACE2 activity", "OBSERVATION", 44, 57], ["pulmonary", "ANATOMY", 126, 135], ["fibrosis", "OBSERVATION", 136, 144], ["decreased", "OBSERVATION_MODIFIER", 165, 174]]], ["These findings may indicate that ACE inhibition may be less effective in scleroderma and hypoxic PH or that it may be more effective in attenuation of remodeling when given earlier during the disease state.", [["scleroderma", "ANATOMY", 73, 84], ["scleroderma", "DISEASE", 73, 84], ["PH", "DISEASE", 97, 99], ["ACE", "GENE_OR_GENE_PRODUCT", 33, 36], ["ACE inhibition", "PROBLEM", 33, 47], ["scleroderma", "PROBLEM", 73, 84], ["hypoxic PH", "PROBLEM", 89, 99], ["the disease state", "PROBLEM", 188, 205], ["scleroderma", "OBSERVATION", 73, 84], ["hypoxic PH", "OBSERVATION_MODIFIER", 89, 99], ["may be", "UNCERTAINTY", 111, 117], ["more effective", "OBSERVATION_MODIFIER", 118, 132], ["attenuation", "OBSERVATION_MODIFIER", 136, 147], ["remodeling", "OBSERVATION", 151, 161]]], ["In addition to regressing remodeling, ACE inhibitors lower systemic blood pressure and therefore may not be beneficial for PH patients with right heart failure.The ACE2-Ang-(1-7)-Mas RAS Axis: Mechanism of Beneficial EffectsThere is a limited amount of evidence to support the mechanistic role of the ACE2-Ang-(1-7)-Mas axis.", [["blood", "ANATOMY", 68, 73], ["right heart", "ANATOMY", 140, 151], ["PH", "DISEASE", 123, 125], ["right heart failure", "DISEASE", 140, 159], ["Ang", "CHEMICAL", 169, 172], ["Ang", "CHEMICAL", 306, 309], ["ACE", "GENE_OR_GENE_PRODUCT", 38, 41], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["patients", "ORGANISM", 126, 134], ["heart", "ORGAN", 146, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 169, 177], ["ACE2", "GENE_OR_GENE_PRODUCT", 301, 305], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 306, 314], ["Mas", "GENE_OR_GENE_PRODUCT", 316, 319], ["ACE2", "PROTEIN", 164, 168], ["ACE2", "PROTEIN", 301, 305], ["patients", "SPECIES", 126, 134], ["regressing remodeling", "PROBLEM", 15, 36], ["ACE inhibitors", "TREATMENT", 38, 52], ["systemic blood pressure", "TEST", 59, 82], ["right heart failure", "PROBLEM", 140, 159], ["The ACE2", "TEST", 160, 168], ["Ang", "TEST", 169, 172], ["Beneficial Effects", "PROBLEM", 206, 224], ["the ACE2", "TEST", 297, 305], ["regressing", "OBSERVATION_MODIFIER", 15, 25], ["remodeling", "OBSERVATION", 26, 36], ["right", "ANATOMY_MODIFIER", 140, 145], ["heart", "ANATOMY", 146, 151], ["failure", "OBSERVATION", 152, 159]]], ["We do not completely understand how the ACE2-Ang-(1-7)-Mas axis protects the lungs from PH.", [["lungs", "ANATOMY", 77, 82], ["Ang", "CHEMICAL", 45, 48], ["PH", "DISEASE", 88, 90], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 45, 53], ["Mas", "GENE_OR_GENE_PRODUCT", 55, 58], ["lungs", "ORGAN", 77, 82], ["ACE2", "PROTEIN", 40, 44], ["the ACE2", "TEST", 36, 44], ["Ang", "TEST", 45, 48], ["lungs", "ANATOMY", 77, 82]]], ["Most of the literature has established that the Mas receptor is a G protein-coupled receptor, and its activation by Ang-(1-7) counteracts the actions of the ACE-Ang II-AT 1 R axis of the RAS system [27] .", [["Ang-(1-7", "CHEMICAL", 116, 124], ["Ang", "CHEMICAL", 161, 164], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 48, 60], ["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 66, 92], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 116, 124], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 157, 174], ["RAS", "GENE_OR_GENE_PRODUCT", 187, 190], ["Mas receptor", "PROTEIN", 48, 60], ["G protein-coupled receptor", "PROTEIN", 66, 92], ["ACE", "PROTEIN", 157, 160], ["Ang II", "PROTEIN", 161, 167], ["Ang", "TEST", 116, 119], ["the ACE", "TEST", 153, 160]]], ["Like ACE2 its downstream targets, Ang-(1-7) and Mas, demonstrate its impact on endothelial function.", [["endothelial", "ANATOMY", 79, 90], ["Ang", "CHEMICAL", 34, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 34, 42], ["Mas", "GENE_OR_GENE_PRODUCT", 48, 51], ["endothelial", "CELL", 79, 90], ["ACE2", "PROTEIN", 5, 9], ["Mas", "PROTEIN", 48, 51], ["Ang", "TEST", 34, 37], ["downstream", "OBSERVATION_MODIFIER", 14, 24], ["targets", "OBSERVATION_MODIFIER", 25, 32], ["endothelial function", "OBSERVATION", 79, 99]]], ["Mas knockout mice exhibited impaired endothelial function and decreased NO and eNOS [28] .", [["endothelial", "ANATOMY", 37, 48], ["NO", "CHEMICAL", 72, 74], ["NO", "CHEMICAL", 72, 74], ["Mas", "GENE_OR_GENE_PRODUCT", 0, 3], ["mice", "ORGANISM", 13, 17], ["endothelial", "CELL", 37, 48], ["NO", "SIMPLE_CHEMICAL", 72, 74], ["eNOS", "GENE_OR_GENE_PRODUCT", 79, 83], ["eNOS", "PROTEIN", 79, 83], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["Mas knockout mice", "PROBLEM", 0, 17], ["impaired endothelial function", "PROBLEM", 28, 57], ["impaired", "OBSERVATION_MODIFIER", 28, 36], ["endothelial function", "OBSERVATION", 37, 57]]], ["In cardiac myocytes from Mas-deficient mice, Mas deficiency impairs Ang-(1-7) signaling [29] .", [["cardiac myocytes", "ANATOMY", 3, 19], ["Ang-(1-7)", "CHEMICAL", 68, 77], ["cardiac myocytes", "CELL", 3, 19], ["mice", "ORGANISM", 39, 43], ["Mas", "GENE_OR_GENE_PRODUCT", 45, 48], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 68, 76], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["Mas deficiency", "PROBLEM", 45, 59], ["Ang", "TEST", 68, 71], ["cardiac myocytes", "ANATOMY", 3, 19], ["Mas deficiency", "OBSERVATION", 45, 59]]], ["In a recent article, brain-selective ACE2 overexpression attenuated neurogenic hypertension, possibly through Mas and AT 2 R upregulation [30] .", [["brain", "ANATOMY", 21, 26], ["hypertension", "DISEASE", 79, 91], ["brain", "ORGAN", 21, 26], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["Mas", "GENE_OR_GENE_PRODUCT", 110, 113], ["AT 2 R", "GENE_OR_GENE_PRODUCT", 118, 124], ["ACE2", "PROTEIN", 37, 41], ["selective ACE2 overexpression attenuated neurogenic hypertension", "PROBLEM", 27, 91], ["Mas", "TEST", 110, 113], ["brain", "ANATOMY", 21, 26], ["neurogenic", "OBSERVATION_MODIFIER", 68, 78], ["hypertension", "OBSERVATION", 79, 91]]], ["Gallagher et al. [31\u2022] reported that Ang-(1-7) prevented the Ang II-mediated reduction in ACE2 mRNA, and this was blocked by the Ang-(1-7) receptor antagonist [D-Ala 7 ]-ANG-(1-7) and mitogenactivated protein (MAP) kinase kinase inhibitor PD98059.", [["Ang-(1-7", "CHEMICAL", 37, 45], ["Ang II", "CHEMICAL", 61, 67], ["Ang", "CHEMICAL", 129, 132], ["[D-Ala 7 ]-ANG-(1-7", "CHEMICAL", 159, 178], ["PD98059", "CHEMICAL", 239, 246], ["[D-Ala", "CHEMICAL", 159, 165], ["PD98059", "CHEMICAL", 239, 246], ["Ang-(1-7", "SIMPLE_CHEMICAL", 37, 45], ["Ang II", "GENE_OR_GENE_PRODUCT", 61, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["Ang-(1-7) receptor", "GENE_OR_GENE_PRODUCT", 129, 147], ["[D-Ala 7 ]-ANG-(1-7)", "SIMPLE_CHEMICAL", 159, 179], ["mitogenactivated protein (MAP) kinase kinase", "GENE_OR_GENE_PRODUCT", 184, 228], ["PD98059", "SIMPLE_CHEMICAL", 239, 246], ["Ang II", "PROTEIN", 61, 67], ["ACE2 mRNA", "RNA", 90, 99], ["Ang-(1-7) receptor", "PROTEIN", 129, 147], ["mitogenactivated protein (MAP) kinase kinase", "PROTEIN", 184, 228], ["Ang", "TEST", 37, 40], ["the Ang II-mediated reduction in ACE2 mRNA", "TREATMENT", 57, 99], ["the Ang", "TEST", 125, 132], ["receptor antagonist", "TEST", 139, 158], ["Ala", "TEST", 162, 165], ["ANG", "TEST", 170, 173], ["mitogenactivated protein (MAP) kinase kinase inhibitor PD98059", "TREATMENT", 184, 246]]], ["They were also the first to demonstrate in vascular SMCs that MAP kinase-phosphatase pathway regulates ACE2 and maintains the balance between Ang II and Ang-(1-7).", [["vascular SMCs", "ANATOMY", 43, 56], ["Ang II", "CHEMICAL", 142, 148], ["Ang", "CHEMICAL", 153, 156], ["vascular SMCs", "CELL", 43, 56], ["MAP kinase-phosphatase", "GENE_OR_GENE_PRODUCT", 62, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 103, 107], ["Ang II", "GENE_OR_GENE_PRODUCT", 142, 148], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 153, 161], ["vascular SMCs", "CELL_TYPE", 43, 56], ["MAP kinase", "PROTEIN", 62, 72], ["phosphatase", "PROTEIN", 73, 84], ["ACE2", "PROTEIN", 103, 107], ["Ang II", "PROTEIN", 142, 148], ["MAP kinase", "TEST", 62, 72], ["ACE2", "TEST", 103, 107], ["Ang", "TEST", 153, 156], ["vascular SMCs", "ANATOMY", 43, 56]]], ["Ang-(1-7) functions through NO or prostaglandins and has antifibrotic and antioxidant properties.", [["Ang-(1-7)", "CHEMICAL", 0, 9], ["NO", "CHEMICAL", 28, 30], ["prostaglandins", "CHEMICAL", 34, 48], ["NO", "CHEMICAL", 28, 30], ["prostaglandins", "CHEMICAL", 34, 48], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["NO", "SIMPLE_CHEMICAL", 28, 30], ["prostaglandins", "SIMPLE_CHEMICAL", 34, 48], ["Ang", "TEST", 0, 3], ["prostaglandins", "TREATMENT", 34, 48], ["antifibrotic and antioxidant properties", "TREATMENT", 57, 96], ["antifibrotic", "OBSERVATION", 57, 69]]], ["Gwathmey et al. [32\u2022\u2022] were the first to demonstrate that Ang-(1-7) promotes the proteolytic conversion of Ang II by ACE2 within the nucleus to potentially endogenously modulate reactive oxygen species (ROS) production.", [["nucleus", "ANATOMY", 133, 140], ["Ang-(1-7", "CHEMICAL", 58, 66], ["Ang II", "CHEMICAL", 107, 113], ["oxygen", "CHEMICAL", 187, 193], ["ROS", "CHEMICAL", 203, 206], ["oxygen", "CHEMICAL", 187, 193], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 58, 66], ["Ang II", "GENE_OR_GENE_PRODUCT", 107, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 117, 121], ["nucleus", "CELLULAR_COMPONENT", 133, 140], ["reactive oxygen species", "SIMPLE_CHEMICAL", 178, 201], ["ROS", "SIMPLE_CHEMICAL", 203, 206], ["Ang II", "PROTEIN", 107, 113], ["ACE2", "PROTEIN", 117, 121], ["Ang", "TEST", 58, 61], ["the proteolytic conversion", "TREATMENT", 77, 103], ["reactive oxygen species", "PROBLEM", 178, 201], ["nucleus", "ANATOMY", 133, 140], ["reactive", "OBSERVATION_MODIFIER", 178, 186], ["oxygen species", "OBSERVATION", 187, 201]]], ["Wang et al. [33, 34] demonstrated that circulating Ang-(1-7) stimulated cardiac endothelial progenitor cell (EPC) proliferation benefiting myocardial infarction.", [["cardiac endothelial progenitor cell", "ANATOMY", 72, 107], ["EPC", "ANATOMY", 109, 112], ["myocardial", "ANATOMY", 139, 149], ["Ang-(1-7)", "CHEMICAL", 51, 60], ["myocardial infarction", "DISEASE", 139, 160], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 51, 59], ["cardiac endothelial progenitor cell", "CELL", 72, 107], ["EPC", "CELL", 109, 112], ["myocardial", "MULTI-TISSUE_STRUCTURE", 139, 149], ["cardiac endothelial progenitor cell", "CELL_TYPE", 72, 107], ["EPC", "CELL_TYPE", 109, 112], ["circulating Ang", "TEST", 39, 54], ["stimulated cardiac endothelial progenitor cell (EPC)", "TREATMENT", 61, 113], ["proliferation benefiting myocardial infarction", "PROBLEM", 114, 160], ["cardiac endothelial", "ANATOMY", 72, 91], ["progenitor cell", "OBSERVATION", 92, 107], ["myocardial", "ANATOMY", 139, 149], ["infarction", "OBSERVATION", 150, 160]]], ["Tallant et al. [35] suggest that Ang-(1-7) inhibits vascular growth through the release of prostacyclin, the prostacyclin-mediated production of cyclic adenosine monophosphate (cAMP), activation of cAMPdependent protein kinase, and the attenuation of MAP kinase activation.", [["vascular", "ANATOMY", 52, 60], ["Ang-(1-7", "CHEMICAL", 33, 41], ["prostacyclin", "CHEMICAL", 91, 103], ["prostacyclin", "CHEMICAL", 109, 121], ["cyclic adenosine monophosphate", "CHEMICAL", 145, 175], ["cAMP", "CHEMICAL", 177, 181], ["prostacyclin", "CHEMICAL", 91, 103], ["prostacyclin", "CHEMICAL", 109, 121], ["cyclic adenosine monophosphate", "CHEMICAL", 145, 175], ["cAMP", "CHEMICAL", 177, 181], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 33, 41], ["vascular", "MULTI-TISSUE_STRUCTURE", 52, 60], ["prostacyclin", "SIMPLE_CHEMICAL", 91, 103], ["prostacyclin", "SIMPLE_CHEMICAL", 109, 121], ["cyclic adenosine monophosphate", "GENE_OR_GENE_PRODUCT", 145, 175], ["cAMP", "SIMPLE_CHEMICAL", 177, 181], ["cAMPdependent protein kinase", "GENE_OR_GENE_PRODUCT", 198, 226], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 251, 261], ["cAMPdependent protein kinase", "PROTEIN", 198, 226], ["MAP kinase", "PROTEIN", 251, 261], ["Ang", "TEST", 33, 36], ["vascular growth", "PROBLEM", 52, 67], ["prostacyclin", "TREATMENT", 91, 103], ["the prostacyclin", "TREATMENT", 105, 121], ["cyclic adenosine monophosphate (cAMP)", "TREATMENT", 145, 182], ["activation of cAMPdependent protein kinase", "TREATMENT", 184, 226], ["MAP kinase activation", "TREATMENT", 251, 272], ["vascular", "ANATOMY", 52, 60]]], ["These mechanistic studies have established that the ACE2-Ang-(1-7)-Mas receptor axis components exist within the nucleus and at every level of the vascular wall, poised to initiate and sustain a vasoprotective effect.Signaling of TGF-\u03b2 and Bone Morphogenetic Proteins in Pulmonary HypertensionAng II promotes growth, proliferation, and fibrosis.", [["nucleus", "ANATOMY", 113, 120], ["vascular wall", "ANATOMY", 147, 160], ["Pulmonary", "ANATOMY", 271, 280], ["Ang", "CHEMICAL", 57, 60], ["HypertensionAng II", "CHEMICAL", 281, 299], ["fibrosis", "DISEASE", 336, 344], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 57, 65], ["nucleus", "CELLULAR_COMPONENT", 113, 120], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 147, 160], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 230, 235], ["ACE2", "PROTEIN", 52, 56], ["Mas receptor", "PROTEIN", 67, 79], ["TGF-\u03b2", "PROTEIN", 230, 235], ["Bone Morphogenetic Proteins", "PROTEIN", 240, 267], ["These mechanistic studies", "TEST", 0, 25], ["the ACE2", "TEST", 48, 56], ["Ang", "TEST", 57, 60], ["TGF", "TEST", 230, 233], ["Bone Morphogenetic Proteins", "PROBLEM", 240, 267], ["proliferation", "PROBLEM", 317, 330], ["fibrosis", "PROBLEM", 336, 344], ["nucleus", "ANATOMY_MODIFIER", 113, 120], ["vascular wall", "ANATOMY", 147, 160], ["vasoprotective effect", "OBSERVATION", 195, 216], ["TGF", "OBSERVATION", 230, 233], ["Bone", "ANATOMY", 240, 244], ["Morphogenetic Proteins", "OBSERVATION", 245, 267], ["Pulmonary", "ANATOMY", 271, 280], ["HypertensionAng", "OBSERVATION", 281, 296], ["growth", "OBSERVATION_MODIFIER", 309, 315], ["proliferation", "OBSERVATION_MODIFIER", 317, 330], ["fibrosis", "OBSERVATION", 336, 344]]], ["TGF-\u03b2 upregulates ACE and downregulates ACE2.", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["ACE", "GENE_OR_GENE_PRODUCT", 18, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["TGF-\u03b2", "PROTEIN", 0, 5], ["ACE", "PROTEIN", 18, 21], ["ACE2", "PROTEIN", 40, 44], ["TGF", "TEST", 0, 3], ["upregulates ACE", "TREATMENT", 6, 21], ["ACE2", "TEST", 40, 44]]], ["The TGF-\u03b2 superfamily encompasses a large number of growth factors such as TGF-\u03b2 ligands, activins, inhibins, and bone morphogenetic proteins (BMPs).", [["bone", "ANATOMY", 114, 118], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 4, 9], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 75, 80], ["activins", "GENE_OR_GENE_PRODUCT", 90, 98], ["inhibins", "GENE_OR_GENE_PRODUCT", 100, 108], ["bone morphogenetic proteins", "GENE_OR_GENE_PRODUCT", 114, 141], ["TGF-\u03b2 superfamily", "PROTEIN", 4, 21], ["growth factors", "PROTEIN", 52, 66], ["TGF-\u03b2 ligands", "PROTEIN", 75, 88], ["activins", "PROTEIN", 90, 98], ["inhibins", "PROTEIN", 100, 108], ["bone morphogenetic proteins", "PROTEIN", 114, 141], ["BMPs", "PROTEIN", 143, 147], ["The TGF", "TEST", 0, 7], ["growth factors", "PROBLEM", 52, 66], ["TGF", "TEST", 75, 78], ["activins, inhibins, and bone morphogenetic proteins", "PROBLEM", 90, 141], ["large", "OBSERVATION_MODIFIER", 36, 41], ["number", "OBSERVATION_MODIFIER", 42, 48], ["bone", "ANATOMY", 114, 118]]], ["BMPS are involved in vascular integrity and control of vascular cell proliferation [36] .", [["vascular", "ANATOMY", 21, 29], ["vascular cell", "ANATOMY", 55, 68], ["BMPS", "GENE_OR_GENE_PRODUCT", 0, 4], ["vascular", "MULTI-TISSUE_STRUCTURE", 21, 29], ["vascular cell", "CELL", 55, 68], ["BMPS", "PROTEIN", 0, 4], ["BMPS", "TREATMENT", 0, 4], ["vascular cell proliferation", "PROBLEM", 55, 82], ["vascular", "ANATOMY", 21, 29], ["integrity", "OBSERVATION_MODIFIER", 30, 39], ["vascular", "ANATOMY", 55, 63], ["cell proliferation", "OBSERVATION", 64, 82]]], ["Both TGF-\u03b2 and BMP isoforms control endothelial cell and SMC proliferation, apoptosis, and extracellular matrix (ECM) secretion and deposition.", [["endothelial cell", "ANATOMY", 36, 52], ["SMC", "ANATOMY", 57, 60], ["extracellular matrix", "ANATOMY", 91, 111], ["ECM", "ANATOMY", 113, 116], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 5, 10], ["BMP", "GENE_OR_GENE_PRODUCT", 15, 18], ["endothelial cell", "CELL", 36, 52], ["SMC", "CELL", 57, 60], ["extracellular matrix", "CELLULAR_COMPONENT", 91, 111], ["ECM", "CELLULAR_COMPONENT", 113, 116], ["TGF-\u03b2", "PROTEIN", 5, 10], ["BMP isoforms", "PROTEIN", 15, 27], ["Both TGF", "TEST", 0, 8], ["BMP isoforms", "TEST", 15, 27], ["endothelial cell", "PROBLEM", 36, 52], ["SMC proliferation", "PROBLEM", 57, 74], ["apoptosis", "PROBLEM", 76, 85], ["BMP isoforms", "OBSERVATION_MODIFIER", 15, 27], ["endothelial cell", "OBSERVATION", 36, 52], ["SMC", "ANATOMY", 57, 60], ["proliferation", "OBSERVATION", 61, 74], ["apoptosis", "OBSERVATION_MODIFIER", 76, 85], ["extracellular", "OBSERVATION_MODIFIER", 91, 104], ["matrix", "OBSERVATION_MODIFIER", 105, 111], ["deposition", "OBSERVATION_MODIFIER", 132, 142]]], ["BMPR-II and BMPR-1A plasma membrane protein expression is decreased in pulmonary endothelial cells in both heritable and sporadic PAH.", [["plasma membrane", "ANATOMY", 20, 35], ["pulmonary endothelial cells", "ANATOMY", 71, 98], ["PAH", "DISEASE", 130, 133], ["PAH", "CHEMICAL", 130, 133], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 0, 7], ["BMPR-1A", "GENE_OR_GENE_PRODUCT", 12, 19], ["pulmonary endothelial cells", "CELL", 71, 98], ["PAH", "CANCER", 130, 133], ["BMPR", "PROTEIN", 0, 4], ["BMPR", "PROTEIN", 12, 16], ["pulmonary endothelial cells", "CELL_TYPE", 71, 98], ["BMPR", "TEST", 0, 4], ["BMPR", "TEST", 12, 16], ["1A plasma membrane protein expression", "TEST", 17, 54], ["pulmonary endothelial cells", "PROBLEM", 71, 98], ["sporadic PAH", "PROBLEM", 121, 133], ["protein expression", "OBSERVATION", 36, 54], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["pulmonary endothelial cells", "OBSERVATION", 71, 98], ["sporadic", "OBSERVATION_MODIFIER", 121, 129], ["PAH", "OBSERVATION", 130, 133]]], ["BMPR-II has been localized to the endothelium and vascular SMCs of small pulmonary arteries [37] .", [["endothelium", "ANATOMY", 34, 45], ["vascular SMCs", "ANATOMY", 50, 63], ["small pulmonary arteries", "ANATOMY", 67, 91], ["BMPR-II", "CHEMICAL", 0, 7], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 0, 7], ["endothelium", "TISSUE", 34, 45], ["vascular SMCs", "TISSUE", 50, 63], ["pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 73, 91], ["BMPR-II", "PROTEIN", 0, 7], ["vascular SMCs", "CELL_TYPE", 50, 63], ["endothelium", "ANATOMY_MODIFIER", 34, 45], ["vascular SMCs", "ANATOMY", 50, 63], ["small", "OBSERVATION_MODIFIER", 67, 72], ["pulmonary arteries", "ANATOMY", 73, 91]]], ["Signal transduction studies reveal that BMP signals are mediated by type I and II receptors through downstream mediators, Smad1, Smad5, and Smad8.", [["BMP", "GENE_OR_GENE_PRODUCT", 40, 43], ["type I and II receptors", "GENE_OR_GENE_PRODUCT", 68, 91], ["Smad1", "GENE_OR_GENE_PRODUCT", 122, 127], ["Smad5", "GENE_OR_GENE_PRODUCT", 129, 134], ["Smad8", "GENE_OR_GENE_PRODUCT", 140, 145], ["BMP", "PROTEIN", 40, 43], ["type I and II receptors", "PROTEIN", 68, 91], ["downstream mediators", "PROTEIN", 100, 120], ["Smad1", "PROTEIN", 122, 127], ["Smad5", "PROTEIN", 129, 134], ["Smad8", "PROTEIN", 140, 145], ["Signal transduction studies", "TEST", 0, 27], ["BMP signals", "PROBLEM", 40, 51], ["Smad1", "TEST", 122, 127], ["Smad5", "TEST", 129, 134], ["Smad8", "TEST", 140, 145]]], ["They form a complex with Smad4 and translocate into the nucleus.", [["nucleus", "ANATOMY", 56, 63], ["Smad4", "GENE_OR_GENE_PRODUCT", 25, 30], ["nucleus", "CELLULAR_COMPONENT", 56, 63], ["Smad4", "PROTEIN", 25, 30], ["nucleus", "ANATOMY", 56, 63]]], ["The function of BMPR-II is to mediate growth suppression and apoptosis in vasculature [38] .", [["vasculature", "ANATOMY", 74, 85], ["BMPR-II", "CHEMICAL", 16, 23], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 16, 23], ["BMPR-II", "PROTEIN", 16, 23], ["BMPR", "TEST", 16, 20], ["growth suppression", "PROBLEM", 38, 56], ["apoptosis in vasculature", "PROBLEM", 61, 85], ["vasculature", "ANATOMY", 74, 85]]], ["Thus a loss of BMPR-II function may lead to the vasculopathy evident in PAH [39] .", [["vasculopathy", "DISEASE", 48, 60], ["PAH", "CHEMICAL", 72, 75], ["PAH", "CHEMICAL", 72, 75], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 15, 22], ["BMPR", "PROTEIN", 15, 19], ["a loss of BMPR-II function", "PROBLEM", 5, 31], ["the vasculopathy", "PROBLEM", 44, 60], ["vasculopathy", "OBSERVATION", 48, 60]]], ["Late cultured EPCs from idiopathic PAH patients with BMPR-II mutation showed a hyperproliferative phenotype with impaired ability to form vascular networks [40] .Signaling of TGF-\u03b2 and Bone Morphogenetic Proteins in Pulmonary HypertensionTGF-\u03b2 signaling controls a number of functions: proliferation, migration, differentiation, apoptosis, ECM deposition, and secretion.", [["EPCs", "ANATOMY", 14, 18], ["vascular networks", "ANATOMY", 138, 155], ["Pulmonary", "ANATOMY", 216, 225], ["ECM", "ANATOMY", 340, 343], ["idiopathic PAH", "DISEASE", 24, 38], ["Hypertension", "DISEASE", 226, 238], ["PAH", "CHEMICAL", 35, 38], ["EPCs", "CELL", 14, 18], ["patients", "ORGANISM", 39, 47], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 53, 60], ["vascular networks", "MULTI-TISSUE_STRUCTURE", 138, 155], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 175, 180], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 238, 243], ["ECM", "CELLULAR_COMPONENT", 340, 343], ["EPCs", "CELL_TYPE", 14, 18], ["BMPR", "PROTEIN", 53, 57], ["TGF-\u03b2", "PROTEIN", 175, 180], ["Bone Morphogenetic Proteins", "PROTEIN", 185, 212], ["TGF-\u03b2", "PROTEIN", 238, 243], ["patients", "SPECIES", 39, 47], ["idiopathic PAH", "PROBLEM", 24, 38], ["BMPR", "TEST", 53, 57], ["II mutation", "PROBLEM", 58, 69], ["a hyperproliferative phenotype", "PROBLEM", 77, 107], ["TGF", "TEST", 175, 178], ["Bone Morphogenetic Proteins", "TEST", 185, 212], ["Pulmonary Hypertension", "PROBLEM", 216, 238], ["TGF", "TEST", 238, 241], ["signaling controls", "PROBLEM", 244, 262], ["proliferation", "PROBLEM", 286, 299], ["apoptosis", "PROBLEM", 329, 338], ["ECM deposition", "TEST", 340, 354], ["hyperproliferative phenotype", "OBSERVATION", 79, 107], ["vascular", "ANATOMY", 138, 146], ["TGF", "OBSERVATION", 175, 178], ["Bone", "ANATOMY", 185, 189], ["Morphogenetic Proteins", "OBSERVATION", 190, 212], ["Pulmonary", "ANATOMY", 216, 225], ["Hypertension", "OBSERVATION", 226, 238], ["TGF", "OBSERVATION_MODIFIER", 238, 241], ["proliferation", "OBSERVATION_MODIFIER", 286, 299], ["migration", "OBSERVATION_MODIFIER", 301, 310]]], ["Mutations in genes encoding either TGF-\u03b2 or BMP signaling systems have been associated with PAH, and research suggests that abnormal TGF-\u03b2 or BMP signaling is imbalanced in PAH [41] .", [["PAH", "CHEMICAL", 92, 95], ["PAH", "CHEMICAL", 173, 176], ["PAH", "CHEMICAL", 92, 95], ["PAH", "CHEMICAL", 173, 176], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 35, 40], ["BMP", "GENE_OR_GENE_PRODUCT", 44, 47], ["PAH", "SIMPLE_CHEMICAL", 92, 95], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 133, 138], ["BMP", "GENE_OR_GENE_PRODUCT", 142, 145], ["TGF-\u03b2", "PROTEIN", 35, 40], ["BMP", "PROTEIN", 44, 47], ["TGF-\u03b2", "PROTEIN", 133, 138], ["BMP", "PROTEIN", 142, 145], ["Mutations in genes", "PROBLEM", 0, 18], ["TGF", "TEST", 35, 38], ["BMP signaling systems", "PROBLEM", 44, 65], ["PAH", "PROBLEM", 92, 95], ["abnormal TGF", "PROBLEM", 124, 136], ["BMP signaling", "PROBLEM", 142, 155], ["PAH", "OBSERVATION", 92, 95]]], ["Thus, TGF-\u03b2 and BMP appear to play opposing roles ( Fig. 1 ) in maintenance and growth of pulmonary artery SMCs and endothelial cells [42] .", [["pulmonary artery SMCs", "ANATOMY", 90, 111], ["endothelial cells", "ANATOMY", 116, 133], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 6, 11], ["BMP", "GENE_OR_GENE_PRODUCT", 16, 19], ["pulmonary artery SMCs", "CELL", 90, 111], ["endothelial cells", "CELL", 116, 133], ["TGF-\u03b2", "PROTEIN", 6, 11], ["BMP", "PROTEIN", 16, 19], ["pulmonary artery SMCs", "CELL_TYPE", 90, 111], ["endothelial cells", "CELL_TYPE", 116, 133], ["TGF", "TEST", 6, 9], ["BMP", "TREATMENT", 16, 19], ["endothelial cells", "TEST", 116, 133], ["pulmonary artery", "ANATOMY", 90, 106], ["SMCs", "ANATOMY", 107, 111], ["endothelial cells", "OBSERVATION", 116, 133]]], ["Studies suggest an inhibitory effect of BMP signaling on pulmonary artery SMCs.", [["pulmonary artery SMCs", "ANATOMY", 57, 78], ["BMP", "GENE_OR_GENE_PRODUCT", 40, 43], ["pulmonary artery SMCs", "CELL", 57, 78], ["BMP", "PROTEIN", 40, 43], ["pulmonary artery SMCs", "CELL_TYPE", 57, 78], ["Studies", "TEST", 0, 7], ["BMP signaling on pulmonary artery SMCs", "PROBLEM", 40, 78], ["inhibitory effect", "OBSERVATION", 19, 36], ["BMP", "OBSERVATION", 40, 43], ["pulmonary artery SMCs", "ANATOMY", 57, 78]]], ["Such cells from PAH patients are resistant to antiproliferative effects of BMP.", [["cells", "ANATOMY", 5, 10], ["PAH", "CHEMICAL", 16, 19], ["PAH", "CHEMICAL", 16, 19], ["cells", "CELL", 5, 10], ["patients", "ORGANISM", 20, 28], ["BMP", "GENE_OR_GENE_PRODUCT", 75, 78], ["BMP", "PROTEIN", 75, 78], ["patients", "SPECIES", 20, 28], ["Such cells", "PROBLEM", 0, 10], ["antiproliferative effects of BMP", "TREATMENT", 46, 78]]], ["TGF-\u03b2 gain of proliferation and BMPR-II loss of growth suppression and inability to promote vascular SMC apoptosis may promote PAH development.Signaling of TGF-\u03b2 and Bone Morphogenetic Proteins in Pulmonary HypertensionHong et al. [5\u2022\u2022] revealed increased RVSP and increased muscularization in Bmpr2 knockout mice with incomplete penetrance.", [["vascular SMC", "ANATOMY", 92, 104], ["PAH", "CHEMICAL", 127, 130], ["Hypertension", "DISEASE", 207, 219], ["PAH", "CHEMICAL", 127, 130], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 32, 39], ["vascular SMC", "CELL", 92, 104], ["PAH", "SIMPLE_CHEMICAL", 127, 130], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 156, 161], ["RVSP", "GENE_OR_GENE_PRODUCT", 256, 260], ["Bmpr2", "GENE_OR_GENE_PRODUCT", 294, 299], ["mice", "ORGANISM", 309, 313], ["TGF-\u03b2", "PROTEIN", 0, 5], ["BMPR", "PROTEIN", 32, 36], ["SMC", "CELL_TYPE", 101, 104], ["TGF-\u03b2", "PROTEIN", 156, 161], ["Bone Morphogenetic Proteins", "PROTEIN", 166, 193], ["RVSP", "PROTEIN", 256, 260], ["Bmpr2", "PROTEIN", 294, 299], ["mice", "SPECIES", 309, 313], ["mice", "SPECIES", 309, 313], ["TGF", "TEST", 0, 3], ["proliferation", "PROBLEM", 14, 27], ["BMPR", "PROBLEM", 32, 36], ["II loss of growth suppression", "PROBLEM", 37, 66], ["inability to promote vascular SMC apoptosis", "PROBLEM", 71, 114], ["TGF", "TEST", 156, 159], ["Bone Morphogenetic Proteins", "PROBLEM", 166, 193], ["Pulmonary Hypertension", "PROBLEM", 197, 219], ["Hong et al.", "TEST", 219, 230], ["increased RVSP", "PROBLEM", 246, 260], ["increased muscularization", "PROBLEM", 265, 290], ["incomplete penetrance", "PROBLEM", 319, 340], ["vascular SMC", "ANATOMY", 92, 104], ["PAH", "OBSERVATION", 127, 130], ["TGF", "OBSERVATION", 156, 159], ["Bone", "ANATOMY", 166, 170], ["Pulmonary", "ANATOMY", 197, 206], ["Hypertension", "OBSERVATION", 207, 219], ["increased", "OBSERVATION_MODIFIER", 246, 255], ["RVSP", "OBSERVATION", 256, 260], ["increased", "OBSERVATION_MODIFIER", 265, 274], ["muscularization", "OBSERVATION", 275, 290], ["Bmpr2 knockout", "OBSERVATION", 294, 308]]], ["Reynolds et al. [43] demonstrated that overexpression of BMPR-II in a hypoxic rat model protects them against PAH development.", [["BMPR-II", "CHEMICAL", 57, 64], ["PAH", "CHEMICAL", 110, 113], ["PAH", "CHEMICAL", 110, 113], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 57, 64], ["rat", "ORGANISM", 78, 81], ["PAH", "SIMPLE_CHEMICAL", 110, 113], ["BMPR-II", "PROTEIN", 57, 64], ["rat", "SPECIES", 78, 81], ["rat", "SPECIES", 78, 81], ["BMPR", "TEST", 57, 61], ["a hypoxic rat model", "TREATMENT", 68, 87]]], ["BMPR-II heterozygous null mice have severe hypoxic PH with a decrease in eNOS expression and activity.Signaling of TGF-\u03b2 and Bone Morphogenetic Proteins in Pulmonary HypertensionTGF-\u03b2 signaling is modulated in MCT rat models and the results are controversial.", [["Pulmonary", "ANATOMY", 156, 165], ["PH", "DISEASE", 51, 53], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 0, 7], ["mice", "ORGANISM", 26, 30], ["eNOS", "GENE_OR_GENE_PRODUCT", 73, 77], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 115, 120], ["HypertensionTGF-\u03b2", "GENE_OR_GENE_PRODUCT", 166, 183], ["MCT rat", "ORGANISM", 210, 217], ["BMPR", "PROTEIN", 0, 4], ["eNOS", "PROTEIN", 73, 77], ["TGF-\u03b2", "PROTEIN", 115, 120], ["Bone Morphogenetic Proteins", "PROTEIN", 125, 152], ["mice", "SPECIES", 26, 30], ["rat", "SPECIES", 214, 217], ["mice", "SPECIES", 26, 30], ["BMPR", "TEST", 0, 4], ["II heterozygous null mice", "PROBLEM", 5, 30], ["severe hypoxic PH", "PROBLEM", 36, 53], ["a decrease in eNOS expression", "PROBLEM", 59, 88], ["Signaling of TGF-\u03b2", "TEST", 102, 120], ["Bone Morphogenetic Proteins", "TEST", 125, 152], ["Pulmonary HypertensionTGF", "TEST", 156, 181], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["hypoxic PH", "OBSERVATION", 43, 53], ["decrease", "OBSERVATION_MODIFIER", 61, 69], ["eNOS expression", "OBSERVATION", 73, 88], ["activity", "OBSERVATION_MODIFIER", 93, 101], ["TGF", "OBSERVATION", 115, 118], ["Bone", "ANATOMY", 125, 129], ["Morphogenetic Proteins", "OBSERVATION", 130, 152], ["Pulmonary", "ANATOMY", 156, 165], ["HypertensionTGF", "OBSERVATION", 166, 181]]], ["Some studies suggest that MCT inhibits signaling, and others suggest that MCT enhances signaling.", [["MCT", "CHEMICAL", 26, 29], ["MCT", "CHEMICAL", 74, 77], ["MCT", "GENE_OR_GENE_PRODUCT", 26, 29], ["MCT", "GENE_OR_GENE_PRODUCT", 74, 77], ["Some studies", "TEST", 0, 12], ["MCT inhibits signaling", "PROBLEM", 26, 48], ["MCT enhances signaling", "PROBLEM", 74, 96]]], ["Inhibition of activin-like kinase 5 (ALK5), a TGF-\u03b2 type I receptor, prevents and reverses PAH [44] .", [["PAH", "CHEMICAL", 91, 94], ["PAH", "CHEMICAL", 91, 94], ["activin-like kinase 5", "GENE_OR_GENE_PRODUCT", 14, 35], ["ALK5", "GENE_OR_GENE_PRODUCT", 37, 41], ["TGF-\u03b2 type I receptor", "GENE_OR_GENE_PRODUCT", 46, 67], ["activin-like kinase 5", "PROTEIN", 14, 35], ["ALK5", "PROTEIN", 37, 41], ["TGF-\u03b2 type I receptor", "PROTEIN", 46, 67], ["activin", "TEST", 14, 21], ["kinase", "TEST", 27, 33], ["a TGF", "TEST", 44, 49]]], ["In both hypoxic and MCT models, BMPR-II mRNA and protein expression are reduced, with increased TGF-\u03b2 and Smad3 signaling in the MCT model and not in the hypoxic model.", [["BMPR-II", "GENE_OR_GENE_PRODUCT", 32, 39], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 96, 101], ["Smad3", "GENE_OR_GENE_PRODUCT", 106, 111], ["MCT", "GENE_OR_GENE_PRODUCT", 129, 132], ["BMPR-II mRNA", "RNA", 32, 44], ["TGF", "PROTEIN", 96, 99], ["Smad3", "PROTEIN", 106, 111], ["MCT models", "TEST", 20, 30], ["BMPR", "TEST", 32, 36], ["protein expression", "TEST", 49, 67], ["increased TGF", "PROBLEM", 86, 99], ["the MCT model", "TEST", 125, 138], ["both", "OBSERVATION_MODIFIER", 3, 7], ["hypoxic", "OBSERVATION_MODIFIER", 8, 15], ["reduced", "OBSERVATION_MODIFIER", 72, 79], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["TGF", "OBSERVATION", 96, 99], ["hypoxic model", "OBSERVATION", 154, 167]]], ["This increase in signaling, RVSP, and vascular remodeling in the MCT model was attenuated by ALK5 inhibition [45] .", [["vascular", "ANATOMY", 38, 46], ["vascular", "MULTI-TISSUE_STRUCTURE", 38, 46], ["MCT", "GENE_OR_GENE_PRODUCT", 65, 68], ["ALK5", "GENE_OR_GENE_PRODUCT", 93, 97], ["RVSP", "PROTEIN", 28, 32], ["ALK5", "PROTEIN", 93, 97], ["RVSP", "TEST", 28, 32], ["vascular remodeling", "PROBLEM", 38, 57], ["the MCT model", "TEST", 61, 74], ["ALK5 inhibition", "TEST", 93, 108], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["RVSP", "OBSERVATION", 28, 32], ["vascular", "ANATOMY", 38, 46], ["remodeling", "OBSERVATION", 47, 57]]], ["Reduction in BMPR-II signaling due to genetic or environmental cues may cause BMPR-II signaling to fall below a threshold that triggers PAH vasculopathy.", [["BMPR-II", "CHEMICAL", 13, 20], ["PAH", "CHEMICAL", 136, 139], ["vasculopathy", "DISEASE", 140, 152], ["PAH", "CHEMICAL", 136, 139], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 13, 20], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 78, 85], ["PAH", "SIMPLE_CHEMICAL", 136, 139], ["BMPR", "PROTEIN", 13, 17], ["BMPR", "PROTEIN", 78, 82], ["Reduction in BMPR", "PROBLEM", 0, 17], ["II signaling", "PROBLEM", 18, 30], ["genetic or environmental cues", "PROBLEM", 38, 67], ["BMPR", "PROBLEM", 78, 82], ["II signaling", "PROBLEM", 83, 95], ["PAH vasculopathy", "PROBLEM", 136, 152], ["PAH vasculopathy", "OBSERVATION", 136, 152]]], ["An imbalance in TGF-\u03b2/BMP signaling promotes PAH development and progression.Future DirectionsSince its discovery in 2000, ACE2 has been investigated in the SARS coronavirus infection and in the cardiovascular, renal, central nervous, and pulmonary systems.", [["cardiovascular", "ANATOMY", 195, 209], ["renal", "ANATOMY", 211, 216], ["central nervous", "ANATOMY", 218, 233], ["pulmonary systems", "ANATOMY", 239, 256], ["PAH", "CHEMICAL", 45, 48], ["SARS coronavirus infection", "DISEASE", 157, 183], ["cardiovascular, renal, central nervous, and pulmonary systems", "DISEASE", 195, 256], ["PAH", "CHEMICAL", 45, 48], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 16, 21], ["BMP", "GENE_OR_GENE_PRODUCT", 22, 25], ["PAH", "CANCER", 45, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 123, 127], ["SARS coronavirus", "ORGANISM", 157, 173], ["cardiovascular", "ANATOMICAL_SYSTEM", 195, 209], ["renal", "CANCER", 211, 216], ["central nervous", "ANATOMICAL_SYSTEM", 218, 233], ["pulmonary", "ORGAN", 239, 248], ["TGF-\u03b2", "PROTEIN", 16, 21], ["BMP", "PROTEIN", 22, 25], ["ACE2", "PROTEIN", 123, 127], ["coronavirus", "SPECIES", 162, 173], ["SARS coronavirus", "SPECIES", 157, 173], ["An imbalance in TGF", "PROBLEM", 0, 19], ["ACE2", "TREATMENT", 123, 127], ["the SARS coronavirus infection", "PROBLEM", 153, 183], ["the cardiovascular, renal, central nervous, and pulmonary systems", "PROBLEM", 191, 256], ["imbalance", "OBSERVATION", 3, 12], ["PAH", "OBSERVATION", 45, 48], ["progression", "OBSERVATION_MODIFIER", 65, 76], ["coronavirus", "OBSERVATION_MODIFIER", 162, 173], ["infection", "OBSERVATION", 174, 183], ["cardiovascular", "ANATOMY", 195, 209], ["renal", "ANATOMY", 211, 216], ["central nervous", "ANATOMY", 218, 233], ["pulmonary systems", "ANATOMY", 239, 256]]], ["The benefit of its overexpression and activation in PAH supports its use in a \"proof of concept\" preclinical trial.", [["PAH", "CHEMICAL", 52, 55], ["PAH", "CHEMICAL", 52, 55], ["PAH", "SIMPLE_CHEMICAL", 52, 55]]], ["It will be interesting to discover the link between TGF-\u03b2, BMPR-II, and the ACE2-Ang-(1-7)-Mas axis because, regardless of the disease etiology, remodeling consists of intimal fibrosis, increased medial thickness, pulmonary arteriolar occlusion, and plexiform lesions.", [["intimal", "ANATOMY", 168, 175], ["medial", "ANATOMY", 196, 202], ["pulmonary arteriolar", "ANATOMY", 214, 234], ["plexiform lesions", "ANATOMY", 250, 267], ["Ang", "CHEMICAL", 81, 84], ["fibrosis", "DISEASE", 176, 184], ["pulmonary arteriolar occlusion", "DISEASE", 214, 244], ["plexiform lesions", "DISEASE", 250, 267], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 52, 57], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 59, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 81, 89], ["Mas", "GENE_OR_GENE_PRODUCT", 91, 94], ["intimal", "TISSUE", 168, 175], ["medial", "TISSUE", 196, 202], ["pulmonary arteriolar", "MULTI-TISSUE_STRUCTURE", 214, 234], ["plexiform lesions", "PATHOLOGICAL_FORMATION", 250, 267], ["TGF-\u03b2", "PROTEIN", 52, 57], ["BMPR", "PROTEIN", 59, 63], ["ACE2", "PROTEIN", 76, 80], ["TGF", "TEST", 52, 55], ["BMPR", "TEST", 59, 63], ["the ACE2", "TEST", 72, 80], ["Ang", "TEST", 81, 84], ["the disease etiology", "PROBLEM", 123, 143], ["intimal fibrosis", "PROBLEM", 168, 184], ["increased medial thickness", "PROBLEM", 186, 212], ["pulmonary arteriolar occlusion", "PROBLEM", 214, 244], ["plexiform lesions", "PROBLEM", 250, 267], ["disease", "OBSERVATION", 127, 134], ["intimal", "OBSERVATION_MODIFIER", 168, 175], ["fibrosis", "OBSERVATION", 176, 184], ["increased", "OBSERVATION_MODIFIER", 186, 195], ["medial", "OBSERVATION_MODIFIER", 196, 202], ["thickness", "OBSERVATION_MODIFIER", 203, 212], ["pulmonary arteriolar", "ANATOMY", 214, 234], ["occlusion", "OBSERVATION", 235, 244], ["plexiform", "OBSERVATION_MODIFIER", 250, 259], ["lesions", "OBSERVATION", 260, 267]]], ["ACE2 has been shown to prevent fibrosis and other components of PVR.", [["fibrosis", "DISEASE", 31, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["PVR", "GENE_OR_GENE_PRODUCT", 64, 67], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["fibrosis", "PROBLEM", 31, 39], ["PVR", "PROBLEM", 64, 67], ["fibrosis", "OBSERVATION", 31, 39], ["PVR", "OBSERVATION", 64, 67]]], ["Therefore, ACE2 therapy may be effective at preventing disease progression in all forms of PH.Future DirectionsPerturbation of BMP signaling is increased with missense mutations, and the knowledge of differences in disease severity and different BMPR-II mutations is critical to therapeutic design.", [["PH", "DISEASE", 91, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["BMP", "GENE_OR_GENE_PRODUCT", 127, 130], ["BMPR-II", "GENE_OR_GENE_PRODUCT", 246, 253], ["ACE2", "PROTEIN", 11, 15], ["BMP", "PROTEIN", 127, 130], ["BMPR", "PROTEIN", 246, 250], ["ACE2 therapy", "TREATMENT", 11, 23], ["disease progression in all forms of PH", "PROBLEM", 55, 93], ["BMP signaling", "PROBLEM", 127, 140], ["missense mutations", "PROBLEM", 159, 177], ["disease severity", "PROBLEM", 215, 231], ["different BMPR-II mutations", "PROBLEM", 236, 263], ["BMP signaling", "OBSERVATION", 127, 140], ["increased", "OBSERVATION_MODIFIER", 144, 153]]], ["Cilostazol, a phosphodiesterase III inhibitor, offers a synergistic benefit in ameliorating MCTinduced PAH in rats [46] .", [["Cilostazol", "CHEMICAL", 0, 10], ["PAH", "CHEMICAL", 103, 106], ["Cilostazol", "CHEMICAL", 0, 10], ["PAH", "CHEMICAL", 103, 106], ["Cilostazol", "SIMPLE_CHEMICAL", 0, 10], ["phosphodiesterase III", "GENE_OR_GENE_PRODUCT", 14, 35], ["PAH", "SIMPLE_CHEMICAL", 103, 106], ["rats", "ORGANISM", 110, 114], ["rats", "SPECIES", 110, 114], ["Cilostazol", "TREATMENT", 0, 10], ["a phosphodiesterase III inhibitor", "TREATMENT", 12, 45], ["a synergistic benefit", "TREATMENT", 54, 75]]], ["Rosuvastatin blunted the increase in RVSP but did not reduce mean arterial pressure in the Ren2 rat [47] .", [["arterial", "ANATOMY", 66, 74], ["Rosuvastatin", "CHEMICAL", 0, 12], ["Rosuvastatin", "CHEMICAL", 0, 12], ["Rosuvastatin", "SIMPLE_CHEMICAL", 0, 12], ["arterial", "MULTI-TISSUE_STRUCTURE", 66, 74], ["rat", "ORGANISM", 96, 99], ["rat", "SPECIES", 96, 99], ["Ren2 rat", "SPECIES", 91, 99], ["Rosuvastatin", "TREATMENT", 0, 12], ["mean arterial pressure", "TEST", 61, 83], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["pressure", "OBSERVATION_MODIFIER", 75, 83]]], ["In a hypoxia-induced PH model, transplantation of Sca1+KDR+CXCR4+ cultured early EPCs failed to reverse vascular remodeling and changes in pulmonary hemodynamics, and intravenous administration of bone marrow cells failed to prevent an increase in RVSP and arterial muscularization, yet Raoul et al. [48] demonstrated that infusion of the same cells was effective in preventing MCT-induced PH.", [["Sca1+KDR+CXCR4", "ANATOMY", 50, 64], ["EPCs", "ANATOMY", 81, 85], ["vascular", "ANATOMY", 104, 112], ["pulmonary", "ANATOMY", 139, 148], ["intravenous", "ANATOMY", 167, 178], ["bone marrow cells", "ANATOMY", 197, 214], ["arterial", "ANATOMY", 257, 265], ["cells", "ANATOMY", 344, 349], ["MCT", "CHEMICAL", 378, 381], ["PH", "DISEASE", 390, 392], ["Sca1", "GENE_OR_GENE_PRODUCT", 50, 54], ["KDR", "GENE_OR_GENE_PRODUCT", 55, 58], ["CXCR4", "GENE_OR_GENE_PRODUCT", 59, 64], ["EPCs", "CELL", 81, 85], ["vascular", "MULTI-TISSUE_STRUCTURE", 104, 112], ["pulmonary", "ORGAN", 139, 148], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 167, 178], ["bone marrow cells", "CELL", 197, 214], ["arterial", "MULTI-TISSUE_STRUCTURE", 257, 265], ["cells", "CELL", 344, 349], ["MCT", "GENE_OR_GENE_PRODUCT", 378, 381], ["Sca1", "PROTEIN", 50, 54], ["KDR", "PROTEIN", 55, 58], ["CXCR4", "PROTEIN", 59, 64], ["EPCs", "CELL_TYPE", 81, 85], ["bone marrow cells", "CELL_TYPE", 197, 214], ["a hypoxia-induced PH model", "TREATMENT", 3, 29], ["Sca1", "PROBLEM", 50, 54], ["KDR", "PROBLEM", 55, 58], ["CXCR4", "PROBLEM", 59, 64], ["reverse vascular remodeling", "PROBLEM", 96, 123], ["changes in pulmonary hemodynamics", "PROBLEM", 128, 161], ["intravenous administration of bone marrow cells", "TREATMENT", 167, 214], ["an increase in RVSP and arterial muscularization", "PROBLEM", 233, 281], ["infusion of the same cells", "TREATMENT", 323, 349], ["MCT-induced PH", "PROBLEM", 378, 392], ["PH model", "OBSERVATION", 21, 29], ["vascular", "ANATOMY", 104, 112], ["remodeling", "OBSERVATION", 113, 123], ["pulmonary", "ANATOMY", 139, 148], ["increase", "OBSERVATION_MODIFIER", 236, 244], ["RVSP", "OBSERVATION", 248, 252], ["arterial", "ANATOMY", 257, 265]]], ["Zhao et al. [49] also showed that bone marrow-derived, endothelial-like progenitor cells were effective in preventing and reversing MCT-induced PH.", [["bone marrow", "ANATOMY", 34, 45], ["endothelial-like progenitor cells", "ANATOMY", 55, 88], ["MCT", "CHEMICAL", 132, 135], ["PH", "DISEASE", 144, 146], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 34, 45], ["endothelial-like progenitor cells", "CELL", 55, 88], ["MCT", "GENE_OR_GENE_PRODUCT", 132, 135], ["endothelial-like progenitor cells", "CELL_TYPE", 55, 88], ["bone marrow", "PROBLEM", 34, 45], ["progenitor cells", "PROBLEM", 72, 88], ["induced PH", "PROBLEM", 136, 146], ["bone marrow", "ANATOMY", 34, 45], ["endothelial", "ANATOMY", 55, 66]]], ["Because pulmonary vascular remodeling encompasses: endothelial dysfunction, fibroblast and SMC activation, crosstalk between cells within the vascular wall, and recruitment of circulating progenitor cells, these may be potential therapeutic targets.Future DirectionsIn addition to targeting activation or overexpression of ACE2, the literature illustrates other possible novel targets for intervention: phosphodiesterase inhibitors, statins, Larginine, antiplatelet agents, serotonin inhibitors, agents to alter ion channel function, gene therapy, elastase inhibitors, antiproliferative heparins, tyrosine kinase inhibitors, and bone marrow-derived endothelial progenitor cell treatment [50] .Future DirectionsThe ACE-Ang II-AT 1 R axis of the RAS has been implicated in PAH, yet intervention studies using ACE inhibitors and ARBs remain controversial.", [["pulmonary vascular", "ANATOMY", 8, 26], ["endothelial", "ANATOMY", 51, 62], ["fibroblast", "ANATOMY", 76, 86], ["SMC", "ANATOMY", 91, 94], ["cells", "ANATOMY", 125, 130], ["vascular wall", "ANATOMY", 142, 155], ["progenitor cells", "ANATOMY", 188, 204], ["bone marrow", "ANATOMY", 629, 640], ["endothelial progenitor cell", "ANATOMY", 649, 676], ["statins", "CHEMICAL", 433, 440], ["Larginine", "CHEMICAL", 442, 451], ["serotonin", "CHEMICAL", 474, 483], ["tyrosine", "CHEMICAL", 597, 605], ["ACE-Ang II", "CHEMICAL", 714, 724], ["PAH", "DISEASE", 771, 774], ["ACE inhibitors", "CHEMICAL", 807, 821], ["statins", "CHEMICAL", 433, 440], ["Larginine", "CHEMICAL", 442, 451], ["serotonin", "CHEMICAL", 474, 483], ["tyrosine", "CHEMICAL", 597, 605], ["PAH", "CHEMICAL", 771, 774], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 8, 26], ["endothelial", "CELL", 51, 62], ["fibroblast", "CELL", 76, 86], ["SMC", "CELL", 91, 94], ["cells", "CELL", 125, 130], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 142, 155], ["progenitor cells", "CELL", 188, 204], ["ACE2", "GENE_OR_GENE_PRODUCT", 323, 327], ["phosphodiesterase inhibitors", "SIMPLE_CHEMICAL", 403, 431], ["statins", "SIMPLE_CHEMICAL", 433, 440], ["Larginine", "SIMPLE_CHEMICAL", 442, 451], ["antiplatelet agents", "SIMPLE_CHEMICAL", 453, 472], ["serotonin", "SIMPLE_CHEMICAL", 474, 483], ["elastase", "GENE_OR_GENE_PRODUCT", 548, 556], ["heparins", "GENE_OR_GENE_PRODUCT", 587, 595], ["tyrosine kinase inhibitors", "SIMPLE_CHEMICAL", 597, 623], ["bone marrow-derived endothelial progenitor cell", "CELL", 629, 676], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 714, 731], ["RAS", "GENE_OR_GENE_PRODUCT", 744, 747], ["PAH", "SIMPLE_CHEMICAL", 771, 774], ["ACE", "GENE_OR_GENE_PRODUCT", 807, 810], ["ARBs", "SIMPLE_CHEMICAL", 826, 830], ["circulating progenitor cells", "CELL_TYPE", 176, 204], ["ACE2", "PROTEIN", 323, 327], ["bone marrow-derived endothelial progenitor cell", "CELL_TYPE", 629, 676], ["Ang II", "PROTEIN", 718, 724], ["RAS", "PROTEIN", 744, 747], ["pulmonary vascular remodeling", "PROBLEM", 8, 37], ["endothelial dysfunction", "PROBLEM", 51, 74], ["fibroblast and SMC activation", "PROBLEM", 76, 105], ["crosstalk between cells", "PROBLEM", 107, 130], ["circulating progenitor cells", "TREATMENT", 176, 204], ["ACE2", "TREATMENT", 323, 327], ["intervention", "TREATMENT", 389, 401], ["phosphodiesterase inhibitors", "TREATMENT", 403, 431], ["statins", "TREATMENT", 433, 440], ["Larginine", "TREATMENT", 442, 451], ["antiplatelet agents", "TREATMENT", 453, 472], ["serotonin inhibitors", "TREATMENT", 474, 494], ["agents", "TREATMENT", 496, 502], ["alter ion channel function", "TREATMENT", 506, 532], ["gene therapy", "TREATMENT", 534, 546], ["elastase inhibitors", "TREATMENT", 548, 567], ["antiproliferative heparins", "TREATMENT", 569, 595], ["tyrosine kinase inhibitors", "TREATMENT", 597, 623], ["bone marrow-derived endothelial progenitor cell treatment", "TREATMENT", 629, 686], ["The ACE-Ang II", "TREATMENT", 710, 724], ["intervention studies", "TEST", 780, 800], ["ACE inhibitors", "TREATMENT", 807, 821], ["ARBs", "TREATMENT", 826, 830], ["pulmonary", "ANATOMY_MODIFIER", 8, 17], ["vascular", "ANATOMY", 18, 26], ["remodeling", "OBSERVATION", 27, 37], ["endothelial dysfunction", "OBSERVATION", 51, 74], ["fibroblast", "OBSERVATION_MODIFIER", 76, 86], ["SMC activation", "OBSERVATION", 91, 105], ["vascular wall", "ANATOMY", 142, 155], ["recruitment", "OBSERVATION_MODIFIER", 161, 172], ["circulating progenitor cells", "OBSERVATION", 176, 204], ["may be potential", "UNCERTAINTY", 212, 228], ["bone", "ANATOMY", 629, 633], ["PAH", "OBSERVATION", 771, 774]]], ["Evidence targeting the ACE2-Ang-(1-7)-Mas axis of the RAS supports the idea that this axis antagonizes the proliferative, fibrotic, and hypertrophic effects of the ACE-Ang II-AT 1 R axis.", [["Ang", "CHEMICAL", 28, 31], ["Ang", "CHEMICAL", 168, 171], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 28, 36], ["RAS", "GENE_OR_GENE_PRODUCT", 54, 57], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 164, 181], ["ACE2", "PROTEIN", 23, 27], ["RAS", "PROTEIN", 54, 57], ["ACE", "PROTEIN", 164, 167], ["Ang II", "PROTEIN", 168, 174], ["the ACE2", "TEST", 19, 27], ["Ang", "TEST", 28, 31], ["hypertrophic effects", "PROBLEM", 136, 156], ["the ACE", "TEST", 160, 167], ["proliferative", "OBSERVATION_MODIFIER", 107, 120], ["fibrotic", "OBSERVATION_MODIFIER", 122, 130], ["hypertrophic", "OBSERVATION_MODIFIER", 136, 148]]], ["In an effort to advance research efforts in PAH therapy, we must consider the efficacy of ACE2 activation in clinical trials, the use of subpressor doses of ACE inhibitors or ARBs in clinical trials, larger clinical trials, the efficacy of ACE inhibitors in regression of established lesions compared with new lesions, the timing of intervention, the identification of bone marrow cell types to treat PAH, and the development of animal models that reflect human PAH.ConclusionsWe need a novel strategic intervention, as PAH is a chronic, fatal disease.", [["lesions", "ANATOMY", 284, 291], ["lesions", "ANATOMY", 310, 317], ["bone marrow cell", "ANATOMY", 369, 385], ["PAH", "CHEMICAL", 44, 47], ["PAH", "DISEASE", 401, 404], ["PAH", "CHEMICAL", 462, 465], ["PAH", "CHEMICAL", 520, 523], ["PAH", "CHEMICAL", 44, 47], ["PAH", "CHEMICAL", 401, 404], ["PAH", "CHEMICAL", 462, 465], ["PAH", "CHEMICAL", 520, 523], ["PAH", "SIMPLE_CHEMICAL", 44, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["ACE", "GENE_OR_GENE_PRODUCT", 157, 160], ["ARBs", "SIMPLE_CHEMICAL", 175, 179], ["ACE", "GENE_OR_GENE_PRODUCT", 240, 243], ["lesions", "PATHOLOGICAL_FORMATION", 284, 291], ["lesions", "PATHOLOGICAL_FORMATION", 310, 317], ["bone marrow cell", "CELL", 369, 385], ["human", "ORGANISM", 456, 461], ["PAH", "SIMPLE_CHEMICAL", 462, 465], ["PAH", "SIMPLE_CHEMICAL", 520, 523], ["ACE2", "PROTEIN", 90, 94], ["bone marrow cell types", "CELL_TYPE", 369, 391], ["human", "SPECIES", 456, 461], ["human", "SPECIES", 456, 461], ["PAH therapy", "TREATMENT", 44, 55], ["ACE2 activation", "TREATMENT", 90, 105], ["subpressor doses", "TREATMENT", 137, 153], ["ACE inhibitors", "TREATMENT", 157, 171], ["ARBs", "TREATMENT", 175, 179], ["ACE inhibitors", "TREATMENT", 240, 254], ["established lesions", "PROBLEM", 272, 291], ["new lesions", "PROBLEM", 306, 317], ["intervention", "TREATMENT", 333, 345], ["bone marrow cell types", "PROBLEM", 369, 391], ["PAH", "PROBLEM", 401, 404], ["animal models", "PROBLEM", 429, 442], ["human PAH", "PROBLEM", 456, 465], ["a novel strategic intervention", "TREATMENT", 485, 515], ["a chronic, fatal disease", "PROBLEM", 527, 551], ["lesions", "OBSERVATION", 284, 291], ["new", "OBSERVATION_MODIFIER", 306, 309], ["lesions", "OBSERVATION", 310, 317], ["bone marrow cell", "OBSERVATION", 369, 385], ["PAH", "OBSERVATION", 401, 404], ["PAH", "OBSERVATION", 462, 465], ["chronic", "OBSERVATION_MODIFIER", 529, 536], ["fatal", "OBSERVATION_MODIFIER", 538, 543], ["disease", "OBSERVATION", 544, 551]]], ["Current therapy addresses vasoconstrictor imbalance and endothelial dysfunction, but vasodilator therapy has yet to improve patient survival.", [["endothelial", "ANATOMY", 56, 67], ["endothelial dysfunction", "DISEASE", 56, 79], ["endothelial", "TISSUE", 56, 67], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["Current therapy", "TREATMENT", 0, 15], ["vasoconstrictor imbalance", "PROBLEM", 26, 51], ["endothelial dysfunction", "PROBLEM", 56, 79], ["vasodilator therapy", "TREATMENT", 85, 104], ["endothelial dysfunction", "OBSERVATION", 56, 79]]], ["Unlike epoprostenol, a prostacyclin analogue and potent vasodilator, most PAH therapies have not improved survival.", [["epoprostenol", "CHEMICAL", 7, 19], ["prostacyclin", "CHEMICAL", 23, 35], ["PAH", "CHEMICAL", 74, 77], ["epoprostenol", "CHEMICAL", 7, 19], ["prostacyclin", "CHEMICAL", 23, 35], ["PAH", "CHEMICAL", 74, 77], ["epoprostenol", "SIMPLE_CHEMICAL", 7, 19], ["prostacyclin", "SIMPLE_CHEMICAL", 23, 35], ["PAH", "SIMPLE_CHEMICAL", 74, 77], ["epoprostenol", "TREATMENT", 7, 19], ["a prostacyclin analogue", "TREATMENT", 21, 44], ["potent vasodilator", "TREATMENT", 49, 67], ["most PAH therapies", "TREATMENT", 69, 87]]], ["Therefore, new therapies that target PVR are emerging.", [["PVR", "GENE_OR_GENE_PRODUCT", 37, 40], ["new therapies", "TREATMENT", 11, 24], ["target PVR", "TREATMENT", 30, 40], ["new", "OBSERVATION_MODIFIER", 11, 14], ["PVR", "OBSERVATION", 37, 40]]], ["Increasing evidence supports the concept of an imbalance in various components of the RAS.", [["RAS", "GENE_OR_GENE_PRODUCT", 86, 89], ["RAS", "PROTEIN", 86, 89], ["an imbalance", "PROBLEM", 44, 56], ["imbalance", "OBSERVATION", 47, 56], ["various", "OBSERVATION_MODIFIER", 60, 67], ["components", "OBSERVATION_MODIFIER", 68, 78]]], ["Animal and human trials demonstrate that an imbalance that favors the ACE-Ang II-AT 1 R axis actions promotes proliferation, fibrosis, and growth.", [["Ang II", "CHEMICAL", 74, 80], ["fibrosis", "DISEASE", 125, 133], ["human", "ORGANISM", 11, 16], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 70, 87], ["ACE", "PROTEIN", 70, 73], ["Ang II", "PROTEIN", 74, 80], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["an imbalance", "PROBLEM", 41, 53], ["the ACE", "TEST", 66, 73], ["fibrosis", "PROBLEM", 125, 133], ["proliferation", "OBSERVATION", 110, 123], ["fibrosis", "OBSERVATION", 125, 133]]], ["There is no current consensus for the efficacy of therapeutic PAH strategies such as ACEs or ARBs in human and animal models, yet the benefit of ACE2 overexpression and activation in lung is consistent.", [["lung", "ANATOMY", 183, 187], ["PAH", "CHEMICAL", 62, 65], ["ARBs", "CHEMICAL", 93, 97], ["PAH", "CHEMICAL", 62, 65], ["PAH", "SIMPLE_CHEMICAL", 62, 65], ["ACEs", "SIMPLE_CHEMICAL", 85, 89], ["ARBs", "SIMPLE_CHEMICAL", 93, 97], ["human", "ORGANISM", 101, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["lung", "ORGAN", 183, 187], ["ACE2", "PROTEIN", 145, 149], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["therapeutic PAH strategies", "TREATMENT", 50, 76], ["ARBs", "TREATMENT", 93, 97], ["ACE2 overexpression", "TREATMENT", 145, 164], ["activation in lung", "PROBLEM", 169, 187], ["no", "UNCERTAINTY", 9, 11], ["PAH", "OBSERVATION", 62, 65], ["lung", "ANATOMY", 183, 187]]], ["In PAH, ACE2 overexpression and activation exerts its effects via the ACE2-Ang-(1-7)-Mas axis, limiting the detrimental actions of the ACE-Ang II-AT 1 R axis and playing a protective role in PH.", [["PAH", "CHEMICAL", 3, 6], ["Ang", "CHEMICAL", 75, 78], ["Ang", "CHEMICAL", 139, 142], ["PH", "DISEASE", 191, 193], ["PAH", "CHEMICAL", 3, 6], ["PAH", "SIMPLE_CHEMICAL", 3, 6], ["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 75, 83], ["Mas", "GENE_OR_GENE_PRODUCT", 85, 88], ["ACE-Ang II-AT 1 R", "GENE_OR_GENE_PRODUCT", 135, 152], ["ACE2", "PROTEIN", 8, 12], ["ACE2", "PROTEIN", 70, 74], ["ACE", "PROTEIN", 135, 138], ["Ang II", "PROTEIN", 139, 145], ["ACE2 overexpression", "TREATMENT", 8, 27], ["the ACE2", "TEST", 66, 74], ["Ang", "TEST", 75, 78], ["the ACE", "TEST", 131, 138], ["PAH", "OBSERVATION", 3, 6]]], ["The exact mechanism of benefit remains elusive, but the benefit in both prevention and reversal studies in animal models is clear.", [["reversal studies", "TEST", 87, 103], ["clear", "OBSERVATION", 124, 129]]], ["Thus, activation of ACE2 is a novel and effective strategy for PAH that must be considered.ConclusionsDisclosure No potential conflicts of interest relevant to this article were reported.", [["PAH", "CHEMICAL", 63, 66], ["PAH", "CHEMICAL", 63, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["PAH", "SIMPLE_CHEMICAL", 63, 66], ["ACE2", "PROTEIN", 20, 24], ["ACE2", "PROBLEM", 20, 24], ["PAH", "PROBLEM", 63, 66], ["No potential", "UNCERTAINTY", 113, 125]]]]}